Science.gov

Sample records for high-energy neutron therapy

  1. High energy neutron radiography

    SciTech Connect

    Gavron, A.; Morley, K.; Morris, C.; Seestrom, S.; Ullmann, J.; Yates, G.; Zumbro, J.

    1996-06-01

    High-energy spallation neutron sources are now being considered in the US and elsewhere as a replacement for neutron beams produced by reactors. High-energy and high intensity neutron beams, produced by unmoderated spallation sources, open potential new vistas of neutron radiography. The authors discuss the basic advantages and disadvantages of high-energy neutron radiography, and consider some experimental results obtained at the Weapons Neutron Research (WNR) facility at Los Alamos.

  2. Neutron spectra and dose equivalents calculated in tissue for high-energy radiation therapy

    PubMed Central

    Kry, Stephen F.; Howell, Rebecca M.; Salehpour, Mohammad; Followill, David S.

    2009-01-01

    Neutrons are by-products of high-energy radiation therapy and a source of dose to normal tissues. Thus, the presence of neutrons increases a patient’s risk of radiation-induced secondary cancer. Although neutrons have been thoroughly studied in air, little research has been focused on neutrons at depths in the patient where radiosensitive structures may exist, resulting in wide variations in neutron dose equivalents between studies. In this study, we characterized properties of neutrons produced during high-energy radiation therapy as a function of their depth in tissue and for different field sizes and different source-to-surface distances (SSD). We used a previously developed Monte Carlo model of an accelerator operated at 18 MV to calculate the neutron fluences, energy spectra, quality factors, and dose equivalents in air and in tissue at depths ranging from 0.1 to 25 cm. In conjunction with the sharply decreasing dose equivalent with increased depth in tissue, the authors found that the neutron energy spectrum changed drastically as a function of depth in tissue. The neutron fluence decreased gradually as the depth increased, while the average neutron energy decreased sharply with increasing depth until a depth of approximately 7.5 cm in tissue, after which it remained nearly constant. There was minimal variation in the quality factor as a function of depth. At a given depth in tissue, the neutron dose equivalent increased slightly with increasing field size and decreasing SSD; however, the percentage depth-dose equivalent curve remained constant outside the primary photon field. Because the neutron dose equivalent, fluence, and energy spectrum changed substantially with depth in tissue, we concluded that when the neutron dose equivalent is being determined at a depth within a patient, the spectrum and quality factor used should be appropriate for depth rather than for in-air conditions. Alternately, an appropriate percent depth-dose equivalent curve should

  3. Neutron therapy facility at the Institute of High Energy Physics, Academia Sinica

    SciTech Connect

    Zhu, Y.C.

    1983-12-01

    The 10 MeV proton linac which was designed as preinjector for the Beijing 50 GeV Proton Synchrotron (BPS) was completed by the end of 1982. Because of the economic readjustment in the People's Republic of China the BPS project was cancelled. Then, the Institute of High Energy Physics decided to increase the energy of the linac from 10 MeV to 35.5 MeV. This increase will take place using the primary five megawatts RF system of the 10 MeV linac. This 35.5 MeV proton linac will be used for research in radiomedicine and radiobiology in general and in particular for research in fast neutron therapy and radiopharmaceutical production. This project has been approved by the Academia Sinica.

  4. Intercomparison of high energy neutron personnel dosimeters

    SciTech Connect

    McDonald, J.C.; Akabani, G.; Loesch, R.M.

    1993-03-01

    An intercomparison of high-energy neutron personnel dosimeters was performed to evaluate the uniformity of the response characteristics of typical neutron dosimeters presently in use at US Department of Energy (DOE) accelerator facilities. It was necessary to perform an intercomparison because there are no national or international standards for high-energy neutron dosimetry. The testing that is presently under way for the Department of Energy Laboratory Accreditation Program (DOELAP) is limited to the use of neutron sources that range in energy from about 1 keV to 2 MeV. Therefore, the high-energy neutron dosimeters presently in use at DOE accelerator facilities are not being tested effectively. This intercomparison employed neutrons produced by the {sup 9}Be(p,n){sup 9}B interaction at the University of Washington cyclotron, using 50-MeV protons. The resulting neutron energy spectrum extended to a maximum of approximately 50-MeV, with a mean energy of about 20-MeV. Intercomparison results for currently used dosimeters, including Nuclear Type A (NTA) film, thermoluminescent dosimeter (TLD)-albedo, and track-etch dosimeters (TEDs), indicated a wide variation in response to identical doses of high-energy neutrons. Results of this study will be discussed along with a description of plans for future work.

  5. High-energy neutron spectroscopy with thick silicon detectors

    NASA Technical Reports Server (NTRS)

    Kinnison, James D.; Maurer, Richard H.; Roth, David R.; Haight, Robert C.

    2003-01-01

    The high-energy neutron component of the space radiation environment in thick structures such as the International Space Station contributes to the total radiation dose received by an astronaut. Detector design constraints such as size and mass have limited the energy range of neutron spectrum measurements in orbit to about 12 MeV in Space Shuttle studies. We present a new method for high-energy neutron spectroscopy using small silicon detectors that can extend these measurements to more than 500 MeV. The methodology is based on measurement of the detector response function for high-energy neutrons and inversion of this response function with measured deposition data to deduce neutron energy spectra. We also present the results of an initial shielding study performed with the thick silicon detector system for high-energy neutrons incident on polyethylene.

  6. Practical neutron dosimetry at high energies

    SciTech Connect

    McCaslin, J.B.; Thomas, R.H.

    1980-10-01

    Dosimetry at high energy particle accelerators is discussed with emphasis on physical measurements which define the radiation environment and provide an immutable basis for the derivation of any quantities subsequently required for risk evaluation. Results of inter-laboratory dosimetric comparisons are reviewed and it is concluded that a well-supported systematic program is needed which would make possible detailed evaluations and inter-comparisons of instruments and techniques in well characterized high energy radiation fields. High-energy dosimetry is so coupled with radiation transport that it is clear their study should proceed concurrently.

  7. Microchannel plate response to high-energy neutrons

    SciTech Connect

    Persing, R.; Medley, S.S.

    1981-07-01

    The response of a chevron microchannel plate (MCP) to high energy neutrons was measured. The large area (4.6 cm x 13 cm) multi-anode MCP performance characteristics in the saturated pulse counting mode of operation were examined prior to neutron testing. This established a linear operating regime in which the neutron detection efficiency was measured to be 0.17% for 2.5 MeV-DD neutrons and 0.64% for 14 MeV-DT neutrons. The higher response measured for the 14 MeV-DT neutrons is attributed to gamma ray contamination induced by neutron collisions with materials located between the neutron source and the MCP detector. Due to their lower energy, the 2.5 MeV-DD response measurements are expected to be relatively free of gamma contamination and, hence, indicative of actual response of the MCP detector to neutrons in the 1 to 10 MeV energy range.

  8. Neutron therapy of cancer

    NASA Technical Reports Server (NTRS)

    Frigerio, N. A.; Nellans, H. N.; Shaw, M. J.

    1969-01-01

    Reports relate applications of neutrons to the problem of cancer therapy. The biochemical and biophysical aspects of fast-neutron therapy, neutron-capture and neutron-conversion therapy with intermediate-range neutrons are presented. Also included is a computer program for neutron-gamma radiobiology.

  9. High-Energy Neutron Spectra and Flux Measurements Below Ground

    NASA Astrophysics Data System (ADS)

    Roecker, Caleb; Bernstein, Adam; Marleau, Peter; Vetter, Kai

    2016-03-01

    High-energy neutrons are a ubiquitous and often poorly measured background. Below ground, these neutrons could potentially interfere with antineutrino based reactor monitoring experiments as well as other rare-event neutral particle detectors. We have designed and constructed a transportable fast neutron detection system for measuring neutron energy spectra and flux ranging from tens to hundreds of MeV. The spectrometer uses a multiplicity technique in order to have a higher effective area than traditional transportable high-energy neutron spectrometers. Transportability ensures a common detector-related systematic bias for future measurements. The spectrometer is composed of two Gd containing plastic scintillator detectors arranged around a lead spallation target. A high-energy neutron may interact in the lead producing many secondary neutrons. The detector records the correlated secondary neutron multiplicity. Over many events, the response can be used to infer the incident neutron energy spectrum and flux. As a validation of the detector response, surface measurements have been performed; results confirm agreement with previous experiments. Below ground measurements have been performed at 3 depths (380, 600, and 1450 m.w.e.); results from these measurements will be presented.

  10. High Energy Neutron Induced Gamma Production

    SciTech Connect

    Brown, D A; Johnson, M; Navratil, P

    2007-09-28

    N Division has an interest in improving the physics and accuracy of the gamma data it provides to its customers. It was asked to look into major gamma producing reactions for 14 MeV incident neutrons for several low-Z materials and determine whether LLNL's processed data files faithfully represent the current state of experimental and theoretical knowledge for these reactions. To address this, we surveyed the evaluations of the requested materials, made recommendations for the next ENDL release and noted isotopes that will require further experimental study. This process uncovered several major problems in our translation and processing of the ENDF formatted evaluations, most of which have been resolved.

  11. High-Energy Neutron Backgrounds for Underground Dark Matter Experiments

    SciTech Connect

    Chen, Yu

    2016-01-01

    Direct dark matter detection experiments usually have excellent capability to distinguish nuclear recoils, expected interactions with Weakly Interacting Massive Particle (WIMP) dark matter, and electronic recoils, so that they can efficiently reject background events such as gamma-rays and charged particles. However, both WIMPs and neutrons can induce nuclear recoils. Neutrons are then the most crucial background for direct dark matter detection. It is important to understand and account for all sources of neutron backgrounds when claiming a discovery of dark matter detection or reporting limits on the WIMP-nucleon cross section. One type of neutron background that is not well understood is the cosmogenic neutrons from muons interacting with the underground cavern rock and materials surrounding a dark matter detector. The Neutron Multiplicity Meter (NMM) is a water Cherenkov detector capable of measuring the cosmogenic neutron flux at the Soudan Underground Laboratory, which has an overburden of 2090 meters water equivalent. The NMM consists of two 2.2-tonne gadolinium-doped water tanks situated atop a 20-tonne lead target. It detects a high-energy (>~ 50 MeV) neutron via moderation and capture of the multiple secondary neutrons released when the former interacts in the lead target. The multiplicity of secondary neutrons for the high-energy neutron provides a benchmark for comparison to the current Monte Carlo predictions. Combining with the Monte Carlo simulation, the muon-induced high-energy neutron flux above 50 MeV is measured to be (1.3 ± 0.2) ~ 10-9 cm-2s-1, in reasonable agreement with the model prediction. The measured multiplicity spectrum agrees well with that of Monte Carlo simulation for multiplicity below 10, but shows an excess of approximately a factor of three over Monte Carlo prediction for multiplicities ~ 10 - 20. In an effort to reduce neutron backgrounds for the dark matter experiment SuperCDMS SNO- LAB, an active neutron veto was developed

  12. Superheated emulsions as high-energy neutron dosemeters.

    PubMed

    Das, Mala; Sawamura, Teruko; Abe, Masashi; Kaneko, Junichi H; Homma, Akira; Fujita, Fumiyuki; Tsuda, Shuichi; Nishitani, Takeo

    2004-01-01

    Superheated emulsions being inexpensive, easy to fabricate, and having tissue equivalent composition make them as one of the popular neutron dosemeters. One more advantage is that they can be made insensitive to gamma rays by the choice of the sensitive liquid. It is observed that the response of commercially available bubble detector to neutron decreases above 20 MeV while its response is roughly flat in the 0.1-15 MeV region. This restricts its application as a dosemeter to high-energy neutrons. The response of bubble detector from Bubble Technology Industries, has been observed by using Pb-breeder for high-energy neutrons from different facilities in Japan. It is observed that 2-3 cm Pb-breeder is effective in increasing the response of the detector to the nominal value. Theoretical calculation using MCNPX code indicates an increase in neutrons in the energy range of 0.1-10 MeV with Pb-breeder. The present work indicates the possibility of using the bubble detector as a dosemeter to high-energy neutron using a Pb-breeder of proper thickness.

  13. Neutron dosimetry with TL albedo dosemeters at high energy accelerators.

    PubMed

    Haninger, T; Fehrenbacher, G

    2007-01-01

    The GSF-Personal Monitoring Service uses the TLD albedo dosemeter as standard neutron personal dosemeter. Due to its low sensitivity for fast neutrons however, it is generally not recommended for workplaces at high-energy accelerators. Test measurements with the albedo dosemeter were performed at the accelerator laboratories of GSI in Darmstadt and DESY in Hamburg to reconsider this hypothesis. It revealed that the albedo dosemeter can also be used as personal dosemeter at these workplaces, because at all measurement locations a significant part of neutrons with lower energies could be found, which were produced by scattering at walls or the ground.

  14. High-Energy Neutron Imaging Development at LLNL

    SciTech Connect

    Hall, J M; Rusnak, B; Shen, S

    2005-02-16

    We are proceeding with the development of a high-energy (10 MeV) neutron imaging system for use as an inspection tool in nuclear stockpile stewardship applications. Our goal is to develop and deploy an imaging system capable of detecting cubic-mm-scale voids, cracks or other significant structural defects in heavily-shielded low-Z materials within nuclear device components. The final production-line system will be relatively compact (suitable for use in existing facilities within the DOE complex) and capable of acquiring both radiographic and tomographic (CT) images. In this report, we will review our recent programmatic accomplishments, focusing primarily on progress made in FY04. The design status of the high-intensity, accelerator-driven neutron source and large-format imaging detector associated with the system will be discussed and results from a recent high-energy neutron imaging experiment conducted at the Ohio University Accelerator Laboratory (OUAL) will also be presented.

  15. A review on photoneutrons characteristics in radiation therapy with high-energy photon beams.

    PubMed

    Naseri, Alireza; Mesbahi, Asghar

    2010-09-22

    In radiation therapy with high-energy photon beams (E > 10 MeV) neutrons are generated mainly in linacs head thorough (γ,n) interactions of photons with nuclei of high atomic number materials that constitute the linac head and the beam collimation system. These neutrons affect the shielding requirements in radiation therapy rooms and also increase the out-of-field radiation dose of patients undergoing radiation therapy with high-energy photon beams. In the current review, the authors describe the factors influencing the neutron production for different medical linacs based on the performed measurements and Monte Carlo studies in the literature.

  16. Neutron emission and fragment yield in high-energy fission

    SciTech Connect

    Grudzevich, O. T. Klinov, D. A.

    2013-07-15

    The KRIS special library of spectra and emission probabilities in the decays of 1500 nuclei excited up to energies between 150 and 250 MeV was developed for correctly taking into account the decay of highly excited nuclei appearing as fission fragments. The emission of neutrons, protons, and photons was taken into account. Neutron emission fromprimary fragments was found to have a substantial effect on the formation of yields of postneutron nuclei. The library was tested by comparing the calculated and measured yields of products originating from the fission of nuclei that was induced by high-energy protons. The method for calculating these yields was tested on the basis of experimental data on the thermal-neutroninduced fission of {sup 235}U nuclei.

  17. Neutron capture therapies

    SciTech Connect

    Yanch, Jacquelyn C.; Shefer, Ruth E.; Klinkowstein, Robert E.

    1999-01-01

    In one embodiment there is provided an application of the .sup.10 B(n,.alpha.).sup.7 Li nuclear reaction or other neutron capture reactions for the treatment of rheumatoid arthritis. This application, called Boron Neutron Capture Synovectomy (BNCS), requires substantially altered demands on neutron beam design than for instance treatment of deep seated tumors. Considerations for neutron beam design for the treatment of arthritic joints via BNCS are provided for, and comparisons with the design requirements for Boron Neutron Capture Therapy (BNCT) of tumors are made. In addition, exemplary moderator/reflector assemblies are provided which produce intense, high-quality neutron beams based on (p,n) accelerator-based reactions. In another embodiment there is provided the use of deuteron-based charged particle reactions to be used as sources for epithermal or thermal neutron beams for neutron capture therapies. Many d,n reactions (e.g. using deuterium, tritium or beryllium targets) are very prolific at relatively low deuteron energies.

  18. Neutron capture therapies

    SciTech Connect

    Yanch, J.C.; Shefer, R.E.; Klinkowstein, R.E.

    1999-11-02

    In one embodiment there is provided an application of the {sup 10}B(n,{alpha}){sup 7}Li nuclear reaction or other neutron capture reactions for the treatment of rheumatoid arthritis. This application, called Boron Neutron Capture Synovectomy (BNCS), requires substantially altered demands on neutron beam design than for instance treatment of deep seated tumors. Considerations for neutron beam design for the treatment of arthritic joints via BNCS are provided for, and comparisons with the design requirements for Boron Neutron Capture Therapy (BNCT) of tumors are made. In addition, exemplary moderator/reflector assemblies are provided which produce intense, high-quality neutron beams based on (p,n) accelerator-based reactions. In another embodiment there is provided the use of deuteron-based charged particle reactions to be used as sources for epithermal or thermal neutron beams for neutron capture therapies. Many d,n reactions (e.g. using deuterium, tritium or beryllium targets) are very prolific at relatively low deuteron energies.

  19. A phoswich detector for high-energy neutrons.

    PubMed

    Takada, M; Nakamura, T

    2007-01-01

    A phoswich detector was developed to measure neutron energy spectra from a few MeV to a few hundreds MeV in aircrafts and space crafts. Radiation fields, which both crafts are exposured, consist of neutrons, gamma rays, protons, etc. The phoswich detector can measure neutrons separately from gamma rays and protons. The capability of particle discrimination was tested at HIMAC and was found to be excellent. Detector response functions to neutrons were simulated with the MCNPX code using the measured light outputs of charged particles and were measured with quasi-mono-energetic neutrons produced by the p-Li reaction at the NIRS cyclotron. Test flight measurements at high altitudes, 6.5 and 8.5 km, were performed above the middle part of Japan (cut-off rigidity, 12 GV).

  20. Characterization of the high-energy neutron beam of the PRISMA beamline using a diamond detector

    NASA Astrophysics Data System (ADS)

    Cazzaniga, C.; Frost, C. D.; Minniti, T.; Schooneveld, E.; Perelli Cippo, E.; Tardocchi, M.; Rebai, M.; Gorini, G.

    2016-07-01

    The high-energy neutron component (En > 10 MeV) of the neutron spectrum of PRISMA, a beam-line at the ISIS spallation source, has been characterized for the first time. Neutron measurements using a Single-crystal Diamond Detector at a short-pulse source are obtained by a combination of pulse height and time of flight analysis. An XY scan provides a 2D map of the high-energy neutron beam which has a diameter of about 40 mm. The high neutron flux, that has been found to be (3.8 ± 0.7) · 105 cm-2s-1 for En > 10 MeV in the centre, opens up for a possible application of the beam-line as a high-energy neutron irradiation position. Results are of interest for the development of the ChipIR beam-line, which will feature an atmospheric-like neutron spectrum for chip irradiation experiment. Furthermore, these results demonstrate that diamond detectors can be used at spallation sources to investigate the transport of high-energy neutrons down instruments which is of interest in general to designers as high-energy neutrons are a source of background in thermal beamlines.

  1. BNCT of skin tumors using the high-energy D-T neutrons.

    PubMed

    Masoudi, S Farhad; Rasouli, Fatemeh S; Ghasemi, Marjan

    2017-04-01

    Owing to the continuing need for providing improved and universally accepted facilities to be used in radiation therapies, a number of recently published BNCT-related studies have focused on investigating appropriate neutron sources as alternatives for nuclear reactors. Of special interest are D-T neutron generators, which theoretically have shown the potential to be utilized as neutron sources for BNCT of deep-seated tumors. This work is devoted to investigate the feasibility of using the high-energy neutrons emitted from these generators for treatment of surface tumors, especially skin. Using a set of MCNPX simulations, the D-T neutrons are passed through an optimized arrangement of materials to slow-down toward the desired energy range, and to remove the neutron and gamma contamination considering the IAEA recommended criteria, especially determined for pre-clinical survey for treatment of surface tumors. By assessment with these parameters, it is shown that the designed beam, corresponding to a configuration composed of natural uranium as neutron multiplier, D2O as moderator, Pb as reflector, Bi as gamma filter, and polyethylene and BeO as collimators provides high-intensity of desired neutrons, and low-background doses as well. It was found that an appropriate material for collimator, if accompanied with an optimized geometry, is an important parameter for keeping the undesired components to the recommended level. A typical simulated phantom, subjected to the irradiation of the designed spectrum, is used to study the performance of the resultant beam in shallow tissue. For an arbitrary chosen (10)B concentration, the evaluated depth-dose curves show that the proposed configuration establishes acceptable agreement between the appropriate neutron intensity and penetration to desired depth in tissue in a reasonable treatment time of about 25-38min. Considering the simulations carried out, the total dose delivered to the tumor is expected to be of about 4.2 times

  2. High energy neutron and gamma-radiation generated during the solar flares

    NASA Technical Reports Server (NTRS)

    Kocharov, G. E.; Mandzhavidze, N. Z.

    1985-01-01

    The problem of high energy neutrons and gamma rays generation in the solar conditions is considered. It is shown that due to a peculiarity of generation and propagation of neutrons corresponding solar flares should be localized at high helio-longitudes.

  3. Fibrosarcoma after high energy radiation therapy for pituitary adenoma

    SciTech Connect

    Martin, W.H.; Cail, W.S.; Morris, J.L.; Constable, W.C.

    1980-11-01

    Pituitary sarcoma is a rare late complication of radiotherapy for pituitary tumors. Although early case reports involved multiple courses of relatively low-energy radiation therapy, pituitary sarcoma has been seen with single courses of high-energy x-ray or heavy particle radiotherapy. This report describes a fibrosarcoma of the pituitary occurring 5 years after 4,500 rad (45 Gy) of x-irradiation delivered in 20 treatments over 3 weeks by an 8 MeV linear accelerator.

  4. A Canadian high-energy neutron spectrometry system for measurements in space

    NASA Astrophysics Data System (ADS)

    Jonkmans, G.; Andrews, H. R.; Clifford, E. T. H.; Frketich, G.; Ing, H.; Koslowsky, V. T.; Noulty, R. A.; Miller, R. C.; Zhou, Y.; Mortimer, A.; Peterson, D.; Wilkinson, R.

    2005-05-01

    Bubble Technology Industries Inc. (BTI), with the support of the Canadian Space Agency, has finished the construction of the Canadian High-Energy Neutron Spectrometry System (CHENSS). This spectrometer is intended to measure the high-energy neutron spectrum ( ˜1-100MeV) encountered in spacecraft in low earth orbit. CHENSS is designed to fly aboard a US space shuttle and its scientific results should facilitate the prediction of neutron dose to astronauts in space from readings of different types of radiation dosimeters that are being used in various missions.

  5. Measurement of high-energy neutron flux above ground utilizing a spallation based multiplicity technique

    DOE PAGES

    Roecker, Caleb; Bernstein, Adam; Marleau, Peter; ...

    2016-11-14

    Cosmogenic high-energy neutrons are a ubiquitous, difficult to shield, poorly measured background. Above ground the high-energy neutron energy-dependent flux has been measured, with significantly varying results. Below ground, high-energy neutron fluxes are largely unmeasured. Here we present a reconstruction algorithm to unfold the incident neutron energy-dependent flux measured using the Multiplicity and Recoil Spectrometer (MARS), simulated test cases to verify the algorithm, and provide a new measurement of the above ground high-energy neutron energy-dependent flux with a detailed systematic uncertainty analysis. Uncertainty estimates are provided based upon the measurement statistics, the incident angular distribution, the surrounding environment of the Montemore » Carlo model, and the MARS triggering efficiency. Quantified systematic uncertainty is dominated by the assumed incident neutron angular distribution and surrounding environment of the Monte Carlo model. The energy-dependent neutron flux between 90 MeV and 400 MeV is reported. Between 90 MeV and 250 MeV the MARS results are comparable to previous Bonner sphere measurements. Over the total energy regime measured, the MARS result are located within the span of previous measurements. Lastly, these results demonstrate the feasibility of future below ground measurements with MARS.« less

  6. Measurement of high-energy neutron flux above ground utilizing a spallation based multiplicity technique

    SciTech Connect

    Roecker, Caleb; Bernstein, Adam; Marleau, Peter; Vetter, Kai

    2016-11-14

    Cosmogenic high-energy neutrons are a ubiquitous, difficult to shield, poorly measured background. Above ground the high-energy neutron energy-dependent flux has been measured, with significantly varying results. Below ground, high-energy neutron fluxes are largely unmeasured. Here we present a reconstruction algorithm to unfold the incident neutron energy-dependent flux measured using the Multiplicity and Recoil Spectrometer (MARS), simulated test cases to verify the algorithm, and provide a new measurement of the above ground high-energy neutron energy-dependent flux with a detailed systematic uncertainty analysis. Uncertainty estimates are provided based upon the measurement statistics, the incident angular distribution, the surrounding environment of the Monte Carlo model, and the MARS triggering efficiency. Quantified systematic uncertainty is dominated by the assumed incident neutron angular distribution and surrounding environment of the Monte Carlo model. The energy-dependent neutron flux between 90 MeV and 400 MeV is reported. Between 90 MeV and 250 MeV the MARS results are comparable to previous Bonner sphere measurements. Over the total energy regime measured, the MARS result are located within the span of previous measurements. Lastly, these results demonstrate the feasibility of future below ground measurements with MARS.

  7. Neutron field for boron neutron capture therapy

    SciTech Connect

    Kanda, K.; Kobayashi, T.

    1986-01-01

    Recently, the development of an epithermal neutron source has been required by medical doctors for deeper neutron penetrations, which is to be used for deep tumor treatment and diagnosis of metastasis. Several attempts have already been made to realize an epithermal neutron field, such as the undermoderated neutron beam, the filtered neutron beam, and the use of a fission plate. At present, these facilities can not be used for actual therapy. For the treatment of deep tumor, another method has been also proposed in normal water in the body is replaced by heavy water to attain a deeper neutron penetration. At Kyoto University's Research Reactor Institute, almost all physics problems have been settled relative to thermal neutron capture therapy that has been used for treating brain tumors and for biological experiments on malignant melanoma. Very recently feasibility studies to use heavy water have been started both theoretically and experimentally. The calculation shows the deeper penetration of neutrons as expected. Two kinds of experiments were done by using the KUR guide tube: 1. Thermal neutron penetration measurement. 2. Heavy water uptake in vitro sample. In addition to the above experiment using heavy water, the development of a new epithermal neutron source using a large fission plate is in progress, which is part of a mockup experiment of an atomic bomb field newly estimated.

  8. FIELD CALIBRATION OF A TLD ALBEDO DOSEMETER IN THE HIGH-ENERGY NEUTRON FIELD OF CERF.

    PubMed

    Haninger, T; Kleinau, P; Haninger, S

    2016-07-15

    The new albedo dosemeter-type AWST-TL-GD 04 has been calibrated in the CERF neutron field (Cern-EU high-energy Reference Field). This type of albedo dosemeter is based on thermoluminescent detectors (TLDs) and used by the individual monitoring service of the Helmholtz Zentrum München (AWST) since 2015 for monitoring persons, who are exposed occupationally against photon and neutron radiation. The motivation for this experiment was to gain a field specific neutron correction factor Nn for workplaces at high-energy particle accelerators. Nn is a dimensionless factor relative to a basic detector calibration with (137)Cs and is used to calculate the personal neutron dose in terms of Hp(10) from the neutron albedo signal. The results show that the sensitivity of the albedo dosemeter for this specific neutron field is not significantly lower as for fast neutrons of a radionuclide source like (252)Cf. The neutron correction factor varies between 0.73 and 1.16 with a midrange value of 0.94. The albedo dosemeter is therefore appropriate to monitor persons, which are exposed at high-energy particle accelerators.

  9. Generation of high-energy neutron beam by fragmentation of relativistic heavy nuclei

    NASA Astrophysics Data System (ADS)

    Yurevich, Vladimir

    2016-09-01

    The phenomenon of multiple production of neutrons in reactions with heavy nuclei induced by high-energy protons and light nuclei is analyzed using a Moving Source Model. The Lorentz transformation of the obtained neutron distributions is used to study the neutron characteristics in the inverse kinematics where relativistic heavy nuclei bombard a light-mass target. The neutron beam generated at 0∘has a Gaussian shape with a maximum at the energy of the projectile nucleons and an energy resolution σE/E < 4% above 6 GeV.

  10. ICF ignition capsule neutron, gamma ray, and high energy x-ray images

    NASA Astrophysics Data System (ADS)

    Bradley, P. A.; Wilson, D. C.; Swenson, F. J.; Morgan, G. L.

    2003-03-01

    Post-processed total neutron, RIF neutron, gamma-ray, and x-ray images from 2D LASNEX calculations of burning ignition capsules are presented. The capsules have yields ranging from tens of kilojoules (failures) to over 16 MJ (ignition), and their implosion symmetry ranges from prolate (flattest at the hohlraum equator) to oblate (flattest towards the laser entrance hole). The simulated total neutron images emphasize regions of high DT density and temperature; the reaction-in-flight neutrons emphasize regions of high DT density; the gamma rays emphasize regions of high shell density; and the high energy x rays (>10 keV) emphasize regions of high temperature.

  11. Biological effects of high-energy neutrons measured in vivo using a vertebrate model.

    PubMed

    Kuhne, Wendy W; Gersey, Brad B; Wilkins, Richard; Wu, Honglu; Wender, Stephen A; George, Varghese; Dynan, William S

    2009-10-01

    Interaction of solar protons and galactic cosmic radiation with the atmosphere and other materials produces high-energy secondary neutrons from below 1 to 1000 MeV and higher. Although secondary neutrons may provide an appreciable component of the radiation dose equivalent received by space and high-altitude air travelers, the biological effects remain poorly defined, particularly in vivo in intact organisms. Here we describe the acute response of Japanese medaka (Oryzias latipes) embryos to a beam of high-energy spallation neutrons that mimics the energy spectrum of secondary neutrons encountered aboard spacecraft and high-altitude aircraft. To determine RBE, embryos were exposed to 0-0.5 Gy of high-energy neutron radiation or 0-15 Gy of reference gamma radiation. The radiation response was measured by imaging apoptotic cells in situ in defined volumes of the embryo, an assay that provides a quantifiable, linear dose response. The slope of the dose response in the developing head, relative to reference gamma radiation, indicates an RBE of 24.9 (95% CI 13.6-40.7). A higher RBE of 48.1 (95% CI 30.0-66.4) was obtained based on overall survival. A separate analysis of apoptosis in muscle showed an overall nonlinear response, with the greatest effects at doses of less than 0.3 Gy. Results of this experiment indicate that medaka are a useful model for investigating biological damage associated with high-energy neutron exposure.

  12. Neutron skin and centrality classification in high-energy heavy-ion collisions at the LHC

    NASA Astrophysics Data System (ADS)

    Paukkunen, Hannu

    2015-05-01

    The concept of centrality in high-energy nuclear collisions has recently become a subject of an active debate. In particular, the experimental methods to determine the centrality that have given reasonable results for many observables in high-energy lead-lead collisions at the LHC have led to surprising behavior in the case of proton-lead collisions. In this letter, we discuss the possibility to calibrate the experimental determination of centrality by asymmetries caused by mutually different spatial distributions of protons and neutrons inside the nuclei - a well-known phenomenon in nuclear physics known as the neutron-skin effect.

  13. Improving the neutron-to-photon discrimination capability of detectors used for neutron dosimetry in high energy photon beam radiotherapy.

    PubMed

    Irazola, L; Terrón, J A; Bedogni, R; Pola, A; Lorenzoli, M; Sánchez-Nieto, B; Gómez, F; Sánchez-Doblado, F

    2016-09-01

    The increasing interest of the medical community to radioinduced second malignancies due to photoneutrons in patients undergoing high-energy radiotherapy, has stimulated in recent years the study of peripheral doses, including the development of some dedicated active detectors. Although these devices are designed to respond to neutrons only, their parasitic photon response is usually not identically zero and anisotropic. The impact of these facts on measurement accuracy can be important, especially in points close to the photon field-edge. A simple method to estimate the photon contribution to detector readings is to cover it with a thermal neutron absorber with reduced secondary photon emission, such as a borated rubber. This technique was applied to the TNRD (Thermal Neutron Rate Detector), recently validated for thermal neutron measurements in high-energy photon radiotherapy. The positive results, together with the accessibility of the method, encourage its application to other detectors and different clinical scenarios.

  14. Computational Transport Modeling of High-Energy Neutrons Found in the Space Environment

    NASA Technical Reports Server (NTRS)

    Cox, Brad; Theriot, Corey A.; Rohde, Larry H.; Wu, Honglu

    2012-01-01

    The high charge and high energy (HZE) particle radiation environment in space interacts with spacecraft materials and the human body to create a population of neutrons encompassing a broad kinetic energy spectrum. As an HZE ion penetrates matter, there is an increasing chance of fragmentation as penetration depth increases. When an ion fragments, secondary neutrons are released with velocities up to that of the primary ion, giving some neutrons very long penetration ranges. These secondary neutrons have a high relative biological effectiveness, are difficult to effectively shield, and can cause more biological damage than the primary ions in some scenarios. Ground-based irradiation experiments that simulate the space radiation environment must account for this spectrum of neutrons. Using the Particle and Heavy Ion Transport Code System (PHITS), it is possible to simulate a neutron environment that is characteristic of that found in spaceflight. Considering neutron dosimetry, the focus lies on the broad spectrum of recoil protons that are produced in biological targets. In a biological target, dose at a certain penetration depth is primarily dependent upon recoil proton tracks. The PHITS code can be used to simulate a broad-energy neutron spectrum traversing biological targets, and it account for the recoil particle population. This project focuses on modeling a neutron beamline irradiation scenario for determining dose at increasing depth in water targets. Energy-deposition events and particle fluence can be simulated by establishing cross-sectional scoring routines at different depths in a target. This type of model is useful for correlating theoretical data with actual beamline radiobiology experiments. Other work exposed human fibroblast cells to a high-energy neutron source to study micronuclei induction in cells at increasing depth behind water shielding. Those findings provide supporting data describing dose vs. depth across a water-equivalent medium. This

  15. Neutron production from flattening filter free high energy medical linac: A Monte Carlo study

    NASA Astrophysics Data System (ADS)

    Najem, M. A.; Abolaban, F. A.; Podolyák, Z.; Spyrou, N. M.

    2015-11-01

    One of the problems arising from using a conventional linac at high energy (>8 MV) is the production of neutrons. One way to reduce neutron production is to remove the flattening filter (FF). The main purpose of this work was to study the effect of FF removal on neutron fluence and neutron dose equivalent inside the treatment room at different photon beam energies. Several simulations based on Monte Carlo techniques were carried out in order to calculate the neutron fluence at different locations in the treatment room from different linac energies with and without a FF. In addition, a step-and-shoot intensity modulated radiotherapy (SnS IMRT) for prostate cancer was modelled using the 15 MV photon beam with and without a FF on a water phantom to calculate the neutron dose received in a full treatment. The results obtained show a significant drop-off in neutrons fluence and dose equivalent when the FF was removed. For example, the neutron fluence was decreased by 54%, 76% and 75% for 10, 15 and 18 MV, respectively. This can decrease the neutron dose to the patient as well as reduce the shielding cost of the treatment room. The neutron dose equivalent of the SnS IMRT for prostate cancer was reduced significantly by 71.3% when the FF was removed. It can be concluded that the flattening filter removal from the head of the linac could reduce the risk of causing secondary cancers and the shielding cost of radiotherapy treatment rooms.

  16. Energy and angular dependence of active-type personal dosemeter for high-energy neutron.

    PubMed

    Rito, Hirotaka; Yamauchi, Tomoya; Oda, Keiji

    2011-07-01

    In order to develop an active-type personal dosemeter having suitable sensitivity to high-energy neutrons, the characteristic response of silicon surface barrier detector has been investigated experimentally and theoretically. An agreement of the shape of pulse-height distribution, its change with radiator thickness and the relative sensitivity was confirmed between the calculated and experimental results for 14.8-MeV neutrons. The angular dependence was estimated for other neutron energies, and found that the angular dependence decreased with the incident energy. The reason was also discussed with regard to the radiator thickness relative to maximum range of recoil protons.

  17. A diamond 14 MeV neutron energy spectrometer with high energy resolution

    SciTech Connect

    Shimaoka, Takehiro Kaneko, Junichi H.; Tsubota, Masakatsu; Shimmyo, Hiroaki; Ochiai, Kentaro; Chayahara, Akiyoshi; Umezawa, Hitoshi; Shikata, Shin-ichi; Watanabe, Hideyuki; Isobe, Mitsutaka; Osakabe, Masaki

    2016-02-15

    A self-standing single-crystal chemical vapor deposited diamond was obtained using lift-off method. It was fabricated into a radiation detector and response function measurements for 14 MeV neutrons were taken at the fusion neutronics source. 1.5% of high energy resolution was obtained by using the {sup 12}C(n, α){sup 9}Be reaction at an angle of 100° with the deuteron beam line. The intrinsic energy resolution, excluding energy spreading caused by neutron scattering, slowing in the target and circuit noises was 0.79%, which was also the best resolution of the diamond detector ever reported.

  18. Monte Carlo calibration of the SMM gamma ray spectrometer for high energy gamma rays and neutrons

    NASA Technical Reports Server (NTRS)

    Cooper, J. F.; Reppin, C.; Forrest, D. J.; Chupp, E. L.; Share, G. H.; Kinzer, R. L.

    1985-01-01

    The Gamma Ray Spectrometer (GRS) on the Solar Maximum Mission spacecraft was primarily designed and calibrated for nuclear gamma ray line measurements, but also has a high energy mode which allows the detection of gamma rays at energies above 10 MeV and solar neutrons above 20 MeV. The GRS response has been extrapolated until now for high energy gamma rays from an early design study employing Monte Carlo calculations. The response to 50 to 600 MeV solar neutrons was estimated from a simple model which did not consider secondary charged particles escaping into the veto shields. In view of numerous detections by the GRS of solar flares emitting high energy gamma rays, including at least two emitting directly detectable neutrons, the calibration of the high energy mode in the flight model has been recalculated by the use of more sophisticated Monte Carlo computer codes. New results presented show that the GRS response to gamma rays above 20 MeV and to neutrons above 100 MeV is significantly lower than the earlier estimates.

  19. Development of high-energy neutron imaging for use in NDE applications

    SciTech Connect

    Dietrich, F; Hall, J; Logan, C; Schmid, G

    1999-06-01

    We are currently developing a high-energy (10 - 15 MeV) neutron imaging system for use in NDE applications. Our goal is to develop an imaging system capable of detecting cubic-mm-scale voids or other structural defects in heavily-shielded low-Z materials within thick sealed objects. The system will be relatively compact (suitable for use in a small laboratory) and capable of acquiring tomographic image data sets. The design of a prototype imaging detector and multi-axis staging system will be discussed and selected results from recent imaging experiments will be presented. The development of an intense, accelerator-driven neutron source suitable for use with the imaging system will also be discussed. Keywords: neutron imaging, neutron radiography, computed tomography, non-destructive inspection, neutron sources

  20. Iodine neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Ahmed, Kazi Fariduddin

    A new technique, Iodine Neutron Capture Therapy (INCT) is proposed to treat hyperthyroidism in people. Present thyroid therapies, surgical removal and 131I treatment, result in hypothyroidism and, for 131I, involve protracted treatment times and excessive whole-body radiation doses. The new technique involves using a low energy neutron beam to convert a fraction of the natural iodine stored in the thyroid to radioactive 128I, which has a 24-minute half-life and decays by emitting 2.12-MeV beta particles. The beta particles are absorbed in and damage some thyroid tissue cells and consequently reduce the production and release of thyroid hormones to the blood stream. Treatment times and whole-body radiation doses are thus reduced substantially. This dissertation addresses the first of the several steps needed to obtain medical profession acceptance and regulatory approval to implement this therapy. As with other such programs, initial feasibility is established by performing experiments on suitable small mammals. Laboratory rats were used and their thyroids were exposed to the beta particles coming from small encapsulated amounts of 128I. Masses of 89.0 mg reagent-grade elemental iodine crystals have been activated in the ISU AGN-201 reactor to provide 0.033 mBq of 128I. This activity delivers 0.2 Gy to the thyroid gland of 300-g male rats having fresh thyroid tissue masses of ˜20 mg. Larger iodine masses are used to provide greater doses. The activated iodine is encapsulated to form a thin (0.16 cm 2/mg) patch that is then applied directly to the surgically exposed thyroid of an anesthetized rat. Direct neutron irradiation of a rat's thyroid was not possible due to its small size. Direct in-vivo exposure of the thyroid of the rat to the emitted radiation from 128I is allowed to continue for 2.5 hours (6 half-lives). Pre- and post-exposure blood samples are taken to quantify thyroid hormone levels. The serum T4 concentration is measured by radioimmunoassay at

  1. Neutron dose measurements with the GSI ball at high-energy accelerators.

    PubMed

    Fehrenbacher, G; Gutermuth, F; Kozlova, E; Radon, T; Schuetz, R

    2007-01-01

    A moderator-type neutron monitor containing pairs of TLD 600/700 elements (Harshaw) modified with the addition of a lead layer (GSI ball) for the measurement of the ambient dose equivalent from neutrons at medium- and high-energy accelerators, is introduced in this work. Measurements were performed with the Gesellschaft für Schwerionenforschung (GSI) ball as well as with conventional polyethylene (PE) spheres at the high-energy accelerator SPS at European Organization for Nuclear Research [CERN (CERF)] and in Cave A of the heavy-ion synchrotron SIS at GSI. The measured dose values are compared with dose values derived from calculated neutron spectra folded with dose conversion coefficients. The estimated reading of the spheres calculated by means of the response functions and the neutron spectra is also included in the comparison. The analysis of the measurements shows that the PE/Pb sphere gives an improved estimate on the ambient dose equivalent of the neutron radiation transmitted through shielding of medium- and high-energy accelerators.

  2. High-energy neutron dosimetry at the Clinton P. Anderson Meson Physics Facility

    SciTech Connect

    Mallett, M.W.; Vasilik, D.G.; Littlejohn, G.J.; Cortez, J.R.

    1990-01-01

    Neutron energy spectrum measurements performed at the Clinton P. Anderson Meson Physics Facility indicated potential areas for high energy neutron exposure to personnel. The low sensitivity of the Los Alamos thermoluminescent dosimeter (TLD) to high energy neutrons warranted issuing a NTA dosimeter in addition to the TLD badge to employees entering these areas. The dosimeter consists of a plastic holder surrounding NTA film that has been desiccated and sealed in a dry nitrogen environment. A study of the fading of latent images in NTA film demonstrated the success of this packaging method to control the phenomenon. The Los Alamos NTA dosimeter is characterized and the fading study discussed. 10 refs., 4 figs., 2 tabs.

  3. Liquid lithium target as a high intensity, high energy neutron source

    DOEpatents

    Parkin, Don M.; Dudey, Norman D.

    1976-01-01

    This invention provides a target jet for charged particles. In one embodiment the charged particles are high energy deuterons that bombard the target jet to produce high intensity, high energy neutrons. To this end, deuterons in a vacuum container bombard an endlessly circulating, free-falling, sheet-shaped, copiously flowing, liquid lithium jet that gushes by gravity from a rectangular cross-section vent on the inside of the container means to form a moving web in contact with the inside wall of the vacuum container. The neutrons are produced via break-up of the beam in the target by stripping, spallation and compound nuclear reactions in which the projectiles (deuterons) interact with the target (Li) to produce excited nuclei, which then "boil off" or evaporate a neutron.

  4. DT High Energy Measurements and Comparison of Multiple Spectra in a He-4 Gas Neutron Detector

    NASA Astrophysics Data System (ADS)

    Gardiner, Hannah E.; Zhu, Ting; Gokhale, Sasmit; Parker, Cody; Richard, Andrea; Massey, Thomas; Baciak, James E.; Enqvisst, Andreas; Jordan, Kelly A.

    2016-09-01

    Neutron spectroscopy is important for a variety of applications to nuclear energy, national security, and basic science research. Currently, organic scintillator neutron detectors are used as a diagnostic tool for neutron spectroscopy in DT fusion research. However, these neutron measurements generate contaminants in common organics from deuteron or carbon break-up that affects the light output spectrum. A potential solution to this problem is to use a He-4 fast neutron gas scintillator detector system. He-4 has excellent gamma rejection due to a low charge density, pulse shape discrimination, and lower light yield and deposited energy from gamma interactions. The detector will also not degrade due to high intensity background gamma radiation. The detector was irradiated with 14.1 MeV neutrons at the Edwards Accelerator Lab at Ohio University. We report on the effectiveness of the He-4 detector system to measure the resulting high energy neutrons and compare this spectrum to other neutron spectra taken with this detector.

  5. Micronuclei Induction in Human Fibroblasts Exposed In Vitro to Los Alamos High-Energy Neutrons

    NASA Technical Reports Server (NTRS)

    Gersey, Brad; Sodolak, John; Hada, Megumi; Saganti, Prem; Wilkins, Richard; Cucinotta, Francis; Wu, Honglu

    2006-01-01

    High-energy secondary neutrons, produced by the interaction of galactic cosmic rays with the atmosphere, spacecraft structure and planetary surfaces, contribute to a significant fraction to the dose equivalent in crew members and passengers during commercial aviation travel, and astronauts in space missions. The Los Alamos Nuclear Science Center (LANSCE) neutron facility#s ICE House 30L beamline is known to generate neutrons that simulate the secondary neutron spectra of earth#s atmosphere. The neutron spectrum is also similar to that measured onboard spacecraft like the MIR and International Space Station (ISS). To evaluate the biological damage, we exposed human fibroblasts in vitro to the LANSCE neutron beams without degrader at an entrance dose rate of 25 mGy/hr and analyzed the micronuclei (MN) induction. The cells were also placed behind a 9.9 cm water column to study effect of shielding in the protection of neutron induced damages. It was found that the dose response in the MN frequency was linear for the samples with and without shielding and the slope of the MN yield behind the shielding was reduced by a factor of 3.5. Compared to the MN induction in human fibroblasts exposed to a gamma source at a low dose rate, the RBE was found to be 16.7 and 10.0 for the neutrons without and with 9.9 cm water shielding, respectively.

  6. Demonstrating a directional detector based on neon for characterizing high energy neutrons

    NASA Astrophysics Data System (ADS)

    Hexley, Allie

    2016-03-01

    MITPC is a gas-based time projection chamber used for detecting fast, MeV-scale neutrons. The standard version of the detector relies on a mixture of 600 torr gas composed of 87.5% helium-4 and 12.5% tetrafluoromethane for precisely measuring the energy and direction of neutron-induced nuclear recoils. I describe studies performed with a prototype detector investigating the use of neon, as a replacement for helium-4, in the gas mixture. My discussion focuses on the advantages of neon as the fast neutron target for high energy neutron events (100 MeV) and a demonstration that the mixture will be effective for this event class. I show that the achievable gain and transverse diffusion of drifting electrons in the neon mixture are acceptable and that the detector uptime lost due to voltage breakdowns in the amplification plane is negligible, compared to 20% with the helium-4 mixture.

  7. Induction of Micronuclei in Human Fibroblasts from the Los Alamos High Energy Neutron Beam

    NASA Technical Reports Server (NTRS)

    Cox, Bradley

    2009-01-01

    The space radiation field includes a broad spectrum of high energy neutrons. Interactions between these neutrons and a spacecraft, or other material, significantly contribute to the dose equivalent for astronauts. The 15 degree beam line in the Weapons Neutron Research beam at Los Alamos Nuclear Science Center generates a neutron spectrum relatively similar to that seen in space. Human foreskin fibroblast (AG1522) samples were irradiated behind 0 to 20 cm of water equivalent shielding. The cells were exposed to either a 0.05 or 0.2 Gy entrance dose. Following irradiation, micronuclei were counted to see how the water shield affects the beam and its damage to cell nuclei. Micronuclei induction was then compared with dose equivalent data provided from a tissue equivalent proportional counter.

  8. Neutron dose per fluence and weighting factors for use at high energy accelerators.

    PubMed

    Cossairt, J Donald; Vaziri, Kamran

    2009-06-01

    In June 2007, the United States Department of Energy incorporated revised values of neutron weighting factors into its occupational radiation protection regulation Title 10, Code of Federal Regulations Part 835, as part of updating its radiation dosimetry system. This has led to a reassessment of neutron radiation fields at high energy accelerators such as those at the Fermi National Accelerator Laboratory (Fermilab) in the context of the amended regulation and contemporary guidance of the International Commission on Radiological Protection (ICRP). Values of dose per fluence factors appropriate for accelerator radiation fields calculated elsewhere are collated and radiation weighting factors compared. The results of this revision to the dosimetric system are applied to americium-beryllium neutron energy spectra commonly used for instrument calibrations. Also, a set of typical accelerator neutron energy spectra previously measured at Fermilab are reassessed in light of the new dosimetry system. The implications of this revision and of recent ICRP publications are found to be of moderate significance.

  9. Neutron dose per fluence and weighting factors for use at high energy accelerators

    SciTech Connect

    Cossairt, J.Donald; Vaziri, Kamran; /Fermilab

    2008-07-01

    In June 2007, the United States Department of Energy incorporated revised values of neutron weighting factors into its occupational radiation protection Regulation 10 CFR Part 835 as part of updating its radiation dosimetry system. This has led to a reassessment of neutron radiation fields at high energy proton accelerators such as those at the Fermi National Accelerator Laboratory (Fermilab). Values of dose per fluence factors appropriate for accelerator radiation fields calculated elsewhere are collated and radiation weighting factors compared. The results of this revision to the dosimetric system are applied to americium-beryllium neutron energy spectra commonly used for instrument calibrations. A set of typical accelerator neutron energy spectra previously measured at Fermilab are reassessed in light of the new dosimetry system. The implications of this revision are found to be of moderate significance.

  10. High energy neutron treatment for pelvic cancers: study stopped because of increased mortality.

    PubMed Central

    Errington, R D; Ashby, D; Gore, S M; Abrams, K R; Myint, S; Bonnett, D E; Blake, S W; Saxton, T E

    1991-01-01

    OBJECTIVE--To compare high energy fast neutron treatment with conventional megavoltage x ray treatment in the management of locally advanced pelvic carcinomas (of the cervix, bladder, prostate, and rectum). DESIGN--Randomised study from February 1986; randomisation to neutron treatment or photon treatment was unstratified and in the ratio of 3 to 1 until January 1988, when randomisation was in the ratio 1 to 1 and stratified by site of tumour. SETTING--Mersey regional radiotherapy centre at Clatterbridge Hospital, Wirral. PATIENTS--151 patients with locally advanced, non-metastatic pelvic cancer (27 cervical, 69 of the bladder, seven prostatic, and 48 of the rectum). INTERVENTION--Randomisation to neutron treatment was stopped in February 1990. MAIN OUTCOME MEASURES--Patient survival and causes of death in relation to the development of metastatic disease and treatment related morbidity. RESULTS--In the first phase of the trial 42 patients were randomised to neutron treatment and 14 to photon treatment, and in the second phase 48 to neutron treatment and 47 to photon treatment. The relative risk of mortality for photons compared with neutrons was 0.66 (95% confidence interval 0.40 to 1.10) after adjustment for site of tumour and other important prognostic factors. Short term and long term complications were similar in both groups. CONCLUSIONS--The trial was stopped because of the increased mortality in patients with cancer of the cervix, bladder, or rectum treated with neutrons. PMID:1903663

  11. Superconducting gamma and fast-neutron spectrometers with high energy resolution

    DOEpatents

    Friedrich, Stephan; , Niedermayr, Thomas R.; Labov, Simon E.

    2008-11-04

    Superconducting Gamma-ray and fast-neutron spectrometers with very high energy resolution operated at very low temperatures are provided. The sensor consists of a bulk absorber and a superconducting thermometer weakly coupled to a cold reservoir, and determines the energy of the incident particle from the rise in temperature upon absorption. A superconducting film operated at the transition between its superconducting and its normal state is used as the thermometer, and sensor operation at reservoir temperatures around 0.1 K reduces thermal fluctuations and thus enables very high energy resolution. Depending on the choice of absorber material, the spectrometer can be configured either as a Gamma-spectrometer or as a fast-neutron spectrometer.

  12. Neutron beam design, development, and performance for neutron capture therapy

    SciTech Connect

    Harling, O.K.; Bernard, J.A. ); Zamenhof, R.G. )

    1990-01-01

    The report presents topics presented at a workshop on neutron beams and neutron capture therapy. Topics include: neutron beam design; reactor-based neutron beams; accelerator-based neutron beams; and dosimetry and treatment planning. Individual projects are processed separately for the databases. (CBS)

  13. Magnetized neutron stars as gamma-ray bursters - Detection rates at high energies

    NASA Technical Reports Server (NTRS)

    Meszaros, P.; Bagoly, Z.; Riffert, H.

    1989-01-01

    Detailed calculations of the escape of high-energy gamma-rays from the dipolar magnetosphere of general relativistic neutron star models are used to model the detection rate of bursters at high photon energies between 0.3 and 10 MeV. This analysis shows the SMM detection rates to be compatible with a magnetized neutron star origin, with a distribution of magnetic field strengths extending at least up to about 4 x 10 to the 12th G, as expected if the (20-60) keV features reported from Konus and Ginga measurements are interpreted as cyclotron lines. Additional implications are discussed for the emission geometry and the neutron star radius.

  14. Neutron dosimetry in boron neutron capture therapy

    SciTech Connect

    Fairchild, R.G.; Miola, U.J.; Ettinger, K.V.

    1981-01-01

    The recent development of various borated compounds and the utilization of one of these (Na/sub 2/B/sub 12/H/sub 11/SH) to treat brain tumors in clinical studies in Japan has renewed interest in neutron capture therapy. In these procedures thermal neutrons interact with /sup 10/B in boron containing cells through the /sup 10/B(n,..cap alpha..)/sup 7/Li reaction producing charged particles with a maximum range of approx. 10..mu..m in tissue. Borated analogs of chlorpromazine, porphyrin, thiouracil and deoxyuridine promise improved tumor uptake and blood clearance. The therapy beam from the Medical Research Reactor in Brookhaven contains neutrons from a modified and filtered fission spectrum and dosimetric consequences of the use of the above mentioned compounds in conjunction with thermal and epithermal fluxes are discussed in the paper. One of the important problems of radiation dosimetry in capture therapy is determination of the flux profile and, hence, the dose profile in the brain. This has been achieved by constructing a brain phantom made of TE plastic. The lyoluminescence technique provides a convenient way of monitoring the neutron flux distributions; the detectors for this purpose utilize /sup 6/Li and /sup 10/B compounds. Such compounds have been synthesized specially for the purpose of dosimetry of thermal and epithermal beams. In addition, standard lyoluminescent phosphors, like glutamine, could be used to determine the collisional component of the dose as well as the contribution of the /sup 14/N(n,p)/sup 14/C reaction. Measurements of thermal flux were compared with calculations and with measurements done with activation foils.

  15. A Monte Carlo model for out-of-field dose calculation from high-energy photon therapy.

    PubMed

    Kry, Stephen F; Titt, Uwe; Followill, David; Pönisch, Falk; Vassiliev, Oleg N; White, R Allen; Stovall, Marilyn; Salehpour, Mohammad

    2007-09-01

    As cancer therapy becomes more efficacious and patients survive longer, the potential for late effects increases, including effects induced by radiation dose delivered away from the treatment site. This out-of-field radiation is of particular concern with high-energy radiotherapy, as neutrons are produced in the accelerator head. We recently developed an accurate Monte Carlo model of a Varian 2100 accelerator using MCNPX for calculating the dose away from the treatment field resulting from low-energy therapy. In this study, we expanded and validated our Monte Carlo model for high-energy (18 MV) photon therapy, including both photons and neutrons. Simulated out-of-field photon doses were compared with measurements made with thermoluminescent dosimeters in an acrylic phantom up to 55 cm from the central axis. Simulated neutron fluences and energy spectra were compared with measurements using moderated gold foil activation in moderators and data from the literature. The average local difference between the calculated and measured photon dose was 17%, including doses as low as 0.01% of the central axis dose. The out-of-field photon dose varied substantially with field size and distance from the edge of the field but varied little with depth in the phantom, except at depths shallower than 3 cm, where the dose sharply increased. On average, the difference between the simulated and measured neutron fluences was 19% and good agreement was observed with the neutron spectra. The neutron dose equivalent varied little with field size or distance from the central axis but decreased with depth in the phantom. Neutrons were the dominant component of the out-of-field dose equivalent for shallow depths and large distances from the edge of the treatment field. This Monte Carlo model is useful to both physicists and clinicians when evaluating out-of-field doses and associated potential risks.

  16. Multigroup neutron dose calculations for proton therapy

    SciTech Connect

    Kelsey Iv, Charles T; Prinja, Anil K

    2009-01-01

    We have developed tools for the preparation of coupled multigroup proton/neutron cross section libraries. Our method is to use NJOY to process evaluated nuclear data files for incident particles below 150 MeV and MCNPX to produce data for higher energies. We modified the XSEX3 program of the MCNPX code system to produce Legendre expansions of scattering matrices generated by sampling the physics models that are comparable to the output of the GROUPR routine of NJOY. Our code combines the low and high energy scattering data with user input stopping powers and energy deposition cross sections that we also calculated using MCNPX. Our code also calculates momentum transfer coefficients for the library and optionally applies an energy straggling model to the scattering cross sections and stopping powers. The motivation was initially for deterministic solution of space radiation shielding calculations using Attila, but noting that proton therapy treatment planning may neglect secondary neutron dose assessments because of difficulty and expense, we have also investigated the feasibility of multi group methods for this application. We have shown that multigroup MCNPX solutions for secondary neutron dose compare well with continuous energy solutions and are obtainable with less than half computational cost. This efficiency comparison neglects the cost of preparing the library data, but this becomes negligible when distributed over many multi group calculations. Our deterministic calculations illustrate recognized obstacles that may have to be overcome before discrete ordinates methods can be efficient alternatives for proton therapy neutron dose calculations.

  17. The 12B counter: an active dosemeter for high-energy neutrons.

    PubMed

    Leuschner, A

    2005-01-01

    High-energy accelerators can produce strong time-structured radiation fields. Such dose shots are generated at linear machines with low duty cycles as well as at circular machines when complete fills are instantaneously lost. The main dose component behind thick shielding is due to high-energy neutrons occurring at that time structure. Dosemeters based on Geiger-Mueller tubes or proportional counters fail here completely. The 12B counter, a novel dosemeter made of a plastic scintillator using carbon activation for event-like exposure, has been introduced. High-energy neutrons activate the carbon nuclei by three inelastic reactions. The decay patterns with half-lives between 20 ms and 20 min can be exploited depending on the time structure of the radiation field. The response of the 12B counter was measured along with some other dosemeters, both active and passive, in the radiation field behind the lateral concrete shielding of a 7.5 GeV proton transfer line.

  18. Gadolinium-doped water cerenkov-based neutron and high energy gamma-ray detector and radiation portal monitoring system

    DOEpatents

    Dazeley, Steven A; Svoboda, Robert C; Bernstein, Adam; Bowden, Nathaniel

    2013-02-12

    A water Cerenkov-based neutron and high energy gamma ray detector and radiation portal monitoring system using water doped with a Gadolinium (Gd)-based compound as the Cerenkov radiator. An optically opaque enclosure is provided surrounding a detection chamber filled with the Cerenkov radiator, and photomultipliers are optically connected to the detect Cerenkov radiation generated by the Cerenkov radiator from incident high energy gamma rays or gamma rays induced by neutron capture on the Gd of incident neutrons from a fission source. The PMT signals are then used to determine time correlations indicative of neutron multiplicity events characteristic of a fission source.

  19. Apparatus, Method and Program Storage Device for Determining High-Energy Neutron/Ion Transport to a Target of Interest

    NASA Technical Reports Server (NTRS)

    Wilson, John W. (Inventor); Tripathi, Ram K. (Inventor); Badavi, Francis F. (Inventor); Cucinotta, Francis A. (Inventor)

    2012-01-01

    An apparatus, method and program storage device for determining high-energy neutron/ion transport to a target of interest. Boundaries are defined for calculation of a high-energy neutron/ion transport to a target of interest; the high-energy neutron/ion transport to the target of interest is calculated using numerical procedures selected to reduce local truncation error by including higher order terms and to allow absolute control of propagated error by ensuring truncation error is third order in step size, and using scaling procedures for flux coupling terms modified to improve computed results by adding a scaling factor to terms describing production of j-particles from collisions of k-particles; and the calculated high-energy neutron/ion transport is provided to modeling modules to control an effective radiation dose at the target of interest.

  20. Disk-accreting magnetic neutron stars as high-energy particle accelerators

    NASA Technical Reports Server (NTRS)

    Hamilton, Russell J.; Lamb, Frederick K.; Miller, M. Coleman

    1994-01-01

    Interaction of an accretion disk with the magnetic field of a neutron star produces large electromotive forces, which drive large conduction currents in the disk-magnetosphere-star circuit. Here we argue that such large conduction currents will cause microscopic and macroscopic instabilities in the magnetosphere. If the minimum plasma density in the magnetosphere is relatively low is less than or aproximately 10(exp 9)/cu cm, current-driven micro-instabilities may cause relativistic double layers to form, producing voltage differences in excess of 10(exp 12) V and accelerating charged particles to very high energies. If instead the plasma density is higher (is greater than or approximately = 10(exp 9)/cu cm, twisting of the stellar magnetic field is likely to cause magnetic field reconnection. This reconnection will be relativistic, accelerating plasma in the magnetosphere to relativistic speeds and a small fraction of particles to very high energies. Interaction of these high-energy particles with X-rays, gamma-rays, and accreting plasma may produce detectable high-energy radiation.

  1. The Fascinating High-Energy World of Neutron Stars and Supernova Remnants

    NASA Astrophysics Data System (ADS)

    Safi-Harb, Samar

    2006-06-01

    The past few years have witnessed a fast growth in the high-energy astrophysics community in Canada, thanks to new opportunities including the University Faculty Award (UFA) program introduced by the Natural Sciences and Engineering Research Council of Canada (NSERC) to appoint promising female researchers to faculty positions in science and engineering. As a UFA fellow at the University of Manitoba, I have had the unique opportunity to contribute to the launch of a new astronomy program in the department of Physics (renamed to Physics and Astronomy). My research focuses on observational studies of neutron stars, pulsar wind nebulae, and supernova remnants. The study of these exotic objects helps address the physics of the extreme and probe some of the most energetic events in the Universe. I will highlight exciting discoveries in this field and some of the questions to be addressed with current and future high-energy missions.

  2. Hexagonal boron nitride thin film thermal neutron detectors with high energy resolution of the reaction products

    NASA Astrophysics Data System (ADS)

    Doan, T. C.; Majety, S.; Grenadier, S.; Li, J.; Lin, J. Y.; Jiang, H. X.

    2015-05-01

    Hexagonal boron nitride (h-BN) is highly promising for solid-state thermal neutron detector applications due to its many outstanding physical properties, especially its very large thermal neutron capture cross-section (~3840 barns for 10B), which is several orders of magnitude larger than those of most other isotopes. The focus of the present work is to carry out studies on h-BN thin film and detector properties to lay the foundation for the development of a direct-conversion solid-state thermal neutron detector with high sensitivity. The measured carrier mobility-lifetime (μτ) product of h-BN thin films grown on sapphire substrates is 2.83×10-7 cm2/V for electrons and holes, which is comparable to the value of about 10-7 cm2/V for GaN thin films grown on sapphire. Detectors based on h-BN thin films were fabricated and the nuclear reaction product pulse height spectra were measured. Under a bias of 20 V, very narrow individual peaks corresponding to the reaction product energies of α and Li particles as well as the sum peaks have been clearly resolved in the pulse height spectrum for the first time by a B-based direct-conversion semiconductor neutron detector. Our results indicate that h-BN thin film detectors possess unique advantages including small size, low weight, portability, low voltage operation and high energy resolution of specific reaction products.

  3. 90° Neutron emission from high energy protons and lead ions on a thin lead target

    NASA Astrophysics Data System (ADS)

    Agosteo, S.; Birattari, C.; Foglio Para, A.; Mitaroff, A.; Silari, M.; Ulrici, L.

    2002-01-01

    The neutron emission from a relatively thin lead target bombarded by beams of high energy protons/pions and lead ions was measured at CERN in one of the secondary beam lines of the Super Proton Synchrotron for radiation protection and shielding calculations. Measurements were performed with three different beams: 208Pb 82+ lead ions at 40 GeV/ c per nucleon and 158 GeV/ c per nucleon, and 40 GeV/ c mixed protons/pions. The neutron yield and spectral fluence per incident ion on target were measured at 90° with respect to beam direction. Monte-Carlo simulations with the FLUKA code were performed for the case of protons and pions and the results found in good agreement with the experimental data. A comparison between simulations and experiment for protons, pions and lead ions have shown that—for such high energy heavy ion beams—a reasonable estimate can be carried out by scaling the result of a Monte-Carlo calculation for protons by the projectile mass number to the power of 0.80-0.84.

  4. Calibration of a Bonner sphere extension (BSE) for high-energy neutron spectrometry

    PubMed Central

    Howell, R.M.; Burgett, E.A.; Wiegel, B.; Hertel, N.E.

    2011-01-01

    In a recent work, we constructed modular multisphere system which expands upon the design of an existing, commercially available Bonner sphere system by adding concentric shells of copper, tungsten, or lead. Our modular multisphere system is referred to as the Bonner Sphere Extension (BSE). The BSE was tested in a high energy neutron beam (thermal to 800 MeV) at Los Alamos Neutron Science Center and provided improvement in the measurement of the neutron spectrum in the energy regions above 20 MeV when compared to the standard BSS (Burgett, 2008 and Howell et al., 2009). However, when the initial test of the system was carried-out at LANSCE, the BSE had not yet been calibrated. Therefore the objective of the present study was to perform calibration measurements. These calibration measurements were carried out using monoenergetic neutron ISO 8529-1 reference beams at the Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany. The following monoenergetic reference beams were used for these experiments: 14.8 MeV, 1.2 MeV, 565 keV, and 144 keV. Response functions for the BSE were calculated using the Monte Carlo N-Particle Code, eXtended (MCNPX). The percent difference between the measured and calculated responses was calculated for each sphere and energy. The difference between measured and calculated responses for individual spheres ranged between 7.9 % and 16.7 % and the arithmetic mean for all spheres was (10.9 ± 1.8) %. These sphere specific correction factors will be applied for all future measurements carried-out with the BSE. PMID:22888283

  5. Arrangement of high-energy neutron irradiation field and shielding experiment using 4 m concrete at KENS.

    PubMed

    Nakao, N; Yashima, H; Kawai, M; Oishi, K; Nakashima, H; Masumoto, K; Matsumura, H; Sasaki, S; Numajiri, M; Sanami, T; Wang, Q; Toyoda, A; Takahashi, K; Iijima, K; Eda, K; Ban, S; Hirayama, H; Muto, S; Nunomiya, T; Yonai, S; Rasolonjatovo, D R H; Terunuma, K; Yamauchi, K; Sarkar, P K; Kim, E; Nakamura, T; Maruhashi, A

    2005-01-01

    An irradiation field of high-energy neutrons produced in the forward direction from a thick tungsten target bombarded by 500 MeV protons was arranged at the KENS spallation neutron source facility. In this facility, shielding experiment was performed with an ordinary concrete shield of 4 m thickness assembled in the irradiation room, 2.5 m downstream from the target centre. Activation detectors of bismuth, aluminium, indium and gold were inserted into eight slots inside the shield and attenuations of neutron reaction rates were obtained by measurements of gamma-rays from the activation detectors. A MARS14 Monte Carlo simulation was also performed down to thermal energy, and comparisons between the calculations and measurements show agreements within a factor of 3. This neutron field is useful for studies of shielding, activation and radiation damage of materials for high-energy neutrons, and experimental data are useful to check the accuracies of the transmission and activation calculation codes.

  6. Workshop on neutron capture therapy

    SciTech Connect

    Fairchild, R.G.; Bond, V.P.

    1986-01-01

    Potentially optimal conditions for Neutron Capture Therapy (NCT) may soon be in hand due to the anticipated development of band-pass filtered beams relatively free of fast neutron contaminations, and of broadly applicable biomolecules for boron transport such as porphyrins and monoclonal antibodies. Consequently, a number of groups in the US are now devoting their efforts to exploring NCT for clinical application. The purpose of this Workshop was to bring these groups together to exchange views on significant problems of mutual interest, and to assure a unified and effective approach to the solutions. Several areas of preclinical investigation were deemed to be necessary before it would be possible to initiate clinical studies. As neither the monomer nor the dimer of sulfhydryl boron hydride is unequivocally preferable at this time, studies on both compounds should be continued until one is proven superior.

  7. Contribution to Neutron Fluence and Neutron Absorbed Dose from Double Scattering Proton Therapy System Components

    PubMed Central

    Pérez-Andújar, A.; Newhauser, W. D.; DeLuca, P. M.

    2010-01-01

    Proton therapy offers low integral dose and good tumor comformality in many deep-seated tumors. However, secondary particles generated during proton therapy, such as neutrons, are a concern, especially for passive scattering systems. In this type of system, the proton beam interacts with several components of the treatment nozzle that lie along the delivery path and can produce secondary neutrons. Neutron production along the beam's central axis in a double scattering passive system was examined using Monte Carlo simulations. Neutron fluence and energy distribution were determined downstream of the nozzle's major components at different radial distances from the central axis. In addition, the neutron absorbed dose per primary proton around the nozzle was investigated. Neutron fluence was highest immediately downstream of the range modulator wheel (RMW) but decreased as distance from the RMW increased. The nozzle's final collimator and snout also contributed to the production of high-energy neutrons. In fact, for the smallest treatment volume simulated, the neutron absorbed dose per proton at isocenter increased by a factor of 20 due to the snout presence when compared with a nozzle without a snout. The presented results can be used to design more effective local shielding components inside the treatment nozzle as well as to better understand the treatment room shielding requirements. PMID:20871789

  8. Applicability of the two-angle differential method to response measurement of neutron-sensitive devices at the RCNP high-energy neutron facility

    NASA Astrophysics Data System (ADS)

    Masuda, Akihiko; Matsumoto, Tetsuro; Iwamoto, Yosuke; Hagiwara, Masayuki; Satoh, Daiki; Sato, Tatsuhiko; Iwase, Hiroshi; Yashima, Hiroshi; Nakane, Yoshihiro; Nishiyama, Jun; Shima, Tatsushi; Tamii, Atsushi; Hatanaka, Kichiji; Harano, Hideki; Nakamura, Takashi

    2017-03-01

    Quasi-monoenergetic high-energy neutron fields induced by 7Li(p,n) reactions are used for the response evaluation of neutron-sensitive devices. The quasi-monoenergetic high-energy field consists of high-energy monoenergetic peak neutrons and unwanted continuum neutrons down to the low-energy region. A two-angle differential method has been developed to compensate for the effect of the continuum neutrons in the response measurements. In this study, the two-angle differential method was demonstrated for Bonner sphere detectors, which are typical examples of moderator-based neutron-sensitive detectors, to investigate the method's applicability and its dependence on detector characteristics. Experiments were performed under 96-387 MeV quasi-monoenergetic high-energy neutron fields at the Research Center for Nuclear Physics (RCNP), Osaka University. The measurement results for large high-density polyethylene (HDPE) sphere detectors agreed well with Monte Carlo calculations, which verified the adequacy of the two-angle differential method. By contrast, discrepancies were observed in the results for small HDPE sphere detectors and metal-induced sphere detectors. The former indicated that detectors that are particularly sensitive to low-energy neutrons may be affected by penetrating neutrons owing to the geometrical features of the RCNP facility. The latter discrepancy could be consistently explained by a problem in the evaluated cross-section data for the metals used in the calculation. Through those discussions, the adequacy of the two-angle differential method was experimentally verified, and practical suggestions were made pertaining to this method.

  9. Neutron capture therapy for melanoma

    SciTech Connect

    Coderre, J.A.; Glass, J.D.; Micca, P.; Fairchild, R.G.

    1988-01-01

    The development of boron-containing compounds which localize selectively in tumor may require a tumor-by-tumor type of approach that exploits any metabolic pathways unique to the particular type of tumor. Melanin-producing melanomas actively transport and metabolize aromatic amino acids for use as precursors in the synthesis of the pigment melanin. It has been shown that the boron-containing amino acid analog p-borono-phenylalanine (BPA) is selectively accumulated in melanoma tissue, producing boron concentrations in tumor that are within the range estimated to be necessary for successful boron neutron capture therapy (BNCT). We report here the results of therapy experiments carried out at the Brookhaven Medical Research Reactor (BMRR). 21 refs., 5 figs., 3 tabs.

  10. A hospital-based proton linac for neutron therapy and radioisotope production

    SciTech Connect

    Lennox, A.J.

    1988-10-01

    Fermilab's Alvarez proton linac has been used routinely for neutron therapy since 1976. The Neutron Therapy Facility (NTF) operates in a mode parasitic to the laboratory's high energy physics program, which uses the linac as an injector for a synchrotron. Parasitic operation is possible because the linac delivers /approximately/1.2 /times/ 10/sup 13/ protons per pulse at a 15 Hz rate, while the high energy physics program requires beam at a rate not greater than 0.5 Hz. Protons not needed for physics experiments strike a beryllium target to produce neutrons for neutron therapy. Encouraging clinical results from NTF have led to a study of the issues involved in providing hospitals with a neutron beam of the type available at Fermilab. This paper describes the issues addressed by that study. 12 refs., 1 fig., 1 tab.

  11. Workplace characterisation in mixed neutron-gamma fields, specific requirements and available methods at high-energy accelerators.

    PubMed

    Silari, Marco

    2007-01-01

    A good knowledge of the radiation field present outside the shielding of high-energy particle accelerators is very important to be able to select the type of detectors (active and/or passive) to be employed for area monitoring and the type of personal dosemeter required for estimating the doses received by individuals. Around high-energy electron and proton accelerators the radiation field is usually dominated by neutrons and photons, with minor contributions from other charged particles. Under certain circumstances, muon radiation in the forward beam direction may also be present. Neutron dosimetry and spectrometry are of primary importance to characterise the radiation field and thus to correctly evaluate personnel exposure. Starting from the beam parameters important for radiation monitoring, the paper first briefly reviews the stray radiation fields encountered around high-energy accelerators and then addresses the relevant techniques employed for their monitoring. Recent developments to increase the response of neutron measuring devices beyond 10-20 MeV are illustrated. Instruments should be correctly calibrated either in reference monoenergetic radiation fields or in a field similar to the field in which they are used (workplace calibration). The importance of the instrument calibration is discussed and available neutron calibration facilities are briefly reviewed.

  12. High-energy focussed extracorporeal shockwave therapy reduces pain in plantar fibromatosis (Ledderhose’s disease)

    PubMed Central

    2012-01-01

    Background Plantar fibromatosis is a benign disease creating nodules on the medial plantar side of affected patients. While surgical removal is regarded as the therapeutic mainstay, recurrence rates and impairment of daily activities remains substantial. High-energy focussed extracorporeal shockwave therapy has been suggested to be potentially effective in plantar fibromatosis in terms of pain reduction. Hypothesis High-energy focussed extracorporeal shockwave therapy reduces pain in plantar fibromatosis. Findings A total number of six patients (5 males, 58±4 years) were included with plantar fibromatosis (Ledderhose’s disease) associated with pain. Three patients were operated on previously, one had concomitant Dupuytren’s contracture. High-energy focussed ESWT was applied using a Storz Duolith SD1 (2000 impulses, 3 Hz, 1.24 mJ/mm2) in two sessions with 7 days between. Pain was 6±2 at baseline, 2±1 after 14 days and 1±1 after 3 months. Softening of the nodules was noted by all patients. No adverse effects were noted. Conclusions High-energy focussed extracorporeal shockwave energy reduces pain in painful plantar fibromatosis (Morbus Ledderhose). Further large-scale prospective trials are warranted to elucidate the value of high-energy focussed extracorporeal shockwave therapy (ESWT) in plantar fibromatosis in terms of recurrence and efficacy. PMID:23031080

  13. Monte Carlo characterizations mapping of the (γ,n) and (n,γ) photonuclear reactions in the high energy X-ray radiation therapy

    PubMed Central

    Ghiasi, Hosein

    2013-01-01

    Aim The aim of this work was to map the characteristics of (n,γ) and (γ,n) reactions in a high energy photon radiation therapy. Background Photoneutrons produced in the high energy X-Ray radiation therapy may damage patients and staff. It is due to high RBE of the produced neutrons according to their energy and isotropic emission. Characterization of the photoneutrons can help us in appropriate shielding. Materials and methods This study focused on the photoneutron and capture gamma ray phenomena. Characteristics such as dose value, fluence and spectra of both the neutrons and the by produced prompt gamma ray were described. Results and discussion Neutron and prompt gamma spectra in different points showed the neutrons to be thermalized when increasing the distance from the linac. Energy of the neutrons changed from about 0.6 MeV at the isocentre to around 10−08 MeV at the outer door position. Although the neutrons were found as fast neutrons, their spectra showed they were thermal neutrons at the outer door position. Additionally, it was seen that the energy of the gamma rays is higher than the scattered X-ray energy. The energy of gamma rays was seen to be up to 10 MeV while the linac photons had energy lower than 1 MeV. Neutron source strength obtained in this work was in good agreement with the published data, which may be a confirmation of our simulation accuracy. Conclusion The study showed that the Monte Carlo simulation can be applied in the radiotherapy and industrial radiation works as a useful and precise estimator. We also concluded that the dose from the prompt gamma ray at the outer door location is higher than the scattered radiation from the linac and should be considered in the shielding. PMID:24936317

  14. Measurements of liquid and glass structures using in-situ high energy x-ray and neutron scattering

    SciTech Connect

    Weber, Richard; Benmore, C. J.; Skinner, Lawrie; Neuefeind, Joerg C; Tumber, Sonia; Jennings, G; Santodonato, Louis J; Jin, D; Du, Jincheng; Parise, John B

    2013-01-01

    Investigation of high temperature molten materials and their evolution to the amorphous state is often hampered by unwanted reactions with container surfaces. This work used aerodynamic levitation in combination with laser beam heating to study high melting point materials that can form supercooled liquids or glasses. Details of the instruments that are being used at the Advanced Photon Source and the Spallation Neutron Source to study molten oxides with high energy x-ray scattering and neutron diffraction with isotope substitution are presented. Examples of measurements are used to illustrate the use of the instruments. Plans for further development and application of the capabilities are presented.

  15. Characteristics of high-energy neutrons estimated using the radioactive spallation products of Au at the 500-MeV neutron irradiation facility of KENS.

    PubMed

    Matsumura, Hiroshi; Masumoto, Kazuyoshi; Nakao, Noriaki; Wang, Qingbin; Toyoda, Akihiro; Kawai, Masayoshi; Aze, Takahiro; Fujimura, Masatsugu

    2005-01-01

    We carried out a shielding experiment of high-energy neutrons, generated from a tungsten target bombarded with primary 500-MeV protons at KENS, which penetrated through a concrete shield in the zero-degree direction. We propose a new method to evaluate the spectra of high-energy neutrons ranging from 8 to 500 MeV. Au foils were set in a concrete shield, and the reaction rates for 13 radionuclides produced by the spallation reactions on the Au targets were measured by radiochemical techniques. The experimental results were compared with those obtained by the MARS14 Monte-Carlo code. A good agreement (between them) was found for energies beyond 100 MeV. The profile of the neutron spectrum, ranging from 8 to 500 MeV, does not depend on the thickness of the concrete shield.

  16. New measurement system for on line in core high-energy neutron flux monitoring in materials testing reactor conditions

    NASA Astrophysics Data System (ADS)

    Geslot, B.; Vermeeren, L.; Filliatre, P.; Lopez, A. Legrand; Barbot, L.; Jammes, C.; Bréaud, S.; Oriol, L.; Villard, J.-F.

    2011-03-01

    Flux monitoring is of great interest for experimental studies in material testing reactors. Nowadays, only the thermal neutron flux can be monitored on line, e.g., using fission chambers or self-powered neutron detectors. In the framework of the Joint Instrumentation Laboratory between SCK-CEN and CEA, we have developed a fast neutron detector system (FNDS) capable of measuring on line the local high-energy neutron flux in fission reactor core and reflector locations. FNDS is based on fission chambers measurements in Campbelling mode. The system consists of two detectors, one detector being mainly sensitive to fast neutrons and the other one to thermal neutrons. On line data processing uses the CEA depletion code DARWIN in order to disentangle fast and thermal neutrons components, taking into account the isotopic evolution of the fissile deposit. The first results of FNDS experimental test in the BR2 reactor are presented in this paper. Several fission chambers have been irradiated up to a fluence of about 7 × 1020 n/cm2. A good agreement (less than 10% discrepancy) was observed between FNDS fast flux estimation and reference flux measurement.

  17. New measurement system for on line in core high-energy neutron flux monitoring in materials testing reactor conditions

    SciTech Connect

    Geslot, B.; Filliatre, P.; Barbot, L.; Jammes, C.; Breaud, S.; Oriol, L.; Villard, J.-F.; Lopez, A. Legrand

    2011-03-15

    Flux monitoring is of great interest for experimental studies in material testing reactors. Nowadays, only the thermal neutron flux can be monitored on line, e.g., using fission chambers or self-powered neutron detectors. In the framework of the Joint Instrumentation Laboratory between SCK-CEN and CEA, we have developed a fast neutron detector system (FNDS) capable of measuring on line the local high-energy neutron flux in fission reactor core and reflector locations. FNDS is based on fission chambers measurements in Campbelling mode. The system consists of two detectors, one detector being mainly sensitive to fast neutrons and the other one to thermal neutrons. On line data processing uses the CEA depletion code DARWIN in order to disentangle fast and thermal neutrons components, taking into account the isotopic evolution of the fissile deposit. The first results of FNDS experimental test in the BR2 reactor are presented in this paper. Several fission chambers have been irradiated up to a fluence of about 7 x 10{sup 20} n/cm{sup 2}. A good agreement (less than 10% discrepancy) was observed between FNDS fast flux estimation and reference flux measurement.

  18. New measurement system for on line in core high-energy neutron flux monitoring in materials testing reactor conditions.

    PubMed

    Geslot, B; Vermeeren, L; Filliatre, P; Lopez, A Legrand; Barbot, L; Jammes, C; Bréaud, S; Oriol, L; Villard, J-F

    2011-03-01

    Flux monitoring is of great interest for experimental studies in material testing reactors. Nowadays, only the thermal neutron flux can be monitored on line, e.g., using fission chambers or self-powered neutron detectors. In the framework of the Joint Instrumentation Laboratory between SCK-CEN and CEA, we have developed a fast neutron detector system (FNDS) capable of measuring on line the local high-energy neutron flux in fission reactor core and reflector locations. FNDS is based on fission chambers measurements in Campbelling mode. The system consists of two detectors, one detector being mainly sensitive to fast neutrons and the other one to thermal neutrons. On line data processing uses the CEA depletion code DARWIN in order to disentangle fast and thermal neutrons components, taking into account the isotopic evolution of the fissile deposit. The first results of FNDS experimental test in the BR2 reactor are presented in this paper. Several fission chambers have been irradiated up to a fluence of about 7 × 10(20) n∕cm(2). A good agreement (less than 10% discrepancy) was observed between FNDS fast flux estimation and reference flux measurement.

  19. The Efficiency of the BC-720 Scintillator in a High-Energy (20--800 MeV) Accelerator Neutron Field

    SciTech Connect

    Miles, Leslie H.

    2005-12-01

    High-energy neutron doses (>20 MeV) are of little importance to most radiation workers. However, space and flight crews, and people working around medical and scientific accelerators receive over half of their radiation dose from high-energy neutrons. Unfortunately, neutrons are difficult to measure, and no suitable dosimetry has yet been developed to measure this radiation. In this paper, basic high-energy neutron interactions, characteristics of high-energy neutron environments, present neutron dosimetry, and quantities used in neutron dosimetry are discussed before looking into the potential of the BC-720 scintillator to improve dosimetry. This research utilized 800 MeV protons impinging upon the WNR Facility spallation neutron source at Los Alamos National Laboratory. Time-of-flight methods and a U-238 Fission Chamber were used to aid evaluation of the efficiency of the BC-720. Results showed that the efficiency is finite over the 20–650 MeV energy region studied, although it decreases by a factor of ten between 40 and 100 MeV. This limits the use of this dosimeter to measure doses at sitespecific locations. It also encourages modifications to use this dosimeter for any unknown neutron field. As such, this dosimeter has the potential for a small, lightweight, real-time dose measurement, which could impact neutron dosimetry in all high-energy neutron environments.

  20. Gamma-ray, neutron, and hard X-ray studies and requirements for a high-energy solar physics facility

    NASA Technical Reports Server (NTRS)

    Ramaty, R.; Dennis, B. R.; Emslie, A. G.

    1988-01-01

    The requirements for future high-resolution spatial, spectral, and temporal observation of hard X-rays, gamma rays and neutrons from solar flares are discussed in the context of current high-energy flare observations. There is much promise from these observations for achieving a deep understanding of processes of energy release, particle acceleration and particle transport in a complicated environment such as the turbulent and highly magnetized atmosphere of the active sun.

  1. Determination of the neutron fluence spectra in the neutron therapy room of KIRAMS.

    PubMed

    Kim, B H; Kim, J S; Kim, J L; Kim, Y S; Yang, T G; Lee, M Y

    2007-01-01

    High energy proton induced neutron fluence spectra were determined at the Korea Institute of Radiological and Medical Sciences (KIRAMS) using an extended Bonner Sphere (BS) set from the Korea Atomic Energy Research Institute (KAERI) in a series of measurements to quantify the neutron field. At the facility of the MC50 cyclotron of KIRAMS, two Be targets of different thicknesses, 1.0 and 10.5 mm, were bombarded by 35 and 45-MeV protons to produce six kinds of neutron fields, which were classified according to the measurement position and the use or no use of a beam collimator such as the gantry of the neutron therapy unit. In order to obtain a priori information to unfold the measured BS data the MCNPX code was used to calculate the neutron spectrum, and the influence of the surrounding materials for cooling the target assembly were also reviewed through this calculation. Some dosimetric quantities were determined by using the spectra determined in this measurement. Dose equivalent rates of these neutron fields ranged from 0.21 to 5.66 mSv h(-1)nA(-1) and the neutron yields for a thick Be target were 3.05 and 4.77% in the case of using a 35 and a 45-MeV proton, respectively.

  2. Proton linacs for boron neutron capture therapy

    SciTech Connect

    Lennox, A.J. |

    1993-08-01

    Recent advances in the ability to deliver boron-containing drugs to brain tumors have generated interest in {approximately}4 MeV linacs as sources of epithermal neutrons for radiation therapy. In addition, fast neutron therapy facilities have been studying methods to moderate their beams to take advantage of the high cross section for epithermal neutrons on boron-10. This paper describes the technical issues involved in each approach and presents the motivation for undertaking such studies using the Fermilab linac. the problems which must be solved before therapy can begin are outlined. Status of preparatory work and results of preliminary measurements are presented.

  3. Modification of the University of Washington Neutron Radiotherapy Facility for optimization of neutron capture enhanced fast-neutron therapy.

    PubMed

    Nigg, D W; Wemple, C A; Risler, R; Hartwell, J K; Harker, Y D; Laramore, G E

    2000-02-01

    A modified neutron production target assembly has been developed to provide improved performance of the proton-cyclotron-based neutron radiotherapy facility at the University of Washington for applications involving neutron capture enhanced fast-neutron therapy. The new target produces a neutron beam that yields essentially the same fast-neutron physical depth-dose distribution as is produced by the current UW clinical system, but that also has an increased fraction of BNCT enhancement relative to the total therapeutic dose. The modified target is composed of a 5-millimeter layer of beryllium, followed by a 2.5-millimeter layer of tungsten, with a water-cooled copper backing. Measurements of the free-field neutron spectrum of the beam produced by the new target were performed using activation foils with a direct spectral unfolding technique. Water phantom measurements were performed using a tissue-equivalent ion chamber to characterize the fast-neutron depth-dose curve and sodium activation in soda-lime glass beads to characterize the thermal-neutron flux (and thus the expected neutron capture dose enhancement) as a function of depth. The results of the various measurements were quite consistent with expectations based on the design calculations for the modified target. The spectrum of the neutron beam produced by the new target features an enhanced low-energy flux component relative to the spectrum of the beam produced by the standard UW target. However, it has essentially the same high-energy neutron flux, with a reduced flux component in the mid-range of the energy spectrum. As a result, the measured physical depth-dose curve in a large water phantom has the same shape compared to the case of the standard UW clinical beam, but approximately twice the level of BNCT enhancement per unit background neutron dose at depths of clinical interest. In-vivo clinical testing of BNCT-enhanced fast-neutron therapy for canine lung tumors using the new beam was recently

  4. A Compact Neutron Source for Boron Neutron Capture Therapy

    NASA Astrophysics Data System (ADS)

    Golubev, S. V.; Izotov, I. V.; Razin, S. V.; Sidorov, A. V.; Skalyga, V. A.

    2017-01-01

    We propose a neutron generator scheme based on a high-current ion source with electron cyclotron resonance plasma heating by high-power millimeter-wave gyrotron radiation. The most promising application of this neutron generator is a medical one, namely, boron neutron capture therapy of oncological diseases. A possibility for using a multi-aperture extraction system for high-current ion beam generation to increase the total current is studied. It is shown that the parameters of the plasma flow leaving a magnetic trap permit the effective use of multi-aperture systems without a significant loss in the ion beam current density. Thus, the use of multi-aperture systems in the ion source of a neutron generator can significantly increase the total neutron yield.

  5. Effect of wall thickness on measurement of dose for high energy neutrons.

    PubMed

    Perez-Nunez, Delia; Braby, Leslie A

    2010-01-01

    Neutrons produced from the interaction between galactic cosmic rays and spacecraft materials are responsible for a very important portion of the dose received by astronauts. The neutron energy spectrum depends on the incident charged particle spectrum and the scattering environment but generally extends to beyond 100 MeV. Tissue-equivalent proportional counters (TEPC) are used to measure the dose during the space mission, but their weight and size are very important factors for their design and construction. To achieve ideal neutron dosimetry, the wall thickness should be at least the range of a proton having the maximum energy of the neutrons to be monitored. This proton range is 0.1 cm for 10 MeV neutrons and 7.6 cm for 100 MeV neutrons. A 7.6 cm wall thickness TEPC would provide charged particle equilibrium (CPE) for neutrons up to 100 MeV, but for space applications it would not be reasonable in terms of weight and size. In order to estimate the errors in measured dose due to absence of CPE, MCNPX simulations of energy deposited by 10 MeV and 100 MeV neutrons in sites with wall thickness between 0.1 cm and 8.5 cm were performed. The results for 100 MeV neutrons show that energy deposition per incident neutron approaches a plateau as the wall thickness approaches 7.6 cm. For the 10 MeV neutrons, energy deposition per incident neutron decreases as the wall thickness increases above 0.1 cm due to attenuation.

  6. A study on the optimum fast neutron flux for boron neutron capture therapy of deep-seated tumors.

    PubMed

    Rasouli, Fatemeh S; Masoudi, S Farhad

    2015-02-01

    High-energy neutrons, named fast neutrons which have a number of undesirable biological effects on tissue, are a challenging problem in beam designing for Boron Neutron Capture Therapy, BNCT. In spite of this fact, there is not a widely accepted criterion to guide the beam designer to determine the appropriate contribution of fast neutrons in the spectrum. Although a number of researchers have proposed a target value for the ratio of fast neutron flux to epithermal neutron flux, it can be shown that this criterion may not provide the optimum treatment condition. This simulation study deals with the determination of the optimum contribution of fast neutron flux in the beam for BNCT of deep-seated tumors. Since the dose due to these high-energy neutrons damages shallow tissues, delivered dose to skin is considered as a measure for determining the acceptability of the designed beam. To serve this purpose, various beam shaping assemblies that result in different contribution of fast neutron flux are designed. The performances of the neutron beams corresponding to such configurations are assessed in a simulated head phantom. It is shown that the previously used criterion, which suggests a limit value for the contribution of fast neutrons in beam, does not necessarily provide the optimum condition. Accordingly, it is important to specify other complementary limits considering the energy of fast neutrons. By analyzing various neutron spectra, two limits on fast neutron flux are proposed and their validity is investigated. The results show that considering these limits together with the widely accepted IAEA criteria makes it possible to have a more realistic assessment of sufficiency of the designed beam. Satisfying these criteria not only leads to reduction of delivered dose to skin, but also increases the advantage depth in tissue and delivered dose to tumor during the treatment time. The Monte Carlo Code, MCNP-X, is used to perform these simulations.

  7. Simulation experiments for gamma-ray mapping of planetary surfaces: Scattering of high-energy neutrons

    NASA Technical Reports Server (NTRS)

    Brueckner, J.; Englert, P.; Reedy, R. C.; Waenke, H.

    1986-01-01

    The concentration and distribution of certain elements in surface layers of planetary objects specify constraints on models of their origin and evolution. This information can be obtained by means of remote sensing gamma-ray spectroscopy, as planned for a number of future space missions, i.e., Mars, Moon, asteroids, and comets. To investigate the gamma-rays made by interactions of neutrons with matter, thin targets of different composition were placed between a neutron-source and a high-resolution germanium spectrometer. Gamma-rays in the range of 0.1 to 8 MeV were accumulated. In one set of experiments a 14-MeV neutron generator using the T(d,n) reaction as neutron-source was placed in a small room. Scattering in surrounding walls produced a spectrum of neutron energies from 14 MeV down to thermal. This complex neutron-source induced mainly neutron-capture lines and only a few scattering lines. As a result of the set-up, there was a considerable background of discrete lines from surrounding materials. A similar situation exists under planetary exploration conditions: gamma-rays are induced in the planetary surface as well as in the spacecraft. To investigate the contribution of neutrons with higher energies, an experiment for the measurement of prompt gamma radiation was set up at the end of a beam-line of an isochronous cyclotron.

  8. Pulse Radiolysis Using Very-high-energy Ions for Optimizing Cancer Therapy.

    PubMed

    Getoff, Nikola

    2016-01-01

    Cancer therapy by means of high-energy ions is very efficient. As a consequence of the linear-energy-transfer effect only a negligible part of the produced free radicals can escape combination processes to form molecular products and to cause undesired side processes. Positrons (e⁺) and γ-rays, generated by the nuclear interaction of high-energy ions in the medium, serve in monitoring the radiation dose absorbed by the tumor. However, due to the dipole nature of water molecules a small proportion of thermalized positrons (e⁺th) can become solvated (e⁺aq). Hence, they are stabilized, live longer and can initiate side reactions. In addition, positronium (Ps), besides solvated electrons (e⁺aq), can be generated and involved in the reaction mechanisms. For a better understanding of the reaction mechanisms involved and to improve cancer therapy, a time-resolved pulse radiolysis instrument using high-energy particles is discussed here. The proposed method is examined and recommended by CERN experts. It is planned to be realized at the MedAustron Radiation Therapy and Research Centre in Wiener Neustadt, Austria.

  9. Study on Response Function of Organic Liquid Scintillator for High-Energy Neutrons

    NASA Astrophysics Data System (ADS)

    Satoh, Daiki; Sato, Tatsuhiko; Endo, Akira; Yamaguchi, Yasuhiro; Takada, Masashi; Ishibashi, Kenji

    2005-05-01

    Response functions of liquid organic scintillator for neutrons up to 800 MeV have been measured at the Heavy-Ion Medical Accelerator in Chiba (HIMAC) of National Institute of Radiological Sciences (NIRS). 800-MeV/u Si ions and 400-MeV/u C ions bombarded a thick carbon target to produce neutrons. The kinetic energies of emitted neutrons were determined by the time-of-flight (TOF) method. Light output for neutrons was evaluated by eliminating events due to gamma-rays and charged particles. The measured response functions were compared with calculations using SCINFUL-QMD and CECIL codes. It was found that SCINFUL-QMD reproduced our experimental data adequately.

  10. OER and RBE of high energy neutron beams for growth inhibition in Vicia faba.

    PubMed

    Van Dam, J; Billiet, G; Zoetelief, J; Broerse, J J; Wambersie, A

    1983-01-01

    The radiobiologic characteristics of 15 MeV neutrons produced by the d + T reaction at the TNO of Rijswijk and of neutrons produced by the d(50) + Be and p(75) + Be reactions at the cyclotron Cyclone of Louvain-la- Neuve were compared. Growth inhibition in Vicia faba bean roots was used as biologic system. An OER value of 1.5 +/- 0.1 ws obtained for the neutron beams compared. The RBE of 15 MeV, d(50) + Be and p(75) + Be neutrons was found equal to 3.4 +/- 0.2, 3.2 +/- 0.2 and 2.9 +/- 0.3, respectively, relative to gamma rays, for a total (n + gamma) absorbed dose of 0.6 Gy.

  11. Measurements of high-energy neutron-induced fission ofnatPb and 209Bi

    NASA Astrophysics Data System (ADS)

    Tarrío, D.; Tassan-Got, L.; Audouin, L.; Berthier, B.; Duran, I.; Ferrant, L.; Isaev, S.; Le Naour, C.; Paradela, C.; Stephan, C.; Trubert, D.; Abbondanno, U.; Aerts, G.; Álvarez, H.; Álvarez-Velarde, F.; Andriamonje, S.; Andrzejewski, J.; Assimakopoulos, P.; Badurek, G.; Baumann, P.; Becvár, F.; Berthoumieux, E.; Calviño, F.; Calviani, M.; Cano-Ott, D.; Capote, R.; Carrapiço, C.; Cennini, P.; Chepel, V.; Chiaveri, E.; Colonna, N.; Cortes, G.; Couture, A.; Cox, J.; Dahlfors, M.; David, S.; Dillmann, I.; Domingo-Pardo, C.; Dridi, W.; Eleftheriadis, C.; Embid-Segura, M.; Ferrari, A.; Ferreira-Marques, R.; Fujii, K.; Furman, W.; Gonçalves, I.; González-Romero, E.; Gramegna, F.; Guerrero, C.; Gunsig, F.; Haas, B.; Haight, R.; Heil, M.; Herrera-Martinez, A.; Igashira, M.; Jericha, E.; Kadi, Y.; Käppeler, F.; Karadimos, D.; Karamanis, D.; Kerveno, M.; Koehler, P.; Kossionides, E.; Krticka, M.; Lampoudis, C.; Leeb, H.; Lindote, A.; Lopes, I.; Lozano, M.; Lukic, S.; Marganiec, J.; Marrone, S.; Martínez, T.; Massimi, C.; Mastinu, P.; Mengoni, A.; Milazzo, P. M.; Moreau, C.; Mosconi, M.; Neves, F.; Oberhummer, H.; O'Brien, S.; Oshima, M.; Pancin, J.; Papachristodoulou, C.; Papadopoulos, C.; Patronis, N.; Pavlik, A.; Pavlopoulos, P.; Perrot, L.; Pigni, M. T.; Plag, R.; Plompen, A.; Plukis, A.; Poch, A.; Praena, J.; Pretel, C.; Quesada, J.; Rauscher, T.; Reifarth, R.; Rubbia, C.; Rudolf, G.; Rullhusen, P.; Salgado, J.; Santos, C.; Sarchiapone, L.; Savvidis, I.; Tagliente, G.; Tain, J. L.; Tavora, L.; Terlizzi, R.; Vannini, G.; Vaz, P.; Ventura, A.; Villamarin, D.; Vicente, M. C.; Vlachoudis, V.; Vlastou, R.; Voss, F.; Walter, S.; Wiescher, M.; Wisshak, K.

    2010-10-01

    The CERN Neutron Time-Of-Flight (n_TOF) facility is well suited to measure low cross sections as those of neutron-induced fission in subactinides. The cross section ratios of natPb and 209Bi relative to 235U and 238U were measured using PPAC detectors and a fragment coincidence method that allows us to identify the fission events. The present experiment provides first results for neutron-induced fission up to 1 GeV. Good agreement is found with previous experimental data below 200 MeV. The comparison with proton-induced fission indicates that the limiting regime where neutron-induced and proton-induced fission reach equal cross sections is close to 1 GeV.

  12. The accelerator neutron source for boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Kasatov, D.; Koshkarev, A.; Kuznetsov, A.; Makarov, A.; Ostreinov, Yu; Shchudlo, I.; Sorokin, I.; Sycheva, T.; Taskaev, S.; Zaidi, L.

    2016-11-01

    The accelerator based epithermal neutron source for Boron Neutron Capture Therapy (BNCT) is proposed, created and used in the Budker Institute of Nuclear Physics. In 2014, with the support of the Russian Science Foundation created the BNCT laboratory for the purpose to the end of 2016 get the neutron flux, suitable for BNCT. For getting 3 mA 2.3 MeV proton beam, was created a new type accelerator - tandem accelerator with vacuum isolation. On this moment, we have a stationary proton beam with 2.3 MeV and current 1.75 mA. Generation of neutrons is carried out by dropping proton beam on to lithium target as a result of threshold reaction 7Li(p,n)7Be. Established facility is a unique scientific installation. It provides a generating of neutron flux, including a monochromatic energy neutrons, gamma radiation, alpha-particles and positrons, and may be used by other research groups for carrying out scientific researches. The article describes an accelerator neutron source, presents and discusses the result of experiments and declares future plans.

  13. Neutron tube design study for boron neutron capture therapy application

    SciTech Connect

    Verbeke, J.M.; Lee, Y.; Leung, K.N.; Vujic, J.; Williams, M.D.; Wu, L.K.; Zahir, N.

    1999-05-06

    Radio-frequency (RF) driven ion sources are being developed in Lawrence Berkeley National Laboratory (LBNL) for sealed-accelerator-tube neutron generator application. By using a 5-cm-diameter RF-driven multicusp source H{sup +} yields over 95% have been achieved. These experimental findings will enable one to develop compact neutron generators based on the D-D or D-T fusion reactions. In this new neutron generator, the ion source, the accelerator and the target are all housed in a sealed metal container without external pumping. Recent moderator design simulation studies have shown that 14 MeV neutrons could be moderated to therapeutically useful energy ranges for boron neutron capture therapy (BNCT). The dose near the center of the brain with optimized moderators is about 65% higher than the dose obtained from a typical neutron spectrum produced by the Brookhaven Medical Research Reactor (BMRR), and is comparable to the dose obtained by other accelerator-based neutron sources. With a 120 keV and 1 A deuteron beam, a treatment time of {approx}35 minutes is estimated for BNCT.

  14. Chromosome Aberrations in Human Epithelial Cells Exposed Los Alamos High-Energy Secondary Neutrons: M-BAND Analysis

    NASA Technical Reports Server (NTRS)

    Hada, M.; Saganti, P. B.; Gersey, B.; Wilkins, R.; Cucinotta, F. A.; Wu, H.

    2007-01-01

    High-energy secondary neutrons, produced by the interaction of galactic cosmic rays (GCR) with the atmosphere, spacecraft structure and planetary surfaces, contribute a significant fraction to the dose equivalent radiation measurement in crew members and passengers of commercial aviation travel as well as astronauts in space missions. The Los Alamos Nuclear Science Center (LANSCE) neutron facility's 30L beam line (4FP30L-A/ICE House) is known to generate neutrons that simulate the secondary neutron spectrum of the Earth's atmosphere at high altitude. The neutron spectrum is also similar to that measured onboard spacecrafts like the MIR and the International Space Station (ISS). To evaluate the biological damage, we exposed human epithelial cells in vitro to the LANSCE neutron beams with an entrance dose rate of 2.5 cGy/hr, and studied the induction of chromosome aberrations that were identified with multicolor-banding in situ hybridization (mBAND) technique. With this technique, individually painted chromosomal bands on one chromosome allowed the identification of inter-chromosomal aberrations (translocation to unpainted chromosomes) and intra-chromosomal aberrations (inversions and deletions within a single painted chromosome). Compared to our previous results with gamma-rays and 600 MeV/nucleon Fe ions of high dose rate at NSRL (NASA Space Radiation Laboratory at Brookhaven National Laboratory), the neutron data from the LANSCE experiments showed significantly higher frequency of chromosome aberrations. However, detailed analysis of the inversion type revealed that all of the three radiation types in the study induced a low incidence of simple inversions. Most of the inversions in gamma-ray irradiated samples were accompanied by other types of intrachromosomal aberrations but few inversions were accompanied by interchromosomal aberrations. In contrast, neutrons and Fe ions induced a significant fraction of inversions that involved complex rearrangements of both

  15. Simulation of neutron displacement damage in bipolar junction transistors using high-energy heavy ion beams.

    SciTech Connect

    Doyle, Barney Lee; Buller, Daniel L.; Hjalmarson, Harold Paul; Fleming, Robert M; Bielejec, Edward Salvador; Vizkelethy, Gyorgy

    2006-12-01

    Electronic components such as bipolar junction transistors (BJTs) are damaged when they are exposed to radiation and, as a result, their performance can significantly degrade. In certain environments the radiation consists of short, high flux pulses of neutrons. Electronics components have traditionally been tested against short neutron pulses in pulsed nuclear reactors. These reactors are becoming less and less available; many of them were shut down permanently in the past few years. Therefore, new methods using radiation sources other than pulsed nuclear reactors needed to be developed. Neutrons affect semiconductors such as Si by causing atomic displacements of Si atoms. The recoiled Si atom creates a collision cascade which leads to displacements in Si. Since heavy ions create similar cascades in Si we can use them to create similar damage to what neutrons create. This LDRD successfully developed a new technique using easily available particle accelerators to provide an alternative to pulsed nuclear reactors to study the displacement damage and subsequent transient annealing that occurs in various transistor devices and potentially qualify them against radiation effects caused by pulsed neutrons.

  16. Approach to magnetic neutron capture therapy

    SciTech Connect

    Kuznetsov, Anatoly A. . E-mail: spod@sky.chph.ras.ru; Podoynitsyn, Sergey N.; Filippov, Victor I.; Komissarova, Lubov Kh.; Kuznetsov, Oleg A.

    2005-11-01

    Purpose: The method of magnetic neutron capture therapy can be described as a combination of two methods: magnetic localization of drugs using magnetically targeted carriers and neutron capture therapy itself. Methods and Materials: In this work, we produced and tested two types of particles for such therapy. Composite ultradispersed ferro-carbon (Fe-C) and iron-boron (Fe-B) particles were formed from vapors of respective materials. Results: Two-component ultradispersed particles, containing Fe and C, were tested as magnetic adsorbent of L-boronophenylalanine and borax and were shown that borax sorption could be effective for creation of high concentration of boron atoms in the area of tumor. Kinetics of boron release into the physiologic solution demonstrate that ultradispersed Fe-B (10%) could be applied for an effective magnetic neutron capture therapy. Conclusion: Both types of the particles have high magnetization and magnetic homogeneity, allow to form stable magnetic suspensions, and have low toxicity.

  17. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

    PubMed

    Blue, Thomas E; Yanch, Jacquelyn C

    2003-01-01

    This paper reviews the development of low-energy light ion accelerator-based neutron sources (ABNSs) for the treatment of brain tumors through an intact scalp and skull using boron neutron capture therapy (BNCT). A major advantage of an ABNS for BNCT over reactor-based neutron sources is the potential for siting within a hospital. Consequently, light-ion accelerators that are injectors to larger machines in high-energy physics facilities are not considered. An ABNS for BNCT is composed of: (1) the accelerator hardware for producing a high current charged particle beam, (2) an appropriate neutron-producing target and target heat removal system (HRS), and (3) a moderator/reflector assembly to render the flux energy spectrum of neutrons produced in the target suitable for patient irradiation. As a consequence of the efforts of researchers throughout the world, progress has been made on the design, manufacture, and testing of these three major components. Although an ABNS facility has not yet been built that has optimally assembled these three components, the feasibility of clinically useful ABNSs has been clearly established. Both electrostatic and radio frequency linear accelerators of reasonable cost (approximately 1.5 M dollars) appear to be capable of producing charged particle beams, with combinations of accelerated particle energy (a few MeV) and beam currents (approximately 10 mA) that are suitable for a hospital-based ABNS for BNCT. The specific accelerator performance requirements depend upon the charged particle reaction by which neutrons are produced in the target and the clinical requirements for neutron field quality and intensity. The accelerator performance requirements are more demanding for beryllium than for lithium as a target. However, beryllium targets are more easily cooled. The accelerator performance requirements are also more demanding for greater neutron field quality and intensity. Target HRSs that are based on submerged-jet impingement and

  18. Neutron producing target for accelerator based neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Bayanov, B.; Belov, V.; Taskaev, S.

    2006-05-01

    Pilot innovative accelerator based neutron source for neutron capture therapy of cancer is under construction now at the Budker Institute. One of the main elements of the facility is lithium target producing neutrons via threshold 7Li(p, n)7Be reaction at 10 mA proton beam with energies of 1.915 MeV or 2.5 MeV. In the present report, choice of target was substantiated. The main problems of lithium target were determined to be: 7Be radioactive isotope activation, keeping lithium layer solid, presence of photons resulted from proton inelastic scattering on lithium nuclei, and radiation blistering. The results of thermal testing of target prototype, investigation of radiation blistering and several simulations are presented. It becomes clear that water is preferable for cooling this target, and that the lithium target 10 cm in diameter is able to run up to 25 kW proton beam before melting. The conception of optimal target is proposed: thin and easy to detach metal disk 10 cm in diameter, evaporated with thin layer of pure lithium from the side of proton beam exposure: its back is intensively cooled with turbulent water flow to maintain lithium layer solid. Design of target for the neutron source constructed at BINP is shown. Conceptions of radiation protection and neutrons, γ-rays and α- particles diagnostics are presented. The immediate plans on obtaining epithermal neutron beam are declared.

  19. Measurement of high-energy neutrons at ISS by SEDA-AP

    NASA Astrophysics Data System (ADS)

    Koga, K.; Goka, T.; Matsumoto, H.; Obara, T.; Muraki, Y.; Yamamoto, T.

    2011-09-01

    A new type of solar neutron detector (NEM) was launched by the space shuttle Endeavour on 16 July 2009 and it began collecting data on 25 August 2009 at the International Space Station (ISS). In this paper we introduce preliminary results obtained by the NEM.

  20. New estimation method of neutron skyshine for a high-energy particle accelerator

    NASA Astrophysics Data System (ADS)

    Oh, Joo-Hee; Jung, Nam-Suk; Lee, Hee-Seock; Ko, Seung-Kook

    2016-09-01

    A skyshine is the dominant component of the prompt radiation at off-site. Several experimental studies have been done to estimate the neutron skyshine at a few accelerator facilities. In this work, the neutron transports from a source place to off-site location were simulated using the Monte Carlo codes, FLUKA and PHITS. The transport paths were classified as skyshine, direct (transport), groundshine and multiple-shine to understand the contribution of each path and to develop a general evaluation method. The effect of each path was estimated in the view of the dose at far locations. The neutron dose was calculated using the neutron energy spectra obtained from each detector placed up to a maximum of 1 km from the accelerator. The highest altitude of the sky region in this simulation was set as 2 km from the floor of the accelerator facility. The initial model of this study was the 10 GeV electron accelerator, PAL-XFEL. Different compositions and densities of air, soil and ordinary concrete were applied in this calculation, and their dependences were reviewed. The estimation method used in this study was compared with the well-known methods suggested by Rindi, Stevenson and Stepleton, and also with the simple code, SHINE3. The results obtained using this method agreed well with those using Rindi's formula.

  1. High-energy astrophysics: A theoretical analysis of thermal radiation from neutron stars

    NASA Technical Reports Server (NTRS)

    Applegate, James H.

    1994-01-01

    The unambiguous detection of thermal radiation from the surface of a cooling neutron star was one of the most anxiously awaited results in neutron star physics. This particular Holy Grail was found by Halpern and Holt, who used ROSAT to detect pulsed X-rays from the gamma-ray source Geminga and demonstrate that it was a neutron star, probably a radio pulsar beamed away from us. At an age of approximately 3.4 x 10(exp 5) years, Geminga is in the photon cooling era. Its surface temperature of 5.2 x 10(exp 5) K can be explained within the contexts of both the slow and fast cooling scenarios. In the slow cooling scenario, the surface temperature is too high unless the specific heat of the interior is reduced by extensive baryon pairing. In the fast cooling scenario, the surface temperature will be much too low unless the fast neutrino cooling is shut off by baryon pairing. Two other pulsars, PSR 0656+14 and PSR 1055-52, have also been detected in thermal X-rays by ROSAT. They are also in the photon cooling era. All of this research's neutron star cooling models to date have used the unmagnetized effective temperature-interior temperature relation for the outer boundary condition. Models are being improved by using published magnetic envelope calculations and assumed geometried for the surface magnetic field to determine local interior temperature-emitted flux relations for the surface of the star.

  2. Time gating for energy selection and scatter rejection: High-energy pulsed neutron imaging at LANSCE

    NASA Astrophysics Data System (ADS)

    Swift, Alicia; Schirato, Richard; McKigney, Edward; Hunter, James; Temple, Brian

    2015-09-01

    The Los Alamos Neutron Science Center (LANSCE) is a linear accelerator in Los Alamos, New Mexico that accelerates a proton beam to 800 MeV, which then produces spallation neutron beams. Flight path FP15R uses a tungsten target to generate neutrons of energy ranging from several hundred keV to ~600 MeV. The beam structure has micropulses of sub-ns width and period of 1.784 ns, and macropulses of 625 μs width and frequency of either 50 Hz or 100 Hz. This corresponds to 347 micropulses per macropulse, or 1.74 x 104 micropulses per second when operating at 50 Hz. Using a very fast, cooled ICCD camera (Princeton Instruments PI-Max 4), gated images of various objects were obtained on FP15R in January 2015. Objects imaged included blocks of lead and borated polyethylene; a tungsten sphere; and a tungsten, polyethylene, and steel cylinder. Images were obtained in 36 min or less, with some in as little as 6 min. This is novel because the gate widths (some as narrow as 10 ns) were selected to reject scatter and other signal not of interest (e.g. the gamma flash that precedes the neutron pulse), which has not been demonstrated at energies above 14 MeV. This proof-of-principle experiment shows that time gating is possible above 14MeV and is useful for selecting neutron energy and reducing scatter, thus forming clearer images. Future work (simulation and experimental) is being undertaken to improve camera shielding and system design and to precisely determine optical properties of the imaging system.

  3. (A neutron scattering experiment to study the high-energy spin dynamics of the itinerant antiferromagnet Mn sub 90 Cu sub 10 )

    SciTech Connect

    Fernandez-Baca, J.A.

    1990-10-26

    The traveler performed a neutron scattering experiment to study the high-energy spin dynamics of the itinerant antiferromagnet. This experiment was conducted at a unique instrument located at the hot-neutron source at the ILL. The traveler also held various scientific discussions with ILL research staff members and visiting scientists.

  4. High-energy transients. [from weakly and strongly magnetic neutron stars

    NASA Technical Reports Server (NTRS)

    Lamb, D. Q.

    1991-01-01

    The observational characteristics of X-ray bursts are reviewed and the thermonuclear-flash model is examined to assess the suitability of the model and the sources of X- and gamma-ray bursts. The profiles of X-ray bursts from five different sources are delineated, and the global analysis of nuclear burning is discussed to review th range possible X-ray burst behavior. The analysis by Fushiki and Lamb (1987) is noted for the description of regions which lie away from the steady-state cut. The discussion of cyclotron lines in gamma-ray bursts emphasizes the source GB880205, and it is shown that Raman and cyclotron resonant scattering can explain the observed positions, strengths, and widths of the dips in the spectrum. X-ray bursts are theorized to emanate from weakly magnetic neutron stars, and gamma-ray bursts are shown to be the products of strongly magnetic neutron stars.

  5. The properties of gamma-radiation and high-energy neutron fluxes in "MIR" station orbit.

    PubMed

    Bogomolov, A V; Bogomolov, V V; Denisov, Yu I; Logachev, Yu I; Svertilov, S I; Kudryavtsev, M I; Lyagushin, V I; Ershova, T V

    2002-10-01

    The study of radiation background components in the near-Earth space is very important for different branches of space research, in particular for space dosimetry and for the planning of gamma-astronomy experiments. Detailed information on the neutral components (gamma-quanta, neutrons) of background radiation was obtained during the Grif-1 experiment onboard Mir orbital station (OS). The measurements of fluxes of 0.05-50 MeV gamma-quanta and >30 MeV neutrons with a large area instrument (approximately 250 cm2 for gamma-quanta, approximately 30 cm2 for neutrons) as well as corresponding charged particle measurements (0.4-1.5 MeV electrons, 1-200 MeV protons) were made during this experiment. The background components induced by the station's own radiation as well as the albedo gamma-rays from the Earth's atmosphere were revealed as the result of data analysis for about 600 h of observation. A mathematical model describing the latitude and energy dependences of atmospheric albedo gamma-rays as well as of those of gamma-quanta produced in the material of the station due to cosmic ray interactions was developed. An analytical approximation of the spectrum of induced gamma-rays from radioactive isotopes stored in the station and instrument's materials is presented. The dynamics of gamma-quantum background fluxes during the geomagnetic disturbances of January 10-11, 1997 are discussed. An analytical representation of the latitude dependence of the integral flux of neutrons with >30 MeV is given.

  6. Characterization of extended range Bonner Sphere Spectrometers in the CERF high-energy broad neutron field at CERN

    NASA Astrophysics Data System (ADS)

    Agosteo, S.; Bedogni, R.; Caresana, M.; Charitonidis, N.; Chiti, M.; Esposito, A.; Ferrarini, M.; Severino, C.; Silari, M.

    2012-12-01

    The accurate determination of the ambient dose equivalent in the mixed neutron-photon fields encountered around high-energy particle accelerators still represents a challenging task. The main complexity arises from the extreme variability of the neutron energy, which spans over 10 orders of magnitude or more. Operational survey instruments, which response function attempts to mimic the fluence-to-ambient dose equivalent conversion coefficient up to GeV neutrons, are available on the market, but their response is not fully reliable over the entire energy range. Extended range rem counters (ERRC) do not require the exact knowledge of the energy distribution of the neutron field and the calibration can be done with a source spectrum. If the actual neutron field has an energy distribution different from the calibration spectrum, the measurement is affected by an added uncertainty related to the partial overlap of the fluence-to-ambient dose equivalent conversion curve and the response function. For this reason their operational use should always be preceded by an "in-field" calibration, i.e. a calibration made against a reference instrument exposed in the same field where the survey-meter will be employed. In practice the extended-range Bonner Sphere Spectrometer (ERBSS) is the only device which can serve as reference instrument in these fields, because of its wide energy range and the possibility to assess the neutron fluence and the ambient dose equivalent (H*(10)) values with the appropriate accuracy. Nevertheless, the experience gained by a number of experimental groups suggests that mandatory conditions for obtaining accurate results in workplaces are: (1) the use of a well-established response matrix, thus implying validation campaigns in reference monochromatic neutrons fields, (2) the expert and critical use of suitable unfolding codes, and (3) the performance test of the whole system (experimental set-up, elaboration and unfolding procedures) in a well

  7. Transport analysis of measured neutron leakage spectra from spheres as tests of evaluated high energy cross sections

    NASA Technical Reports Server (NTRS)

    Bogart, D. D.; Shook, D. F.; Fieno, D.

    1973-01-01

    Integral tests of evaluated ENDF/B high-energy cross sections have been made by comparing measured and calculated neutron leakage flux spectra from spheres of various materials. An Am-Be (alpha,n) source was used to provide fast neutrons at the center of the test spheres of Be, CH2, Pb, Nb, Mo, Ta, and W. The absolute leakage flux spectra were measured in the energy range 0.5 to 12 MeV using a calibrated NE213 liquid scintillator neutron spectrometer. Absolute calculations of the spectra were made using version 3 ENDF/B cross sections and an S sub n discrete ordinates multigroup transport code. Generally excellent agreement was obtained for Be, CH2, Pb, and Mo, and good agreement was observed for Nb although discrepancies were observed for some energy ranges. Poor comparative results, obtained for Ta and W, are attributed to unsatisfactory nonelastic cross sections. The experimental sphere leakage flux spectra are tabulated and serve as possible benchmarks for these elements against which reevaluated cross sections may be tested.

  8. Microdosimetry for Boron Neutron Capture Therapy

    SciTech Connect

    Maughan, R.L.; Kota, C.

    2000-09-05

    The specific aims of the research proposal were as follows: (1) To design and construct small volume tissue equivalent proportional counters for the dosimetry and microdosimetry of high intensity thermal and epithermal neutron beams used in BNCT, and of modified fast neutron beams designed for boron neutron capture enhanced fast neutron therapy (BNCEFNT). (2) To develop analytical methods for estimating the biological effectiveness of the absorbed dose in BNCT and BNCEFNT based on the measured microdosimetric spectra. (3) To develop an analytical framework for comparing the biological effectiveness of different epithermal neutron beams used in BNCT and BNCEFNT, based on correlated sets of measured microdosimetric spectra and radiobiological data. Specific aims (1) and (2) were achieved in their entirety and are comprehensively documented in Jay Burmeister's Ph.D. dissertation entitled ''Specification of physical and biologically effective absorbed dose in radiation therapies utilizing the boron neutron capture reaction'' (Wayne State University, 1999). Specific aim (3) proved difficult to accomplish because of a lack of sufficient radiobiological data.

  9. Boron neutron capture therapy for cancer

    SciTech Connect

    Barth, R.E.; Soloway, A.H. ); Fairchild, R.G. State Univ. of New York, Stony Brook )

    1990-10-01

    Boron neutron capture therapy (BNCT) bring together two components that when kept separate have only minor effects on normal cells. The first component is a stable isotope of boron (boron 10) that can be concentrated in tumor cells. The second is a beam of low-energy neutrons that produces short-range radiation when absorbed, or captured, by the boron. The combination of these two conditions at the site of a tumor releases intense radiation that can destroy malignant tissues. BNCT is based on the nuclear reaction that occurs when boron 10 is irradiated with an absorbs neutrons. The neutrons that it takes up are called thermal, or slow, neutrons. They are of such low energy that they cause little tissue damage as compared with other forms of radiation such as protons, gamma rays and fast neutrons. When an atom of boron 10 captures a neutron, an unstable isotope, boron 11, forms. The boron 11 instantly fissions, yielding lithium 7 nuclei and energetic alpha particles. These heavy particles, which carry 2.79 million electron volts of energy, are a highly lethal form of radiation. If the treatment proceeds as intended, the destructive effects of the capture reaction would occur primarily in those cancer cells that have accumulated boron 10. Normal cells with low concentrations of boron would be spared.

  10. Boron Neutron Capture Therapy - A Literature Review

    PubMed Central

    Nedunchezhian, Kavitaa; Thiruppathy, Manigandan; Thirugnanamurthy, Sarumathi

    2016-01-01

    Boron Neutron Capture Therapy (BNCT) is a radiation science which is emerging as a hopeful tool in treating cancer, by selectively concentrating boron compounds in tumour cells and then subjecting the tumour cells to epithermal neutron beam radiation. BNCT bestows upon the nuclear reaction that occurs when Boron-10, a stable isotope, is irradiated with low-energy thermal neutrons to yield α particles (Helium-4) and recoiling lithium-7 nuclei. A large number of 10 Boron (10B) atoms have to be localized on or within neoplastic cells for BNCT to be effective, and an adequate number of thermal neutrons have to be absorbed by the 10B atoms to maintain a lethal 10B (n, α) lithium-7 reaction. The most exclusive property of BNCT is that it can deposit an immense dose gradient between the tumour cells and normal cells. BNCT integrates the fundamental focusing perception of chemotherapy and the gross anatomical localization proposition of traditional radiotherapy. PMID:28209015

  11. A theoretical model for the production of Ac-225 for cancer therapy by neutron capture transmutation of Ra-226.

    PubMed

    Melville, G; Melville, P

    2013-02-01

    Radium needles that were once implanted into tumours as a cancer treatment are now obsolete and constitute a radioactive waste problem, as their half-life is 1600 years. We are investigating the reduction of radium by transmutation by bombarding Ra-226 with high-energy neutrons from a neutron source to produce Ra-225 and hence Ac-225, which can be used as a generator to produce Bi-213 for use in 'Targeted Alpha Therapy' for cancer. This paper examines the possibility of producing Ac-225 by neutron capture using a theoretical model in which neutron energy is convoluted with the corresponding neutron cross sections of Ra-226. The total integrated yield can then be obtained. This study shows that an intense beam of high-energy neutrons could initiate neutron capture on Ra-226 to produce Ra-225 and hence practical amounts of Ac-225 and a useful reduction of Ra-226.

  12. High-energy quasi-monoenergetic neutron fields: existing facilities and future needs.

    PubMed

    Pomp, S; Bartlett, D T; Mayer, S; Reitz, G; Röttger, S; Silari, M; Smit, F D; Vincke, H; Yasuda, H

    2014-10-01

    The argument that well-characterised quasi-monoenergetic neutron (QMN) sources reaching into the energy domain >20 MeV are needed is presented. A brief overview of the existing facilities is given, and a list of key factors that an ideal QMN source for dosimetry and spectrometry should offer is presented. The authors conclude that all of the six QMN facilities currently in existence worldwide operate in sub-optimal conditions for dosimetry. The only currently available QMN facility in Europe capable of operating at energies >40 MeV, TSL in Uppsala, Sweden, is threatened with shutdown in the immediate future. One facility, NFS at GANIL, France, is currently under construction. NFS could deliver QMN beams up to about 30 MeV. It is, however, so far not clear if and when NFS will be able to offer QMN beams or operate with only so-called white neutron beams. It is likely that by 2016, QMN beams with energies >40 MeV will be available only in South Africa and Japan, with none in Europe.

  13. 21 CFR 892.5300 - Medical neutron radiation therapy system.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 21 Food and Drugs 8 2014-04-01 2014-04-01 false Medical neutron radiation therapy system. 892.5300... (CONTINUED) MEDICAL DEVICES RADIOLOGY DEVICES Therapeutic Devices § 892.5300 Medical neutron radiation therapy system. (a) Identification. A medical neutron radiation therapy system is a device intended...

  14. 21 CFR 892.5300 - Medical neutron radiation therapy system.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 21 Food and Drugs 8 2011-04-01 2011-04-01 false Medical neutron radiation therapy system. 892.5300... (CONTINUED) MEDICAL DEVICES RADIOLOGY DEVICES Therapeutic Devices § 892.5300 Medical neutron radiation therapy system. (a) Identification. A medical neutron radiation therapy system is a device intended...

  15. 21 CFR 892.5300 - Medical neutron radiation therapy system.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 8 2012-04-01 2012-04-01 false Medical neutron radiation therapy system. 892.5300... (CONTINUED) MEDICAL DEVICES RADIOLOGY DEVICES Therapeutic Devices § 892.5300 Medical neutron radiation therapy system. (a) Identification. A medical neutron radiation therapy system is a device intended...

  16. 21 CFR 892.5300 - Medical neutron radiation therapy system.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 21 Food and Drugs 8 2010-04-01 2010-04-01 false Medical neutron radiation therapy system. 892.5300... (CONTINUED) MEDICAL DEVICES RADIOLOGY DEVICES Therapeutic Devices § 892.5300 Medical neutron radiation therapy system. (a) Identification. A medical neutron radiation therapy system is a device intended...

  17. 21 CFR 892.5300 - Medical neutron radiation therapy system.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 21 Food and Drugs 8 2013-04-01 2013-04-01 false Medical neutron radiation therapy system. 892.5300... (CONTINUED) MEDICAL DEVICES RADIOLOGY DEVICES Therapeutic Devices § 892.5300 Medical neutron radiation therapy system. (a) Identification. A medical neutron radiation therapy system is a device intended...

  18. Porphyrins for boron neutron capture therapy

    DOEpatents

    Miura, Michiko; Gabel, Detlef

    1990-01-01

    Novel compounds for treatment of brain tumors in Boron Neutron Capture Therapy are disclosed. A method for preparing the compounds as well as pharmaceutical compositions containing said compounds are also disclosed. The compounds are water soluble, non-toxic and non-labile boronated porphyrins which show significant uptake and retention in tumors.

  19. Canted-Cosine-Theta Superconducting Accelerator Magnets for High Energy Physics and Ion Beam Cancer Therapy

    NASA Astrophysics Data System (ADS)

    Brouwer, Lucas Nathan

    Advances in superconducting magnet technology have historically enabled the construction of new, higher energy hadron colliders. Looking forward to the needs of a potential future collider, a significant increase in magnet field and performance is required. Such a task requires an open mind to the investigation of new design concepts for high field magnets. Part I of this thesis will present an investigation of the Canted-Cosine-Theta (CCT) design for high field Nb3Sn magnets. New analytic and finite element methods for analysis of CCT magnets will be given, along with a discussion on optimization of the design for high field. The design, fabrication, and successful test of the 2.5 T NbTi dipole CCT1 will be presented as a proof-of-principle step towards a high field Nb3Sn magnet. Finally, the design and initial steps in the fabrication of the 16 T Nb3Sn dipole CCT2 will be described. Part II of this thesis will investigate the CCT concept extended to a curved magnet for use in an ion beam therapy gantry. The introduction of superconducting technology in this field shows promise to reduce the weight and cost of gantries, as well as open the door to new beam optics solutions with high energy acceptance. An analytic approach developed for modeling curved CCT magnets will be presented, followed by a design study of a superconducting magnet for a proton therapy gantry. Finally, a new magnet concept called the "Alternating Gradient CCT" (AG-CCT) will be introduced. This concept will be shown to be a practical magnet solution for achieving the alternating quadrupole fields desired for an achromatic gantry, allowing for the consideration of treatment with minimal field changes in the superconducting magnets. The primary motivation of this thesis is to share new developments for Canted-Cosine-Theta superconducting magnets, with the hope this design will improve technology for high energy physics and ion beam cancer therapy.

  20. Optimization of intensity-modulated very high energy (50-250 MeV) electron therapy

    NASA Astrophysics Data System (ADS)

    Yeboah, C.; Sandison, G. A.; Moskvin, V.

    2002-04-01

    This work evaluates the potential of very high energy (50-250 MeV) electron beams for dose conformation and identifies those variables that influence optimized dose distributions for this modality. Intensity-modulated plans for a prostate cancer model were optimized as a function of the importance factors, beam energy and number of energy bins, number of beams, and the beam orientations. A trial-and-error-derived constellation of importance factors for target and sensitive structures to achieve good conformal dose distributions was 500, 50, 10 and 1 for the target, rectum, bladder and normal tissues respectively. Electron energies greater than 100 MeV were found to be desirable for intensity-modulated very high energy electron therapy (VHEET) of prostate cancer. Plans generated for lower energy beams had relatively poor conformal dose distributions about the target region and delivered high doses to sensitive structures. Fixed angle beam treatments utilizing a large number of fields in the range 9-21 provided acceptable plans. Using more than 21 beams at fixed gantry angles had an insignificant effect on target coverage, but resulted in an increased dose to sensitive structures and an increased normal tissue integral dose. Minor improvements in VHEET plans utilizing a `small' number (=<9) of beams may be achieved if, in addition to intensity modulation, energy modulation is implemented using a small number (=<3) of beam energies separated by 50 to 100 MeV. Rotation therapy provided better target dose homogeneity but unfortunately resulted in increased rectal dose, bladder dose and normal tissue integral dose relative to the 21-field fixed angle treatment plan. Modulation of the beam energy for rotation therapy had no beneficial consequences on the optimized dose distributions. Lastly, selection of beam orientations influenced the optimized treatment plan even when a large number of beams (approximately 15) were employed.

  1. SU-E-T-543: Measurement of Neutron Activation From Different High Energy Varian Linear Accelerators

    SciTech Connect

    Thatcher, T; Madsen, S; Sudowe, R; Meigooni, A Soleimani

    2015-06-15

    Purpose: Linear accelerators producing photons above 10 MeV may induce photonuclear reactions in high Z components of the accelerator. These liberated neutrons can then activate the structural components of the accelerator and other materials in the beam path through neutron capture reactions. The induced activity within the accelerator may contribute to additional dose to both patients and personnel. This project seeks to determine the total activity and activity per activated isotope following irradiation in different Varian accelerators at energies above 10 MeV. Methods: A Varian 21IX accelerator was used to irradiate a 30 cm × 30 cm × 20 cm solid water phantom with 15 MV x-rays. The phantom was placed at an SSD of 100 cm and at the center of a 20 cm × 20 cm field. Activation induced gamma spectra were acquired over a 5 minute interval after 1 and 15 minutes from completion of the irradiation. All measurements were made using a CANBERRA Falcon 5000 Portable HPGe detector. The majority of measurements were made in scattering geometry with the detector situated at 90° to the incident beam, 30 cm from the side of the phantom and approximately 10 cm from the top. A 5 minute background count was acquired and automatically subtracted from all subsequent measurements. Photon spectra were acquired for both open and MLC fields. Results: Based on spectral signatures, nuclides have been identified and their activities calculated for both open and MLC fields. Preliminary analyses suggest that activities from the activation products in the microcurie range. Conclusion: Activation isotopes have been identified and their relative activities determined. These activities are only gross estimates since efficiencies have not been determined for this source-detector geometry. Current efforts are focused on accurate determination of detector efficiencies using Monte Carlo calculations.

  2. High energy neutron and pion-decay gamma-ray emissions from solar flares

    NASA Astrophysics Data System (ADS)

    Chupp, Edward L.; Ryan, James M.

    2009-01-01

    Solar flare gamma-ray emissions from energetic ions and electrons have been detected and measured to GeV energies since 1980. In addition, neutrons produced in solar flares with 100 MeV to GeV energies have been observed at the Earth. These emissions are produced by the highest energy ions and electrons accelerated at the Sun and they provide our only direct (albeit secondary) knowledge about the properties of the accelerator(s) acting in a solar flare. The solar flares, which have direct evidence for pion-decay gamma-rays, are unique and are the focus of this paper. We review our current knowledge of the highest energy solar emissions, and how the characteristics of the acceleration process are deduced from the observations. Results from the RHESSI, INTEGRAL and CORONAS missions will also be covered. The review will also cover the solar flare capabilities of the new mission, FERMI GAMMA RAY SPACE TELESCOPE, launched on 2008 June 11. Finally, we discuss the requirements for future missions to advance this vital area of solar flare physics.

  3. Recent advances in neutron capture therapy (NCT)

    SciTech Connect

    Fairchild, R.G.

    1985-01-01

    The application of the /sup 10/B(n,..cap alpha..)/sup 7/Li reaction to cancer radiotherapy (Neutron Capture therapy, or NCT) has intrigued investigators since the discovery of the neutron. This paper briefly summarizes data describing recently developed boronated compounds with evident tumor specificity and extended biological half-lives. The implication of these compounds to NCT is evaluated in terms of Therapeutic Gain (TG). The optimization of NCT using band-pass filtered beams is described, again in terms of TG, and irradiation times with these less intense beams are estimated. 24 refs., 3 figs., 3 tabs.

  4. Laser-driven high-energy-density deuterium and tritium ions for neutron production in a double-cone configuration

    SciTech Connect

    Hu, Li-Xiang; Yu, Tong-Pu Shao, Fu-Qiu; Yin, Yan; Ma, Yan-Yun; Zhu, Qing-Jun

    2015-12-15

    By using two-dimensional particle-in-cell simulations, we investigate laser-driven ion acceleration and compression from a thin DT foil in a double-cone configuration. By using two counterpropagating laser pulses, it is shown that a double-cone structure can effectively guide, focus, and strengthen the incident laser pulses, resulting in the enhanced acceleration and compression of D{sup +} and T{sup +}. Due to the ion Coulomb repulsion and the effective screening from the external laser electric fields, the transverse diffusion of ions is significantly suppressed. Finally, the peak energy density of the compressed ions exceeds 2.73 × 10{sup 16 }J/m{sup 3}, which is about five orders of magnitude higher than the threshold for high energy density physics, 10{sup 11 }J/m{sup 3}. Under this condition, DT fusion reactions are initiated and the neutron production rate per volume is estimated to be as high as 7.473 × 10{sup 35}/m{sup 3} s according to Monte Carlo simulations. It is much higher than that of the traditional large neutron sources, which may facilitate many potential applications.

  5. Accelerator-driven boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Edgecock, Rob

    2014-05-01

    Boron Neutron Capture Therapy is a binary treatment for certain types of cancer. It works by loading the cancerous cells with a boron-10 carrying compound. This isotope has a large cross-section for thermal neutrons, the reaction producing a lithium nucleus and alpha particle that kill the cell in which they are produced. Recent studies of the boron carrier compound indicate that the uptake process works best in particularly aggressive cancers. Most studied is glioblastoma multiforme and a trial using a combination of BNCT and X-ray radiotherapy has shown an increase of nearly a factor of two in mean survival over the state of the art. However, the main technical problem with BNCT remains producing a sufficient flux of neutrons for a reasonable treatment duration in a hospital environment. This paper discusses this issue.

  6. Applicability of self-activation of an NaI scintillator for measurement of photo-neutrons around a high-energy X-ray radiotherapy machine.

    PubMed

    Wakabayashi, Genichiro; Nohtomi, Akihiro; Yahiro, Eriko; Fujibuchi, Toshioh; Fukunaga, Junichi; Umezu, Yoshiyuki; Nakamura, Yasuhiko; Nakamura, Katsumasa; Hosono, Makoto; Itoh, Tetsuo

    2015-01-01

    The applicability of the activation of an NaI scintillator for neutron monitoring at a clinical linac was investigated experimentally. Thermal neutron fluence rates are derived by measurement of the I-128 activity generated in an NaI scintillator irradiated by neutrons; β-rays from I-128 are detected efficiently by the NaI scintillator. In order to verify the validity of this method for neutron measurement, we irradiated an NaI scintillator at a research reactor, and the neutron fluence rate was estimated. The method was then applied to neutron measurement at a 10-MV linac (Varian Clinac 21EX), and the neutron fluence rate was estimated at the isocenter and at 30 cm from the isocenter. When the scintillator was irradiated directly by high-energy X-rays, the production of I-126 was observed due to photo-nuclear reactions, in addition to the generation of I-128 and Na-24. From the results obtained by these measurements, it was found that the neutron measurement by activation of an NaI scintillator has a great advantage in estimates of a low neutron fluence rate by use of a quick measurement following a short-time irradiation. Also, the future application of this method to quasi real-time monitoring of neutrons during patient treatments at a radiotherapy facility is discussed, as well as the method of evaluation of the neutron dose.

  7. Pancreatic carcinoma: results with fast neutron therapy

    SciTech Connect

    Kaul, R.; Cohen, L.; Hendrickson, F.; Awschalom, M.; Hrejsa, A.F.; Rosenberg, I.

    1981-02-01

    Results of therapy in 31 of 50 patients who were treated for advanced pancreatic carcinoma at Fermi National Accelerator Laboratory are presented here. To date, six patients are alive and four are free of disease. Since the main reason for failure was lack of control of primary tumor, the tumor dose has been increased by 15%. Based on our results, a nationwide study has been launched to assess the effectiveness of neutrons vs photons in the treatment of locally advanced pancreatic carcinoma.

  8. Design and characterization of an SRAM-based neutron detector for particle therapy

    NASA Astrophysics Data System (ADS)

    Ytre-Hauge, Kristian S.; Velure, Arild; Larsen, Eivind F.; Stokkevåg, Camilla H.; Röhrich, Dieter; Brekke, Njål; Odland, Odd Harald

    2015-12-01

    A neutron detector based on registration of radiation effects in Static Random Access Memories (SRAMs) has been developed at the University of Bergen for applications in particle therapy. Nine different SRAMs were tested and a 16 Mibit SRAM from Cypress was chosen for the final detector. The SRAMs were irradiated in beam lines at PTB Braunschweig, the Oslo Cyclotron Laboratory, The Svedberg Laboratory, The Institute for Energy Technology (IFE, Kjeller) and the CERN-EU high-energy reference field. The results from the measurements demonstrate the feasibility of using the selected SRAMs for neutron detection. The results indicate low or no sensitivity to thermal neutrons while the cross section for fast neutrons increases with neutron energy before reaching a more stable level at energies of several tenths of MeV.

  9. Are neutrons responsible for the dose discrepancies between Monte Carlo calculations and measurements in the build-up region for a high-energy photon beam?

    PubMed

    Ding, George X; Duzenli, Cheryl; Kalach, Nina I

    2002-09-07

    This study presents measured neutron dose using a neutron dosimeter in a water phantom and investigates a hypothesis that neutrons in a high-energy photon beam may be responsible for the reported significant dose discrepancies between Monte Carlo calculations and measurements at the build-up region in large fields. Borated polyethylene slabs were inserted between the accelerator head and the phantom in order to remove neutrons generated in the accelerator head. The thickness of the slab ranged from 2.5 cm to 10 cm. A lead slab of 3 mm thickness was also used in the study. The superheated drop neutron dosimeter was used to measure the depth-dose curve of neutrons in a high-energy photon beam and to verify the effectiveness of the slab to remove these neutrons. Total dose measurements were performed in water using a WELLHOFER WP700 beam scanner with an IC-10 ionization chamber. The Monte Carlo code BEAM was used to simulate an 18 MV photon beam from a Varian Clinac-2100EX accelerator. Both EGS4/DOSXYZ and EGSnrc/DOSRZnrc were used in the dose calculations. Measured neutron dose equivalents as a function of depth per unit total dose in water were presented for 10 x 10 and 40 x 40 cm2 fields. The measured results have shown that a 5-10 cm thick borated polyethylene slab can reduce the neutron dose by a factor of 2 when inserted between the accelerator head and the detector. In all cases the measured neutron dose equivalent was less than 0.5% of the photon dose. In order to study if the ion chamber was highly sensitive to the neutron dose, we have investigated the disagreement between the Monte Carlo calculated and measured central-axis depth-dose curves in the build-up region when different shielding materials were used. The result indicated that the IC-10 chamber was not highly sensitive to the neutron dose. Therefore, neutrons present in a high-energy photon beam were unlikely to be responsible for the reported discrepancies in the build-up region for large fields.

  10. Development of dose delivery verification by PET imaging of photonuclear reactions following high energy photon therapy

    NASA Astrophysics Data System (ADS)

    Janek, S.; Svensson, R.; Jonsson, C.; Brahme, A.

    2006-11-01

    A method for dose delivery monitoring after high energy photon therapy has been investigated based on positron emission tomography (PET). The technique is based on the activation of body tissues by high energy bremsstrahlung beams, preferably with energies well above 20 MeV, resulting primarily in 11C and 15O but also 13N, all positron-emitting radionuclides produced by photoneutron reactions in the nuclei of 12C, 16O and 14N. A PMMA phantom and animal tissue, a frozen hind leg of a pig, were irradiated to 10 Gy and the induced positron activity distributions were measured off-line in a PET camera a couple of minutes after irradiation. The accelerator used was a Racetrack Microtron at the Karolinska University Hospital using 50 MV scanned photon beams. From photonuclear cross-section data integrated over the 50 MV photon fluence spectrum the predicted PET signal was calculated and compared with experimental measurements. Since measured PET images change with time post irradiation, as a result of the different decay times of the radionuclides, the signals from activated 12C, 16O and 14N within the irradiated volume could be separated from each other. Most information is obtained from the carbon and oxygen radionuclides which are the most abundant elements in soft tissue. The predicted and measured overall positron activities are almost equal (-3%) while the predicted activity originating from nitrogen is overestimated by almost a factor of two, possibly due to experimental noise. Based on the results obtained in this first feasibility study the great value of a combined radiotherapy-PET-CT unit is indicated in order to fully exploit the high activity signal from oxygen immediately after treatment and to avoid patient repositioning. With an RT-PET-CT unit a high signal could be collected even at a dose level of 2 Gy and the acquisition time for the PET could be reduced considerably. Real patient dose delivery verification by means of PET imaging seems to be

  11. Development of dose delivery verification by PET imaging of photonuclear reactions following high energy photon therapy.

    PubMed

    Janek, S; Svensson, R; Jonsson, C; Brahme, A

    2006-11-21

    A method for dose delivery monitoring after high energy photon therapy has been investigated based on positron emission tomography (PET). The technique is based on the activation of body tissues by high energy bremsstrahlung beams, preferably with energies well above 20 MeV, resulting primarily in 11C and 15O but also 13N, all positron-emitting radionuclides produced by photoneutron reactions in the nuclei of 12C, 16O and 14N. A PMMA phantom and animal tissue, a frozen hind leg of a pig, were irradiated to 10 Gy and the induced positron activity distributions were measured off-line in a PET camera a couple of minutes after irradiation. The accelerator used was a Racetrack Microtron at the Karolinska University Hospital using 50 MV scanned photon beams. From photonuclear cross-section data integrated over the 50 MV photon fluence spectrum the predicted PET signal was calculated and compared with experimental measurements. Since measured PET images change with time post irradiation, as a result of the different decay times of the radionuclides, the signals from activated 12C, 16O and 14N within the irradiated volume could be separated from each other. Most information is obtained from the carbon and oxygen radionuclides which are the most abundant elements in soft tissue. The predicted and measured overall positron activities are almost equal (-3%) while the predicted activity originating from nitrogen is overestimated by almost a factor of two, possibly due to experimental noise. Based on the results obtained in this first feasibility study the great value of a combined radiotherapy-PET-CT unit is indicated in order to fully exploit the high activity signal from oxygen immediately after treatment and to avoid patient repositioning. With an RT-PET-CT unit a high signal could be collected even at a dose level of 2 Gy and the acquisition time for the PET could be reduced considerably. Real patient dose delivery verification by means of PET imaging seems to be

  12. Boron neutron capture therapy: Moving toward targeted cancer therapy.

    PubMed

    Mirzaei, Hamid Reza; Sahebkar, Amirhossein; Salehi, Rasoul; Nahand, Javid Sadri; Karimi, Ehsan; Jaafari, Mahmoud Reza; Mirzaei, Hamed

    2016-01-01

    Boron neutron capture therapy (BNCT) occurs when a stable isotope, boton-10, is irradiated with low-energy thermal neutrons to yield stripped down helium-4 nuclei and lithium-7 nuclei. It is a binary therapy in the treatment of cancer in which a cytotoxic event is triggered when an atom placed in a cancer cell. Here, we provide an overview on the application of BNCT in cancer therapy as well as current preclinical and clinical evidence on the efficacy of BNCT in the treatment of melanoma, brain tumors, head and neck cancer, and thyroid cancer. Several studies have shown that BNCT is effective in patients who had been treated with a full dose of conventional radiotherapy, because of its selectivity. In addition, BNCT is dependent on the normal/tumor tissue ratio of boron distribution. Increasing evidence has shown that BNCT can be combined with different drug delivery systems to enhance the delivery of boron to cancer cells. The flexibility of BNCT to be used in combination with different tumor-targeting approaches has made this strategy a promising option for cancer therapy. This review aims to provide a state-of-the-art overview of the recent advances in the use of BNCT for targeted therapy of cancer.

  13. A comprehensive spectrometry study of a stray neutron radiation field in scanning proton therapy

    NASA Astrophysics Data System (ADS)

    Mares, Vladimir; Romero-Expósito, Maite; Farah, Jad; Trinkl, Sebastian; Domingo, Carles; Dommert, Martin; Stolarczyk, Liliana; Van Ryckeghem, Laurent; Wielunski, Marek; Olko, Pawel; Harrison, Roger M.

    2016-06-01

    The purpose of this study is to characterize the stray neutron radiation field in scanning proton therapy considering a pediatric anthropomorphic phantom and a clinically-relevant beam condition. Using two extended-range Bonner sphere spectrometry systems (ERBSS), Working Group 9 of the European Radiation Dosimetry Group measured neutron spectra at ten different positions around a pediatric anthropomorphic phantom irradiated for a brain tumor with a scanning proton beam. This study compares the different systems and unfolding codes as well as neutron spectra measured in similar conditions around a water tank phantom. The ten spectra measured with two ERBSS systems show a generally similar thermal component regardless of the position around the phantom while high energy neutrons (above 20 MeV) were only registered at positions near the beam axis (at 0°, 329° and 355°). Neutron spectra, fluence and ambient dose equivalent, H *(10), values of both systems were in good agreement (<15%) while the unfolding code proved to have a limited effect. The highest H *(10) value of 2.7 μSv Gy-1 was measured at 329° to the beam axis and 1.63 m from the isocenter where high-energy neutrons (E  ⩾  20 MeV) contribute with about 53%. The neutron mapping within the gantry room showed that H *(10) values significantly decreased with distance and angular position with respect to the beam axis dropping to 0.52 μSv Gy-1 at 90° and 3.35 m. Spectra at angles of 45° and 135° with respect to the beam axis measured here with an anthropomorphic phantom showed a similar peak structure at the thermal, fast and high energy range as in the previous water-tank experiments. Meanwhile, at 90°, small differences at the high-energy range were observed. Using ERBSS systems, neutron spectra mapping was performed to characterize the exposure of scanning proton therapy patients. The ten measured spectra provide precise information about the exposure of healthy organs to thermal

  14. NIFTI and DISCOS: New concepts for a compact accelerator neutron source for boron neutron capture therapy applications

    SciTech Connect

    Powell, J.; Ludewig, H.; Todosow, M.; Reich, M.

    1995-06-01

    Two new concepts, NIFTI and DISCOS, are described. These concepts enable the efficient production of epithermal neutrons for BNCT (Boron Neutron Capture Therapy) medical treatment, utilizing a low current, low energy proton beam impacting on a lithium target. The NIFTI concept uses fluoride compounds, such as lead or beryllium fluoride, to efficiently degrade high energy neutrons from the lithium target to the lower energies required for BNCT. The fluoride compounds are in turn encased in an iron layer that strongly impedes the transmission of neutrons with energies above 24 KeV. Lower energy neutrons readily pass through this iron filter, which has a deep window in its scattering cross section at 24 KeV. The DISCOS concept uses a rapidly rotating, high g disc to create a series of thin ({approximately} 1 micron thickness) liquid lithium targets in the form of continuous films or sheets of discrete droplets--through which the proton beam passes. The average energy lost by a proton as it passes through a single target is small, approximately 10 KeV. Between the targets, the proton beam is re-accelerated by an applied DC electric field. The DISCOS approach enables the accelerator--target facility to operate with a beam energy only slightly above the threshold value for neutron production--resulting in an output beam of low-energy epithermal neutrons--while achieving a high yield of neutrons per milliamp of proton beam current. Parametric trade studies of the NIFTI and DISCOS concepts are described. These include analyses of a broad range of NIFTI designs using the Monte carlo MCNP neutronics code, as well as mechanical and thermal-hydraulic analyses of various DISCOS designs.

  15. Research needs for neutron capture therapy

    SciTech Connect

    1995-12-01

    Key issues and questions addressed by the workshop related to optimization of Boron Neutron Capture Therapy (BNCT), in general, and to the possibility of success of the present BNCT trials at Brookhaven National Laboratory (BNL) and Massachusetts Institute of Technology (MIT), in particular. Both trials use nuclear fission reactors as neutron sources for BNCT of glioblastoma multiforme (BNL) and of deep seated melanoma (MIT). Presentations and discussions focussed on optimal boron-labeled compounds, mainly for brain tumors such as glioblastoma multiforme, and the best mode of compound delivery to the tumor. Also, optimizing neutron irradiation with dose delivery to the tumor cells and the issues of dosimetry of BNCT especially in the brain were discussed. Planning of treatment and of follow-up of patients, coordination of BNCT at various treatment sites, and the potential of delivering BNCT to various types of cancer with an appropriately tailored protocol were additional issues. The need for multicentric interdisciplinary cooperation among the different medical specialties was highlighted.

  16. Progress in neutron capture therapy for cancer

    SciTech Connect

    Allen, B.J.; Harrington, B.V. ); Moore, D.E. )

    1992-01-01

    Prognosis for some cancers is good, but for others, few patients will survive 12 months. This latter group of cancers is characterised by a proclivity to disseminate malignant cells in the host organ. In some cases systemic metastases occur, but in other cases, failure to achieve local control results in death. First among these cancers are the high grade brain tumours, astrocytoma 3,4 and glioblastoma multiforme. Local control of these tumors should lead to cure. Other cancers melanoma metastatic to the brain, for which a useful palliative therapy is not yet available, and pancreatic cancer for which localised control at an early stage could bring about improved prognosis. Patients with these cancers have little grounds for hope. Our primary objective is to reverse this situation with Neutron Capture Therapy (NCT). The purpose of this fourth symposium is to hasten the day whereby patients with these cancers can reasonably hope for substantial remissions.

  17. Progress in neutron capture therapy for cancer

    SciTech Connect

    Allen, B.J.; Harrington, B.V.; Moore, D.E.

    1992-09-01

    Prognosis for some cancers is good, but for others, few patients will survive 12 months. This latter group of cancers is characterised by a proclivity to disseminate malignant cells in the host organ. In some cases systemic metastases occur, but in other cases, failure to achieve local control results in death. First among these cancers are the high grade brain tumours, astrocytoma 3,4 and glioblastoma multiforme. Local control of these tumors should lead to cure. Other cancers melanoma metastatic to the brain, for which a useful palliative therapy is not yet available, and pancreatic cancer for which localised control at an early stage could bring about improved prognosis. Patients with these cancers have little grounds for hope. Our primary objective is to reverse this situation with Neutron Capture Therapy (NCT). The purpose of this fourth symposium is to hasten the day whereby patients with these cancers can reasonably hope for substantial remissions.

  18. Head phantom experiment and calculation for boron neutron capture therapy.

    PubMed

    Matsumoto, T; Aizawa, O

    1988-06-01

    Head phantom experiments with various neutron beams and calculations were carried out in order to provide useful information for boron neutron capture therapy (BNCT). Thermal neutron beams for thermal neutron capture therapy were used for phantom experiments with various neutron collimator aperture sizes. The filtered beam neutrons of 24 and 144 keV generated with iron and silicon filters were also used to investigate the possible application of BNCT in the treatment of deep-seated cancers. Thermal neutron fluence and induced capture gamma dose distributions within the phantom were calculated with a transport code DOT 3.5 and compared with the experimental results. The results showed that the calculation used was consistent with the experimental results and provided useful information on BNCT. The filtered beam neutron may be very useful for the treatment of deep or widespread cancer, if there were a high power research reactor constructed for this purpose.

  19. Liposomal boron delivery for neutron capture therapy.

    PubMed

    Nakamura, Hiroyuki

    2009-01-01

    Tumor cell destruction in boron neutron capture therapy (BNCT) is due to the nuclear reaction between (10)B and thermal neutrons. The thermal neutrons have an energy of 0.025 eV, clearly below the threshold energy required to ionize tissue components. However, neutron capture by (10)B produces lithium ion and helium (alpha-particles), which are high linear energy transfer (LET) particles, and dissipate their kinetic energy before traveling one cell diameter (5-9 microm) in biological tissues, ensuring their potential for precise cell killing. BNCT has been applied clinically for the treatment of malignant brain tumors, malignant melanoma, head and neck cancer, and hepatoma using two boron compounds: sodium borocaptate (Na(2)(10)B(12)H(11)SH; Na(2)(10)BSH) and l-p-boronophenylalanine (l-(10)BPA). These low molecular weight compounds are cleared easily from the cancer cells and blood. Therefore, high accumulation and selective delivery of boron compounds into tumor tissues are most important to achieve effective BNCT and to avoid damage of adjacent healthy cells. Much attention has been focused on the liposomal drug delivery system (DDS) as an attractive, intelligent technology of targeting and controlled release of (10)B compounds. Two approaches have been investigated for incorporation of (10)B into liposomes: (1) encapsulation of (10)B compounds into liposomes and (2) incorporation of (10)B-conjugated lipids into the liposomal bilayer. Our laboratory has developed boron ion cluster lipids for application of the latter approach. In this chapter, our boron lipid liposome approaches as well as recent developments of the liposomal boron delivery system are summarized.

  20. Neutron capture therapy: Years of experimentation---Years of reflection

    SciTech Connect

    Farr, L.E.

    1991-12-16

    This report describes early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments. This work carried out over eighteen years, beginning over forty years ago. Yet, it is only fitting to start by relating how neutron capture therapy became part of Brookhaven's Medical Research Center program.

  1. Measurements of the neutron dose equivalent for various radiation qualities, treatment machines and delivery techniques in radiation therapy

    NASA Astrophysics Data System (ADS)

    Hälg, R. A.; Besserer, J.; Boschung, M.; Mayer, S.; Lomax, A. J.; Schneider, U.

    2014-05-01

    In radiation therapy, high energy photon and proton beams cause the production of secondary neutrons. This leads to an unwanted dose contribution, which can be considerable for tissues outside of the target volume regarding the long term health of cancer patients. Due to the high biological effectiveness of neutrons in regards to cancer induction, small neutron doses can be important. This study quantified the neutron doses for different radiation therapy modalities. Most of the reports in the literature used neutron dose measurements free in air or on the surface of phantoms to estimate the amount of neutron dose to the patient. In this study, dose measurements were performed in terms of neutron dose equivalent inside an anthropomorphic phantom. The neutron dose equivalent was determined using track etch detectors as a function of the distance to the isocenter, as well as for radiation sensitive organs. The dose distributions were compared with respect to treatment techniques (3D-conformal, volumetric modulated arc therapy and intensity-modulated radiation therapy for photons; spot scanning and passive scattering for protons), therapy machines (Varian, Elekta and Siemens linear accelerators) and radiation quality (photons and protons). The neutron dose equivalent varied between 0.002 and 3 mSv per treatment gray over all measurements. Only small differences were found when comparing treatment techniques, but substantial differences were observed between the linear accelerator models. The neutron dose equivalent for proton therapy was higher than for photons in general and in particular for double-scattered protons. The overall neutron dose equivalent measured in this study was an order of magnitude lower than the stray dose of a treatment using 6 MV photons, suggesting that the contribution of the secondary neutron dose equivalent to the integral dose of a radiotherapy patient is small.

  2. Measurements of the neutron dose equivalent for various radiation qualities, treatment machines and delivery techniques in radiation therapy.

    PubMed

    Hälg, R A; Besserer, J; Boschung, M; Mayer, S; Lomax, A J; Schneider, U

    2014-05-21

    In radiation therapy, high energy photon and proton beams cause the production of secondary neutrons. This leads to an unwanted dose contribution, which can be considerable for tissues outside of the target volume regarding the long term health of cancer patients. Due to the high biological effectiveness of neutrons in regards to cancer induction, small neutron doses can be important. This study quantified the neutron doses for different radiation therapy modalities. Most of the reports in the literature used neutron dose measurements free in air or on the surface of phantoms to estimate the amount of neutron dose to the patient. In this study, dose measurements were performed in terms of neutron dose equivalent inside an anthropomorphic phantom. The neutron dose equivalent was determined using track etch detectors as a function of the distance to the isocenter, as well as for radiation sensitive organs. The dose distributions were compared with respect to treatment techniques (3D-conformal, volumetric modulated arc therapy and intensity-modulated radiation therapy for photons; spot scanning and passive scattering for protons), therapy machines (Varian, Elekta and Siemens linear accelerators) and radiation quality (photons and protons). The neutron dose equivalent varied between 0.002 and 3 mSv per treatment gray over all measurements. Only small differences were found when comparing treatment techniques, but substantial differences were observed between the linear accelerator models. The neutron dose equivalent for proton therapy was higher than for photons in general and in particular for double-scattered protons. The overall neutron dose equivalent measured in this study was an order of magnitude lower than the stray dose of a treatment using 6 MV photons, suggesting that the contribution of the secondary neutron dose equivalent to the integral dose of a radiotherapy patient is small.

  3. Dose prescription in boron neutron capture therapy

    SciTech Connect

    Gupta, N.M.S.; Gahbauer, R.A. ); Blue, T.E. ); Wambersie, A. )

    1994-03-30

    The purpose of this paper is to address some aspects of the many considerations that need to go into a dose prescription in boron neutron capture therapy (BNCT) for brain tumors; and to describe some methods to incorporate knowledge from animal studies and other experiments into the process of dose prescription. Previously, an algorithm to estimate the normal tissue tolerance to mixed high and low linear energy transfer radiations in BNCT was proposed. The authors have developed mathematical formulations and computational methods to represent this algorithm. Generalized models to fit the central axis dose rate components for an epithermal neutron field were also developed. These formulations and beam fitting models were programmed into spreadsheets to simulate two treatment techniques which are expected to be used in BNCT: a two-field bilateral scheme and a single-field treatment scheme. Parameters in these spreadsheets can be varied to represent the fractionation scheme used, the [sup 10]B microdistribution in normal tissue, and the ratio of [sup 10]B in tumor to normal tissue. Most of these factors have to be determined for a given neutron field and [sup 10]B compound combination from large animal studies. The spreadsheets have been programmed to integrate all of the treatment-related information and calculate the location along the central axis where the normal tissue tolerance is exceeded first. This information is then used to compute the maximum treatment time allowable and the maximum tumor dose that may be delivered for a given BNCT treatment. The effect of different treatment variables on the treatment time and tumor dose has been shown to be very significant. It has also been shown that the location of D[sub max] shifts significantly, depending on some of the treatment variables-mainly the fractionation scheme used. These results further emphasize the fact that dose prescription in BNCT is very complicated and nonintuitive. 11 refs., 6 figs., 3 tabs.

  4. Boron thermal/epithermal neutron capture therapy

    SciTech Connect

    Fairchild, R.G.

    1982-01-01

    The development of various particle beams for radiotherapy represents an attempt to improve dose distribution, and to provide high LET radiations which are less sensitive to ambient physical and radiobiological factors such as oxygen tension, cell cycle, and dose rate. In general, a compromise is necessary as effective RBE is reduced in order to spread the dose distribution over the anticipated tumor volume. The approach of delivering stable non-toxic isotopes to tumor, and then activating these atoms subsequently via an external radiation beam has mator advantages; problems associated with high uptake of these isotopes in competing cell pools are obviated, and the general tumor volume can be included in the treatment field of the activating beam. As long as the normal tissues supporting tumor show a low uptake of the isotope to be activated, and as long as the range of the reaction products is short, dose will be restricted to tumor, with a consequent high therapeutic ratio. Neutron Capture Therapy (NCT) is generally carried out by activating boron-10 with low energy neutrons. The range of the high LET, low OER particles from the /sup 10/B(n, ..cap alpha..)/sup 7/Li reaction is approx. 10..mu.., or one cell diameter, a situation that is optimal for cell killing. Significant advantages may be gained by using the NCT procedure in conjunction with improved tissue penetration provided with epithermal or filtered beams, and new compounds showing physiological binding to tumor.

  5. Out-of-field neutron and leakage photon exposures and the associated risk of second cancers in high-energy photon radiotherapy: current status.

    PubMed

    Takam, R; Bezak, E; Marcu, L G; Yeoh, E

    2011-10-01

    Determination and understanding of out-of-field neutron and photon doses in accelerator-based radiotherapy is an important issue since linear accelerators operating at high energies (>10 MV) produce secondary radiations that irradiate parts of the patient's anatomy distal to the target region, potentially resulting in detrimental health effects. This paper provides a compilation of data (technical and clinical) reported in the literature on the measurement and Monte Carlo simulations of peripheral neutron and photon doses produced from high-energy medical linear accelerators and the reported risk and/or incidence of second primary cancer of tissues distal to the target volume. Information in the tables facilitates easier identification of (1) the various methods and measurement techniques used to determine the out-of-field neutron and photon radiations, (2) reported linac-dependent out-of-field doses, and (3) the risk/incidence of second cancers after radiotherapy due to classic and modern treatment methods. Regardless of the measurement technique and type of accelerator, the neutron dose equivalent per unit photon dose ranges from as low as 0.1 mSv/Gy to as high as 20.4 mSv/Gy. This radiation dose potentially contributes to the induction of second primary cancer in normal tissues outside the treated area.

  6. Neutron sources for a neutron capture therapy facility

    SciTech Connect

    Lennox, A.J.

    1993-04-01

    Recent advances in the development of boron pharmaceuticals have reopened the possibility of using epithermal neutrons to treat brain tumors containing boron-10. This paper summarizes the approaches being used to generate the neutron sources and identifies specific areas where more research and development are needed.

  7. A fundamental study on hyper-thermal neutrons for neutron capture therapy.

    PubMed

    Sakurai, Y; Kobayashi, T; Kanda, K

    1994-12-01

    The utilization of hyper-thermal neutrons, which have an energy spectrum with a Maxwellian distribution at a higher temperature than room temperature (300 K), was studied in order to improve the thermal neutron flux distribution at depth in a living body for neutron capture therapy. Simulation calculations were carried out using a Monte Carlo code 'MCNP-V3' in order to investigate the characteristics of hyper-thermal neutrons, i.e. (i) depth dependence of the neutron energy spectrum, and (ii) depth distribution of the reaction rate in a water phantom for materials with 1/v neutron absorption. It is confirmed that hyper-thermal neutron irradiation can improve the thermal neutron flux distribution in the deeper areas in a living body compared with thermal neutron irradiation. When hyper-thermal neutrons with a 3000 K Maxwellian distribution are incident on a body, the reaction rates of 1/v materials such as 14N, 10B etc are about twice that observed for incident thermal neutrons at 300 K, at a depth of 5 cm. The limit of the treatable depth for tumours having 30 ppm 10B is expected to be about 1.5 cm greater by utilizing hyper-thermal neutrons at 3000 K compared with the incidence of thermal neutrons at 300 K.

  8. Neutron therapy for salivary and thyroid gland cancer

    NASA Astrophysics Data System (ADS)

    Gribova, O. V.; Musabaeva, L. I.; Choynzonov, E. L.; Lisin, V. A.; Novikov, V. A.

    2016-08-01

    The purpose of this study was to analyze the results of the combined modality treatment and radiation therapy using 6.3 MeV fast neutrons for salivary gland cancer and prognostically unfavorable thyroid gland cancer. The study group comprised 127 patients with salivary gland cancer and 46 patients with thyroid gland cancer, who received neutron therapy alone and in combination with surgery. The results obtained demonstrated that the combined modality treatment including fast neutron therapy led to encouraging local control in patients with salivary and thyroid gland cancers.

  9. Scintillating Fiber Array Characterization and Alignment for Neutron Imaging using the High Energy X-ray (HEX) Facility

    SciTech Connect

    Buckles, R. A., Ali, Z. A., Cradick, J. R., Traille, A. J., Warthan, W. A.

    2009-09-04

    The Neutron Imager diagnostic at the National Ignition Facility (NIF) located at Lawrence Livermore National Laboratory (LLNL) will produce high-resolution, gated images of neutron-generating implosions. A similar pinhole imaging experiment (PINEX) diagnostic was recently deployed at the Z facility at Sandia National Laboratories (SNL). Both the SNL and LLNL neutron imagers use similar fiber array scintillators (BCF-99-555). Despite diverse resolution and magnification requirements, both diagnostics put significant onus on the scintillator spatial quality and alignment precision to maintain optimal point spread. Characterization and alignment of the Z-PINEX scintillator and imaging system were done at NSTec/Livermore Operations in 2009, and is currently underway for the NIF Neutron Imager.

  10. Laser-plasma generated very high energy electrons in radiation therapy of the prostate

    NASA Astrophysics Data System (ADS)

    DesRosiers, Colleen; Moskvin, Vadim; Cao, Minsong; Joshi, Chandrashekhar J.; Langer, Mark

    2008-02-01

    Monte Carlo simulation experiments have shown that very high energy electrons (VHEE), 150-250 MeV, have potential advantages in prostate cancer treatment over currently available electrons, photon and proton beam treatment. Small diameter VHEE beamlets can be scanned, thereby producing a finer resolution intensity modulated treatment than photon beams. VHEE beams may be delivered with greater precision and accelerators may be constructed at significantly lower cost than proton beams. A VHEE accelerator may be optimally designed using laser-plasma technology. If the accelerator is constructed to additionally produce low energy photon beams along with VHEE, real time imaging, bioprobing, and dose enhancement may be performed simultaneously. This paper describes a Monte Carlo experiment, using the parameters of the electron beam from the UCLA laser-plasma wakefield accelerator, whereby dose distributions on a human prostate are generated. The resulting dose distributions of the very high energy electrons are shown to be comparable to photon beam dose distributions. This simple experiment illustrates that the nature of the dose distribution of electrons is comparable to that of photons. However, the main advantage of electrons over photons and protons lies in the delivery and manipulation of electrons, rather than the nature of the dose distribution. This paper describes the radiation dose delivery of electrons employing technologies currently in exploration and evaluates potential benefits as compared with currently available photon and protons beams in the treatment of prostate and other cancers, commonly treated with radiation.

  11. Neutron capture therapy: Years of experimentation---Years of reflection

    SciTech Connect

    Farr, L.E.

    1991-12-16

    This report describes early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments. This work carried out over eighteen years, beginning over forty years ago. Yet, it is only fitting to start by relating how neutron capture therapy became part of Brookhaven`s Medical Research Center program.

  12. Neutron capture therapy research in Australia.

    PubMed

    Allen, B J

    1989-01-01

    Neutron capture therapy research in Australia has continued to grow since the first Australia-Japan workshop in April, 1986. The support base has broadened and the wide range of contributing laboratories includes universities, research institutes, and hospitals. Considerable progress has been made in boron chemistry--an accurate boron assay technique has been developed, boron analogues of chlorpromazine and thiouracil have been synthesised or nearly so, and decaborane conjugation with monoclonal antibodies has been achieved to the required loadings. In vitro cell survival experiments are proceeding in the Moata reactor using human melanoma and mouse cell lines incubated with enriched boronophenylalanine and boron tetraphenyl porphyrins. Electron microscopy examination of radiation damaged morphology shows considerable differences between cell lines. Progress with the nude mouse human melanoma model has been slow because of the lack of a reliable in vivo melanotic melanoma line, and the B16 mouse line is found to be more efficacious. Tailored beam calculations for the 10 MW HIFAR reactor indicate the difficulty of obtaining a suitable therapeutic beam because of the generated gamma dose in the beam filters. A new approach to NCT utilises the enormous cross section of 157Gd and the induced-Auger effect which has been shown to cause double strand breaks in circular DNA.

  13. Neutron capture therapy research in Australia

    SciTech Connect

    Allen, B.J.

    1989-07-01

    Neutron capture therapy research in Australia has continued to grow since the first Australia-Japan workshop in April, 1986. The support base has broadened and the wide range of contributing laboratories includes universities, research institutes, and hospitals. Considerable progress has been made in boron chemistry--an accurate boron assay technique has been developed, boron analogues of chlorpromazine and thiouracil have been synthesised or nearly so, and decaborane conjugation with monoclonal antibodies has been achieved to the required loadings. In vitro cell survival experiments are proceeding in the Moata reactor using human melanoma and mouse cell lines incubated with enriched boronophenylalanine and boron tetraphenyl porphyrins. Electron microscopy examination of radiation damaged morphology shows considerable differences between cell lines. Progress with the nude mouse human melanoma model has been slow because of the lack of a reliable in vivo melanotic melanoma line, and the B16 mouse line is found to be more efficacious. Tailored beam calculations for the 10 MW HIFAR reactor indicate the difficulty of obtaining a suitable therapeutic beam because of the generated gamma dose in the beam filters. A new approach to NCT utilises the enormous cross section of 157Gd and the induced-Auger effect which has been shown to cause double strand breaks in circular DNA. 34 references.

  14. [Boron neutron capture therapy (BNCT) as cancer treatment].

    PubMed

    Joensuu, Heikki; Kankaanranta, Leena; Tenhunen, Mikko; Saarilahti, Kauko

    2011-01-01

    Boron neutron capture therapy leads to a strong local radiotherapy effect. The efficacy of the method in cancer therapy requires sufficient accumulation of boron into and a fairly superficial location of the tumor. The efficacy and tolerability of this therapy has been investigated in Finland especially in locally recurring head and neck cancer. These tumors have responded favorably to boron neutron capture therapy and the treatment has been relatively well tolerated, although most cancers have recurred locally with few cases of durable complete remission.

  15. Monte Carlo simulation of the neutron spectral fluence and dose equivalent for use in shielding a proton therapy vault.

    PubMed

    Zheng, Yuanshui; Newhauser, Wayne; Klein, Eric; Low, Daniel

    2009-11-21

    Neutron production is of principal concern when designing proton therapy vault shielding. Conventionally, neutron calculations are based on analytical methods, which do not accurately consider beam shaping components and nozzle shielding. The goal of this study was to calculate, using Monte Carlo modeling, the neutron spectral fluence and neutron dose equivalent generated by a realistic proton therapy nozzle and evaluate how these data could be used in shielding calculations. We modeled a contemporary passive scattering proton therapy nozzle in detail with the MCNPX simulation code. The neutron spectral fluence and dose equivalent at various locations in the treatment room were calculated and compared to those obtained from a thick iron target bombarded by parallel proton beams, the simplified geometry on which analytical methods are based. The neutron spectral fluence distributions were similar for both methods, with deeply penetrating high-energy neutrons (E > 10 MeV) being most prevalent along the beam central axis, and low-energy neutrons predominating the neutron spectral fluence in the lateral region. However, unlike the inverse square falloff used in conventional analytical methods, this study shows that the neutron dose equivalent per therapeutic dose in the treatment room decreased with distance approximately following a power law, with an exponent of about -1.63 in the lateral region and -1.73 in the downstream region. Based on the simulated data according to the detailed nozzle modeling, we developed an empirical equation to estimate the neutron dose equivalent at any location and distance in the treatment vault, e.g. for cases in which detailed Monte Carlo modeling is not feasible. We applied the simulated neutron spectral fluence and dose equivalent to a shielding calculation as an example.

  16. High energy neutron response characteristics of a passive survey instrument for the determination of cosmic radiation fields in aircraft.

    PubMed

    Bartlett, D T; Tanner, R J; Hager, L G

    2002-01-01

    A passive survey instrument has been developed for the determination of cosmic radiation fields in aircraft. The instrument contains 30 TLDs and 36 PADC etched track detectors in order to obtain the required precision and an isotropic response. Two active electronic personal dosemeters are included to record the time profile of the field intensity. The instrument is robust and reliable, and is particularly useful to verify values of route doses based on calculations. The energy of the neutron component of the field to be determined extends to over 500 MeV, but with the majority of the dose equivalent below 200 MeV. The results are reported of measurements at Uppsala University and Physikalisch-Technische Bundesanstalt of the response characteristics of the instrument to quasi-monoenergetic neutrons in the energy range 60 to 180 MeV and for monoenergetic neutrons of energy from 70 keV to 14.7 MeV.

  17. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy

    DOEpatents

    Miura, Michiko; Slatkin, Daniel N.

    1997-03-18

    A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na.sub.4 B.sub.12 I.sub.11 SSB.sub.12 I.sub.11, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy.

  18. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy

    DOEpatents

    Miura, Michiko; Slatkin, Daniel N.

    1995-10-03

    A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na.sub.4 B.sub.12 I.sub.11 SSB.sub.12 I.sub.11, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy.

  19. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy

    DOEpatents

    Miura, Michiko; Slatkin, Daniel N.

    1997-08-05

    A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized. by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na.sub.4 B.sub.12 I.sub.11 SSB.sub.12 I.sub.11, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy.

  20. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy

    DOEpatents

    Miura, M.; Slatkin, D.N.

    1995-10-03

    A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na{sub 4}B{sub 12}I{sub 11}SSB{sub 12}I{sub 11}, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy. 1 fig.

  1. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy

    DOEpatents

    Miura, M.; Slatkin, D.N.

    1997-03-18

    A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na{sub 4}B{sub 12}I{sub 11}SSB{sub 12}I{sub 11}, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy. 1 fig.

  2. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy

    DOEpatents

    Miura, M.; Slatkin, D.N.

    1997-08-05

    A method for performing boron neutron capture therapy for the treatment of tumors is disclosed. The method includes administering to a patient an iodinated sulfidohydroborane, a boron-10-containing compound. The site of the tumor is localized by visualizing the increased concentration of the iodine labelled compound at the tumor. The targeted tumor is then irradiated with a beam of neutrons having an energy distribution effective for neutron capture. Destruction of the tumor occurs due to high LET particle irradiation of the tissue secondary to the incident neutrons being captured by the boron-10 nuclei. Iodinated sulfidohydroboranes are disclosed which are especially suitable for the method of the invention. In a preferred embodiment, a compound having the formula Na{sub 4}B{sub 12}I{sub 11}SSB{sub 12}I{sub 11}, or another pharmaceutically acceptable salt of the compound, may be administered to a cancer patient for boron neutron capture therapy. 1 fig.

  3. Immediate Dose-Response Effect of High-Energy Versus Low-Energy Extracorporeal Shock Wave Therapy on Cutaneous Microcirculation.

    PubMed

    Kraemer, Robert; Sorg, Heiko; Forstmeier, Vinzent; Knobloch, Karsten; Liodaki, Eirini; Stang, Felix Hagen; Mailaender, Peter; Kisch, Tobias

    2016-12-01

    Elucidation of the precise mechanisms and therapeutic options of extracorporeal shock wave therapy (ESWT) is only at the beginning. Although immediate real-time effects of ESWT on cutaneous hemodynamics have recently been described, the dose response to different ESWT energies in cutaneous microcirculation has never been examined. Thirty-nine Sprague-Dawley rats were randomly assigned to three groups that received either focused high-energy shock waves (group A: total of 1000 impulses, 10 J) to the lower leg of the hind limb, focused low-energy shock waves (group B: total of 300 impulses, 1 J) or placebo shock wave treatment (group C: 0 impulses, 0 J) using a multimodality shock wave delivery system (Duolith SD-1 T-Top, Storz Medical, Tägerwilen, Switzerland). Immediate microcirculatory effects were assessed with the O2C (oxygen to see) system (LEA Medizintechnik, Giessen, Germany) before and for 20 min after application of ESWT. Cutaneous tissue oxygen saturation increased significantly higher after high-energy ESWT than after low-energy and placebo ESWT (A: 29.4% vs. B: 17.3% vs. C: 3.3%; p = 0.003). Capillary blood velocity was significantly higher after high-energy ESWT and lower after low-energy ESWT versus placebo ESWT (group A: 17.8% vs. group B: -22.1% vs. group C: -5.0%, p = 0.045). Post-capillary venous filling pressure was significantly enhanced in the high-energy ESWT group in contrast to the low-energy ESWT and placebo groups (group A: 25% vs. group B: 2% vs. group C: -4%, p = 0.001). Both high-energy and low-energy ESWT affect cutaneous hemodynamics in a standard rat model. High-energy ESWT significantly increases parameters of cutaneous microcirculation immediately after application, resulting in higher tissue oxygen saturation, venous filling pressure and blood velocity, which suggests higher tissue perfusion with enhanced oxygen saturation, in contrast to low-energy as well as placebo ESWT. Low-energy ESWT also increased tissue oxygen

  4. Alterations in dose and lineal energy spectra under different shieldings in the Los Alamos high-energy neutron field

    NASA Technical Reports Server (NTRS)

    Badhwar, G. D.; Huff, H.; Wilkins, R.

    2000-01-01

    Nuclear interactions of space radiation with shielding materials result in alterations in dose and lineal energy spectra that depend on the specific elemental composition, density and thickness of the material. The shielding characteristics of materials have been studied using charged-particle beams and radiation transport models by examining the risk reduction using the conventional dose-equivalent approach. Secondary neutrons contribute a significant fraction of the total radiation exposure in space. An experiment to study the changes in dose and lineal energy spectra by shielding materials was carried out at the Los Alamos Nuclear Science Center neutron facility. In the energy range of about 2 to 200 MeV, this neutron spectrum is similar in shape within a factor of about 2 to the spectrum expected in the International Space Station habitable modules. It is shown that with a shielding thickness of about 5 g cm(-2), the conventional radiation risk increases, in some cases by as much as a factor of 2, but decreases with thicknesses of about of 20 g cm(-2). This suggests that care must be taken in evaluating the shielding effectiveness of a given material by including both the charged-particle and neutron components of space radiation.

  5. Tissue composition effect on dose distribution in neutron brachytherapy/neutron capture therapy

    PubMed Central

    Khosroabadi, Mohsen; Farhood, Bagher; Ghorbani, Mahdi; Hamzian, Nima; Moghaddam, Homa Rezaei; Davenport, David

    2016-01-01

    Aim The aim of this study is to assess the effect of the compositions of various soft tissues and tissue-equivalent materials on dose distribution in neutron brachytherapy/neutron capture therapy. Background Neutron brachytherapy and neutron capture therapy are two common radiotherapy modalities. Materials and methods Dose distributions were calculated around a low dose rate 252Cf source located in a spherical phantom with radius of 20.0 cm using the MCNPX code for seven soft tissues and three tissue-equivalent materials. Relative total dose rate, relative neutron dose rate, total dose rate, and neutron dose rate were calculated for each material. These values were determined at various radial distances ranging from 0.3 to 15.0 cm from the source. Results Among the soft tissues and tissue-equivalent materials studied, adipose tissue and plexiglass demonstrated the greatest differences for total dose rate compared to 9-component soft tissue. The difference in dose rate with respect to 9-component soft tissue varied with compositions of the materials and the radial distance from the source. Furthermore, the total dose rate in water was different from that in 9-component soft tissue. Conclusion Taking the same composition for various soft tissues and tissue-equivalent media can lead to error in treatment planning in neutron brachytherapy/neutron capture therapy. Since the International Commission on Radiation Units and Measurements (ICRU) recommends that the total dosimetric uncertainty in dose delivery in radiotherapy should be within ±5%, the compositions of various soft tissues and tissue-equivalent materials should be considered in dose calculation and treatment planning in neutron brachytherapy/neutron capture therapy. PMID:26900352

  6. Measurements of High Energy Neutron Spectrum (> 10 MeV) by Using Yttrium Foils in a U/Pb Assembly

    NASA Astrophysics Data System (ADS)

    Bielewicz, M.; Strugalska-Gola, E.; Szuta, M.; Wojciechowski, A.; Kadykov, M.; Tyutyunnikov, S.

    2014-05-01

    Study of deep subcritical electronuclear systems and radioactive waste transmutation using relativistic beams were performed. This work is a preliminary step toward the study of the physical properties of Accelerator Driven Systems, in which a deeply subcritical active core is irradiated by a pulsed beam of relativistic ions. The long-range goal of the project is to study the capabilities of such systems with a hard neutron spectrum, for transmutation of radioactive nuclear wastes. Two experimental assemblies, “Energy plus Transmutation” (2006-2009) and “Quinta” (2011-), were irradiated by 1 to 6 GeV deuteron beams using the JINR NUCLOTRON accelerator. The main difference between the two experimental setups is the spallation target - lead or natural uranium. We attempt to obtain neutron energy spectra inside the volume of these assemblies using threshold reactions in natural yttrium (89Y) foils. Some results from three different experiments are presented.

  7. Neutron and proton therapy in the treatment of cancer

    SciTech Connect

    Lennox, A.J. |

    1996-08-01

    Several decades of clinical research have established that neutron and proton therapy constitute useful and practical additions to the radiation oncologist`s treatment modalities. This paper discusses the rationale for using these therapies and describes practical solutions to their implementation.

  8. Accelerator Based Neutron Beams for Neutron Capture Therapy

    SciTech Connect

    Yanch, Jacquelyn C.

    2003-04-11

    The DOE-funded accelerator BNCT program at the Massachusetts Institute of Technology has resulted in the only operating accelerator-based epithermal neutron beam facility capable of generating significant dose rates in the world. With five separate beamlines and two different epithermal neutron beam assemblies installed, we are currently capable of treating patients with rheumatoid arthritis in less than 15 minutes (knee joints) or 4 minutes (finger joints) or irradiating patients with shallow brain tumors to a healthy tissue dose of 12.6 Gy in 3.6 hours. The accelerator, designed by Newton scientific Incorporated, is located in dedicated laboratory space that MIT renovated specifically for this project. The Laboratory for Accelerator Beam Applications consists of an accelerator room, a control room, a shielded radiation vault, and additional laboratory space nearby. In addition to the design, construction and characterization of the tandem electrostatic accelerator, this program also resulted in other significant accomplishments. Assemblies for generating epithermal neutron beams were designed, constructed and experimentally evaluated using mixed-field dosimetry techniques. Strategies for target construction and target cooling were implemented and tested. We demonstrated that the method of submerged jet impingement using water as the coolant is capable of handling power densities of up to 6 x 10(sup 7) W/m(sup 2) with heat transfer coefficients of 10(sup 6)W/m(sup 2)-K. Experiments with the liquid metal gallium demonstrated its superiority compared with water with little effect on the neutronic properties of the epithermal beam. Monoenergetic proton beams generated using the accelerator were used to evaluate proton RBE as a function of LET and demonstrated a maximum RBE at approximately 30-40 keV/um, a finding consistent with results published by other researchers. We also developed an experimental approach to biological intercomparison of epithermal beams and

  9. High Energy Neutrinos Produced in the Accretion Disks by Neutrons from Nuclei Disintegrated in the AGN Jets

    NASA Astrophysics Data System (ADS)

    Bednarek, W.

    2016-12-01

    We investigate the consequences of acceleration of nuclei in jets of active galaxies not far from the surface of an accretion disk. The nuclei can be accelerated in the re-connection regions in the jet and/or at the jet boundary, between the relativistic jet and its cocoon. It is shown that the relativistic nuclei can efficiently fragment onto specific nucleons in collisions with the disk radiation. Neutrons, directed toward the accretion disk, take a significant part of energy from the relativistic nuclei. These neutrons develop a cascade in the dense accretion disk. We calculate the neutrino spectra produced in such a hadronic cascade within the accretion disk. We propose that the neutrinos produced in such a scenario, from the whole population of super-massive black holes in active galaxies, can explain the extragalactic neutrino background recently measured by the IceCube neutrino detector, provided that a 5% fraction of galaxies have an active galactic nucleus and a few percent of neutrons reach the accretion disk. We predict that the neutrino signals in the present neutrino detectors, produced in terms of such a model, will not be detectable even from the nearby radio galaxies similar to M87.

  10. Search for Sources of High-energy Neutrons with Four Years of Data from the IceTop Detector

    NASA Astrophysics Data System (ADS)

    Aartsen, M. G.; Abraham, K.; Ackermann, M.; Adams, J.; Aguilar, J. A.; Ahlers, M.; Ahrens, M.; Altmann, D.; Andeen, K.; Anderson, T.; Ansseau, I.; Anton, G.; Archinger, M.; Argüelles, C.; Auffenberg, J.; Axani, S.; Bai, X.; Barwick, S. W.; Baum, V.; Bay, R.; Beatty, J. J.; Becker Tjus, J.; Becker, K.-H.; BenZvi, S.; Berghaus, P.; Berley, D.; Bernardini, E.; Bernhard, A.; Besson, D. Z.; Binder, G.; Bindig, D.; Bissok, M.; Blaufuss, E.; Blot, S.; Bohm, C.; Börner, M.; Bos, F.; Bose, D.; Böser, S.; Botner, O.; Braun, J.; Brayeur, L.; Bretz, H.-P.; Burgman, A.; Carver, T.; Casier, M.; Cheung, E.; Chirkin, D.; Christov, A.; Clark, K.; Classen, L.; Coenders, S.; Collin, G. H.; Conrad, J. M.; Cowen, D. F.; Cross, R.; Day, M.; de André, J. P. A. M.; De Clercq, C.; del Pino Rosendo, E.; Dembinski, H.; De Ridder, S.; Desiati, P.; de Vries, K. D.; de Wasseige, G.; de With, M.; DeYoung, T.; Díaz-Vélez, J. C.; di Lorenzo, V.; Dujmovic, H.; Dumm, J. P.; Dunkman, M.; Eberhardt, B.; Ehrhardt, T.; Eichmann, B.; Eller, P.; Euler, S.; Evenson, P. A.; Fahey, S.; Fazely, A. R.; Feintzeig, J.; Felde, J.; Filimonov, K.; Finley, C.; Flis, S.; Fösig, C.-C.; Franckowiak, A.; Friedman, E.; Fuchs, T.; Gaisser, T. K.; Gallagher, J.; Gerhardt, L.; Ghorbani, K.; Giang, W.; Gladstone, L.; Glagla, M.; Glüsenkamp, T.; Goldschmidt, A.; Golup, G.; Gonzalez, J. G.; Grant, D.; Griffith, Z.; Haack, C.; Haj Ismail, A.; Hallgren, A.; Halzen, F.; Hansen, E.; Hansmann, B.; Hansmann, T.; Hanson, K.; Hebecker, D.; Heereman, D.; Helbing, K.; Hellauer, R.; Hickford, S.; Hignight, J.; Hill, G. C.; Hoffman, K. D.; Hoffmann, R.; Holzapfel, K.; Hoshina, K.; Huang, F.; Huber, M.; Hultqvist, K.; In, S.; Ishihara, A.; Jacobi, E.; Japaridze, G. S.; Jeong, M.; Jero, K.; Jones, B. J. P.; Jurkovic, M.; Kappes, A.; Karg, T.; Karle, A.; Katz, U.; Kauer, M.; Keivani, A.; Kelley, J. L.; Kemp, J.; Kheirandish, A.; Kim, M.; Kintscher, T.; Kiryluk, J.; Kittler, T.; Klein, S. R.; Kohnen, G.; Koirala, R.; Kolanoski, H.; Konietz, R.; Köpke, L.; Kopper, C.; Kopper, S.; Koskinen, D. J.; Kowalski, M.; Krings, K.; Kroll, M.; Krückl, G.; Krüger, C.; Kunnen, J.; Kunwar, S.; Kurahashi, N.; Kuwabara, T.; Labare, M.; Lanfranchi, J. L.; Larson, M. J.; Lauber, F.; Lennarz, D.; Lesiak-Bzdak, M.; Leuermann, M.; Leuner, J.; Lu, L.; Lünemann, J.; Madsen, J.; Maggi, G.; Mahn, K. B. M.; Mancina, S.; Mandelartz, M.; Maruyama, R.; Mase, K.; Maunu, R.; McNally, F.; Meagher, K.; Medici, M.; Meier, M.; Meli, A.; Menne, T.; Merino, G.; Meures, T.; Miarecki, S.; Mohrmann, L.; Montaruli, T.; Moulai, M.; Nahnhauer, R.; Naumann, U.; Neer, G.; Niederhausen, H.; Nowicki, S. C.; Nygren, D. R.; Obertacke Pollmann, A.; Olivas, A.; O'Murchadha, A.; Palczewski, T.; Pandya, H.; Pankova, D. V.; Penek, Ö.; Pepper, J. A.; Pérez de los Heros, C.; Pieloth, D.; Pinat, E.; Price, P. B.; Przybylski, G. T.; Quinnan, M.; Raab, C.; Rädel, L.; Rameez, M.; Rawlins, K.; Reimann, R.; Relethford, B.; Relich, M.; Resconi, E.; Rhode, W.; Richman, M.; Riedel, B.; Robertson, S.; Rongen, M.; Rott, C.; Ruhe, T.; Ryckbosch, D.; Rysewyk, D.; Sabbatini, L.; Sanchez Herrera, S. E.; Sandrock, A.; Sandroos, J.; Sarkar, S.; Satalecka, K.; Schimp, M.; Schlunder, P.; Schmidt, T.; Schoenen, S.; Schöneberg, S.; Schumacher, L.; Seckel, D.; Seunarine, S.; Soldin, D.; Song, M.; Spiczak, G. M.; Spiering, C.; Stahlberg, M.; Stanev, T.; Stasik, A.; Steuer, A.; Stezelberger, T.; Stokstad, R. G.; Stössl, A.; Ström, R.; Strotjohann, N. L.; Sullivan, G. W.; Sutherland, M.; Taavola, H.; Taboada, I.; Tatar, J.; Tenholt, F.; Ter-Antonyan, S.; Terliuk, A.; Tešić, G.; Tilav, S.; Toale, P. A.; Tobin, M. N.; Toscano, S.; Tosi, D.; Tselengidou, M.; Turcati, A.; Unger, E.; Usner, M.; Vandenbroucke, J.; van Eijndhoven, N.; Vanheule, S.; van Rossem, M.; van Santen, J.; Veenkamp, J.; Vehring, M.; Voge, M.; Vraeghe, M.; Walck, C.; Wallace, A.; Wallraff, M.; Wandkowsky, N.; Weaver, Ch.; Weiss, M. J.; Wendt, C.; Westerhoff, S.; Whelan, B. J.; Wickmann, S.; Wiebe, K.; Wiebusch, C. H.; Wille, L.; Williams, D. R.; Wills, L.; Wolf, M.; Wood, T. R.; Woolsey, E.; Woschnagg, K.; Xu, D. L.; Xu, X. W.; Xu, Y.; Yanez, J. P.; Yodh, G.; Yoshida, S.; Zoll, M.; IceCube Collaboration

    2016-10-01

    IceTop is an air-shower array located on the Antarctic ice sheet at the geographic South Pole. IceTop can detect an astrophysical flux of neutrons from Galactic sources as an excess of cosmic-ray air showers arriving from the source direction. Neutrons are undeflected by the Galactic magnetic field and can typically travel 10 (E/PeV) pc before decay. Two searches are performed using 4 yr of the IceTop data set to look for a statistically significant excess of events with energies above 10 PeV (1016 eV) arriving within a small solid angle. The all-sky search method covers from -90° to approximately -50° in declination. No significant excess is found. A targeted search is also performed, looking for significant correlation with candidate sources in different target sets. This search uses a higher-energy cut (100 PeV) since most target objects lie beyond 1 kpc. The target sets include pulsars with confirmed TeV energy photon fluxes and high-mass X-ray binaries. No significant correlation is found for any target set. Flux upper limits are determined for both searches, which can constrain Galactic neutron sources and production scenarios.

  11. High-energy particle production in solar flares (SEP, gamma-ray and neutron emissions). [solar energetic particles

    NASA Technical Reports Server (NTRS)

    Chupp, E. L.

    1987-01-01

    Electrons and ions, over a wide range of energies, are produced in association with solar flares. Solar energetic particles (SEPs), observed in space and near earth, consist of electrons and ions that range in energy from 10 keV to about 100 MeV and from 1 MeV to 20 GeV, respectively. SEPs are directly recorded by charged particle detectors, while X-ray, gamma-ray, and neutron detectors indicate the properties of the accelerated particles (electrons and ions) which have interacted in the solar atmosphere. A major problem of solar physics is to understand the relationship between these two groups of charged particles; in particular whether they are accelerated by the same mechanism. The paper reviews the physics of gamma-rays and neutron production in the solar atmosphere and the method by which properties of the primary charged particles produced in the solar flare can be deduced. Recent observations of energetic photons and neutrons in space and at the earth are used to present a current picture of the properties of impulsively flare accelerated electrons and ions. Some important properties discussed are time scale of production, composition, energy spectra, accelerator geometry. Particular attention is given to energetic particle production in the large flare on June 3, 1982.

  12. Applications of Storage Phosphor Technology to High-Energy Portal Imaging in Radiation Therapy.

    NASA Astrophysics Data System (ADS)

    Weiser, John Conrad

    1990-01-01

    This investigation is a study of the application of a storage phosphor based digital image acquisition and processing system to portal imaging. Laser printed storage phosphor film is compared to conventional film, and digitized conventional film is compared to storage phosphor images using CRT displays. The reader's impression of image quality, general perception of anatomical detail, accuracy of interpretation, and ability to detect low contrast objects are used as comparison criteria. In addition unsharp masking, analog contrast stretching, and digital windowing and leveling are evaluated as image processing options. A new technique for obtaining electron treatment verification images is developed and used to investigate the precision of high energy electron treatment delivery. The results indicate that the quality of unprocessed laser printed storage phosphor images is perceived to be at least as good as that of conventional film, with a notable increase in perceived quality of head, neck, and chest images as compared to images of the abdomen and pelvis. Application of an analog contrast enhancement technique to storage phosphor images of the abdomen and pelvis does not result in a statistically significant improvement over conventional film, but the combination of contrast and edge enhancement by unsharp masking does result in a significant improvement in perception of anatomical landmarks. Digitized conventional film is perceived to be as good as storage phosphor images when similarly processed by an unsharp masking routine and displayed on a workstation with window and level control. The reader's perception of anatomical detail and accuracy of interpretation show the most promise as comparison criteria for evaluation of the various modalities available for portal imaging. The development of a scoring system based on perception of specific anatomical landmarks for the various treatment fields would provide a more objective method of assessing alternative

  13. Design criteria for a high energy Compton Camera and possible application to targeted cancer therapy

    NASA Astrophysics Data System (ADS)

    Conka Nurdan, T.; Nurdan, K.; Brill, A. B.; Walenta, A. H.

    2015-07-01

    The proposed research focuses on the design criteria for a Compton Camera with high spatial resolution and sensitivity, operating at high gamma energies and its possible application for molecular imaging. This application is mainly on the detection and visualization of the pharmacokinetics of tumor targeting substances specific for particular cancer sites. Expected high resolution (< 0.5 mm) permits monitoring the pharmacokinetics of labeled gene constructs in vivo in small animals with a human tumor xenograft which is one of the first steps in evaluating the potential utility of a candidate gene. The additional benefit of high sensitivity detection will be improved cancer treatment strategies in patients based on the use of specific molecules binding to cancer sites for early detection of tumors and identifying metastasis, monitoring drug delivery and radionuclide therapy for optimum cell killing at the tumor site. This new technology can provide high resolution, high sensitivity imaging of a wide range of gamma energies and will significantly extend the range of radiotracers that can be investigated and used clinically. The small and compact construction of the proposed camera system allows flexible application which will be particularly useful for monitoring residual tumor around the resection site during surgery. It is also envisaged as able to test the performance of new drug/gene-based therapies in vitro and in vivo for tumor targeting efficacy using automatic large scale screening methods.

  14. Application of low-cost Gallium Arsenide light-emitting-diodes as kerma dosemeter and fluence monitor for high-energy neutrons.

    PubMed

    Mukherjee, B; Simrock, S; Khachan, J; Rybka, D; Romaniuk, R

    2007-01-01

    Displacement damage (DD) caused by fast neutrons in unbiased Gallium Arsenide (GaAs) light emitting diodes (LED) resulted in a reduction of the light output. On the other hand, a similar type of LED irradiated with gamma rays from a (60)Co source up to a dose level in excess of 1.0 kGy (1.0 x 10(5) rad) was found to show no significant drop of the light emission. This phenomenon was used to develop a low cost passive fluence monitor and kinetic energy released per unit mass dosemeter for accelerator-produced neutrons. These LED-dosemeters were used to assess the integrated fluence of photoneutrons, which were contaminated with a strong bremsstrahlung gamma-background generated by the 730 MeV superconducting electron linac driving the free electron laser in Hamburg (FLASH) at Deutsches Elektronen-Synchrotron. The applications of GaAs LED as a routine neutron fluence monitor and DD precursor for the electronic components located in high-energy accelerator environment are highlighted.

  15. Theoretical and experimental physical methods of neutron-capture therapy

    NASA Astrophysics Data System (ADS)

    Borisov, G. I.

    2011-09-01

    This review is based to a substantial degree on our priority developments and research at the IR-8 reactor of the Russian Research Centre Kurchatov Institute. New theoretical and experimental methods of neutron-capture therapy are developed and applied in practice; these are: A general analytical and semi-empiric theory of neutron-capture therapy (NCT) based on classical neutron physics and its main sections (elementary theories of moderation, diffuse, reflection, and absorption of neutrons) rather than on methods of mathematical simulation. The theory is, first of all, intended for practical application by physicists, engineers, biologists, and physicians. This theory can be mastered by anyone with a higher education of almost any kind and minimal experience in operating a personal computer.

  16. Calculation of energy deposition, photon and neutron production in proton therapy of thyroid gland using MCNPX.

    PubMed

    Mowlavi, Ali Asghar; Fornasie, Maria Rosa; de Denaro, Mario

    2011-01-01

    In this study, the MCNPX code has been used to simulate a proton therapy in thyroid gland, in order to calculate the proton energy deposition in the target region. As well as, we have calculated the photon and neutron production spectra due to proton interactions with the tissue. We have considered all the layers of tissue, from the skin to the thyroid gland, and an incident high energy pencil proton beam. The results of the simulation show that the best proton energy interval, to cover completely the thyroid tissue, is from 42 to 54 MeV, assuming that the thyroid gland has a 14 mm thickness and is located 11.2mm under the skin surface. The most percentage of deposited energy (78%) is related to the 54 MeV proton energy beam. Total photon and neutron production are linear and polynomial second order functions of the proton energy, respectively.

  17. Measurement of activation cross-sections for high-energy neutron-induced reactions of Bi and Pb

    NASA Astrophysics Data System (ADS)

    Zaman, Muhammad; Kim, Guinyun; Kim, Kwangsoo; Naik, Haladhara; Shahid, Muhammad; Lee, Manwoo

    2015-08-01

    The cross-sections for 209Bi(n, 4n)206Bi, 209Bi(n, 5n)205Bi, natPb(n, xn)204mPb, natPb(n, xn)203Pb, natPb(n, xn)202mPb,natPb(n, xn)201Pb, natPb(n, xn)200Pb, natPb(n, αxn)203Hg and natPb(n, p xn)202Tl reactions were determined at the Korean Institute of Radiological and Medical Sciences (KIRAMS), Korea in the neutron energy range of 15.2 to 37.2 MeV. The above cross-sections were obtained by using the activation and off-line γ-ray spectrometric technique. The quasi-monoenergetic neutron used for the above reactions are based on the 9Be(p, n) reaction. Simulations of the spectral flux from the Be target were done using the MCNPX program. The cross-sections were estimated with the TALYS 1.6 code using the default parameter. The data from the present work and literature were compared with the data from the EAF-2010 and the TENDL-2013 libraries, and calculated values of TALYS 1.6 code. It shows that appropriate level density model, the γ-ray strength function, and the spin cut-off parameter are needed to obtain a good agreement between experimental data and theoretical values from TALYS 1.6 code.

  18. Determination of Endpoint Energy and Bremsstrahlung Spectra for High-Energy Radiation-Therapy Beams

    NASA Astrophysics Data System (ADS)

    Landry, Danny Joe

    Few attempts have been made to experimentally determine thick-target bremsstrahlung spectra of megavoltage therapy beams. For spectral studies using the Compton scattering technique, sodium iodine (NaI) detectors with relatively poor energy resolution have been used. Other experimental techniques for determining spectra are generally not suited for a clinical environment with the inherent time and space constraints. To gather more spectral information than previously obtained in the region near the endpoint energy, the use of a high-resolution intrinsic-germanium (Ge) detector was proposed. A response function matrix was determined from experimentally obtained pulse height distributions on the multichannel analyzer. The distributions were for nine various monoenergetic sources between 280 adn 1525 keV. The response function was used to convert the measured pulse height distributions to photon flux spectra using an iterative approximation technique with a computer. Photon flux spectra from the Sagittaire Linear Accelerator were obtained at average-electron endpoint energies of 15, 20, and 25 MeV. Two spectra were measured at the 25 MeV setting; one spectrum was measured along the central axis and one spectrum at 4(DEGREES) off axis. Photon spectra were also obtained for a Van de Graaff generator at the nominal endpoint energies of 2.2, 2.35, and 2.5 MeV. The results for both the linac and the Van de Graaff generator were compared with theoretical spectra and previously measured spectra where available. Also, photon spectra from a Theratron-80 (('60)Co) unit were determined for three field sizes and for a 10 x 10 cm. field with a lucite tray or a 45(DEGREES) wedge in the beam. The resulting spectra were compared to previously measured ('60)Co spectra.

  19. Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.

    PubMed

    Luderer, Micah John; de la Puente, Pilar; Azab, Abdel Kareem

    2015-09-01

    Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death. Since cellular destruction is limited to approximately the diameter of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged. However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron containing agents. While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clinical agents, new agents are desperately needed due to their suboptimal tumor selectivity. This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.

  20. Comparison of graphite, aluminum, and TransHab shielding material characteristics in a high-energy neutron field

    NASA Technical Reports Server (NTRS)

    Badhwar, G. D.; Huff, H.; Wilkins, R.; Thibeault, Sheila

    2002-01-01

    Space radiation transport models clearly show that low atomic weight materials provide a better shielding protection for interplanetary human missions than high atomic weight materials. These model studies have concentrated on shielding properties against charged particles. A light-weight, inflatable habitat module called TransHab was built and shown to provide adequate protection against micrometeoroid impacts and good shielding properties against charged particle radiation in the International Space Station orbits. An experiment using a tissue equivalent proportional counter, to study the changes in dose and lineal energy spectra with graphite, aluminum, and a TransHab build-up as shielding, was carried out at the Los Alamos Nuclear Science Center neutron facility. It is a continuation of a previous study using regolith and doped polyethylene materials. This paper describes the results and their comparison with the previous study. Published by Elsevier Science Ltd.

  1. Comparison of graphite, aluminum, and TransHab shielding material characteristics in a high-energy neutron field.

    PubMed

    Badhwar, G D; Huff, H; Wilkins, R; Thibeault, Sheila

    2002-12-01

    Space radiation transport models clearly show that low atomic weight materials provide a better shielding protection for interplanetary human missions than high atomic weight materials. These model studies have concentrated on shielding properties against charged particles. A light-weight, inflatable habitat module called TransHab was built and shown to provide adequate protection against micrometeoroid impacts and good shielding properties against charged particle radiation in the International Space Station orbits. An experiment using a tissue equivalent proportional counter, to study the changes in dose and lineal energy spectra with graphite, aluminum, and a TransHab build-up as shielding, was carried out at the Los Alamos Nuclear Science Center neutron facility. It is a continuation of a previous study using regolith and doped polyethylene materials. This paper describes the results and their comparison with the previous study.

  2. Ground-based observations of thunderstorm-correlated fluxes of high-energy electrons, gamma rays, and neutrons

    SciTech Connect

    Chilingarian, A.; Daryan, A.; Arakelyan, K.; Hovhannisyan, A.; Mailyan, B.; Melkumyan, L.; Hovsepyan, G.; Chilingaryan, S.; Reymers, A.; Vanyan, L.

    2010-08-15

    The Aragats Space Environmental Center facilities continuously measure fluxes of neutral and charged secondary cosmic ray incidents on the Earth's surface. Since 2003 in the 1-minute time series we have detected more than 100 enhancements in the electron, gamma ray, and neutron fluxes correlated with thunderstorm activities. During the periods of the count rate enhancements, lasting tens of minutes, millions of additional particles were detected. Based on the largest particle event of September 19, 2009, we show that our measurements support the existence of long-lasting particle multiplication and acceleration mechanisms in the thunderstorm atmosphere. For the first time we present the energy spectra of electrons and gamma rays from the particle avalanches produced in the thunderstorm atmosphere, reaching the Earth's surface.

  3. System and method for delivery of neutron beams for medical therapy

    DOEpatents

    Nigg, D.W.; Wemple, C.A.

    1999-07-06

    A neutron delivery system that provides improved capability for tumor control during medical therapy is disclosed. The system creates a unique neutron beam that has a bimodal or multi-modal energy spectrum. This unique neutron beam can be used for fast-neutron therapy, boron neutron capture therapy (BNCT), or both. The invention includes both an apparatus and a method for accomplishing the purposes of the invention. 5 figs.

  4. System and method for delivery of neutron beams for medical therapy

    DOEpatents

    Nigg, David W.; Wemple, Charles A.

    1999-01-01

    A neutron delivery system that provides improved capability for tumor control during medical therapy. The system creates a unique neutron beam that has a bimodal or multi-modal energy spectrum. This unique neutron beam can be used for fast-neutron therapy, boron neutron capture therapy (BNCT), or both. The invention includes both an apparatus and a method for accomplishing the purposes of the invention.

  5. Research in Boron Neutron Capture Therapy at MIT LABA

    SciTech Connect

    Yanch, J.C.; Shefer, R.E.; Klinkowstein, R.E.; Howard, W.B.; Song, H.; Blackburn, B.; Binello, E.

    1997-02-01

    A 4.1 MeV tandem electrostatic accelerator designed for research into Boron Neutron Capture Therapy (BNCT) has recently been installed in the MIT Laboratory for Accelerator Beam Applications (LABA). This accelerator uses a very high current switch mode high voltage power supply in conjunction with a multi-cusp negative ion source to supply the multimilliampere current required for clinical BNCT applications. A number of individual research projects aimed at evaluating the potential of this accelerator design as a hospital-based neutron source for radiation therapy of both tumors and rheumatoid arthritis are described here. {copyright} {ital 1997 American Institute of Physics.}

  6. Accelerator-based neutron source for boron neutron capture therapy (BNCT) and method

    DOEpatents

    Yoon, Woo Y.; Jones, James L.; Nigg, David W.; Harker, Yale D.

    1999-01-01

    A source for boron neutron capture therapy (BNCT) comprises a body of photoneutron emitter that includes heavy water and is closely surrounded in heat-imparting relationship by target material; one or more electron linear accelerators for supplying electron radiation having energy of substantially 2 to 10 MeV and for impinging such radiation on the target material, whereby photoneutrons are produced and heat is absorbed from the target material by the body of photoneutron emitter. The heavy water is circulated through a cooling arrangement to remove heat. A tank, desirably cylindrical or spherical, contains the heavy water, and a desired number of the electron accelerators circumferentially surround the tank and the target material as preferably made up of thin plates of metallic tungsten. Neutrons generated within the tank are passed through a surrounding region containing neutron filtering and moderating materials and through neutron delimiting structure to produce a beam or beams of epithermal neutrons normally having a minimum flux intensity level of 1.0.times.10.sup.9 neutrons per square centimeter per second. Such beam or beams of epithermal neutrons are passed through gamma ray attenuating material to provide the required epithermal neutrons for BNCT use.

  7. Accelerator-based neutron source for boron neutron capture therapy (BNCT) and method

    DOEpatents

    Yoon, W.Y.; Jones, J.L.; Nigg, D.W.; Harker, Y.D.

    1999-05-11

    A source for boron neutron capture therapy (BNCT) comprises a body of photoneutron emitter that includes heavy water and is closely surrounded in heat-imparting relationship by target material; one or more electron linear accelerators for supplying electron radiation having energy of substantially 2 to 10 MeV and for impinging such radiation on the target material, whereby photoneutrons are produced and heat is absorbed from the target material by the body of photoneutron emitter. The heavy water is circulated through a cooling arrangement to remove heat. A tank, desirably cylindrical or spherical, contains the heavy water, and a desired number of the electron accelerators circumferentially surround the tank and the target material as preferably made up of thin plates of metallic tungsten. Neutrons generated within the tank are passed through a surrounding region containing neutron filtering and moderating materials and through neutron delimiting structure to produce a beam or beams of epithermal neutrons normally having a minimum flux intensity level of 1.0{times}10{sup 9} neutrons per square centimeter per second. Such beam or beams of epithermal neutrons are passed through gamma ray attenuating material to provide the required epithermal neutrons for BNCT use. 3 figs.

  8. The radiation biology of boron neutron capture therapy.

    PubMed

    Coderre, J A; Morris, G M

    1999-01-01

    Boron neutron capture therapy (BNCT) is a targeted radiation therapy that significantly increases the therapeutic ratio relative to conventional radiotherapeutic modalities. BNCT is a binary approach: A boron-10 (10B)-labeled compound is administered that delivers high concentrations of 10B to the target tumor relative to surrounding normal tissues. This is followed by irradiation with thermal neutrons or epithermal neutrons which become thermalized at depth in tissues. The short range (5-9 microm) of the alpha and 7Li particles released from the 10B(n,alpha)7Li neutron capture reaction make the microdistribution of 10B of critical importance in therapy. The radiation field in tissues during BNCT consists of a mixture of components with differing LET characteristics. Studies have been carried out in both normal and neoplastic tissues to characterize the relative biological effectiveness of each radiation component. The distribution patterns and radiobiological characteristics of the two 10B delivery agents in current clinical use, the amino acid p-boronophenylalanine (BPA) and the sulfhydryl borane (BSH), have been evaluated in a range of normal tissues and tumor types. Considered overall, BSH-mediated BNCT elicits proportionately less damage to normal tissue than does BNCT mediated with BPA. However, BPA exhibits superior in vivo tumor targeting and has proven much more effective in the treatment of brain tumors in rats. In terms of fractionation effects, boron neutron capture irradiation modalities are comparable with other high-LET radiation modalities such as fast-neutron therapy. There was no appreciable advantage in increasing the number of daily fractions of thermal neutrons beyond two with regard to sparing of normal tissue in the rat spinal cord model. The experimental studies described in this review constitute the radiobiological basis for the new BNCT clinical trials for glioblastoma at Brookhaven National Laboratory, at the Massachusetts Institute of

  9. Design of a boron neutron capture enhanced fast neutron therapy assembly

    SciTech Connect

    Wang, Zhonglu

    2006-12-01

    The use of boron neutron capture to boost tumor dose in fast neutron therapy has been investigated at several fast neutron therapy centers worldwide. This treatment is termed boron neutron capture enhanced fast neutron therapy (BNCEFNT). It is a combination of boron neutron capture therapy (BNCT) and fast neutron therapy (FNT). It is believed that BNCEFNT may be useful in the treatment of some radioresistant brain tumors, such as glioblastoma multiform (GBM). A boron neutron capture enhanced fast neutron therapy assembly has been designed for the Fermilab Neutron Therapy Facility (NTF). This assembly uses a tungsten filter and collimator near the patient's head, with a graphite reflector surrounding the head to significantly increase the dose due to boron neutron capture reactions. The assembly was designed using Monte Carlo radiation transport code MCNP version 5 for a standard 20x20 cm2 treatment beam. The calculated boron dose enhancement at 5.7-cm depth in a water-filled head phantom in the assembly with a 5x5 cm2 collimation was 21.9% per 100-ppm 10B for a 5.0-cm tungsten filter and 29.8% for a 8.5-cm tungsten filter. The corresponding dose rate for the 5.0-cm and 8.5-cm thick filters were 0.221 and 0.127 Gy/min, respectively; about 48.5% and 27.9% of the dose rate of the standard 10x10 cm2 fast neutron treatment beam. To validate the design calculations, a simplified BNCEFNT assembly was built using four lead bricks to form a 5x5 cm2 collimator. Five 1.0-cm thick 20x20 cm2 tungsten plates were used to obtain different filter thicknesses and graphite bricks/blocks were used to form a reflector. Measurements of the dose enhancement of the simplified assembly in a water-filled head phantom were performed using a pair of tissue-equivalent ion chambers. One of the ion chambers is loaded with 1000-ppm natural boron (184-ppm 10B) to measure dose due to boron neutron capture. The measured

  10. Secondary neutron spectrum from 250-MeV passively scattered proton therapy: Measurement with an extended-range Bonner sphere system

    PubMed Central

    Howell, Rebecca M.; Burgett, E. A.

    2014-01-01

    Purpose: Secondary neutrons are an unavoidable consequence of proton therapy. While the neutron dose is low compared to the primary proton dose, its presence and contribution to the patient dose is nonetheless important. The most detailed information on neutrons includes an evaluation of the neutron spectrum. However, the vast majority of the literature that has reported secondary neutron spectra in proton therapy is based on computational methods rather than measurements. This is largely due to the inherent limitations in the majority of neutron detectors, which are either not suitable for spectral measurements or have limited response at energies greater than 20 MeV. Therefore, the primary objective of the present study was to measure a secondary neutron spectrum from a proton therapy beam using a spectrometer that is sensitive to neutron energies over the entire neutron energy spectrum. Methods: The authors measured the secondary neutron spectrum from a 250-MeV passively scattered proton beam in air at a distance of 100 cm laterally from isocenter using an extended-range Bonner sphere (ERBS) measurement system. Ambient dose equivalent H*(10) was calculated using measured fluence and fluence-to-ambient dose equivalent conversion coefficients. Results: The neutron fluence spectrum had a high-energy direct neutron peak, an evaporation peak, a thermal peak, and an intermediate energy continuum between the thermal and evaporation peaks. The H*(10) was dominated by the neutrons in the evaporation peak because of both their high abundance and the large quality conversion coefficients in that energy interval. The H*(10) 100 cm laterally from isocenter was 1.6 mSv per proton Gy (to isocenter). Approximately 35% of the dose equivalent was from neutrons with energies ≥20 MeV. Conclusions: The authors measured a neutron spectrum for external neutrons generated by a 250-MeV proton beam using an ERBS measurement system that was sensitive to neutrons over the entire

  11. Analytic estimates of secondary neutron dose in proton therapy.

    PubMed

    Anferov, V

    2010-12-21

    Proton beam losses in various components of a treatment nozzle generate secondary neutrons, which bring unwanted out of field dose during treatments. The purpose of this study was to develop an analytic method for estimating neutron dose to a distant organ at risk during proton therapy. Based on radiation shielding calculation methods proposed by Sullivan, we developed an analytical model for converting the proton beam losses in the nozzle components and in the treatment volume into the secondary neutron dose at a point of interest. Using the MCNPx Monte Carlo code, we benchmarked the neutron dose rates generated by the proton beam stopped at various media. The Monte Carlo calculations confirmed the validity of the analytical model for simple beam stop geometry. The analytical model was then applied to neutron dose equivalent measurements performed on double scattering and uniform scanning nozzles at the Midwest Proton Radiotherapy Institute (MPRI). Good agreement was obtained between the model predictions and the data measured at MPRI. This work provides a method for estimating analytically the neutron dose equivalent to a distant organ at risk. This method can be used as a tool for optimizing dose delivery techniques in proton therapy.

  12. Anharmonicity and disorder in simple and complex perovskites: a high energy synchrotron and hot neutron diffraction study

    NASA Astrophysics Data System (ADS)

    Kiat, Jean-Michel; Baldinozzi, Gianguido; Dunlop, Muriel; Malibert, Charlotte; Dkhil, Brahim; Ménoret, Carole; Masson, Olivier; Fernandez-Diaz, Maria-Teresa

    2000-10-01

    We report a study of simple ABO3 type perovskites BaTiO3, PbTiO3, KNbO3, SrTiO3 and the relaxor perovskites PbSc1/2Nb1/2O3 (PSN) in their cubic phase using hard synchrotron radiation and hot neutrons. Gram-Charlier expansions of the thermal parameters have been performed and have revealed interesting features about the probability density function and the one-particle potential of the different atoms. This description is compared with other descriptions in terms of the split atom model and in terms of the rotator model. Structural trends regarding the order-disorder versus displacive character of the phase transitions have been obtained. It is concluded that SrTiO3 and BaTiO3 are quasi-harmonic systems whereas KNbO3 shows weak anharmonicity and PbTiO3 and PSN display strong anharmonic features.

  13. High energy x-ray and neutron studies of disordered energy-related materials at extreme conditions

    SciTech Connect

    Parise, John

    2016-05-16

    The fundamental scientific accomplishments are: (1) advances in a general description of the liquid state by employing structural models constrained by measurements to interpret experimental results and extend them to liquids in general, with special emphasis on (2) The structure of the high-temperature crystal and molten UO2 and 3) water. Specifically, samples of UO2 and water were probed using high-energy x-rays at the Advanced Photon Source. The high Z of UO2, and the 2-3mm diameter droplet shape of the molten sample, means that >100keV X-rays are required to minimize absorption and multiple scattering, which can distort the measured structure factor. A high flux of x-rays is also required to obtain sufficient statistical accuracy in short (a few seconds) measurement times. The scattered x-ray data were analyzed and pair distribution functions, extracted that characterize the local and long-range atomic structure of the material. The measurements of the hot UO2 solid show a substantial increase in oxygen disorder and, upon melting, the average U-O coordination was found to decrease from 8 to 6.7±0.5. The research incorporated development of diffraction techniques, sample environment optimization and state-of-the-art simulation techniques. The symbiotic nature of the advances in simulation and experiment allowed for a more focused and informed development of future experiments, effective use of expensive beam time and generated new research agendas for the growing number of research groups, within the US and internationally, that focus on the structure of liquids. Molecular dynamics (MD) provided detailed information when combined with high-quality XN data including addressing key issues in liquids; the relationship between cooling path, structure and fictive temperature, and the trade-offs between network over connectedness in liquids containing low-coordination cations.

  14. In situ high-energy X-ray diffraction study of tensile deformation of neutron-irradiated polycrystalline Fe-9%Cr alloy

    SciTech Connect

    Zhang, Xuan; Li, Meimei; Park, Jun -Sang; Kenesei, Peter; Almer, Jonathan; Xu, Chi; Stubbins, James F.

    2016-12-30

    The effect of neutron irradiation on tensile deformation of a Fe-9wt.%Cr alloy was investigated using in situ high-energy synchrotron X-ray diffraction during room-temperature uniaxial tensile tests. New insights into the deformation mechanisms were obtained through the measurements of lattice strain evolution and the analysis of diffraction peak broadening using the modified Williamson-Hall method. Two neutron-irradiated specimens, one irradiated at 300 °C to 0.01 dpa and the other at 450 °C to 0.01dpa, were tested along with an unirradiated specimen. The macroscopic stress–strain curves of the irradiated specimens showed increased strength, reduced ductility and work-hardening exponent compared to the unirradiated specimen. The evolutions of the lattice strain, the dislocation density and the coherent scattering domain size in the deformation process revealed different roles of the submicroscopic defects in the 300°C/0.01 dpa specimen and the TEM-visible nanometer-sized dislocation loops in the 450°C/0.01 dpa specimen: submicroscopic defects extended the linear work hardening stage (stage II) to a higher strain, while irradiation-induced dislocation loops were more effective in dislocation pinning. Lastly, while the work hardening rate of stage II was unaffected by irradiation, significant dynamic recovery in stage III in the irradiated specimens led to the early onset of necking without stage IV as observed in the unirradiated specimen.

  15. Target studies for accelerator-based boron neutron capture therapy

    SciTech Connect

    Powell, J.R.; Ludewig, H.; Todosow, M.; Reich, M.

    1996-03-01

    Two new concepts, NIFTI and DISCOS, are described. These concepts enable the efficient production of epithermal neutrons for BNCT (Boron Neutron Capture Therapy) medical treatment, utilizing a low current, low energy proton beam impacting on a lithium target. The NIFTI concept uses an iron layer that strongly impedes the transmission of neutrons with energies above 24 KeV. Lower energy neutrons readily pass through this iron ``filter``, which has a deep ``window`` in its scattering cross section at 24 KeV. The DISCOS concept uses a rapidly rotating, high g disc to create a series of thin ({approximately} 1 micron thickness) liquid lithium targets in the form of continuous films through which the proton beam passes. The average energy lost by a proton as it passes through a single target is small, approximately 10 KeV. Between the targets, the proton beam is reaccelerated by an applied DC electric field. The DISCOS approach enables the accelerator -- target facility to operate with a beam energy only slightly above the threshold value for neutron production -- resulting in an output beam of low-energy epithermal neutrons -- while achieving a high yield of neutrons per milliamp of proton beam current.

  16. Microdosimetric investigations at the fast neutron therapy facility at Fermilab

    SciTech Connect

    Langen, K.M.

    1997-12-01

    Microdosimetry was used to investigate three issues at the neutron therapy facility (NTF) at Fermilab. Firstly, the conversion factor from absorbed dose in A-150 tissue equivalent plastic to absorbed dose in ICRU tissue was determined. For this, the effective neutron kerma factor ratios, i.e., oxygen tissue equivalent plastic and carbon to A-150 tissue equivalent plastic, were measured in the neutron beam. An A-150 tissue equivalent plastic to ICRU tissue absorbed dose conversion factor of 0.92 {+-} 0.04 was determined. Secondly, variations in the radiobiological effectiveness (RBE) in the beam were mapped by determining variations in two related quantities, e{sup *} and R, with field size and depth in tissue. Maximal variation in e{sup *} and R of 9% and 15% respectively were determined. Lastly, the feasibility of utilizing the boron neutron capture reaction on boron-10 to selectively enhance the tumor dose in the NTF beam was investigated.

  17. [Minimally invasive cytoselective radiation therapy using boron neutron capture reaction].

    PubMed

    Nakamura, Hiroyuki

    2010-12-01

    The cell-killing effect of boron neutron capture therapy (BNCT) is due to the nuclear reaction of two essentially nontoxic species, boron-10 ((10)B) and thermal neutrons, whose destructive effect is well observed in boron-loaded tissues. High accumulation and selective delivery of boron into tumor tissue are the most important requirements to achieve efficient neutron capture therapy of cancers. This review focuses on liposomal boron delivery system (BDS) as a recent promising approach that meet these requirements for BNCT. BDS involves two strategies: (1) encapsulation of boron in the aqueous core of liposomes and (2) accumulation of boron in the liposomal bilayer. In this review, recent development of liposomal boron delivery system is summarized.

  18. Neutron Tube Design Study for Boron Neutron Capture TherapyApplication

    SciTech Connect

    Verbeke, J.M.; Lee, Y.; Leung, K.N.; Vujic, J.; Williams, M.D.; Wu, L.K.; Zahir, N.

    1998-01-04

    Radio-frequency (RF) driven ion sources are being developed in Lawrence Berkeley National Laboratory (LBNL) for sealed-accelerator-tube neutron generator application. By using a 5-cm-diameter RF-driven multicusp source H{sup +} yields over 95% have been achieved. These experimental findings will enable one to develop compact neutron generators based on the D-D or D-T fusion reactions. In this new neutron generator, the ion source, the accelerator and the target are all housed in a sealed metal container without external pumping. Recent moderator design simulation studies have shown that 14 MeV neutrons could be moderated to therapeutically useful energy ranges for boron neutron capture therapy (BNCT). The dose near the center of the brain with optimized moderators is about 65% higher than the dose obtained from a typical neutron spectrum produced by the Brookhaven Medical Research Reactor (BMRR), and is comparable to the dose obtained by other accelerator-based neutron sources. With a 120 keV and 1 A deuteron beam, a treatment time of {approx}35 minutes is estimated for BNCT.

  19. Gyrotron-driven high current ECR ion source for boron-neutron capture therapy neutron generator

    NASA Astrophysics Data System (ADS)

    Skalyga, V.; Izotov, I.; Golubev, S.; Razin, S.; Sidorov, A.; Maslennikova, A.; Volovecky, A.; Kalvas, T.; Koivisto, H.; Tarvainen, O.

    2014-12-01

    Boron-neutron capture therapy (BNCT) is a perspective treatment method for radiation resistant tumors. Unfortunately its development is strongly held back by a several physical and medical problems. Neutron sources for BNCT currently are limited to nuclear reactors and accelerators. For wide spread of BNCT investigations more compact and cheap neutron source would be much more preferable. In present paper an approach for compact D-D neutron generator creation based on a high current ECR ion source is suggested. Results on dense proton beams production are presented. A possibility of ion beams formation with current density up to 600 mA/cm2 is demonstrated. Estimations based on obtained experimental results show that neutron target bombarded by such deuteron beams would theoretically yield a neutron flux density up to 6·1010 cm-2/s. Thus, neutron generator based on a high-current deuteron ECR source with a powerful plasma heating by gyrotron radiation could fulfill the BNCT requirements significantly lower price, smaller size and ease of operation in comparison with existing reactors and accelerators.

  20. Optimal Neutron Source & Beam Shaping Assembly for Boron Neutron Capture Therapy

    SciTech Connect

    J. Vujic; E. Greenspan; W.E. Kastenber; Y. Karni; D. Regev; J.M. Verbeke, K.N. Leung; D. Chivers; S. Guess; L. Kim; W. Waldron; Y. Zhu

    2003-04-30

    There were three objectives to this project: (1) The development of the 2-D Swan code for the optimization of the nuclear design of facilities for medical applications of radiation, radiation shields, blankets of accelerator-driven systems, fusion facilities, etc. (2) Identification of the maximum beam quality that can be obtained for Boron Neutron Capture Therapy (BNCT) from different reactor-, and accelerator-based neutron sources. The optimal beam-shaping assembly (BSA) design for each neutron source was also to e obtained. (3) Feasibility assessment of a new neutron source for NCT and other medical and industrial applications. This source consists of a state-of-the-art proton or deuteron accelerator driving and inherently safe, proliferation resistant, small subcritical fission assembly.

  1. A Sealed-Accelerator-Tube Neutron Generator for Boron Neutron Capture Therapy Application

    SciTech Connect

    Leung, K.-N.; Leung, K.N.; Lee, Y.; Verbeke, J.M.; Vurjic, J.; Williams, M.D.; Wu, L.K.; Zahir, N.

    1998-06-01

    Radio-frequency (RF) driven ion sources are being developed in Lawrence Berkeley National Laboratory (LBNL) for sealed-accelerator-tube neutron generator applications. By using a 2.5-cm-diameter RF-driven multicusp source and a computer designed 100 keV accelerator column, peak extractable hydrogen current exceeding 1 A from a 3-mm-diameter aperture, together with H{sup +} yields over 94% have been achieved. These experimental findings together with recent moderator design will enable one to develop compact 14 MeV neutron generators based on the D-T fusion reaction. In this new neutron generator, the ion source, the accelerator and the target are all housed in a sealed metal container without pumping. With a 120 keV and 1 A deuteron beam, it is estimated that a treatment time of {approx} 45 minutes is needed for boron neutron capture therapy.

  2. Proceedings of the first international symposium on neutron capture therapy

    SciTech Connect

    Fairchild, R.G.; Brownell, G.L.

    1982-01-01

    This meeting was arranged jointly by MIT and BNL in order to illuminate progress in the synthesis and targeting of boron compounds and to evaluate and document progress in radiobiological and dosimetric aspects of neutron capture therapy. It is hoped that this meeting will facilitate transfer of information between groups working in these fields, and encourage synergistic collaboration.

  3. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality.

    PubMed

    Barth, R F; Soloway, A H; Goodman, J H; Gahbauer, R A; Gupta, N; Blue, T E; Yang, W; Tjarks, W

    1999-03-01

    Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10, a stable isotope, is irradiated with low-energy thermal neutrons to yield alpha particles and recoiling lithium-7 nuclei. For BNCT to be successful, a large number of 10B atoms must be localized on or preferably within neoplastic cells, and a sufficient number of thermal neutrons must be absorbed by the 10B atoms to sustain a lethal 10B (n, alpha) lithium-7 reaction. There is a growing interest in using BNCT in combination with surgery to treat patients with high-grade gliomas and possibly metastatic brain tumors. The present review covers the biological and radiobiological considerations on which BNCT is based, boron-containing low- and high-molecular weight delivery agents, neutron sources, clinical studies, and future areas of research. Two boron compounds currently are being used clinically, sodium borocaptate and boronophenylalanine, and a number of new delivery agents are under investigation, including boronated porphyrins, nucleosides, amino acids, polyamines, monoclonal and bispecific antibodies, liposomes, and epidermal growth factor. These are discussed, as is optimization of their delivery. Nuclear reactors currently are the only source of neutrons for BNCT, and the fission reaction within the core produces a mixture of lower energy thermal and epithermal neutrons, fast or high-energy neutrons, and gamma-rays. Although thermal neutron beams have been used clinically in Japan to treat patients with brain tumors and cutaneous melanomas, epithermal neutron beams now are being used in the United States and Europe because of their superior tissue-penetrating properties. Currently, there are clinical trials in progress in the United States, Europe, and Japan using a combination of debulking surgery and then BNCT to treat patients with glioblastomas. The American and European studies are Phase I trials using boronophenylalanine and sodium borocaptate, respectively

  4. MONDO: a neutron tracker for particle therapy secondary emission characterisation.

    PubMed

    Marafini, M; Gasparini, L; Mirabelli, R; Pinci, D; Patera, V; Sciubba, A; Spiriti, E; Stoppa, D; Traini, G; Sarti, A

    2017-04-21

    Tumour control is performed in particle therapy using particles and ions, whose high irradiation precision enhances the effectiveness of the treatment, while sparing the healthy tissue surrounding the target volume. Dose range monitoring devices using photons and charged particles produced by the beam interacting with the patient's body have already been proposed, but no attempt has been made yet to exploit the detection of the abundant neutron component. Since neutrons can release a significant dose far away from the tumour region, precise measurements of their flux, production energy and angle distributions are eagerly sought in order to improve the treatment planning system (TPS) software. It will thus be possible to predict not only the normal tissue toxicity in the target region, but also the risk of late complications in the whole body. The aforementioned issues underline the importance of an experimental effort devoted to the precise characterisation of neutron production, aimed at the measurement of their abundance, emission point and production energy. The technical challenges posed by a neutron detector aimed at high detection efficiency and good backtracking precision are addressed within the MONDO (monitor for neutron dose in hadrontherapy) project, whose main goal is to develop a tracking detector that can target fast and ultrafast neutrons. A full reconstruction of two consecutive elastic scattering interactions undergone by the neutrons inside the detector material will be used to measure their energy and direction. The preliminary results of an MC simulation performed using the FLUKA software are presented here, together with the DSiPM (digital SiPM) readout implementation. New detector readout implementations specifically tailored to the MONDO tracker are also discussed, and the neutron detection efficiency attainable with the proposed neutron tracking strategy are reported.

  5. Epithermal neutron beams from the 7 Li(p,n) reaction near the threshold for neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Porras, I.; Praena, J.; Arias de Saavedra, F.; Pedrosa, M.; Esquinas, P.; L. Jiménez-Bonilla, P.

    2016-11-01

    Two applications for neutron capture therapy of epithermal neutron beams calculated from the 7Li ( p , n reaction are discussed. In particular, i) for a proton beam of 1920 keV of a 30 mA, a neutron beam of adequate features for BNCT is found at an angle of 80° from the forward direction; and ii) for a proton beam of 1910 keV, a neutron beam is obtained at the forward direction suitable for performing radiobiology experiments for the determination of the biological weighting factors of the fast dose component in neutron capture therapy.

  6. A NEW SINGLE-CRYSTAL FILTERED THERMAL NEUTRON SOURCE FOR NEUTRON CAPTURE THERAPY RESEARCH AT THE UNIVERSITY OF MISSOURI

    SciTech Connect

    John D. Brockman; David W. Nigg; M. Frederick Hawthorne

    2008-09-01

    Parameter studies, design calculations and initial neutronic performance measurements have been completed for a new thermal neutron beamline to be used for neutron capture therapy cell and small-animal radiobiology studies at the University of Missouri Research Reactor. The beamline features the use of single-crystal silicon and bismuth sections for neutron filtering and for reduction of incident gamma radiation. The calculated and measured thermal neutron flux produced at the irradiation location is on the order of 9.5x108 neutrons/cm2-s, with a measured cadmium ratio (Au foils) of 105, indicating a well-thermalized spectrum.

  7. Application of an ultraminiature thermal neutron monitor for irradiation field study of accelerator-based neutron capture therapy.

    PubMed

    Ishikawa, Masayori; Tanaka, Kenichi; Endo, Satrou; Hoshi, Masaharu

    2015-03-01

    Phantom experiments to evaluate thermal neutron flux distribution were performed using the Scintillator with Optical Fiber (SOF) detector, which was developed as a thermal neutron monitor during boron neutron capture therapy (BNCT) irradiation. Compared with the gold wire activation method and Monte Carlo N-particle (MCNP) calculations, it was confirmed that the SOF detector is capable of measuring thermal neutron flux as low as 10(5) n/cm(2)/s with sufficient accuracy. The SOF detector will be useful for phantom experiments with BNCT neutron fields from low-current accelerator-based neutron sources.

  8. Application of an ultraminiature thermal neutron monitor for irradiation field study of accelerator-based neutron capture therapy

    PubMed Central

    Ishikawa, Masayori; Tanaka, Kenichi; Endo, Satrou; Hoshi, Masaharu

    2015-01-01

    Phantom experiments to evaluate thermal neutron flux distribution were performed using the Scintillator with Optical Fiber (SOF) detector, which was developed as a thermal neutron monitor during boron neutron capture therapy (BNCT) irradiation. Compared with the gold wire activation method and Monte Carlo N-particle (MCNP) calculations, it was confirmed that the SOF detector is capable of measuring thermal neutron flux as low as 105 n/cm2/s with sufficient accuracy. The SOF detector will be useful for phantom experiments with BNCT neutron fields from low-current accelerator-based neutron sources. PMID:25589504

  9. High-energy magnetic excitations in overdoped La2-xSrxCuO4 studied by neutron and resonant inelastic X-ray scattering

    DOE PAGES

    Wakimoto, S.; Ishii, K.; Kimura, H.; ...

    2015-05-21

    We have performed neutron inelastic scattering and resonant inelastic x-ray scattering (RIXS) at the Cu-L3 edge to study high-energy magnetic excitations at energy transfers of more than 100 meV for overdoped La2₋xSrxCuO4 with x=0.25 (Tc=15 K) and x=0.30 (nonsuperconducting) using identical single-crystal samples for the two techniques. From constant-energy slices of neutron-scattering cross sections, we have identified magnetic excitations up to ~250 meV for x=0.25. Although the width in the momentum direction is large, the peak positions along the (π,π) direction agree with the dispersion relation of the spin wave in the nondoped La2CuO4 (LCO), which is consistent with themore » previous RIXS results of cuprate superconductors. Using RIXS at the Cu-L3 edge, we have measured the dispersion relations of the so-called paramagnon mode along both (π,π) and (π,0) directions. Although in both directions the neutron and RIXS data connect with each other and the paramagnon along (π,0) agrees well with the LCO spin-wave dispersion, the paramagnon in the (π,π) direction probed by RIXS appears to be less dispersive and the excitation energy is lower than the spin wave of LCO near (π/2,π/2). Thus, our results indicate consistency between neutron inelastic scattering and RIXS, and elucidate the entire magnetic excitation in the (π,π) direction by the complementary use of two probes. The polarization dependence of the RIXS profiles indicates that appreciable charge excitations exist in the same energy range of magnetic excitations, reflecting the itinerant character of the overdoped sample. Lastly, we find a possible anisotropy in the charge excitation intensity might explain the apparent differences in the paramagnon dispersion in the (π,π) direction as detected by the x-ray scattering.« less

  10. Boron neutron capture therapy (BNCT): A radiation oncology perspective

    SciTech Connect

    Dorn, R.V. III Idaho National Engineering Lab., Idaho Falls, ID )

    1994-03-30

    Boron neutron capture therapy (BNCT) offers considerable promise in the search for the ideal cancer therapy, a therapy which selectively and maximally damages malignant cells while sparing normal tissue. This bimodal treatment modality selectivity concentrates a boron compound in malignant cells, and then [open quotes]activates[close quotes] this compound with slow neutrons resulting in a highly lethal event within the cancer cell. This article reviews this treatment modality from a radiation oncology, biology, and physics perspective. The remainder of the articles in this special issue provide a survey of the current [open quotes]state-of-the-art[close quotes] in this rapidly expanding field, including information with regard to boron compounds and their localization. 118 refs., 3 figs.

  11. Towards epithermal Boron Neutron Capture Therapy for cancer

    SciTech Connect

    Allen, B.J.

    1994-12-31

    Progress in the treatment of local disseminating cancer such as high grade brain tumours is poor, and the ability to kill individual cancer cells in the midst of normal cells has not been achieved. Binary therapies hold the most promise of this, and of these Boron Neutron Capture Therapy is the most advanced. Epithermal neutron beams are essential for outpatient treatment of high grade brain tumours and these are now installed and being characterised in Europe and the USA, and are at the design stage in Australia. These beams would allow the bilateral irradiation of the entire brain, and as such are ideally suited for the prophylactic therapy of subclinical metastases. When coupled with appropriate cancer affined boron compounds, therapeutic ratios of 2-3 should be achieved. At present the only source of an epithermal neutron beam is a nuclear reactor. The Euratom reactor at Petten and the Brookhaven Medical Reactor have been retrofitted with filters to produce an epithermal neutron beam. These beams have been characterised and used in dose escalation studies with dogs to study normal tissue tolerance using borocaptate (BSH). Another beam is available at the MIT medical research reactor. Clinical trials at Petten for glioblastoma with BSH and at MIT using boronophenylalanine for melanoma metastases to the extremities are expected to commence this year. The state of the art of reactor based BNCT is reviewed and the potential for a major change in the prognosis of local control of disseminating cancer is explored.

  12. In situ high-energy X-ray diffraction study of tensile deformation of neutron-irradiated polycrystalline Fe-9%Cr alloy

    DOE PAGES

    Zhang, Xuan; Li, Meimei; Park, Jun -Sang; ...

    2016-12-30

    The effect of neutron irradiation on tensile deformation of a Fe-9wt.%Cr alloy was investigated using in situ high-energy synchrotron X-ray diffraction during room-temperature uniaxial tensile tests. New insights into the deformation mechanisms were obtained through the measurements of lattice strain evolution and the analysis of diffraction peak broadening using the modified Williamson-Hall method. Two neutron-irradiated specimens, one irradiated at 300 °C to 0.01 dpa and the other at 450 °C to 0.01dpa, were tested along with an unirradiated specimen. The macroscopic stress–strain curves of the irradiated specimens showed increased strength, reduced ductility and work-hardening exponent compared to the unirradiated specimen.more » The evolutions of the lattice strain, the dislocation density and the coherent scattering domain size in the deformation process revealed different roles of the submicroscopic defects in the 300°C/0.01 dpa specimen and the TEM-visible nanometer-sized dislocation loops in the 450°C/0.01 dpa specimen: submicroscopic defects extended the linear work hardening stage (stage II) to a higher strain, while irradiation-induced dislocation loops were more effective in dislocation pinning. Lastly, while the work hardening rate of stage II was unaffected by irradiation, significant dynamic recovery in stage III in the irradiated specimens led to the early onset of necking without stage IV as observed in the unirradiated specimen.« less

  13. Evaluation of absorbed dose in Gadolinium neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Abdullaeva, Gayane; Djuraeva, Gulnara; Kim, Andrey; Koblik, Yuriy; Kulabdullaev, Gairatulla; Rakhmonov, Turdimukhammad; Saytjanov, Shavkat

    2015-02-01

    Gadolinium neutron capture therapy (GdNCT) is used for treatment of radioresistant malignant tumors. The absorbed dose in GdNCT can be divided into four primary dose components: thermal neutron, fast neutron, photon and natural gadolinium doses. The most significant is the dose created by natural gadolinium. The amount of gadolinium at the irradiated region is changeable and depends on the gadolinium delivery agent and on the structure of the location where the agent is injected. To de- fine the time dependence of the gadolinium concentration ρ(t) in the irradiated region the pharmacokinetics of gadolinium delivery agent (Magnevist) was studied at intratumoral injection in mice and intramuscular injection in rats. A polynomial approximation was applied to the experimental data and the influence of ρ(t) on the relative change of the absorbed dose of gadolinium was studied.

  14. Preliminary investigations of Monte Carlo Simulations of neutron energy and LET spectra for fast neutron therapy facilities

    SciTech Connect

    Kroc, T.K.; /Fermilab

    2009-10-01

    No fast neutron therapy facility has been built with optimized beam quality based on a thorough understanding of the neutron spectrum and its resulting biological effectiveness. A study has been initiated to provide the information necessary for such an optimization. Monte Carlo studies will be used to simulate neutron energy spectra and LET spectra. These studies will be bench-marked with data taken at existing fast neutron therapy facilities. Results will also be compared with radiobiological studies to further support beam quality ptimization. These simulations, anchored by this data, will then be used to determine what parameters might be optimized to take full advantage of the unique LET properties of fast neutron beams. This paper will present preliminary work in generating energy and LET spectra for the Fermilab fast neutron therapy facility.

  15. Secondary Neutron Doses for Several Beam Configurations for Proton Therapy

    SciTech Connect

    Shin, Dongho; Yoon, Myonggeun; Kwak, Jungwon; Shin, Jungwook; Lee, Se Byeong Park, Sung Yong; Park, Soah; Kim, Dae Yong; Cho, Kwan Ho

    2009-05-01

    Purpose: To compare possible neutron doses produced in scanning and scattering modes, with the latter assessed using a newly built passive-scattering proton beam line. Methods and Materials: A 40 x 30.5 x 30-cm water phantom was irradiated with 230-MeV proton beams using a gantry angle of 270{sup o}, a 10-cm-diameter snout, and a brass aperture with a diameter of 7 cm and a thickness of 6.5 cm. The secondary neutron doses during irradiation were measured at various points using CR-39 detectors, and these measurements were cross-checked using a neutron survey meter with a 22-cm range and a 5-cm spread-out Bragg peak. Results: The maximum doses due to secondary neutrons produced by a scattering beam-delivery system were on the order of 0.152 mSv/Gy and 1.17 mSv/Gy at 50 cm from the beam isocenter in the longitudinal (0{sup o}) and perpendicular (90{sup o}) directions, respectively. The neutron dose equivalent to the proton absorbed dose, measured from 10 cm to 100 cm from the isocenter, ranged from 0.071 mSv/Gy to 1.96 mSv/Gy in the direction of the beam line (i.e., {phi} = 0 deg.). The largest neutron dose, of 3.88 mSv/Gy, was observed at 135{sup o} and 25 cm from the isocenter. Conclusions: Although the secondary neutron doses in proton therapy were higher when a scattering mode rather than a scanning mode was used, they did not exceed the scattered photon dose in typical photon treatments.

  16. Strategic planning workshop on research needs for neutron capture therapy.

    PubMed

    Feinendegen, L E

    1997-05-01

    The workshop 'Research Needs for Neutron Capture Therapy', held in Williamsburg, VA, May 9-12. 1995 addressed key issues and questions related to optimization of boron neutron capture therapy (BNCT), in general, and to the possibility of success of the present BNCT trials at the Brookhaven National Laboratory (BNL) and Massachusetts Institute of Technology (MIT), in particular. Both trials use nuclear fission reactors as neutron sources for BNCT of glioblastoma multiforme (BNL) and of deep seated melanoma (MIT). Presentations and discussions focussed on optimal boron-labeled compounds, mainly for brain tumors such as glioblastoma multiforme, and the best mode of compound delivery to the tumor. Also, optimizing neutron irradiation with dose delivery to the tumor cells and the issues of dosimetry of BNCT especially in the brain were discussed. Planning of treatment and of follow-up of patients, coordination of BNCT at various treatment sites, and the potential of delivery BNCT to various types of cancer with an appropriately tailored protocol were additional issues. The need for multicentric interdisciplinary cooperation among the different medical specialties was highlighted.

  17. Radiation Therapy for Testicular Cancer

    MedlinePlus

    ... Therapy for Testicular Cancer Radiation therapy uses a beam of high-energy rays (such as gamma rays or x-rays) or particles (such as electrons, protons, or neutrons) to destroy cancer cells or ...

  18. Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics.

    PubMed

    Wheeler, F J; Nigg, D W; Capala, J; Watkins, P R; Vroegindeweij, C; Auterinen, I; Seppälä, T; Bleuel, D

    1999-07-01

    The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal-neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well-characterized epithermal-neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR-1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p-Boronophenylaline Fructose (BPA-F) and a hypothetical next-generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal-neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy-tissue tolerance and a reduction in the hydrogen-recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR-1 beam has the better quality (lower hydrogen-recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR-1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully

  19. Design of a californium-based epithermal neutron beam for neutron capture therapy.

    PubMed

    Yanch, J C; Kim, J K; Wilson, M J

    1993-08-01

    The potential of the spontaneously fissioning isotope, 252Cf, to provide epithermal neutrons for use in boron neutron capture therapy (BNCT) has been investigated using Monte Carlo simulation. The Monte Carlo code MCNP was used to design an assembly composed of a 26 cm long, 11 cm radius cylindrical D2O moderator followed by a 64 cm long Al filter. Lithium filters are placed between the moderator and the filter and between the Al and the patient. A reflector surrounding the moderator/filter assembly is required in order to maintain adequate therapy flux at the patient position. An ellipsoidal phantom composed of skull- and brain-equivalent material was used to determine the dosimetric effect of this beam. It was found that both advantage depths and advantage ratios compare very favourably with reactor and accelerator epithermal neutron sources. The dose rate obtainable, on the other hand, is 4.1 RBE cGy min-1, based on a very large (1.0 g) source of 252Cf. This dose rate is two to five times lower than those provided by existing reactor beams and can be viewed as a drawback of using 252Cf as a neutron source. Radioisotope sources, however, do offer the advantage of in-hospital installation.

  20. Neutron dosimetry, moderated energy spectrum, and neutron capture therapy for californium-252 medical sources

    NASA Astrophysics Data System (ADS)

    Rivard, Mark Joseph

    Examination of neutron dosimetry for 252Cf has been conducted using calculative and experimental means. Monte Carlo N-Particle (MCNP) transport code was used in a distributed computing environment as a parallel virtual machine (PVM) to determine the absorbed neutron dose and neutron energy spectrum from 252Cf in a variety of clinically relevant materials. Herein, a Maxwellian spectrum was used to model the 252Cf neutron emissions within these materials. 252Cf mixed-field dosimetry of Applicator Tube (AT) type sources was measured using 1.0 and 0.05 cm3 tissue-equivalent ion chambers and a miniature GM counter. A dosimetry protocol was formulated similar that of ICRU 45. The 252Cf AT neutron dosimetry was determined in the cylindrical coordinate system formalism recommended by the AAPM Task Group 43. These results demonstrated the overwhelming dependence of dosimetry on the source geometry factor as there was no significant neutron attenuation within the source or encapsulation. Gold foils and TLDs were used to measure the thermal flux in the vicinity of 252Cf AT sources to compare with the results calculated using MCNP. As the fast neutron energy spectrum did not markedly changed at increasing distances from the AT source, neutron dosimetry results obtained with paired ion chambers using fixed sensitivity factors agreed well with MCNP results and those in the literature. Calculations of moderated 252Cf neutron energy spectrum with various loadings of 10B and 157Gd were performed, in addition to analysis of neutron capture therapy dosimetry with these isotopes. Radiological concerns such as personnel exposure and shielding of 252Cf emissions were examined. Feasibility of a high specific-activity 252Cf HDR source was investigated through radiochemical and metallurgical studies using stand-ins such as Tb, Gd and 249Cf. Issues such as capsule burst strength due to helium production for a variety of proposed HDR sources were addressed. A recommended 252Cf source

  1. Characteristics of a heavy water photoneutron source in boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Danial, Salehi; Dariush, Sardari; M. Salehi, Jozani

    2013-07-01

    Bremsstrahlung photon beams produced by medical linear accelerators are currently the most commonly used method of radiation therapy for cancerous tumors. Photons with energies greater than 8-10 MeV potentially generate neutrons through photonuclear interactions in the accelerator's treatment head, patient's body, and treatment room ambient. Electrons impinging on a heavy target generate a cascade shower of bremsstrahlung photons, the energy spectrum of which shows an end point equal to the electron beam energy. By varying the target thickness, an optimum thickness exists for which, at the given electron energy, maximum photon flux is achievable. If a source of high-energy photons i.e. bremsstrahlung, is conveniently directed to a suitable D2O target, a novel approach for production of an acceptable flux of filterable photoneturons for boron neutron capture therapy (BNCT) application is possible. This study consists of two parts. 1. Comparison and assessment of deuterium photonuclear cross section data. 2. Evaluation of the heavy water photonuclear source.

  2. Measurements of neutron distribution in neutrons-gamma-rays mixed field using imaging plate for neutron capture therapy.

    PubMed

    Tanaka, Kenichi; Endo, Satoru; Hoshi, Masaharu

    2010-01-01

    The imaging plate (IP) technique is tried to be used as a handy method to measure the spatial neutron distribution via the (157)Gd(n,gamma)(158)Gd reaction for neutron capture therapy (NCT). For this purpose, IP is set in a water phantom and irradiated in a mixed field of neutrons and gamma-rays. The Hiroshima University Radiobiological Research Accelerator is utilized for this experiment. The neutrons are moderated with 20-cm-thick D(2)O to obtain suitable neutron field for NCT. The signal for IP doped with Gd as a neutron-response enhancer is subtracted with its contribution by gamma-rays, which was estimated using IP without Gd. The gamma-ray response of Gd-doped IP to non-Gd IP is set at 1.34, the value measured for (60)Co gamma-rays, in estimating the gamma-ray contribution to Gd-doped IP signal. Then measured distribution of the (157)Gd(n,gamma)(158)Gd reaction rate agrees within 10% with the calculated value based on the method that has already been validated for its reproducibility of Au activation. However, the evaluated distribution of the (157)Gd(n,gamma)(158)Gd reaction rate is so sensitive to gamma-ray energy, e.g. the discrepancy of the (157)Gd(n,gamma)(158)Gd reaction rate between measurement and calculation becomes 30% for the photon energy change from 33keV to 1.253MeV.

  3. Boron Neutron Capture Therapy for Malignant Brain Tumors

    PubMed Central

    MIYATAKE, Shin-Ichi; KAWABATA, Shinji; HIRAMATSU, Ryo; KUROIWA, Toshihiko; SUZUKI, Minoru; KONDO, Natsuko; ONO, Koji

    2016-01-01

    Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting. PMID:27250576

  4. Microdosimetric investigations at the Fast Neutron Therapy Facility at Fermilab

    SciTech Connect

    Langen, Katja Maria

    1997-01-01

    Microdosimetry was used to investigate three issues at the neutron therapy facility (NTF) at Fermilab. Firstly, the conversion factor from absorbed dose in A-150 tissue equivalent plastic to absorbed dose in ICRU tissue was determined. For this, the effective neutron kerma factor ratios, i.e. oxygen tissue equivalent plastic and carbon to A-150 tissue equivalent plastic, were measured in the neutron beam. An A-150 tissue equivalent plastic to ICRU tissue absorbed dose conversion factor of 0.92 ± 0.04 determined. Secondly, variations in the radiobiological effectiveness (RBE) in the beam were mapped by determining variations in two related quantities, e* and R, with field size and depth in tissue. Maximal variation in e* and R of 9% and 15% respectively were determined. Lastly, the feasibility of utilizing the boron neutron capture reaction on boron-10 to selectively enhance the tumor dose in the NTF beam was investigated. In the unmodified beam, a negligible enhancement for a 50 ppm boron loading was measured. To boost the boron dose enhancement to 3% it was necessary to change the primary proton energy from 66 MeV and to filter the beam by 90 mm of tungsten.

  5. Boron Neutron Capture Therapy for Malignant Brain Tumors.

    PubMed

    Miyatake, Shin-Ichi; Kawabata, Shinji; Hiramatsu, Ryo; Kuroiwa, Toshihiko; Suzuki, Minoru; Kondo, Natsuko; Ono, Koji

    2016-07-15

    Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting.

  6. The clinical potential of high energy, intensity and energy modulated electron beams optimized by simulated annealing for conformal radiation therapy

    NASA Astrophysics Data System (ADS)

    Salter, Bill Jean, Jr.

    Purpose. The advent of new, so called IVth Generation, external beam radiation therapy treatment machines (e.g. Scanditronix' MM50 Racetrack Microtron) has raised the question of how the capabilities of these new machines might be exploited to produce extremely conformal dose distributions. Such machines possess the ability to produce electron energies as high as 50 MeV and, due to their scanned beam delivery of electron treatments, to modulate intensity and even energy, within a broad field. Materials and methods. Two patients with 'challenging' tumor geometries were selected from the patient archives of the Cancer Therapy and Research Center (CTRC), in San Antonio Texas. The treatment scheme that was tested allowed for twelve, energy and intensity modulated beams, equi-spaced about the patient-only intensity was modulated for the photon treatment. The elementary beams, incident from any of the twelve allowed directions, were assumed parallel, and the elementary electron beams were modeled by elementary beam data. The optimal arrangement of elementary beam energies and/or intensities was optimized by Szu-Hartley Fast Simulated Annealing Optimization. Optimized treatment plans were determined for each patient using both the high energy, intensity and energy modulated electron (HIEME) modality, and the 6 MV photon modality. The 'quality' of rival plans were scored using three different, popular objective functions which included Root Mean Square (RMS), Maximize Dose Subject to Dose and Volume Limitations (MDVL - Morrill et. al.), and Probability of Uncomplicated Tumor Control (PUTC) methods. The scores of the two optimized treatments (i.e. HIEME and intensity modulated photons) were compared to the score of the conventional plan with which the patient was actually treated. Results. The first patient evaluated presented a deeply located target volume, partially surrounding the spinal cord. A healthy right kidney was immediately adjacent to the tumor volume, separated

  7. Computational Dosimetry and Treatment Planning Considerations for Neutron Capture Therapy

    SciTech Connect

    Nigg, David Waler

    2003-03-01

    Specialized treatment planning software systems are generally required for neutron capture therapy (NCT) research and clinical applications. The standard simplifying approximations that work well for treatment planning computations in the case of many other modalities are usually not appropriate for application to neutron transport. One generally must obtain an explicit three-dimensional numerical solution of the governing transport equation, with energy-dependent neutron scattering completely taken into account. Treatment planning systems that have been successfully introduced for NCT applications over the past 15 years rely on the Monte Carlo stochastic simulation method for the necessary computations, primarily because of the geometric complexity of human anatomy. However, historically, there has also been interest in the application of deterministic methods, and there have been some practical developments in this area. Most recently, interest has turned toward the creation of treatment planning software that is not limited to any specific therapy modality, with NCT as only one of several applications. A key issue with NCT treatment planning has to do with boron quantification, and whether improved information concerning the spatial biodistribution of boron can be effectively used to improve the treatment planning process. Validation and benchmarking of computations for NCT are also of current developmental interest. Various institutions have their own procedures, but standard validation models are not yet in wide use.

  8. SU-E-T-90: Accuracy of Calibration of Lithium-6 and -7 Enriched LiF TLDs for Neutron Measurements in High Energy Radiotherapy

    SciTech Connect

    Keehan, S; Franich, R; Taylor, M; Lonski, P; Kron, T

    2015-06-15

    Purpose: To determine the potential error involved in the interpretation of neutron measurements from medical linear accelerators (linacs) using TLD-600H and TLD-700H if standard AmBe and {sup 252}Cf neutron sources are used for calibration without proper inclusion of neutron energy spectrum information. Methods: The Kerma due to neutrons can be calculated from the energy released by various nuclear interactions (elastic and inelastic scatter, (n,α), (n,p), (n,d), (n,t), (n,2n), etc.). The response of each TLD can be considered the sum of the neutron and gamma components; each proportional to the Kerma. Using the difference between the measured TLD responses and the ratio of the calculated Kerma for each material, the neutron component of the response can be calculated. The Monte Carlo code MCNP6 has been used to calculate the neutron energy spectra resulting from photonuclear interactions in a Varian 21EX linac. TLDs have been exposed to the mixed (γ-n) field produced by a linac and AmBe and {sup 252}Cf standard neutron sources. Results: For dosimetry of neutrons from AmBe or {sup 252}Cf sources, assuming TLD-700H insensitivity to neutrons will Result in 10% or 20% overestimation of neutron doses respectively.For dosimetry of neutrons produced in a Varian 21EX, applying a calibration factor derived from a standard AmBe or {sup 252}Cf source will Result in an overestimation of neutron fluence, by as much as a factor of 47.The assumption of TLD-700H insensitivity to neutrons produced by linacs leads to a negligible error due to the extremely high Kerma ratio (600H/700H) of 3000 for the assumed neutron spectrum. Conclusion: Lithium-enriched TLDs calibrated with AmBe and/or {sup 252}Cf neutron sources are not accurate for use under the neutron energy spectrum produced by a medical linear accelerator.

  9. Thermal neutron irradiation field design for boron neutron capture therapy of human explanted liver.

    PubMed

    Bortolussi, S; Altieri, S

    2007-12-01

    The selective uptake of boron by tumors compared to that by healthy tissue makes boron neutron capture therapy (BNCT) an extremely advantageous technique for the treatment of tumors that affect a whole vital organ. An example is represented by colon adenocarcinoma metastases invading the liver, often resulting in a fatal outcome, even if surgical resection of the primary tumor is successful. BNCT can be performed by irradiating the explanted organ in a suitable neutron field. In the thermal column of the Triga Mark II reactor at Pavia University, a facility was created for this purpose and used for the irradiation of explanted human livers. The neutron field distribution inside the organ was studied both experimentally and by means of the Monte Carlo N-particle transport code (MCNP). The liver was modeled as a spherical segment in MCNP and a hepatic-equivalent solution was used as an experimental phantom. In the as-built facility, the ratio between maximum and minimum flux values inside the phantom ((phi(max)/phi(min)) was 3.8; this value can be lowered to 2.3 by rotating the liver during the irradiation. In this study, the authors proposed a new facility configuration to achieve a uniform thermal neutron flux distribution in the liver. They showed that a phi(max)/phi(min) ratio of 1.4 could be obtained without the need for organ rotation. Flux distributions and dose volume histograms were reported for different graphite configurations.

  10. A high yield neutron target for cancer therapy

    NASA Technical Reports Server (NTRS)

    Alger, D. L.; Steinberg, R.

    1972-01-01

    A rotating target was developed that has the potential for providing an initial yield of 10 to the 13th power neutrons per second by the T(d,n)He-4 reaction, and a useable lifetime in excess of 600 hours. This yield and lifetime are indicated for a 300 Kv and 30 mA deuteron accelerator and a 30 microns thick titanium tritide film formed of the stoichiometric compound TiT2. The potential for extended lifetime is made possible by incorporating a sputtering electrode that permits use of titanium tritide thicknesses much greater than the deuteron range. The electrode is used to remove in situ depleted titanium layers to expose fresh tritide beneath. The utilization of the rotating target as a source of fast neutrons for cancer therapy is discussed.

  11. Monte Carlo simulation of secondary radiation exposure from high-energy photon therapy using an anthropomorphic phantom.

    PubMed

    Frankl, Matthias; Macián-Juan, Rafael

    2016-03-01

    The development of intensity-modulated radiotherapy treatments delivering large amounts of monitor units (MUs) recently raised concern about higher risks for secondary malignancies. In this study, optimised combinations of several variance reduction techniques (VRTs) have been implemented in order to achieve a high precision in Monte Carlo (MC) radiation transport simulations and the calculation of in- and out-of-field photon and neutron dose-equivalent distributions in an anthropomorphic phantom using MCNPX, v.2.7. The computer model included a Varian Clinac 2100C treatment head and a high-resolution head phantom. By means of the applied VRTs, a relative uncertainty for the photon dose-equivalent distribution of <1 % in-field and 15 % in average over the rest of the phantom could be obtained. Neutron dose equivalent, caused by photonuclear reactions in the linear accelerator components at photon energies of approximately >8 MeV, has been calculated. Relative uncertainty, calculated for each voxel, could be kept below 5 % in average over all voxels of the phantom. Thus, a very detailed neutron dose distribution could be obtained. The achieved precision now allows a far better estimation of both photon and especially neutron doses out-of-field, where neutrons can become the predominant component of secondary radiation.

  12. Carborane derivative development for boron neutron capture therapy. Final report

    SciTech Connect

    Barnum, Beverly A.; Yan Hao; Moore, Roger; Hawthorne, M. Frederick; Baum, Kurt

    1999-04-01

    Boron Neutron Capture Therapy [BNCT] is a binary method of cancer therapy based on the capture of neutrons by a boron-10 atom [{sup 10}B]. Cytotoxic {sup 7}Li nuclei and {alpha}-particles are emitted, with a range in tissue of 9 and 5 {micro}m, respectively, about one cell diameter. The major obstacle to clinically viable BNCT is the selective localization of 5-30 ppm {sup 10}B in tumor cells required for effective therapy. A promising approach to BNCT is based on hydrophilic boron-rich oligomeric phosphate diesters, or ''trailers'' that have been shown to concentrate selectively in tumor tissue. Examples of these compounds were prepared previously at high cost using an automated DNA synthesizer. Direct synthesis methods are needed for the production of gram-scale quantities for further biological evaluation. The work accomplished as a result of the collaboration between Fluorochem, Inc. and UCLA demonstrates that short oligomers containing at least five carborane units with four phosphodiester linkages can be prepared in substantial quantities. This work was accomplished by the application of standard phosphoramidite coupling chemistry.

  13. Initial Performance Characterization for a Thermalized Neutron Beam for Neutron Capture Therapy Research at Washington State University

    SciTech Connect

    David W. Nigg; P.E> Sloan; J.R. Venhuizen; C.A. Wemple

    2005-11-01

    The Idaho National Engineering and Environmental Laboratory (INEEL) and Washington State University (WSU) have constructed a new epithermal-neutron beam for collaborative Boron Neutron Capture Therapy (BNCT) preclinical research at the WSU TRIGATM research reactor facility1. More recently, additional beamline components were developed to permit the optional thermalization of the beam for certain types of studies where it is advantageous to use a thermal neutron source rather than an epithermal source. This article summarizes the results of some initial neutronic performance measurements for the thermalized system, with a comparison to the expected performance from the design computations.

  14. Experimental Transport Benchmarks for Physical Dosimetry to Support Development of Fast-Neutron Therapy with Neutron Capture Augmentation

    SciTech Connect

    D. W. Nigg; J. K. Hartwell; J. R. Venhuizen; C. A. Wemple; R. Risler; G. E. Laramore; W. Sauerwein; G. Hudepohl; A. Lennox

    2006-06-01

    The Idaho National Laboratory (INL), the University of Washington (UW) Neutron Therapy Center, the University of Essen (Germany) Neutron Therapy Clinic, and the Northern Illinois University(NIU) Institute for Neutron Therapy at Fermilab have been collaborating in the development of fast-neutron therapy (FNT) with concurrent neutron capture (NCT) augmentation [1,2]. As part of this effort, we have conducted measurements to produce suitable benchmark data as an aid in validation of advanced three-dimensional treatment planning methodologies required for successful administration of FNT/NCT. Free-beam spectral measurements as well as phantom measurements with Lucite{trademark} cylinders using thermal, resonance, and threshold activation foil techniques have now been completed at all three clinical accelerator facilities. The same protocol was used for all measurements to facilitate intercomparison of data. The results will be useful for further detailed characterization of the neutron beams of interest as well as for validation of various charged particle and neutron transport codes and methodologies for FNT/NCT computational dosimetry, such as MCNP [3], LAHET [4], and MINERVA [5].

  15. Nanodosimetric measurements and calculations in a neutron therapy beam.

    PubMed

    Grindborg, J-E; Lillhök, J E; Lindborg, L; Gudowska, I; Söderberg, J; Carlsson, G Alm; Nikjoo, H

    2007-01-01

    A comparison of calculated and measured values of the dose mean lineal energy (y(D)) for the former neutron therapy beam at Louvain-la-Neuve is reported. The measurements were made with wall-less tissue-equivalent proportional counters using the variance-covariance method and simulating spheres with diameters between 10 nm and 15 microm. The calculated y(D)-values were obtained from simulated energy distributions of neutrons and charged particles inside an A-150 phantom and from published y(D)-values for mono-energetic ions. The energy distributions of charged particles up to oxygen were determined with the SHIELD-HIT code using an MCNPX simulated neutron spectrum as an input. The mono-energetic ion y(D)-values in the range 3-100 nm were taken from track-structure simulations in water vapour done with PITS/KURBUC. The large influence on the dose mean lineal energy from the light ion (A > 4) absorbed dose fraction, may explain an observed difference between experiment and calculation. The latter being larger than earlier reported result. Below 50 nm, the experimental values increase while the calculated decrease.

  16. Treatment Planning for Accelerator-Based Boron Neutron Capture Therapy

    SciTech Connect

    Herrera, Maria S.; Gonzalez, Sara J.; Minsky, Daniel M.; Kreiner, Andres J.

    2010-08-04

    Glioblastoma multiforme and metastatic melanoma are frequent brain tumors in adults and presently still incurable diseases. Boron Neutron Capture Therapy (BNCT) is a promising alternative for this kind of pathologies. Accelerators have been proposed for BNCT as a way to circumvent the problem of siting reactors in hospitals and for their relative simplicity and lower cost among other advantages. Considerable effort is going into the development of accelerator-based BNCT neutron sources in Argentina. Epithermal neutron beams will be produced through appropriate proton-induced nuclear reactions and optimized beam shaping assemblies. Using these sources, computational dose distributions were evaluated in a real patient with diagnosed glioblastoma treated with BNCT. The simulated irradiation was delivered in order to optimize dose to the tumors within the normal tissue constraints. Using Monte Carlo radiation transport calculations, dose distributions were generated for brain, skin and tumor. Also, the dosimetry was studied by computing cumulative dose-volume histograms for volumes of interest. The results suggest acceptable skin average dose and a significant dose delivered to tumor with low average whole brain dose for irradiation times less than 60 minutes, indicating a good performance of an accelerator-based BNCT treatment.

  17. Osteogenic Sarcoma of the Maxilla: Neutron Therapy for Unresectable Disease

    DOE PAGES

    Smoron, Geoffrey L.; Lennox, Arlene J.; Mcgee, James L.

    1999-01-01

    Purpose. To present a case study involving the use of fast neutron therapy to treat an extensive unresectable osteogenic sarcoma arising from the left maxilla. Patient. A 14-year-old male presented with a massive tumor producing severe distortion of his facial structures. He had already received six courses of chemotherapy, which had reduced his pain, but had not measurably reduced the tumor. Methods. The patient was treated with 66 MeV fast neutrons to a dose of 20.4 Gy in 13 fractions over 35 days. Results. CT assessments indicate gradually increasing calcification and noticeable reduction of soft-tissue disease in the frontalmore » sinus, orbit and maxillary antrum.There has been some recontouring of the facial structures.The boy conducts an active life, has no pain, and feels well. He was 17 years old at the last follow-up. Discussion. Fast neutrons have a greater biological effectiveness than conventional photon beams. Their use has been associated with improved chance for local control of unresectable disease.This case illustrates their effectiveness in controlling an unusual and aggressive osteogenic sarcoma of the facial bone and sinuses.« less

  18. Optimization of Beam-Shaping Assemblies for BNCS Using the High-Energy Neutron Sources D-D and D-T

    SciTech Connect

    Verbeke, Jerome M.; Chen, Allen S.; Vujic, Jasmina L.; Leung, Ka-Ngo

    2001-06-15

    Boron neutron capture synovectomy is a novel approach for the treatment of rheumatoid arthritis. The goal of the treatment is the ablation of diseased synovial membranes in articulating joints. The treatment of knee joints is the focus of this work. A method was developed, as discussed previously, to predict the dose distribution in a knee joint from any neutron and photon beam spectra incident on the knee. This method is validated and used to design moderators for the deuterium-deuterium (D-D) and deuterium-tritium (D-T) neutron sources. Treatment times >2 h were obtained with the D-D reaction. They could potentially be reduced if the {sup 10}B concentration in the synovium was increased. For D-T neutrons, high therapeutic ratios and treatment times <5 min were obtained for neutron yields of 10{sup 14} s{sup -1}. This treatment time makes the D-T reaction attractive for boron neutron capture synovectomy.

  19. Measurements of high energy neutrons penetrated through iron shields using the Self-TOF detector and an NE213 organic liquid scintillator

    NASA Astrophysics Data System (ADS)

    Sasaki, M.; Nakao, N.; Nunomiya, T.; Nakamura, T.; Fukumura, A.; Takada, M.

    2002-11-01

    Neutron energy spectra penetrated through iron shields were measured using the Self-TOF detector and an NE213 organic liquid scintillator which have been newly developed by our group at the Heavy-Ion Medical Accelerator in Chiba (HIMAC) of National Institute of Radiological Sciences (NIRS), Japan. Neutrons were generated by bombarding 400 MeV/nucleon C ion on a thick (stopping-length) copper target. The neutron spectra in the energy range from 20 to 800 MeV were obtained through the FORIST unfolding code with their response functions and compared with the MCNPX calculations combined with the LA150 cross section library. The neutron fluence measured by the NE213 detector was simulated by the track length estimator in the MCNPX, and evaluated the contribution of the room-scattered neutrons. The calculations are in fairly good agreement with the measurements. Neutron fluence attenuation lengths were obtained from the experimental results and the calculation.

  20. Thiourea derivatives, methods of their preparation and their use in neutron capture therapy of malignant melanoma

    DOEpatents

    Gabel, D.

    1991-06-04

    The present invention pertains to boron containing thiouracil derivatives, their method of preparations, and their use in the therapy of malignant melanoma using boron neutron capture therapy. No Drawings

  1. Boron containing compounds and their preparation and use in neutron capture therapy

    DOEpatents

    Gabel, D.

    1992-09-01

    The present invention pertains to boron containing thiouracil derivatives, their method of preparations, and their use in the therapy of malignant melanoma using boron neutron capture therapy. No Drawings

  2. Boron neutron capture therapy for malignant melanoma: An experimental approach

    SciTech Connect

    Larsson, B.S.; Larsson, B.; Roberto, A. )

    1989-07-01

    Previous studies have shown that some thioamides, e.g., thiouracil, are incorporated as false precursors into melanin during its synthesis. If boronated analogs of the thioamides share this property, the melanin of melanotic melanomas offers a possibility for specific tumoural uptake and retention of boron as a basis for neutron capture therapy. We report on the synthesis of boronated 1H-1,2,4-triazole-3-thiol (B-TZT), boronated 5-carboxy-2-thiouracil (B-CTU), and boronated 5-diethylaminomethyl-2-thiouracil (B-DEAMTU) and the localization of these substances in melanotic melanomas transplanted to mice. The distribution in the mice was studied by boron neutron capture radiography. B-TZT and B-CTU showed the highest tumour:normal tissue concentration ratios, with tumour:liver ratios of about 4 and tumour:muscle ratios of about 14; B-DEAMTU showed corresponding ratios of 1.4 and 5, respectively. The absolute concentration of boron in the tumours, however, was more than three times higher in the mice injected with B-TZT, compared with B-CTU. The results suggest that B-TZT may be the most promising compound of the three tested with regard to possible therapy of melanotic melanomas.

  3. Dose homogeneity in boron neutron capture therapy using an epithermal neutron beam.

    PubMed

    Konijnenberg, M W; Dewit, L G; Mijnheer, B J; Raaijmakers, C P; Watkins, P R

    1995-06-01

    Simulation models based on the neutron and photon Monte Carlo code MCNP were used to study the therapeutic possibilities of the HB11 epithermal neutron beam at the High Flux Reactor in Petten. Irradiations were simulated in two types of phantoms filled with water or tissue-equivalent material for benchmark treatment planning calculations. In a cuboid phantom the influence of different field sizes on the thermal-neutron-induced dose distribution was investigated. Various shapes of collimators were studied to test their efficacy in optimizing the thermal-neutron distribution over a planning target volume and healthy tissues. Using circular collimators of 8, 12 and 15 cm diameter it was shown that with the 15-cm field a relatively larger volume within 85% of the maximum neutron-induced dose was obtained than with the 8- or 12-cm-diameter field. However, even for this large field the maximum diameter of this volume was 7.5 cm. In an ellipsoid head phantom the neutron-induced dose was calculated assuming the skull to contain 10 ppm 10B, the brain 5 ppm 10B and the tumor 30 ppm 10B. It was found that with a single 15-cm-diameter circular beam a very inhomogenous dose distribution in a typical target volume was obtained. Applying two equally weighted opposing 15-cm-diameter fields, however, a dose homogeneity within +/- 10% in this planning target volume was obtained. The dose in the surrounding healthy brain tissue is 30% at maximum of the dose in the center of the target volume. Contrary to the situation for the 8-cm field, combining four fields of 15 cm diameter gave no large improvement of the dose homogeneity over the target volume or a lower maximum dose in the healthy brain. Dose-volume histograms were evaluated for the planning target volume as well as for the healthy brain to compare different irradiation techniques, yielding a graphical confirmation of the above conclusions. Therapy with BNCT on brain tumors must be performed either with an 8-cm four

  4. Neutron capture therapy with deep tissue penetration using capillary neutron focusing

    DOEpatents

    Peurrung, Anthony J.

    1997-01-01

    An improved method for delivering thermal neutrons to a subsurface cancer or tumor which has been first doped with a dopant having a high cross section for neutron capture. The improvement is the use of a guide tube in cooperation with a capillary neutron focusing apparatus, or neutron focusing lens, for directing neutrons to the tumor, and thereby avoiding damage to surrounding tissue.

  5. Experimental verification of improved depth-dose distribution using hyper-thermal neutron incidence in neutron capture therapy.

    PubMed

    Sakurai, Y; Kobayashi, T

    2001-01-01

    We have proposed the utilization of 'hyper-thermal neutrons' for neutron capture therapy (NCT) from the viewpoint of the improvement in the dose distribution in a human body. In order to verify the improved depth-dose distribution due to hyper-thermal neutron incidence, two experiments were carried out using a test-type hyper-thermal neutron generator at a thermal neutron irradiation field in Kyoto University Reactor (KUR), which is actually utilized for NCT clinical irradiation. From the free-in-air experiment for the spectrum-shift characteristics, it was confirmed that the hyper-thermal neutrons of approximately 860 K at maximum could be obtained by the generator. From the phantom experiment, the improvement effect and the controllability for the depth-dose distribution were confirmed. For example, it was found that the relative neutron depth-dose distribution was about 1 cm improved with the 860 K hyper-thermal neutron incidence, compared to the normal thermal neutron incidence.

  6. Development and characteristics of the HANARO neutron irradiation facility for applications in the boron neutron capture therapy field.

    PubMed

    Kim, Myong-Seop; Lee, Byung-Chul; Hwang, Sung-Yul; Kim, Heonil; Jun, Byung-Jin

    2007-05-07

    The HANARO neutron irradiation facility for various applications in the boron neutron capture therapy (BNCT) field was developed, and its characteristics were investigated. In order to obtain the sufficient thermal neutron flux with a low level of contamination by fast neutrons and gamma rays, a radiation filtering method was adopted. The radiation filter was designed by using a silicon single crystal, cooled by liquid nitrogen, and a bismuth crystal. The installation of the main components of the irradiation facility and the irradiation room was finished. Neutron beam characteristics were measured by using bare and cadmium-covered gold foils and wires. The in-phantom neutron flux distribution was measured for flux mapping inside the phantom. The gamma-ray dose was determined by using TLD-700 thermoluminescence dosimeters. The thermal and fast neutron fluxes and the gamma-ray dose were calculated by using the MCNP code, and they were compared with experimental data. The thermal neutron flux and Cd ratio available at this facility were confirmed to be 1.49 x 10(9) n cm(-2) s(-1) and 152, respectively. The maximum neutron flux inside the phantom was measured to be 2.79 x 10(9) n cm(-2) s(-1) at a depth of 3 mm in the phantom. The two-dimensional in-phantom neutron flux distribution was determined, and significant neutron irradiation was observed within 20 mm from the phantom surface. The gamma-ray dose rate for the free beam condition was expected to be about 80 cGy h(-1). These experimental results were reasonably well supported by calculation using the facility design code. This HANARO thermal neutron facility can be used not only for clinical trials, but also for various pre-clinical studies in the BNCT field.

  7. [Use of negative pressure therapy in the treatment of primary infected traumatic wounds of the foot caused by high energy impact].

    PubMed

    Marinović, Marin; Spanjol, Josip; Laginja, Stanislava; Grzalja, Nikola; Stiglić, Damir; Ekl, Darko; Fumić, Nera; Sepac, Brigita

    2013-10-01

    Foot injuries caused by firearms and high pressure washing machines are not common, but due to high energy can be very destructive and contaminated with microorganisms. Due to the anatomical specificity of the foot, injures of the specific structure such as blood vessels, nerves and tendon-ligament apparatus are frequent. Soft tissue defect is often present. Functional and aesthetic recovery of the foot is a challenge for the surgeon. Direct and indirect effect of the negative pressure therapy helps in wound healing and provides good preparation for definitive surgical management of wounds.

  8. Boron neutron capture therapy for the treatment of cerebral gliomas. I. Theoretical evaluation of the efficacy of various neutron beams.

    PubMed

    Zamenhof, R G; Murray, B W; Brownell, G L; Wellum, G R; Tolpin, E I

    1975-01-01

    The technique of boron neutron capture therapy in the treatment of cerebral gliomas depends upon the selective loading of the tumor with a 10B-enriched compound and subsequent irradiation of the brain with low-energy neutrons. The charged particles produced in the 10B (n,alpha) 7Li reaction have ranges in tissue of less than 10 mum so that the dose distribution closely follows the 10B distribution even to the cellular level. The effectiveness of this therapy procedure is dependent not only on the 10B compound but on the spectral characteristics of the neutron source as well. Hence, an optimization of these characteristics will increase the chances of therapeutic success. Transport calculations using a neutral particle transport code have been made to determine the dose-depth distributions within a simple head phantom for five different incident neutron beams. Comparison of these beams to determine their relative therapeutic efficacy was made by the use of a maximum useable depth criterion. In particular, with presently available compounds, the MIT reactor (MITR) therapy beam (a) is not inferior to a pure thermal neutron beam, (b) would be marginally improved if its gamma-ray contamination were eliminated, (c) is superior to a partially 10B-filtered MITR beam, and (d) produces a maximum useable depth which is strongly dependent upon the tumor-to-blood ratio of 10B concentrations and weakly dependent upon the absolute 10B concentration in tumor. A pure epithermal neutron beam with a mean energy of 37 eV is shown to have close to the optimal characteristics for boron neutron capture therapy. Futhermore, these optimal characteristics can be approximated by a judiciously D2O moderated and 10B-filtered 252Cf neutron source. This tailored 252Cf source would have at least a 1.5 cm greater maximum useable depth than the MITR therapy beam for realistic 10B concentrations. However, at least one gram of 252Cf would be needed to make this a practical therapy source. If the

  9. IMPROVED COMPUTATIONAL CHARACTERIZATION OF THE THERMAL NEUTRON SOURCE FOR NEUTRON CAPTURE THERAPY RESEARCH AT THE UNIVERSITY OF MISSOURI

    SciTech Connect

    Stuart R. Slattery; David W. Nigg; John D. Brockman; M. Frederick Hawthorne

    2010-05-01

    Parameter studies, design calculations and initial neutronic performance measurements have been completed for a new thermal neutron beamline to be used for neutron capture therapy cell and small-animal radiobiology studies at the University of Missouri Research Reactor. The beamline features the use of single-crystal silicon and bismuth sections for neutron filtering and for reduction of incident gamma radiation. The computational models used for the final beam design and performance evaluation are based on coupled discrete-ordinates and Monte Carlo techniques that permit detailed modeling of the neutron transmission properties of the filtering crystals with very few approximations. This is essential for detailed dosimetric studies required for the anticipated research program.

  10. The evaluation of neutron and gamma ray dose equivalent distributions in patients and the effectiveness of shield materials for high energy photons radiotherapy facilities.

    PubMed

    Ghassoun, J; Senhou, N

    2012-04-01

    In this study, the MCNP5 code was used to model radiotherapy room of a medical linear accelerator operating at 18 MV and to evaluate the neutron and the secondary gamma ray fluences, the energy spectra and the dose equivalent distributions inside a liquid tissue-equivalent (TE) phantom. The obtained results were compared with measured data published in the literature. Moreover, the shielding effects of various neutron material shields on the radiotherapy room wall were also investigated. Our simulation results showed that paraffin wax containing boron carbide presents enough effectiveness to reduce both neutron and secondary gamma ray doses.

  11. Biological activity of N(4)-boronated derivatives of 2'-deoxycytidine, potential agents for boron-neutron capture therapy.

    PubMed

    Nizioł, Joanna; Uram, Łukasz; Szuster, Magdalena; Sekuła, Justyna; Ruman, Tomasz

    2015-10-01

    Boron-neutron capture therapy (BNCT) is a binary anticancer therapy that requires boron compound for nuclear reaction during which high energy alpha particles and lithium nuclei are formed. Unnatural, boron-containing nucleoside with hydrophobic pinacol moiety was investigated as a potential BNCT boron delivery agent. Biological properties of this compound are presented for the first time and prove that boron nucleoside has low cytotoxicity and that observed apoptotic effects suggest alteration of important functions of cancer cells. Mass spectrometry analysis of DNA from cancer cells proved that boron nucleoside is inserted into nucleic acids as a functional nucleotide derivative. NMR studies present very high degree of similarity of natural dG-dC base pair with dG-boron nucleoside system.

  12. Malignant melanoma cure by selective thermal neutron capture therapy

    SciTech Connect

    Mishima, Y.; Ichihashi, M.; Hatta, S.

    1986-01-01

    Thermal neutrons are easily absorbed by the nonradioactive isotope /sup 10/B, resulting in the emission of alpha particles and lithium atoms, which release an energy of 2.33 MeV for up to a 14-..mu..m-diam melanoma cell. Thus, if /sup 10/B can be selectively accumulated in melanoma, it can be destroyed without injury to the surrounding normal tissues by concentrating high linear energy transfer particles. The authors have synthesized seven melanoma-seeking /sup 10/B compounds, two of which, /sup 10/B12-chlorpromazine(/sup 10/B/sup 12/-CPZ) and /sup 10/B/sub 1/-p-boronophenylalanine(/sup 10/B/sub 1/-BPA), are found to be highly effective. The enhanced melanoma-killing effect of the /sup 10/B compounds is found by in vitro radiobiological analysis. A chemical assay and alpha-track analysis 28 h after systemic administration to melanoma-bearing hamsters reveals a /sup 10/B melanoma/blood ratio of 11.5 and a melanoma/liver ratio of 15. Establishment of a clinical therapeutic method for curing human melanoma without failure is underway by correlating biophysical, biochemical, biological, and therapeutic data analysis. Recently, the authors have also been working to develop neutron capture therapy using /sup 10/B-monoclonal antibodies for melanoma and were able to make some /sup 10/B conjugates with the specific m259-0 antibody.

  13. Proceedings of the Specialists' Meeting on High Energy Nuclear Data

    NASA Astrophysics Data System (ADS)

    Fukahori, Tokio

    1992-03-01

    This report consists of the Proceedings of the Specialists' Meeting on High Energy Nuclear Data. The meeting was held on October 3-4, 1991, at the Tokai Research Establishment, Japan Atomic Energy Research Institute with the participation of forty-odd specialists, who were the evaluators, theorists, experimentalists, and users of high energy nuclear data including the members of Japanese Nuclear Data Committee. The need of the nuclear data in the high energy region up to a few GeV was stressed in the meeting for many applications, such as spallation neutron sources for radioactive waste treatment, accelerator shielding design, medical isotope production, radiation therapy, the effects of space radiation on astronauts and their equipment, and the cosmic history of meteorites and other galactic substances. Although the neutron nuclear data below 20 MeV have been well evaluated for fission and fusion reactor applications, the nuclear data in the high energy region have never been prepared in Japan. With the view of producing an evaluated high energy nuclear data file, theoretical models and codes, available and necessary measurements, needs of nuclear data, and various applications were reviewed and discussed. The consensus, that the wide collaboration was necessary to produce the evaluated file and should be established, has been obtained.

  14. Boron neutron capture therapy for the prevention of restenosis

    SciTech Connect

    Yanch, J.C.; Delfaus, M.L.

    1997-12-01

    The potential application of boron neutron capture therapy (BNCT) for the prevention of restenosis following angioplasty is under investigation at Massachusetts Institute of Technology`s Laboratory for Accelerator Beam Applications. The process of Percutaneous transluminal coronary angioplasty involves the insertion of a balloon dilation catheter into the occluded artery. The balloon is then inflated for several minutes to dilate the artery. The blockage is decreased, and blood flow through the artery is improved. This procedure is, initially, very successful. However, 30 to 60% of patients treated also show restenosis within 6 months. Although many physiological processes may contribute to restenosis, the primary mechanism is thought to be abnormal proliferation of the smooth muscle cells in the treated artery.

  15. Boron neutron capture therapy at the crossroads: challenges and opportunities.

    PubMed

    Barth, Rolf F

    2009-07-01

    Over the past 25 years research on boron neutron capture therapy (BNCT) has progressed relatively slowly but steadily with the greatest progress in the field of clinical studies. These specifically have included the use of BNCT to treat a variety of malignancies other than high grade gliomas and melanomas. However, there are a number of key areas where little, if any, significant progress has been made. First and foremost among these has been the lack of new boron delivery agents. Improvement in drug delivery and the development of the best dosing paradigms for both boronophenylalanine (BPA) and sodium borocaptate (BSH) are of major importance and these still have not been optimized. Dosimetry for BNCT is still imprecise and is based on treating to normal tissue tolerance, based on blood boron values, rather than any real-time information on the boron content of the residual tumor that is to be irradiated. Another major problem has been the total dependence on nuclear reactors as neutron sources for BNCT. However, this will change in the near future when a clinically useful accelerator comes into use in 2009. Like it or not, in order to gain the credibility of a broad community of physicians who treat brain tumor patients, there will have to be a randomized clinical trial. Finally, BNCT will have to compete with new therapeutic approaches that are less costly and more effective for the treatment of brain tumors. These challenges notwithstanding, BNCT can fill an important niche for those malignancies, whether primary or recurrent, for which there is currently no effective therapy.

  16. Measurement of the High Energy Neutron Flux on the Surface of the Natural Uranium Target Assembly QUINTA Irradiated by Deuterons of 4 and 8 GeV Energy

    NASA Astrophysics Data System (ADS)

    Adam, J.; Baldin, A. A.; Chilap, V.; Furman, W.; Katovsky, K.; Khushvaktov, J.; Kumar, V.; Pronskikh, V.; Mar'in, I.; Solnyshkin, A.; Suchopar, M.; Tsupko-Sitnikov, V.; Tyutyunnikov, S.; Vrzalova, J.; Wagner, V.; Zavorka, L.

    Experiments with the natural uranium target assembly "QUINTA" exposed to 4 and 8 GeV deuteron beams of the Nuclotron accelerator at the Joint Institute for Nuclear Research (Dubna) are analyzed. The reaction rates of 27Al(n,y1)24Na, 27Al(n,y2)22Na and 27Al(n,y3)7Be reactions with effective threshold energies of 5, 27, and 119 MeV were measured at both 4 GeV and 8 GeV deuteron beam energies. The average neutron fluxes between the effective threshold energies and the effective ends of the neutron spectra (which are 800 or 1000 MeV for 4 or 8 GeV deuterons) were determined. The evidence for the intensity shift of the neutron spectra to higher neutron energies with the increase of the deuteron energy from 4 GeV to 8 GeV was found from the ratios of the average neutron fluxes. The reaction rates and the average neutron fluxes were calculated with the MCNPX 2.7 code.

  17. Neutron capture therapy with deep tissue penetration using capillary neutron focusing

    DOEpatents

    Peurrung, A.J.

    1997-08-19

    An improved method is disclosed for delivering thermal neutrons to a subsurface cancer or tumor which has been first doped with a dopant having a high cross section for neutron capture. The improvement is the use of a guide tube in cooperation with a capillary neutron focusing apparatus, or neutron focusing lens, for directing neutrons to the tumor, and thereby avoiding damage to surrounding tissue. 1 fig.

  18. New compounds for neutron capture therapy (NCT) and their significance

    SciTech Connect

    Fairchild, R.G.; Bond, V.P.

    1982-01-01

    Clearly the most effective tumor therapy would be obtained by the selective targeting of cytotoxic agents to tumor cells. Although many biomolecules are known to be taken up in tumors, the targeting of cytotoxic agents to tumors is limited by the fact that other essential cell pools compete with equal or even greater effectiveness. The approach of delivering stable non-toxic isotopes to tumor, with activation by means of an external radiation beam, is advantageous for two reasons: (1) it obviates problems associated with high uptake of isotopes in normal tissues, as these cell pools can be excluded from the radiation field, and (2) the general tumor area can be included in the activating beam field; thus, the possibility exists that all microscopic tumor extensions can be irradiated. As long as range of reaction products is short, dose will be restricted to the tumor, with a resultant high therapeutic ratio. This method can be accomplished with either photon activation therapy (PAT) or Neutron Capture Therapy (NCT), the latter will be emphasized here. The range of the high LET, low OER particles from the /sup 10/B(n,..cap alpha..)/sup 7/Li reaction is approx. 10 ..mu..m, or one cell diameter; hence this reaction is optimal for cell killing. A number of biomolecules have been investigated as possible vehicles for transport of boron to tumors, including phenothiazines, thiouracils, porphyrins, nucleosides, and amino acids. Biodistributions of these compounds show selective concentration in tumor adequate for therapy. The biological halflives are in the order of days, allowing the possibility of fractionated or protracted irradiations. The radiobiological and physical implication of these parameters on NCT are discussed. The possibility of using an approximately-monoenergetic, scandium-filtered beam of about 2 keV, to reduce the dose from background radiations by about 85%, is also discussed. (ERB)

  19. Study of optical model parameters for high energy neutron cross sections from 5 to 50 MeV in the mass-140 region

    SciTech Connect

    Phillips, T.W.; Camarda, H.S.; White, R.M.

    1980-05-08

    A study of the neutron optical potential on nuclei near mass-140 was begun to extend the energy range and improve the precision of previous neutron total cross section measurements. The extended energy range of this measurement reveals maxima and minima in the total cross section that are evidence of the nuclear Ramsauer effect. A 100-MeV linear accelerator is used to produce a continuum of neutron energies from a Ta-Be conversion target. A 250-meter flight path is used to measure neutron energies by the time-of-flight method. Transmission data for /sup 140/Ce and transmission ratios for /sup 142/Ce, /sup 141/Pr, and /sup 139/La relative to /sup 140/Ce were obtained. The /sup 140/Ce data have a precision of 1 to 3% and the ratios are obtained with a precision of about 0.3%. To analyze these total cross section data a computer code was developed to calculate the total elastic, reaction, and differential elastic scattering cross sections for a neutron interacting with a nucleus. The interaction is represented by a spherically symmetric complex potential that includes spin-orbit coupling. The parameters of this potential were adjusted to approximate the /sup 140/Ce total cross over the energy range from 2.5 to 60 MeV. The energy dependence of these parameters is described. 5 figures, 1 table.

  20. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy.

    PubMed

    Hiramatsu, Ryo; Kawabata, Shinji; Tanaka, Hiroki; Sakurai, Yoshinori; Suzuki, Minoru; Ono, Koji; Miyatake, Shin-ichi; Kuroiwa, Toshihiko; Hao, Erhong; Vicente, M Graça H

    2015-03-01

    Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate TPFC's applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery (CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell surviving fraction following laser irradiation (9 J/cm(2) ) was 0.035 whereas in the in vitro BNCT study, the cell surviving fraction following neutron irradiation (thermal neutron = 1.73 × 10(12) n/cm(2) ) was 0.04. In the in vivo BNCT study, the median survival time following concomitant administration of BPA (i.v.) and TPFC (CED) was 42 days (95% confidence interval; 37-43 days).

  1. Tetrakis(p-Carboranylthio-Tetrafluorophenyl)Chlorin (TPFC): Application for Photodynamic Therapy and Boron Neutron Capture Therapy

    PubMed Central

    HIRAMATSU, RYO; KAWABATA, SHINJI; TANAKA, HIROKI; SAKURAI, YOSHINORI; SUZUKI, MINORU; ONO, KOJI; MIYATAKE, SHIN-ICHI; KUROIWA, TOSHIHIKO; HAO, ERHONG; VICENTE, M. GRAÇA H.

    2015-01-01

    Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate TPFC’s applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery (CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell surviving fraction following laser irradiation (9 J/cm2) was 0.035 whereas in the in vitro BNCT study, the cell surviving fraction following neutron irradiation (thermal neutron = 1.73 × 1012 n/cm2) was 0.04. In the in vivo BNCT study, the median survival time following concomitant administration of BPA (i.v.) and TPFC (CED) was 42 days (95% confidence interval; 37–43 days). PMID:25546823

  2. Dosimetric implications of new compounds for neutron capture therapy (NCT)

    SciTech Connect

    Fairchild, R.G.

    1982-01-01

    Systemic application of radiolabeled or cytotoxic agents should allow targeting of primary and metastatic neoplasms on a cellular level. In fact, drug uptake in non-target cell pools often exceeds toxic levels before sufficient amounts are delivered to tumor. In addition, at the large concentration of molecules necessary for therapy, effects of saturation are often found. Application of NCT can circumvent problems associated with high uptake in competing non-target cell pools, as the /sup 10/B(n,..cap alpha..)/sup 7/Li reaction is activated only within the radiation field. A comparison with other modes of particle therapy indicated that NCT provides significant advantages. It is however, difficult to obtain vehicles for boron transport which demonstrate both the tumor specificity and concentration requisite for NCT. A number of biomolecules have been investigated which show both the necessary concentration and specificity. These include chlorpromazine, thiouracil, porphyrins, amino acids, and nucleosides. However, these analogs have yet to be made available for NCT. Dosimetric implications of binding sites are considered, as well as alternate neutron sources. (ERB)

  3. Monte Carlo based dosimetry for neutron capture therapy of brain tumors

    NASA Astrophysics Data System (ADS)

    Zaidi, Lilia; Belgaid, Mohamed; Khelifi, Rachid

    2016-11-01

    Boron Neutron Capture Therapy (BNCT) is a biologically targeted, radiation therapy for cancer which combines neutron irradiation with a tumor targeting agent labeled with a boron10 having a high thermal neutron capture cross section. The tumor area is subjected to the neutron irradiation. After a thermal neutron capture, the excited 11B nucleus fissions into an alpha particle and lithium recoil nucleus. The high Linear Energy Transfer (LET) emitted particles deposit their energy in a range of about 10μm, which is of the same order of cell diameter [1], at the same time other reactions due to neutron activation with body component are produced. In-phantom measurement of physical dose distribution is very important for BNCT planning validation. Determination of total absorbed dose requires complex calculations which were carried out using the Monte Carlo MCNP code [2].

  4. Feasibility of a boron loaded scintillation detector for dose measurements related to boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Kim, Don-Soo; Egan, James J.; Kegel, Gunter H. R.; Desimone, David

    2002-04-01

    The feasibility of the use of a boron loaded scintillation detector in a head phantom for boron neutron capture therapy dose estimates was evaluated. Several monoenergetic neutron groups were produced via the ^7Li(p,n)^7Be reaction in a metallic lithium target using the Van de Graaff accelerator at University of Massachusetts Lowell. The pulse-height spectra were taken from a natural boron loaded (10205-, 304-, 407-, 507-, 570-, 702-, and 780-keV incident neutrons. The results shows that a boron loaded scintillator could be used to distinguish the doses from different radiation sources in boron neutron capture therapy. This detector may be used in the estimation of doses due to fast neutrons, alpha particles and recoil lithium from ^10B(n,α)^7Li, and photons at the same time during neutron irradiation procedures.

  5. Towards an optimum design of a P-MOS radiation detector for use in high-energy medical photon beams and neutron facilities: analysis of activation materials.

    PubMed

    Price, Robert A

    2005-01-01

    The behaviour of packaged and unpackaged ESAPMOS4 RadFET radiation detectors (NMRC Cork, Ireland) was investigated when used in the mixed photon and neutron environment of a medical linear accelerator operating above the nucleon separation energy and in a 14 MeV neutron field provided by a D-T generator. Within the uncertainty of the experimental set-up (4% at 95% confidence level) the unpackaged device was found to have essentially zero activation dose-burden whereas the packaged device exhibits a considerable degree of post irradiation absorbed dose due to deactivation radiation.

  6. (A clinical trial of neutron capture therapy for brain tumors)

    SciTech Connect

    Zamenhof, R.G.

    1988-01-01

    This report describes progress made in refining of neutron-induced alpha tract autoradiography, in designing epithermal neutron bean at MITR-II and in planning treatment dosimetry using Monte Carlo techniques.

  7. MCNP speed advances for boron neutron capture therapy

    SciTech Connect

    Goorley, J.T.; McKinney, G.; Adams, K.; Estes, G.

    1998-04-01

    The Boron Neutron Capture Therapy (BNCT) treatment planning process of the Beth Israel Deaconess Medical Center-M.I.T team relies on MCNP to determine dose rates in the subject`s head for various beam orientations. In this time consuming computational process, four or five potential beams are investigated. Of these, one or two final beams are selected and thoroughly evaluated. Recent advances greatly decreased the time needed to do these MCNP calculations. Two modifications to the new MCNP4B source code, lattice tally and tracking enhancements, reduced the wall-clock run times of a typical one million source neutrons run to one hour twenty five minutes on a 200 MHz Pentium Pro computer running Linux and using the GNU FORTRAN compiler. Previously these jobs used a special version of MCNP4AB created by Everett Redmond, which completed in two hours two minutes. In addition to this 30% speedup, the MCNP4B version was adapted for use with Parallel Virtual Machine (PVM) on personal computers running the Linux operating system. MCNP, using PVM, can be run on multiple computers simultaneously, offering a factor of speedup roughly the same as the number of computers used. With two 200 MHz Pentium Pro machines, the run time was reduced to forty five minutes, a 1.9 factor of improvement over the single Linux computer. While the time of a single run was greatly reduced, the advantages associated with PVM derive from using computational power not already used. Four possible beams, currently requiring four separate runs, could be run faster when each is individually run on a single machine under Windows NT, rather than using Linux and PVM to run one after another with each multiprocessed across four computers. It would be advantageous, however, to use PVM to distribute the final two beam orientations over four computers.

  8. The dose rate dependence of synthetic diamond detectors in the relative dosimetry of high-energy electron therapy beams

    NASA Astrophysics Data System (ADS)

    Ade, N.; Nam, T. L.; Derry, T. E.; Mhlanga, S. H.

    2014-05-01

    Evaluation of the linear response of a radiation detector with absorbed dose rate should be of paramount importance in clinical dosimetry. As modelled by Fowler, electrical conductivity, σ, of a solid-state detector and absorbed dose rate, Dr, are related by σ~DrΔ where Δ is the linearity index. The detector is thus independent of dose rate if Δ is unity. This contribution investigates and evaluates the dependence of Δ of synthetic diamond detectors of various types on therapy electron energy and its influence in relative electron dosimetry with the aim of selecting a suitable crystal. The study was conducted initially on one HPHT and eight CVD synthesised diamonds of optical grade (OG) and detector grade (DG) qualities using 6-14 MeV electron therapy beams. For quality control, the diamond specimens were characterised by Raman spectroscopy and electron spin resonance (ESR). Values of Δ ranging between 0.79 and 1.03 were obtained for all the nine diamond detectors at 1000 V/cm for 7 and 12 MeV electron beams. Whereas the Δ values of the HPHT diamond were found not to vary with the electron energies, those of three CVD samples of a given class varied with the electron energies within 2%. In addition, a very strong variation of about 9% was observed for two OG crystals of another class. The Δ values were found to decrease with increasing dose rate and there was a tendency for the Δ values to change with defect levels present within the crystals. Due to the independence of the HPHT diamond's Δ values on electron energy and its better stability of response to radiation, a small-size HPHT crystal was then evaluated of its potential applications in small radiation fields. Relative dose distributions measured with the diamond probe on exposure to 6, 12 and 14 MeV electron beams between 1×1 cm2 and 10×10 cm2 fields were compared with those obtained with reference ion chambers and a Dosimetry Diode E. The results showed that with careful selection of a suitable

  9. Optimization study for an epithermal neutron beam for boron neutron capture therapy at the University of Virginia Research Reactor

    SciTech Connect

    Burns, Jr., Thomas Dean

    1995-05-01

    The non-surgical brain cancer treatment modality, Boron Neutron Capture Therapy (BNCT), requires the use of an epithermal neutron beam. This purpose of this thesis was to design an epithermal neutron beam at the University of Virginia Research Reactor (UVAR) suitable for BNCT applications. A suitable epithermal neutron beam for BNCT must have minimal fast neutron and gamma radiation contamination, and yet retain an appreciable intensity. The low power of the UVAR core makes reaching a balance between beam quality and intensity a very challenging design endeavor. The MCNP monte carlo neutron transport code was used to develop an equivalent core radiation source, and to perform the subsequent neutron transport calculations necessary for beam model analysis and development. The code accuracy was validated by benchmarking output against experimental criticality measurements. An epithermal beam was designed for the UVAR, with performance characteristics comparable to beams at facilities with cores of higher power. The epithermal neutron intensity of this beam is 2.2 x 108 n/cm2 • s. The fast neutron and gamma radiation KERMA factors are 10 x 10-11cGy•cm2/nepi and 20 x 10-11 cGy•cm2/nepi , respectively, and the current-to-flux ratio is 0.85. This thesis has shown that the UVAR has the capability to provide BNCT treatments, however the performance characteristics of the final beam of this study were limited by the low core power.

  10. Commercial Clinical Application of Boron Neutron Capture Therapy

    SciTech Connect

    N /A

    1999-09-03

    CRADA No. 95-CR-09 among the LITCO--now Bechtel BWXT Idaho, LLC; a private company, Neutron Therapies Limited Liability Company, NTL formerly Ionix Corporation; and Washington State University was established in 1996 to further the development of BNCT. NTL has established a laboratory for the synthesis, under US FDA approved current Good Manufacturing Practices (cGMP) guidelines, of key boron intermediates and final boron agents for BNCT. The company has focused initially on the development of the compound GB-10 (Na{sub 2}B{sub 10}H{sub 10}) as the first boron agent of interest. An Investigational New Drug (IND) application for GB-10 has been filed and approved by the FDA for a Phase I human biodistribution trial in patients with non-small cell lung cancer and glioblastoma multiforme at UW under the direction of Professor Keith Stelzer, Principal Investigator (PI). These trials are funded by NTL under a contract with the UW, Department of Radiation Oncology, and the initial phases are nearing completion. Initial results show that boron-10 concentrations on the order of 100 micrograms per gram (100 ppm) can be achieved and maintained in blood with no indication of toxicity.

  11. A new analytical formula for neutron capture gamma dose calculations in double-bend mazes in radiation therapy

    PubMed Central

    Ghiasi, Hosein; Mesbahi, Asghar

    2012-01-01

    Background Photoneutrons are produced in radiation therapy with high energy photons. Also, capture gamma rays are the byproduct of neutrons interactions with wall material of radiotherapy rooms. Aim In the current study an analytical formula was proposed for capture gamma dose calculations in double bend mazes in radiation therapy rooms. Materials and methods A total of 40 different layouts with double-bend mazes and a 18 MeV photon beam of Varian 2100 Clinac were simulated using MCNPX Monte Carlo (MC) code. Neutron capture gamma ray dose equivalent was calculated by the MC method along the maze and at the maze entrance door of all the simulated rooms. Then, all MC resulted data were fitted to an empirical formula for capture gamma dose calculations. Wu–McGinley analytical formula for capture gamma dose equivalent at the maze entrance door in single-bend mazes was also used for comparison purposes. Results For capture gamma dose equivalents at the maze entrance door, the difference of 2–11% was seen between MC and the derived equation, while the difference of 36–87% was found between MC and the Wu–McGinley methods. Conclusion Our results showed that the derived formula results were consistent with the MC results for all of 40 different geometries. However, as a new formula, further evaluations are required to validate its use in practical situations. Finally, its application is recommend for capture gamma dose calculations in double-bend mazes to improve shielding calculations. PMID:24377027

  12. In-phantom two-dimensional thermal neutron distribution for intraoperative boron neutron capture therapy of brain tumours

    NASA Astrophysics Data System (ADS)

    Yamamoto, T.; Matsumura, A.; Yamamoto, K.; Kumada, H.; Shibata, Y.; Nose, T.

    2002-07-01

    The aim of this study was to determine the in-phantom thermal neutron distribution derived from neutron beams for intraoperative boron neutron capture therapy (IOBNCT). Gold activation wires arranged in a cylindrical water phantom with (void-in-phantom) or without (standard phantom) a cylinder styrene form placed inside were irradiated by using the epithermal beam (ENB) and the mixed thermal-epithermal beam (TNB-1) at the Japan Research Reactor No 4. With ENB, we observed a flattened distribution of thermal neutron flux and a significantly enhanced thermal flux delivery at a depth compared with the results of using TNB-1. The thermal neutron distribution derived from both the ENB and TNB-1 was significantly improved in the void-in-phantom, and a double high dose area was formed lateral to the void. The flattened distribution in the circumference of the void was observed with the combination of ENB and the void-in-phantom. The measurement data suggest that the ENB may provide a clinical advantage in the form of an enhanced and flattened dose delivery to the marginal tissue of a post-operative cavity in which a residual and/or microscopically infiltrating tumour often occurs. The combination of the epithermal neutron beam and IOBNCT will improve the clinical results of BNCT for brain tumours.

  13. In-phantom two-dimensional thermal neutron distribution for intraoperative boron neutron capture therapy of brain tumours.

    PubMed

    Yamamoto, T; Matsumura, A; Yamamoto, K; Kumada, H; Shibata, Y; Nose, T

    2002-07-21

    The aim of this study was to determine the in-phantom thermal neutron distribution derived from neutron beams for intraoperative boron neutron capture therapy (IOBNCT). Gold activation wires arranged in a cylindrical water phantom with (void-in-phantom) or without (standard phantom) a cylinder styrene form placed inside were irradiated by using the epithermal beam (ENB) and the mixed thermal-epithermal beam (TNB-1) at the Japan Research Reactor No 4. With ENB, we observed a flattened distribution of thermal neutron flux and a significantly enhanced thermal flux delivery at a depth compared with the results of using TNB-1. The thermal neutron distribution derived from both the ENB and TNB-1 was significantly improved in the void-in-phantom, and a double high dose area was formed lateral to the void. The flattened distribution in the circumference of the void was observed with the combination of ENB and the void-in-phantom. The measurement data suggest that the ENB may provide a clinical advantage in the form of an enhanced and flattened dose delivery to the marginal tissue of a post-operative cavity in which a residual and/or microscopically infiltrating tumour often occurs. The combination of the epithermal neutron beam and IOBNCT will improve the clinical results of BNCT for brain tumours.

  14. High-Current Experiments for Accelerator-Based Neutron Capture Therapy Applications

    SciTech Connect

    Gierga, D.P.; Klinkowstein, R.E.; Hughey, B.H.; Shefer, R.E.; Yanch, J.C.; Blackburn, B.W.

    1999-06-06

    Several accelerator-based neutron capture therapy applications are under development. These applications include boron neutron capture therapy for glioblastoma multiform and boron neutron capture synovectomy (BNCS) for rheumatoid arthritis. These modalities use accelerator-based charged-particle reactions to create a suitable neutron source. Neutrons are produced using a high-current, 2-MV terminal tandem accelerator. For these applications to be feasible, high accelerator beam currents must be routinely achievable. An effort was undertaken to explore the operating regime of the accelerator in the milliampere range. In preparation for high-current operation of the accelerator, computer simulations of charged-particle beam optics were performed to establish high-current operating conditions. Herein we describe high beam current simulations and high beam current operation of the accelerator.

  15. Improvement of a p(65)+Be neutron beam for therapy at Cyclone, Louvain-la-Neuve.

    PubMed

    Vynckier, S; Pihet, P; Flémal, J M; Meulders, J P; Wambersie, A

    1983-06-01

    The variable energy cyclotron of the Catholic University of Louvain is used to produce intense neutron beams for neutron therapy purposes. As a first step, neutrons were produced by bombarding a Be target with 50 MeV deuterons; at present they are produced by 65 MeV protons. This paper describes the improvements to the target system. A new (17 mm) Be target together with the old (10 mm) Be target are inserted in a movable support which allows the production of neutrons either by 65 MeV protons or by 50 MeV deuterons. Both targets can be removed for proton beam therapy. The dosimetric characteristics of the p(65)+Be and d(50)+Be neutron beams are compared: dose rate, gamma-contribution, depth dose and room activation.

  16. Feasibility of sealed D-T neutron generator as neutron source for liver BNCT and its beam shaping assembly.

    PubMed

    Liu, Zheng; Li, Gang; Liu, Linmao

    2014-04-01

    This paper involves the feasibility of boron neutron capture therapy (BNCT) for liver tumor with four sealed neutron generators as neutron source. Two generators are placed on each side of the liver. The high energy of these emitted neutrons should be reduced by designing a beam shaping assembly (BSA) to make them useable for BNCT. However, the neutron flux decreases as neutrons pass through different materials of BSA. Therefore, it is essential to find ways to increase the neutron flux. In this paper, the feasibility of using low enrichment uranium as a neutron multiplier is investigated to increase the number of neutrons emitted from D-T neutron generators. The neutron spectrum related to our system has a proper epithermal flux, and the fast and thermal neutron fluxes comply with the IAEA recommended values.

  17. Multipolarity analysis for {sup 14}C high-energy resonance populated by ({sup 18}O,{sup 16}O) two-neutron transfer reaction

    SciTech Connect

    Carbone, D. Cavallaro, M.; Bondì, M.; Agodi, C.; Cunsolo, A.; Cappuzzello, F.; Azaiez, F.; Franchoo, S.; Khan, E.; Bonaccorso, A.; Fortunato, L.; Foti, A.; Linares, R.; Lubian, J.; Scarpaci, J. A.; Vitturi, A.

    2015-10-15

    The {sup 12}C({sup 18}O,{sup 16}O){sup 14}C reaction at 84 MeV incident energy has been explored up to high excitation energy of the residual nucleus thanks to the use of the MAGNEX spectrometer to detect the ejectiles. In the region above the two-neutron separation energy, a resonance has been observed at 16.9 MeV. A multipolarity analysis of the cross section angular distribution indicates an L = 0 character for such a transition.

  18. High-Energy Astrophysics: An Overview

    NASA Technical Reports Server (NTRS)

    Fishman, Gerald J.

    2007-01-01

    High-energy astrophysics is the study of objects and phenomena in space with energy densities much greater than that found in normal stars and galaxies. These include black holes, neutron stars, cosmic rays, hypernovae and gamma-ray bursts. A history and an overview of high-energy astrophysics will be presented, including a description of the objects that are observed. Observing techniques, space-borne missions in high-energy astrophysics and some recent discoveries will also be described. Several entirely new types of astronomy are being employed in high-energy astrophysics. These will be briefly described, along with some NASA missions currently under development.

  19. Inelastic Neutron Scattering Studies of High-Energy Spin Excitations in Superconducting BaFe1.9Ni0.1As2

    NASA Astrophysics Data System (ADS)

    Liu, Mengshu; Abernathy, Douglas; Zhao, Jun; Wang, Meng; Zhang, Chenglin; Wang, Miaoyin; Dai, Pengcheng

    2010-03-01

    Understanding how the spin fluctuations evolve with doping in iron pnictide superconductors is important because spin fluctuations may mediate electron pairing for superconductivity in these materials. Upon doping, the spin fluctuation persists long after the long-range antiferromagnetism is destroyed. More importantly, spin excitations are coupled to superconductivity in the appearance of a neutron magnetic resonance and a superconductivity-induced spin gap. However, all current neutron scattering results in iron based superconductors are confined to low energy excitations except for the ``11'' FeTe1-xSex system, which shows incommensurate excitations that are not found in other iron pnictide systems. Therefore, how the spin waves in parent compounds of the ``122'' (AFe2As2, A = Ca, Sr, Ba) system will evolve when the system becomes an optimal superconductor is still an open question. We use time-of-flight spectroscopy to determine S (Q,φ) at energy regions not accessed before. We compare spin fluctuations of iron arsenide superconductors with those of high-Tc copper oxides and discuss their role in the superconductivity of these materials.

  20. Carboranyl Nucleosides & Oligonucleotides for Neutron Capture Therapy Final Report

    SciTech Connect

    Schinazi, Raymond F.

    2004-12-01

    This proposal enabled us to synthesize and develop boron-rich nucleosides and oligonucleotide analogues for boron neutron capture therapy (BNCT) and the treatment of various malignancies. First, we determined the relationship between structure, cellular accumulation and tissue distribution of 5-o-carboranyl-2'-deoxyuridine (D-CDU) and its derivatives D-ribo-CU and 5-o-carboranyluracil (CU), to potentially target brain and other solid tumors for neutron capture therapy. Synthesized carborane containing nucleoside derivatives of CDU, D- and L-enantiomers of CDU, D-ribo-CU and CU were used. We measured tissue disposition in xenografted mice bearing 9479 human prostate tumors xenografts and in rats bearing 9L gliosarcoma isografts in their flanks and intracranially. The accumulation of D-CDU, 1-({beta}-L-arabinosyl)-5-o-carboranyluracil, D-ribo-CU, and CU were also studied in LnCap human prostate tumor cells and their retention was measured in male nude mice bearing LnCap and 9479 human prostate tumor xenografts. D-CDU, D-ribo-CU and CU levels were measured after administration in mice bearing 9479 human prostate tumors in their flanks. D-CDU achieved high cellular concentrations in LnCap cells and up to 2.5% of the total cellular compound was recovered in the 5'-monophosphorylated form. D-CDU cellular concentrations were similar in LnCap and 9479 tumor xenografts. Studies in tumor bearing animals indicated that increasing the number of hydroxyl moieties in the sugar constituent of the carboranyl nucleosides lead to increased rate and extent of renal elimination, a decrease in serum half-lives and an increased tissue specificity. Tumor/brain ratios were greatest for CDU and D-ribo-CU, while tumor/prostate ratios were greatest with CU. CDU and D-ribo-CU have potential for BNCT of brain malignancies, while CU may be further developed for prostate cancer. A method was developed for the solid phase synthesis of oligonucleotides containing (ocarboran-1-yl

  1. Development of a dual phantom technique for measuring the fast neutron component of dose in boron neutron capture therapy

    SciTech Connect

    Sakurai, Yoshinori Tanaka, Hiroki; Kondo, Natsuko; Kinashi, Yuko; Suzuki, Minoru; Masunaga, Shinichiro; Ono, Koji; Maruhashi, Akira

    2015-11-15

    Purpose: Research and development of various accelerator-based irradiation systems for boron neutron capture therapy (BNCT) is underway throughout the world. Many of these systems are nearing or have started clinical trials. Before the start of treatment with BNCT, the relative biological effectiveness (RBE) for the fast neutrons (over 10 keV) incident to the irradiation field must be estimated. Measurements of RBE are typically performed by biological experiments with a phantom. Although the dose deposition due to secondary gamma rays is dominant, the relative contributions of thermal neutrons (below 0.5 eV) and fast neutrons are virtually equivalent under typical irradiation conditions in a water and/or acrylic phantom. Uniform contributions to the dose deposited from thermal and fast neutrons are based in part on relatively inaccurate dose information for fast neutrons. This study sought to improve the accuracy in the dose estimation for fast neutrons by using two phantoms made of different materials in which the dose components can be separated according to differences in the interaction cross sections. The development of a “dual phantom technique” for measuring the fast neutron component of dose is reported. Methods: One phantom was filled with pure water. The other phantom was filled with a water solution of lithium hydroxide (LiOH) capitalizing on the absorbing characteristics of lithium-6 (Li-6) for thermal neutrons. Monte Carlo simulations were used to determine the ideal mixing ratio of Li-6 in LiOH solution. Changes in the depth dose distributions for each respective dose component along the central beam axis were used to assess the LiOH concentration at the 0, 0.001, 0.01, 0.1, 1, and 10 wt. % levels. Simulations were also performed with the phantom filled with 10 wt. % {sup 6}LiOH solution for 95%-enriched Li-6. A phantom was constructed containing 10 wt. % {sup 6}LiOH solution based on the simulation results. Experimental characterization of the

  2. Radiotherapy dose enhancement using BNCT in conventional LINACs high-energy treatment: Simulation and experiment

    PubMed Central

    Alikaniotis, Katia; Borla, Oscar; Monti, Valeria; Vivaldo, Gianna; Zanini, Alba; Giannini, Gianrossano

    2016-01-01

    Aim To employ the thermal neutron background that affects the patient during a traditional high-energy radiotherapy treatment for BNCT (Boron Neutron Capture Therapy) in order to enhance radiotherapy effectiveness. Background Conventional high-energy (15–25 MV) linear accelerators (LINACs) for radiotherapy produce fast secondary neutrons in the gantry with a mean energy of about 1 MeV due to (γ, n) reaction. This neutron flux, isotropically distributed, is considered as an unavoidable undesired dose during the treatment. Considering the moderating effect of human body, a thermal neutron fluence is localized in the tumour area: this neutron background could be employed for BNCT by previously administering 10B-Phenyl-Alanine (10BPA) to the patient. Materials and methods Monte Carlo simulations (MCNP4B-GN code) were performed to estimate the total amount of neutrons outside and inside human body during a traditional X-ray radiotherapy treatment. Moreover, a simplified tissue equivalent anthropomorphic phantom was used together with bubble detectors for thermal and fast neutron to evaluate the moderation effect of human body. Results Simulation and experimental results confirm the thermal neutron background during radiotherapy of 1.55E07 cm−2 Gy−1. The BNCT equivalent dose delivered at 4 cm depth in phantom is 1.5 mGy-eq/Gy, that is about 3 Gy-eq (4% of X-rays dose) for a 70 Gy IMRT treatment. Conclusions The thermal neutron component during a traditional high-energy radiotherapy treatment could produce a localized BNCT effect, with a localized therapeutic dose enhancement, corresponding to 4% or more of photon dose, following tumour characteristics. This BNCT additional dose could thus improve radiotherapy, acting as a localized radio-sensitizer. PMID:26933394

  3. Boron neutron capture therapy of malignant brain tumors at the Brookhaven Medical Research Reactor

    SciTech Connect

    Joel, D.D.; Coderre, J.A.; Chanana, A.D.

    1996-12-31

    Boron neutron capture therapy (BNCT) is a bimodal form of radiation therapy for cancer. The first component of this treatment is the preferential localization of the stable isotope {sup 10}B in tumor cells by targeting with boronated compounds. The tumor and surrounding tissue is then irradiated with a neutron beam resulting in thermal neutron/{sup 10}B reactions ({sup 10}B(n,{alpha}){sup 7}Li) resulting in the production of localized high LET radiation from alpha and {sup 7}Li particles. These products of the neutron capture reaction are very damaging to cells, but of short range so that the majority of the ionizing energy released is microscopically confined to the vicinity of the boron-containing compound. In principal it should be possible with BNCT to selectively destroy small nests or even single cancer cells located within normal tissue. It follows that the major improvements in this form of radiation therapy are going to come largely from the development of boron compounds with greater tumor selectivity, although there will certainly be advances made in neutron beam quality as well as the possible development of alternative sources of neutron beams, particularly accelerator-based epithermal neutron beams.

  4. Proliferative characteristics of intestinal stem cells. Response and protection to high-energy or fission spectrum neutrons or photons. Technical report, 1 December 1983-1 December 1985

    SciTech Connect

    Hanson, W.R.

    1986-04-30

    Cytosine Arabinoside (Ara/C) is an S-phase cytoxic agent. Since nearly half the proliferating cells in the murine crypt are in the S phase, Ara/c treatment, the clonogenic cells (the cells responsible for tissue regeneration) in the crypt are considerably less sensitive to photon radiation than colonogenic cells of control animals. Evidence suggests that the reason for this radioprotection by a toxic agent is the Ara/c-induced alteration in the cell age distribution of the clonogenic cells. Normally, the clonogenic cells are in a G/sub 1/ or G/sub 0/ stage of the cell cycle and are unaffected directly by Ara/c; however, following Ara/c treatment of an animal, the clonogenic cells enter the cell cycle. By 12 hours, the clonogenic cells proceed in a partially synchronized fashion to a mid toi late S phase of the cell cycle where they are less sensitive. WR-2721 appears to protect cells from radiation throughout the cell cycle and most likely acts through a mechanism different from Ara/c. Results of this contrast showed that the combination of Ara/c and WR-2721 protected the gut from photon injury to a greater extent than each agent alone. The protection from Fermilab neutrons by the combination was slightly better than each agent and there was no additional protection of Ara/c combined with WR-2721 for injury by JANUS fission spectrum neutrons. These treatments did not alter the animal response at doses in the bone marrow lethal range.

  5. Evaluation of an iron-filtered epithermal neutron beam for neutron-capture therapy.

    PubMed

    Musolino, S V; McGinley, P H; Greenwood, R C; Kliauga, P; Fairchild, R G

    1991-01-01

    An epithermal neutron filter using iron, aluminum, and sulfur was evaluated to determine if the therapeutic performance could be improved with respect to aluminum-sulfur-based filters. An empirically optimized filter was developed that delivered a 93% pure beam of 24-keV epithermal neutrons. It was expected that a thick filter using iron with a density thickness greater than 200 g/cm2 would eliminate the excess gamma contamination found in Al-S filters. This research showed that prompt gamma production from neutron interactions in iron was the dominant dose component. Dosimetric parameters of the beam were determined from the measurement of absorbed dose in air, thermal neutron flux in a head phantom, neutron and gamma spectroscopy, and microdosimetry.

  6. Fission converter and metal-oxide-semiconductor field effect transistor study of thermal neutron flux distribution in an epithermal neutron therapy beam.

    PubMed

    Kaplan, G I; Rosenfeld, A B; Allen, B J; Coderre, J A; Liu, H B

    1999-09-01

    The depth distribution of the thermal neutron flux is a major factor in boron neutron capture therapy (BNCT) in determining the efficiency of cell sterilization. In this paper the fission detector method is developed and applied to measure the in-phantom thermal neutron flux depth distribution. Advantages of the fission detector include small size, direct measurement of thermal neutron flux in a mixed radiation field of BNCT beam, self-calibration, and the possibility of on-line measurement. The measurements were performed at epithermal a BNCT facility. The experimental results were compared with the thermal neutron flux calculated by the Monte Carlo method and found to be in good agreement.

  7. Final Stage in the Design of a Boron Neutron Capture Therapy facility at CEADEN, Cuba

    NASA Astrophysics Data System (ADS)

    Cabal, F. Padilla; Martín, G.

    2008-08-01

    A neutron beam simulation study is carried out to determine the most suitable neutron energy for treatment of shallow and deep-seated brain tumors in the context of Boron Neutron Capture Therapy (BNCT). Two figures-of-merit, the therapeutic gain and the neutron fluence are utilized as beam assessment parameters. An irradiation cavity is used instead of a parallel beam port for the therapy. Calculations are performed using the MCNP5 code. After the optimization of our beam-shaper a study of the dose distribution in the head, neck, tyroids, lungs and upper and middle spine had been made. The therapeutic gain is increased while the current required for one hour treatment is decreased in comparison with the trading prototypes of NG used for BNCT

  8. Final Stage in the Design of a Boron Neutron Capture Therapy facility at CEADEN, Cuba

    SciTech Connect

    Cabal, F. Padilla; Martin, G.

    2008-08-11

    A neutron beam simulation study is carried out to determine the most suitable neutron energy for treatment of shallow and deep-seated brain tumors in the context of Boron Neutron Capture Therapy (BNCT). Two figures-of-merit, the therapeutic gain and the neutron fluence are utilized as beam assessment parameters. An irradiation cavity is used instead of a parallel beam port for the therapy. Calculations are performed using the MCNP5 code. After the optimization of our beam-shaper a study of the dose distribution in the head, neck, tyroids, lungs and upper and middle spine had been made. The therapeutic gain is increased while the current required for one hour treatment is decreased in comparison with the trading prototypes of NG used for BNCT.

  9. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy.

    PubMed

    Ueno, Manabu; Ban, Hyun Seung; Nakai, Kei; Inomata, Ryu; Kaneda, Yasufumi; Matsumura, Akira; Nakamura, Hiroyuki

    2010-05-01

    Closo-dodecaborate lipid liposomes were developed as new vehicles for boron delivery system (BDS) of neutron capture therapy. The current approach is unique because the liposome shell itself possesses cytocidal potential in combination with neutron irradiation. The liposomes composed of closo-dodecaborate lipids DSBL and DPBL displayed high cytotoxicity with thermal neutron irradiation. The closo-dodecaborate lipid liposomes were taken up into the cytoplasm by endocytosis without degradation of the liposomes. Boron concentration of 22.7 ppm in tumor was achieved by injection with DSBL-25% PEG liposomes at 20mg B/kg. Promising BNCT effects were observed in the mice injected with DSBL-25% PEG liposomes: the tumor growth was significantly suppressed after thermal neutron irradiation (1.8 x 10(12)neutrons/cm(2)).

  10. SU-E-T-75: Commissioning Optically Stimulated Luminescence Dosimeters for Fast Neutron Therapy

    SciTech Connect

    Young, L; Yang, F; Sandison, G; Woodworth, D; McCormick, Z

    2014-06-01

    Purpose: Fast neutrons therapy used at the University of Washington is clinically proven to be more effective than photon therapy in treating salivary gland and other cancers. A nanodot optically stimulated luminescence (OSL) system was chosen to be commissioned for patient in vivo dosimetry for neutron therapy. The OSL-based radiation detectors are not susceptible to radiation damage caused by neutrons compared to diodes or MOSFET systems. Methods: An In-Light microStar OSL system was commissioned for in vivo use by radiating Landauer nanodots with neutrons generated from 50.0 MeV protons accelerated onto a beryllium target. The OSLs were calibrated the depth of maximum dose in solid water localized to 150 cm SAD isocenter in a 10.3 cm square field. Linearity was tested over a typical clinical dose fractionation range i.e. 0 to 150 neutron-cGy. Correction factors for transient signal fading, trap depletion, gantry angle, field size, and wedge factor dependencies were also evaluated. The OSLs were photo-bleached between radiations using a tungsten-halogen lamp. Results: Landauer sensitivity factors published for each nanodot are valid for measuring photon and electron doses but do not apply for neutron irradiation. Individually calculated nanodot calibration factors exhibited a 2–5% improvement over calibration factors computed by the microStar InLight software. Transient fading effects had a significant impact on neutron dose reading accuracy compared to photon and electron in vivo dosimetry. Greater accuracy can be achieved by calibrating and reading each dosimeter within 1–2 hours after irradiation. No additional OSL correction factors were needed for field size, gantry angle, or wedge factors in solid water phantom measurements. Conclusion: OSL detectors are a useful for neutron beam in vivo dosimetry verification. Dosimetric accuracy comparable to conventional diode systems can be achieved. Accounting for transient fading effects during the neutron beam

  11. Power Burst Facility/Boron Neutron Capture Therapy program for cancer treatment, Volume 4, No. 7

    SciTech Connect

    Ackermann, A.L.

    1990-07-01

    This report discusses the monthly progress of the Power Burst Facility/Boron Neutron Capture Therapy (PBF/BNLT) program for cancer treatment. Highlights of the PBF/BNCT Program during July 1990 include progress within the areas of: Gross boron analysis in tissue, blood, and urine; noninvasive boron quantitative determination; analytical radiation transport and interaction modeling for BNCT; large animal model studies; neutron source and facility preparation; administration and common support and PBF operations.

  12. Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

    SciTech Connect

    Ackermann, A.L.; Dorn, R.V. III.

    1990-08-01

    This report discusses monthly progress in the Power Boron Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program for Cancer Treatment. Highlights of the PBF/BNCT Program during August 1990 include progress within the areas of: Gross Boron Analysis in Tissue, Blood, and Urine, boron microscopic (subcellular) analytical development, noninvasive boron quantitative determination, analytical radiation transport and interaction modeling for BNCT, large animal model studies, neutron source and facility preparation, administration and common support and PBF operations.

  13. SU-E-T-566: Neutron Dose Cloud Map for Compact ProteusONE Proton Therapy

    SciTech Connect

    Syh, J; Patel, B; Syh, J; Rosen, L; Wu, H

    2015-06-15

    Purpose: To establish the base line of neutron cloud during patient treatment in our new compact Proteus One proton pencil beam scanning (PBS) system with various beam delivery gantry angles, with or without range shifter (RS) at different body sites. Pencil beam scanning is an emerging treatment technique, for the concerns of neutron exposure, this study is to evaluate the neutron dose equivalent per given delivered dose under various treatment conditions at our proton therapy center. Methods: A wide energy neutron dose equivalent detector (SWENDI-II, Thermo Scientific, MA) was used for neutron dose measurements. It was conducted in the proton therapy vault during beam was on. The measurement location was specifically marked in order to obtain the equivalent dose of neutron activities (H). The distances of 100, 150 and 200 cm at various locations are from the patient isocenter. The neutron dose was measured of proton energy layers, # of spots, maximal energy range, modulation width, field radius, gantry angle, snout position and delivered dose in CGE. The neutron dose cloud is reproducible and is useful for the future reference. Results: When distance increased the neutron equivalent dose (H) reading did not decrease rapidly with changes of proton energy range, modulation width or spot layers. For cranial cases, the average mSv/CGE was about 0.02 versus 0.032 for pelvis cases. RS will induce higher H to be 0.10 mSv/CGE in average. Conclusion: From this study, neutron per dose ratio (mSv/CGE) slightly depends upon various treatment parameters for pencil beams. For similar treatment conditions, our measurement demonstrates this value for pencil beam scanning beam has lowest than uniform scanning or passive scattering beam with a factor of 5. This factor will be monitored continuously for other upcoming treatment parameters in our facility.

  14. Improved monitoring system of neutron flux during boron-neutron capture therapy

    SciTech Connect

    Harasawa, S.; Nakamoto, A.; Hayakawa, Y.; Egawa, J.

    1981-10-01

    Continuous and simultaneous monitoring of neutron flux in the course of a boron-neutron capture operation on a brain tumor has been achieved using a new monitoring system. A silicon surface barrier diode mounted with /sup 6/LiF instead of the previously reported borax is used to sense neutrons. The pulse heights of /sup 3/H and ..cap alpha.. particles from /sup 6/Li(n, ..cap alpha..)/sup 2/H reaction are sufficiently high and well separated from noises due to ..gamma.. rays. The effect of pulse-height reduction due to the radiation damage of the diode thus becomes smaller, permitting continuous monitoring. The relative error of the monitoring is within 2% over 5 hr for a neutron-flux density of 2 x 10/sup 9/ n/cm/sup 2/ sec.

  15. High Energy Astronomy Observatory (HEAO)

    NASA Technical Reports Server (NTRS)

    1972-01-01

    This is an artist's concept describing the High Energy Astronomy Observatory (HEAO). The HEAO project involved the launching of three unmarned scientific observatories into low Earth orbit between 1977 and 1979 to study some of the most intriguing mysteries of the universe; pulsars, black holes, neutron stars, and super nova. This concept was painted by Jack Hood of the Marshall Space Flight Center (MSFC). Hardware support for the imaging instruments was provided by American Science and Engineering. The HEAO spacecraft were built by TRW, Inc. under project management of the MSFC.

  16. Monte Carlo calculations of lung dose in ORNL phantom for boron neutron capture therapy.

    PubMed

    Krstic, D; Markovic, V M; Jovanovic, Z; Milenkovic, B; Nikezic, D; Atanackovic, J

    2014-10-01

    Monte Carlo simulations were performed to evaluate dose for possible treatment of cancers by boron neutron capture therapy (BNCT). The computational model of male Oak Ridge National Laboratory (ORNL) phantom was used to simulate tumours in the lung. Calculations have been performed by means of the MCNP5/X code. In this simulation, two opposite neutron beams were considered, in order to obtain uniform neutron flux distribution inside the lung. The obtained results indicate that the lung cancer could be treated by BNCT under the assumptions of calculations.

  17. TU-F-CAMPUS-T-01: Dose and Energy Spectra From Neutron Induced Radioactivity in Medical Linear Accelerators Following High Energy Total Body Irradiation

    SciTech Connect

    Keehan, S; Taylor, M; Franich, R; Smith, R; Dunn, L; Kron, T

    2015-06-15

    Purpose: To assess the risk posed by neutron induced activation of components in medical linear accelerators (linacs) following the delivery of high monitor unit 18 MV photon beams such as used in TBI. Methods: Gamma spectroscopy was used to identify radioisotopes produced in components of a Varian 21EX and an Elekta Synergy following delivery of photon beams. Dose and risk estimates for TBI were assessed using dose deliveries from an actual patient treatment. A 1 litre spherical ion chamber (PTW, Germany) has been used to measure the dose at the beam exit window and at the total body irradiation (TBI) treatment couch following large and small field beams with long beam-on times. Measurements were also made outside of the closed jaws to quantify the benefit of the attenuation provided by the jaws. Results: The radioisotopes produced in the linac head have been identified as {sup 187}W, {sup 56}Mn, {sup 24}Na and {sup 28}Al, which have half-lives from between 2.3 min to 24 hours. The dose at the beam exit window following an 18 MV 2197 MU TBI beam delivery was 12.6 µSv in ten minutes. The dose rate at the TBI treatment couch 4.8 m away is a factor of ten lower. For a typical TBI delivered in six fractions each consisting of four beams and an annual patient load of 24, the annual dose estimate for a staff member at the treatment couch for ten minutes is 750 µSv. This can be further reduced by a factor of about twelve if the jaws are closed before entering the room, resulting in a dose estimate of 65 µSv. Conclusion: The dose resulting from the activation products for a representative TBI workload at our clinic of 24 patients per year is 750 µSv, which can be further reduced to 65 µSv by closing the jaws.

  18. SU-E-T-329: Tissue-Equivalent Phantom Materials for Neutron Dosimetry in Proton Therapy

    SciTech Connect

    Halg, R; Lomax, A; Clarke, S; Wieger, B; Pryser, E; Arghal, R; Pozzi, S; Bashkirov, V; Schulte, R; Schneider, U

    2014-06-01

    Purpose: To characterize tissue equivalence of phantom materials in terms of secondary neutron production and dose deposition from neutrons produced in radiation therapy phantom materials in the context of proton therapy using Monte Carlo simulations and measurements. Methods: In order to study the influence of material choice on neutron production in therapeutic proton beams, Monte Carlo simulations using the Geant4 and MCNPX-PoliMi transport codes were performed to generate the neutron fields produced by protons of 155 and 200 MeV. A simple irradiation geometry was used to investigate the effect of different materials. The proton beams were stopped in slab phantoms to study the production of secondary neutrons. The investigated materials were water, Lucite, and tissue-equivalent phantom materials (CIRS Inc., Norfolk, VA). Neutron energy spectra and absorbed dose by neutrons and their secondary particles were scored. In addition, simulations were performed for reference tissues (ICRP/ICRU) to assess tissue equivalence with respect to neutron generation and transport. In order to benchmark the simulation results, measurements were performed with a system developed at the University of Michigan; organic liquid scintillators were used to detect the neutron emissions from the irradiation of tissue-equivalent materials. Additionally, the MPPost code was used to calculate the scintillator response from the MCNPX-PoliMi output. Results: The simulated energy spectra and depth dose curves of the neutrons produced in different phantom materials showed similar shape. The differences of spectra and fluences between all studied materials and reference tissues were well within the achievable precision of neutron dosimetry. The shape of the simulated detector response of the liquid scintillators agreed well with measurements on the proton beamline. Conclusion: Based on Geant4 and MCNPX-PoliMi simulations, the investigated materials appear to be suitable to study the production

  19. Routine operation of the University of Washington fast neutron therapy facility and plans for improvements

    SciTech Connect

    Risler, R.; Emery, R.; Laramore, G. E.

    1999-06-10

    The fast neutron therapy facility in Seattle is based on a cyclotron, which produces a 50.5 MeV proton beam. Neutrons are produced in a beryllium target installed in an isocentric gantry equipped with a multi-leaf collimator. The system has been in routine operation for 14 years and over 1800 patients have been treated. Downtime has been minimal, over the past 10 years less than 1.5% of the scheduled daily treatment sessions could not be delivered for equipment related reasons. Fast neutron therapy has been shown to be highly effective for the treatment of salivary gland tumors, sarcomas of bone and soft tissues and for certain prostate cancers. In addition there are situations such as non-small cell lung cancer, where results are promising, but success is limited by normal tissue complications. A relatively small selective increase in the tumor dose might lead to a significant clinical improvement in these situations. The use of a boron neutron capture (BNC) boost, utilizing the moderated slow neutrons naturally present in the tissue during fast neutron therapy, may be beneficial for such patients. Experimental work to adapt the facility for such a modified treatment modality is presently ongoing.

  20. Routine operation of the University of Washington fast neutron therapy facility and plans for improvements

    NASA Astrophysics Data System (ADS)

    Risler, R.; Emery, R.; Laramore, G. E.

    1999-06-01

    The fast neutron therapy facility in Seattle is based on a cyclotron, which produces a 50.5 MeV proton beam. Neutrons are produced in a beryllium target installed in an isocentric gantry equipped with a multi-leaf collimator. The system has been in routine operation for 14 years and over 1800 patients have been treated. Downtime has been minimal, over the past 10 years less than 1.5% of the scheduled daily treatment sessions could not be delivered for equipment related reasons. Fast neutron therapy has been shown to be highly effective for the treatment of salivary gland tumors, sarcomas of bone and soft tissues and for certain prostate cancers. In addition there are situations such as non-small cell lung cancer, where results are promising, but success is limited by normal tissue complications. A relatively small selective increase in the tumor dose might lead to a significant clinical improvement in these situations. The use of a boron neutron capture (BNC) boost, utilizing the moderated slow neutrons naturally present in the tissue during fast neutron therapy, may be beneficial for such patients. Experimental work to adapt the facility for such a modified treatment modality is presently ongoing.

  1. Feasibility of the utilization of BNCT in the fast neutron therapy beam at Fermilab

    SciTech Connect

    Langen, Katja; Lennox, Arlene J.; Kroc, Thomas K.; DeLuca, Jr., Paul M.

    2000-06-23

    The Neutron Therapy Facility at Fermilab has treated cancer patients since 1976. Since then more than 2,300 patients have been treated and a wealth of clinical information accumulated. The therapeutic neutron beam at Fermilab is produced by bombarding a beryllium target with 66 MeV protons. The resulting continuous neutron spectrum ranges from thermal to 66 MeV in neutron energy. It is clear that this spectrum is not well suited for the treatment of tumors with boron neutron capture therapy (BNCT) only However, since this spectrum contains thermal and epithermal components the authors are investigating whether BNCT can be used in this beam to boost the tumor dose. There are clinical scenarios in which a selective tumor dose boost of 10 - 15% could be clinically significant. For these cases the principal treatment would still be fast neutron therapy but a tumor boost could be used either to deliver a higher dose to the tumor tissue or to reduce the dose to the normal healthy tissue while maintaining the absorbed dose level in the tumor tissue.

  2. Feasibility of the Utilization of BNCT in the Fast Neutron Therapy Beam at Fermilab

    DOE R&D Accomplishments Database

    Langen, Katja; Lennox, Arlene J.; Kroc, Thomas K.; DeLuca, Jr., Paul M.

    2000-06-01

    The Neutron Therapy Facility at Fermilab has treated cancer patients since 1976. Since then more than 2,300 patients have been treated and a wealth of clinical information accumulated. The therapeutic neutron beam at Fermilab is produced by bombarding a beryllium target with 66 MeV protons. The resulting continuous neutron spectrum ranges from thermal to 66 MeV in neutron energy. It is clear that this spectrum is not well suited for the treatment of tumors with boron neutron capture therapy (BNCT) only However, since this spectrum contains thermal and epithermal components the authors are investigating whether BNCT can be used in this beam to boost the tumor dose. There are clinical scenarios in which a selective tumor dose boost of 10 - 15% could be clinically significant. For these cases the principal treatment would still be fast neutron therapy but a tumor boost could be used either to deliver a higher dose to the tumor tissue or to reduce the dose to the normal healthy tissue while maintaining the absorbed dose level in the tumor tissue.

  3. Estimation of Secondary Neutron Dose during Proton Therapy

    NASA Astrophysics Data System (ADS)

    Urban, Tomas; Klusoň, Jaroslav

    2014-06-01

    During proton radiotherapy, secondary neutrons are produced by nuclear interactions in the material along the beam path, in the treatment nozzle (including the fixed scatterer, range modulator, etc.) and, of course, after entering the patient. The dose equivalent deposited by these neutrons is usually not considered in routine treatment planning. In this study, there has been estimated the neutron dose in patient (in as well as around the target volume) during proton radiotherapy using scattering and scanning techniques. The proton induced neutrons (and photons) have been simulated in the simple geometry of the single scattering and the pencil beam scanning universal nozzles and in geometry of the plastic phantom (made of tissue equivalent material - RW3 - imitate the patient). In simulations of the scattering nozzle, different types of brass collimators have been used as well. Calculated data have been used as an approximation of the radiation field in and around the chosen/potential target volume in the patient (plastic phantom). For the dose equivalent evaluation, fluence-to-dose conversion factors from ICRP report have been employed. The results of calculated dose from neutrons in various distances from the spot for different treatment technique and for different energies of incident protons have been compared and evaluated in the context of the dose deposited in the target volume. This work was supported by RVO: 68407700 and Grant Agency of the CTU in Prague, grant No. SGS12/200/OHK4/3T/14.

  4. MONDO: A neutron tracker for particle therapy secondary emission fluxes measurements

    NASA Astrophysics Data System (ADS)

    Marafini, M.; Patera, V.; Pinci, D.; Sarti, A.; Sciubba, A.; Spiriti, E.

    2016-07-01

    Cancer treatment is performed, in Particle Therapy, using accelerated charged particles whose high irradiation precision and conformity allows the tumor destruction while sparing the surrounding healthy tissues. Dose release monitoring devices using photons and charged particles produced by the beam interaction with the patient body have already been proposed, but no attempt based on the detection of the abundant secondary radiation neutron component has been made yet. The reduced attenuation length of neutrons yields a secondary particle sample that is larger in number when compared to photons and charged particles. Furthermore, neutrons allow for a backtracking of the emission point that is not affected by multiple scattering. Since neutrons can release a significant dose far away from the tumor region, a precise measurement of their flux, production energy and angle distributions is eagerly needed in order to improve the Treatment Planning Systems (TPS) software, so to predict not only the normal tissue toxicity in the target region but also the risk of late complications in the whole body. All the aforementioned issues underline the importance for an experimental effort devoted to the precise characterization of the neutron production gaining experimental access both to the emission point and production energy. The technical challenges posed by a neutron detector aiming for a high detection efficiency and good backtracking precision will be addressed within the MONDO (MOnitor for Neutron Dose in hadrOntherapy) project. The MONDO's main goal is to develop a tracking detector targeting fast and ultrafast secondary neutrons. The tracker is composed by a scintillating fiber matrix (4 × 4 × 8cm3). The full reconstruction of protons, produced in elastic interactions, will be used to measure energy and direction of the impinging neutron. The neutron tracker will measure the neutron production yields, as a function of production angle and energy, using different

  5. Controllability of depth dose distribution for neutron capture therapy at the Heavy Water Neutron Irradiation Facility of Kyoto University Research Reactor.

    PubMed

    Sakurai, Yoshinori; Kobayashi, Tooru

    2002-10-01

    The updating construction of the Heavy Water Neutron Irradiation Facility of the Kyoto University Research Reactor has been performed from November 1995 to March 1996 mainly for the improvement in neutron capture therapy. On the performance, the neutron irradiation modes with the variable energy spectra from almost pure thermal to epi-thermal neutrons became available by the control of the heavy-water thickness in the spectrum shifter and by the open-and-close of the cadmium and boral thermal neutron filters. The depth distributions of thermal, epi-thermal and fast neutron fluxes were measured by activation method using gold and indium, and the depth distributions of gamma-ray absorbed dose rate were measured using thermo-luminescent dosimeter of beryllium oxide for the several irradiation modes. From these measured data, the controllability of the depth dose distribution using the spectrum shifter and the thermal neutron filters was confirmed.

  6. Secondary neutron doses received by paediatric patients during intracranial proton therapy treatments.

    PubMed

    Sayah, R; Farah, J; Donadille, L; Hérault, J; Delacroix, S; De Marzi, L; De Oliveira, A; Vabre, I; Stichelbaut, F; Lee, C; Bolch, W E; Clairand, I

    2014-06-01

    This paper's goal is to assess secondary neutron doses received by paediatric patients treated for intracranial tumours using a 178 MeV proton beam. The MCNPX Monte Carlo model of the proton therapy facility, previously validated through experimental measurements for both proton and neutron dosimetry, was used. First, absorbed dose was calculated for organs located outside the clinical target volume using a series of hybrid computational phantoms for different ages and considering a realistic treatment plan. In general, secondary neutron dose was found to decrease as the distance to the treatment field increases and as the patient age increases. In addition, secondary neutron doses were studied as a function of the beam incidence. Next, neutron equivalent dose was assessed using organ-specific energy-dependent radiation weighting factors determined from Monte Carlo simulations of neutron spectra at each organ. The equivalent dose was found to reach a maximum value of ∼155 mSv at the level of the breasts for a delivery of 49 proton Gy to an intracranial tumour of a one-year-old female patient. Finally, a thorough comparison of the calculation results with published data demonstrated the dependence of neutron dose on the treatment configuration and proved the need for facility-specific and treatment-dependent neutron dose calculations.

  7. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    SciTech Connect

    Mitchell, Hannah E.

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 107 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF3 composite and a stacked Al/Teflon design) at various incident electron energies.

  8. Improvement of dose distribution by central beam shielding in boron neutron capture therapy.

    PubMed

    Sakurai, Yoshinori; Ono, Koji

    2007-12-21

    Since boron neutron capture therapy (BNCT) with epithermal neutron beams started at the Kyoto University Reactor (KUR) in June 2002, nearly 200 BNCT treatments have been carried out. The epithermal neutron irradiation significantly improves the dose distribution, compared with the previous irradiation mainly using thermal neutrons. However, the treatable depth limit still remains. One effective technique to improve the limit is the central shield method. Simulations were performed for the incident neutron energies and the annular components of the neutron source. It was clear that thermal neutron flux distribution could be improved by decreasing the lower energy neutron component and the inner annular component of the incident beam. It was found that a central shield of 4-6 cm diameter and 10 mm thickness is effective for the 12 cm diameter irradiation field. In BNCT at KUR, the depth dose distribution can be much improved by the central shield method, resulting in a relative increase of the dose at 8 cm depth by about 30%. In addition to the depth dose distribution, the depth dose profile is also improved. As the dose rate in the central area is reduced by the additional shielding, the necessary irradiation time, however, increases by about 30% compared to normal treatment.

  9. Nominal effective radiation doses delivered during clinical trials of boron neutron capture therapy

    SciTech Connect

    Capala, J.; Diaz, A.Z.; Chanana, A.D.

    1997-12-31

    Boron neutron capture therapy (BNCT) is a binary system that, in theory, should selectively deliver lethal, high linear energy transfer (LET) radiation to tumor cells dispersed within normal tissues. It is based on the nuclear reaction 10-B(n, {alpha})7-Li, which occurs when the stable nucleus of boron-10 captures a thermal neutron. Due to the relatively high cross-section of the 10-B nucleus for thermal neutron capture and short ranges of the products of this reaction, tumor cells in the volume exposed to thermal neutrons and containing sufficiently high concentration of 10-B would receive a much higher radiation dose than the normal cells contained within the exposed volume. Nevertheless, radiation dose deposited in normal tissue by gamma and fast neutron contamination of the neutron beam, as well as neutron capture in nitrogen, 14-N(n,p)14-C, hydrogen, 1-H(n,{gamma})2-H, and in boron present in blood and normal cells, limits the dose that can be delivered to tumor cells. It is, therefore, imperative for the success of the BNCT the dosed delivered to normal tissues be accurately determined in order to optimize the irradiation geometry and to limit the volume of normal tissue exposed to thermal neutrons. These are the major objectives of BNCT treatment planning.

  10. Preliminary treatment planning and dosimetry for a clinical trial of neutron capture therapy using a fission converter epithermal neutron beam.

    PubMed

    Kiger, W S; Lu, X Q; Harling, O K; Riley, K J; Binns, P J; Kaplan, J; Patel, H; Zamenhof, R G; Shibata, Y; Kaplan, I D; Busse, P M; Palmer, M R

    2004-11-01

    A Phase I/II clinical trial of neutron capture therapy (NCT) was conducted at Harvard-MIT using a fission converter epithermal neutron beam. This epithermal neutron beam has nearly ideal performance characteristics (high intensity and purity) and is well-suited for clinical use. Six glioblastoma multiforme (GBM) patients were treated with NCT by infusion of the tumor-selective amino acid boronophenylalanine-fructose (BPA-F) at a dose of 14.0 g/m(2) body surface area over 90 min followed by irradiation with epithermal neutrons. Treatments were planned using NCTPlan and an accelerated version of the Monte Carlo radiation transport code MCNP 4B. Treatments were delivered in two fractions with two or three fields. Field order was reversed between fractions to equalize the average blood boron concentration between fields. The initial dose in the dose escalation study was 7.0 RBEGy, prescribed as the mean dose to the whole brain volume. This prescription dose was increased by 10% to 7.7 RBEGy in the second cohort of patients. A pharmacokinetic model was used to predict the blood boron concentration for determination of the required beam monitor units with good accuracy; differences between prescribed and delivered doses were 1.5% or less. Estimates of average tumor doses ranged from 33.7 to 83.4 RBEGy (median 57.8 RBEGy), a substantial improvement over our previous trial where the median value of the average tumor dose was 25.8 RBEGy.

  11. Monte Carlo simulations of neutron spectral fluence, radiation weighting factor and ambient dose equivalent for a passively scattered proton therapy unit

    NASA Astrophysics Data System (ADS)

    Zheng, Yuanshui; Fontenot, Jonas; Taddei, Phil; Mirkovic, Dragan; Newhauser, Wayne

    2008-01-01

    Stray neutron exposures pose a potential risk for the development of secondary cancer in patients receiving proton therapy. However, the behavior of the ambient dose equivalent is not fully understood, including dependences on neutron spectral fluence, radiation weighting factor and proton treatment beam characteristics. The objective of this work, therefore, was to estimate neutron exposures resulting from the use of a passively scattered proton treatment unit. In particular, we studied the characteristics of the neutron spectral fluence, radiation weighting factor and ambient dose equivalent with Monte Carlo simulations. The neutron spectral fluence contained two pronounced peaks, one a low-energy peak with a mode around 1 MeV and one a high-energy peak that ranged from about 10 MeV up to the proton energy. The mean radiation weighting factors varied only slightly, from 8.8 to 10.3, with proton energy and location for a closed-aperture configuration. For unmodulated proton beams stopped in a closed aperture, the ambient dose equivalent from neutrons per therapeutic absorbed dose (H*(10)/D) calculated free-in-air ranged from about 0.3 mSv/Gy for a small scattered field of 100 MeV proton energy to 19 mSv/Gy for a large scattered field of 250 MeV proton energy, revealing strong dependences on proton energy and field size. Comparisons of in-air calculations with in-phantom calculations indicated that the in-air method yielded a conservative estimation of stray neutron radiation exposure for a prostate cancer patient.

  12. [Possibilities of boron neutron capture therapy in the treatment of malignant brain tumors].

    PubMed

    Kanygin, V V; Kichigin, A I; Gubanova, N V; Taskaev, S Yu

    2015-01-01

    Boron neutron capture therapy (BNCT) that is of the highest attractiveness due to its selective action directly on malignant tumor cells is a promising approach to treating cancers. Clinical interest in BNCT focuses in neuro-oncology on therapy for gliomas, glioblastoma in particular, and BNCT may be used in brain metastatic involvement. This needs an epithermal neutron source that complies with the requirements for BNCT, as well as a 10B-containing agent that will selectively accumulate in tumor tissue. The introduction of BNCT into clinical practice to treat patients with glial tumors will be able to enhance therapeutic efficiency.

  13. High-energy magnetic excitations in overdoped La2-xSrxCuO4 studied by neutron and resonant inelastic X-ray scattering

    SciTech Connect

    Wakimoto, S.; Ishii, K.; Kimura, H.; Fujita, M.; Dellea, G.; Kummer, K.; Braicovich, L.; Ghiringhelli, G.; Debeer-Schmitt, Lisa M.; Granroth, Garrett E.

    2015-05-21

    We have performed neutron inelastic scattering and resonant inelastic x-ray scattering (RIXS) at the Cu-L3 edge to study high-energy magnetic excitations at energy transfers of more than 100 meV for overdoped La2₋xSrxCuO4 with x=0.25 (Tc=15 K) and x=0.30 (nonsuperconducting) using identical single-crystal samples for the two techniques. From constant-energy slices of neutron-scattering cross sections, we have identified magnetic excitations up to ~250 meV for x=0.25. Although the width in the momentum direction is large, the peak positions along the (π,π) direction agree with the dispersion relation of the spin wave in the nondoped La2CuO4 (LCO), which is consistent with the previous RIXS results of cuprate superconductors. Using RIXS at the Cu-L3 edge, we have measured the dispersion relations of the so-called paramagnon mode along both (π,π) and (π,0) directions. Although in both directions the neutron and RIXS data connect with each other and the paramagnon along (π,0) agrees well with the LCO spin-wave dispersion, the paramagnon in the (π,π) direction probed by RIXS appears to be less dispersive and the excitation energy is lower than the spin wave of LCO near (π/2,π/2). Thus, our results indicate consistency between neutron inelastic scattering and RIXS, and elucidate the entire magnetic excitation in the (π,π) direction by the complementary use of two probes. The polarization dependence of the RIXS profiles indicates that appreciable charge excitations exist in the same energy range of magnetic excitations, reflecting the itinerant character of the overdoped sample. Lastly, we find a possible anisotropy in the charge excitation intensity might explain the apparent differences in the paramagnon dispersion in the (π,π) direction as detected by the x-ray scattering.

  14. (A clinical trial of neutron capture therapy for brain tumors)

    SciTech Connect

    Zamenhof, R.G.

    1990-01-01

    This document briefly describes recent advances in the author's laboratory. Topics described include neutron beam design, high- resolution autoradiography, boronated phenylalanine (BPA) distribution and survival studies in glioma bearing mice, computer- aided treatment planning, prompt gamma boron 10 analysis facility at MITI-II, non-rodent BPA toxicity studies, and preparations for clinical studies.

  15. (A clinical trial of neutron capture therapy for brain tumors)

    SciTech Connect

    Zamenhof, R.G.

    1989-01-01

    This report describes accomplishments by this laboratory concerning development of high-resolution alpha-autoradiography design of an optimized epithermal neutron beam dosimetry and treatment planning Using Monte Carlo techniques development of a prompt-gamma {sup 10}B analysis facility.

  16. The MONDO project: A secondary neutron tracker detector for particle therapy

    NASA Astrophysics Data System (ADS)

    Valle, S. M.; Battistoni, G.; Patera, V.; Pinci, D.; Sarti, A.; Sciubba, A.; Spiriti, E.; Marafini, M.

    2017-02-01

    During Particle Therapy treatments the patient irradiation produces, among different types of secondary radiation, an abundant flux of neutrons that can release a significant dose far away from the tumour region. A precise measurement of their flux, energy and angle distributions is eagerly needed in order to improve the Treatment Planning Systems software and to properly take into account the risk of late complications in the whole body. The technical challenges posed by a neutron detector aiming for high detection efficiency and good backtracking precision will be addressed within the MONDO project, whose main goal is to develop a tracking detector targeting fast and ultra-fast secondary neutrons. The neutron tracking principle is based on the reconstruction of two consequent elastic scattering interactions of a neutron with a target material. Reconstructing the recoiling protons it is hence possible to measure the energy and incoming direction of the neutron. Plastic scintillators will be used as scattering and detection media: the tracker is being developed as a matrix of squared scintillating fibres of 250 μm side. The light produced and collected in fibres will be amplified using a triple GEM-based image intensifier and acquired using CMOS Single Photon Avalanche Diode arrays. Using therapeutic beams, the principal detector goal will be the measurement of the neutron production yields, as a function of production angle and energy.

  17. Combination of boron and gadolinium compounds for neutron capture therapy. An in vitro study.

    PubMed

    Matsumura, A; Zhang, T; Nakai, K; Endo, K; Kumada, H; Yamamoto, T; Yoshida, F; Sakurai, Y; Yamamoto, K; Nose, T

    2005-03-01

    In neutron capture therapy, the therapeutic effect of the boron compound is based on alpha particles produced by the B(n, alpha) reaction while with the gadolinium compound the main radiation effect is from gamma rays derived from the Gd(n, gamma) reaction. The uptake and distribution within the tumor may be different among these compounds. Thus, the combination of the boron and gadolinium compounds may be beneficial for enhancing the radiation dose to the tumor. Chinese hamster fibroblast V79 cells were used. For the neutron targeting compounds, 10B (BSH) at 0, 5, 10, and 15 ppm, and 157Gd (Gd-BOPTA) at 0, 800, 1600, 2400, 3200, and 4800 ppm, were combined. The neutron irradiation was performed with thermal neutrons for 30 min. (neutron flux: 0.84 x 10(8) n/cm2/s in free air). The combination of the boron and gadolinium compounds showed an additive effect when the gadolinium concentration was lower than 1600 ppm. This additive effect decreased as a function of gadolinium concentration at 2400 ppm and resulted in no additive effect at more than 3200 ppm of gadolinium. In conclusion, the combination of the boron and gadolinium compounds can enhance the therapeutic effect with an optimum concentration ratio. When the gadolinium concentration is too high, it may weaken the boron neutron capture reaction due to the high cross-section of gadolinium compound against neutrons.

  18. Calculation of dose components in head phantom for boron neutron capture therapy.

    PubMed

    da Silva, Ademir X; Crispim, Verginia R

    2002-11-01

    Application of neutrons to cancer treatment has been a subject of considerable clinical and research interest since the discovery of the neutron by Chadwick in 1932 (3). Boron neutron capture therapy (BNCT) is a technique of radiation oncology which is used in treating brain cancer (glioblastoma multiform) or melanoma and that consists of preferentially loading a compound containing 10B into the tumor location, followed by the irradiation of the patient with a beam of neutron. Dose distribution for BNCT is mainly based on Monte Carlo simulations. In this work, the absorbed dose spatial distribution resultant from an idealized neutron beam incident upon ahead phantom is investigated using the Monte Carlo N-particles code, MCNP 4B. The phantom model used is based on the geometry of a circular cylinder on which sits an elliptical cylinder capped by half an ellipsoid representing the neck and head, both filled with tissue-equivalent material. The neutron flux and the contribution of individual absorbed dose components, as a function of depths and of radial distance from the beam axis (dose profiles) in phantom model, is presented and discussed. For the studied beam the maximum thermal neutron flux is at a depth of 2 cm and the maximum gamma dose at a depth of 4 cm.

  19. Early clinical experience of boron neutron capture therapy for glioblastoma multiforme

    SciTech Connect

    Joel, D.D.; Bergland, R.; Capala, J.

    1995-12-31

    Boron neutron capture therapy (BNCT) is a binary treatment modality that can selectively irradiate tumor tissue. BNCT uses drugs containing a stable isotope of boron. {sup 10}B, to sensitize tumor cells to irradiation by low energy (thermal) neutrons. The interaction of the {sup 10}B with a thermal neutron (neutron capture) causes the {sup 10}B nucleus to split, releasing an alpha particle and a lithium nucleus. These products of the {sup 10}B(n, {alpha}){sup 7}Li reaction are very damaging to cells but have a combined path length in tissue of approximately 14 {mu}m, or roughly the diameter of one or two cells. Thus, most of the ionizing energy imparted to tissue is localized to {sup 10}B-loaded cells.

  20. Analysis of Neutron Production in Passively Scattered Ion-Beam Therapy.

    PubMed

    Heo, Seunguk; Yoo, Seunghoon; Song, Yongkeun; Kim, Eunho; Shin, Jaeik; Han, Soorim; Jung, Wongyun; Nam, Sanghee; Lee, Rena; Lee, Kitae; Cho, Sungho

    2016-11-24

    A new treatment facility for heavy ion therapy since 2010 was constructed. In the broad beam, a range shifter, ridge filter and multi leaf collimator (MLC) for the generation of the spread-out Bragg peak is used. In this case, secondary neutrons produced by the interactions of the ion field with beam-modifying devices (e.g. double-scattering system, beam shaping collimators and range compensators) are very important for patient safety. Therefore, these components must be carefully examined in the context of secondary neutron yield and associated secondary cancer risk. In this article, Monte Carlo simulation has been carried out with the FLUktuierende KAskade particle transport code, the fluence and distribution of neutron generation and the neutron dose equivalent from the broad beam components are compared using carbon and proton beams. As a result, it is confirmed that the yield of neutron production using a carbon beam from all components of the broad beam was higher than using a proton beam. The ambient dose by neutrons per heavy ion and proton ion from the MLC surface was 0.12-0.18 and 0.0067-0.0087 pSv, respectively, which shows that heavy ions generate more neutrons than protons. However, ambient dose per treatment 2 Gy, which means physical dose during treatment by ion beam, is higher than carbon beam because proton therapy needs more beam flux to make 2-Gy prescription dose. Therefore, the neutron production from the MLC, which is closed to the patient, is a very important parameter for patient safety.

  1. [Development of the method of magnetic neutron capture therapy of cancer].

    PubMed

    Kuznetsov, A A; Podoĭnitsyn, S N; Filippov, V I; Komissarova, L Kh

    2005-01-01

    The method of magnetic neutron capture therapy (MNTC) of cancer can be described as a combination of two methods: the targeted delivery of drugs using magnetic carriers and the proper neutron capture therapy which consists in tumor irradiation with thermal neutrons following the delivery of 10B compounds to the tumor site. Two-component ultradispersed particles containing Fe and C were tested as magnetic adsorbents of boron phenylalanine and borax. The quantities of absorbed borax proved sufficient for high concentration of boron atoms at the tumor site. The kinetics of boron release to saline substantiates the application of Fe-B (10%) ultradispersed particles for efficient MNTC. Both particle types have high magnetization and magnetic homogeneity, can form stable magnetic suspensions, and have low toxicity.

  2. A beam-modification assembly for experimental neutron capture therapy of brain tumors

    SciTech Connect

    Slatkin, D.N.; Kalef-Ezra, J.A.; Saraf, S.K.; Joel, D.D.

    1989-01-01

    Recent attempts to treat intracerebral rat gliomas by boron neutron capture therapy (BNCT) have been somewhat disappointing, perhaps in part because of excessive whole-body and nasopharyngeal irradiation. Intracerebral rat gliomas were treated by BNCT with more success using a new beam-modification assembly. 3 refs., 2 figs.

  3. Spermidinium closo-dodecaborate-encapsulating liposomes as efficient boron delivery vehicles for neutron capture therapy.

    PubMed

    Tachikawa, Shoji; Miyoshi, Tatsuro; Koganei, Hayato; El-Zaria, Mohamed E; Viñas, Clara; Suzuki, Minoru; Ono, Koji; Nakamura, Hiroyuki

    2014-10-21

    closo-Dodecaborate-encapsulating liposomes were developed as boron delivery vehicles for neutron capture therapy. The use of spermidinium as a counter cation of closo-dodecaborates was essential not only for the preparation of high boron content liposome solutions but also for efficient boron delivery to tumors.

  4. Implications for clinical treatment from the micrometer site dosimetric calculations in boron neutron capture therapy.

    PubMed

    Nichols, Trent L; Kabalka, George W; Miller, Laurence F; McCormack, Michael T; Johnson, Andrew

    2009-07-01

    Boron neutron capture therapy has now been used for several malignancies. Most clinical trials have addressed its use for the treatment of glioblastoma multiforme. A few trials have focused on the treatment of malignant melanoma with brain metastases. Trial results for the treatment of glioblastoma multiforme have been encouraging, but have not achieved the success anticipated. Results of trials for the treatment of malignant melanoma have been very promising, though with too few patients for conclusions to be drawn. Subsequent to these trials, regimens for undifferentiated thyroid carcinoma, hepatic metastases from adenocarcinoma of the colon, and head and neck malignancies have been developed. These tumors have also responded well to boron neutron capture therapy. Glioblastoma is an infiltrative tumor with distant individual tumor cells that might create a mechanism for therapeutic failure though recurrences are often local. The microdosimetry of boron neutron capture therapy can provide an explanation for this observation. Codes written to examine the micrometer scale energy deposition in boron neutron capture therapy have been used to explore the effects of near neighbor cells. Near neighbor cells can contribute a significantly increased dose depending on the geometric relationships. Different geometries demonstrate that tumors which grow by direct extension have a greater near neighbor effect, whereas infiltrative tumors lose this near neighbor dose which can be a significant decrease in dose to the cells that do not achieve optimal boron loading. This understanding helps to explain prior trial results and implies that tumors with small, closely packed cells that grow by direct extension will be the most amenable to boron neutron capture therapy.

  5. SU-E-T-274: Radiation Therapy with Very High-Energy Electron (VHEE) Beams in the Presence of Metal Implants

    SciTech Connect

    Jensen, C; Palma, B; Qu, B; Maxim, P; Loo, B; Bazalova, M; Hardemark, B; Hynning, E

    2014-06-01

    Purpose: To evaluate the effect of metal implants on treatment plans for radiation therapy with very high-energy electron (VHEE) beams. Methods: The DOSXYZnrc/BEAMnrc Monte Carlo (MC) codes were used to simulate 50–150MeV VHEE beam dose deposition and its effects on steel and titanium (Ti) heterogeneities in a water phantom. Heterogeneities of thicknesses ranging from 0.5cm to 2cm were placed at 10cm depth. MC was also used to calculate electron and photon spectra generated by the VHEE beams' interaction with metal heterogeneities. The original VMAT patient dose calculation was planned in Eclipse. Patient dose calculations with MC-generated beamlets were planned using a Matlab GUI and research version of RayStation. VHEE MC treatment planning was performed on water-only geometry and water with segmented prostheses (steel and Ti) geometries with 100MeV and 150MeV beams. Results: 100MeV PDD 5cm behind steel/Ti heterogeneity was 51% less than in the water-only phantom. For some cases, dose enhancement lateral to the borders of the phantom increased the dose by up to 22% in steel and 18% in Ti heterogeneities. The dose immediately behind steel heterogeneity decreased by an average of 6%, although for 150MeV, the steel heterogeneity created a 23% increase in dose directly behind it. The average dose immediately behind Ti heterogeneities increased 10%. The prostate VHEE plans resulted in mean dose decrease to the bowel (20%), bladder (7%), and the urethra (5%) compared to the 15MV VMAT plan. The average dose to the body with prosthetic implants was 5% higher than to the body without implants. Conclusion: Based on MC simulations, metallic implants introduce dose perturbations to VHEE beams from lateral scatter and backscatter. However, when performing clinical planning on a prostate case, the use of multiple beams and inverse planning still produces VHEE plans that are dosimetrically superior to photon VMAT plans. BW Loo and P Maxim received research support from Ray

  6. Microdosimetric measurements for neutron-absorbed dose determination during proton therapy

    PubMed Central

    Pérez-Andújar, Angélica; DeLuca, Paul M.; Thornton, Allan F.; Fitzek, Markus; Hecksel, Draik; Farr, Jonathan

    2012-01-01

    This work presents microdosimetric measurements performed at the Midwest Proton Radiotherapy Institute in Bloomington, Indiana, USA. The measurements were done simulating clinical setups with a water phantom and for a variety of stopping targets. The water phantom was irradiated by a proton spread out Bragg peak (SOBP) and by a proton pencil beam. Stopping target measurements were performed only for the pencil beam. The targets used were made of polyethylene, brass and lead. The objective of this work was to determine the neutron-absorbed dose for a passive and active proton therapy delivery, and for the interactions of the proton beam with materials typically in the beam line of a proton therapy treatment nozzle. Neutron doses were found to be higher at 45° and 90° from the beam direction for the SOBP configuration by a factor of 1.1 and 1.3, respectively, compared with the pencil beam. Meanwhile, the pencil beam configuration produced neutron-absorbed doses 2.2 times higher at 0° than the SOBP. For stopping targets, lead was found to dominate the neutron-absorbed dose for most angles due to a large production of low-energy neutrons emitted isotropically. PMID:22334761

  7. Sublethal and potentially lethal damage repair on thermal neutron capture therapy

    SciTech Connect

    Utsumi, H.; Ichihashi, M.; Kobayashi, T.; Elkind, M.M. )

    1989-07-01

    Tonicity shock or caffeine postirradiation treatment makes evident fast-type potentially lethal damage (PLD). Caffeine expresses fast-type PLD more efficiently than tonicity shock in X-irradiated B-16 mouse melanoma cells, compared with V79 Chinese hamster cells. The survival curves of thermal neutrons for either V79 or B-16 cells exhibit no shoulder. Neither V79 nor B-16 cells show the sublethal damage (SLD) repair of thermal neutrons. Caffeine-sensitive fast-type PLD repairs exist in X-irradiated B-16 cells, as well as V79 cells. The fast-type PLD repair of B-16 cells exposed to thermal neutrons alone is rather less than that of X-irradiated cells. Furthermore, an extremely low level of fast-type PLD repair of B-16 cells with 10B1-paraboronophenylalanine (BPA) preincubation (20 hours) followed by thermal neutron irradiation indicated that 10B(n,alpha)7Li reaction effectively eradicates actively growing melanoma cells. The plateau-phase B-16 cells are well able to repair the slow-type PLD of X-rays. However, cells can not repair the slow-type PLD induced by thermal neutron irradiation with or without 10B1-BPA preincubation. These results suggest that thermal neutron capture therapy can effectively kill radioresistant melanoma cells in both proliferating and quiescent phases.

  8. Relative biological effects of neutron mixed-beam irradiation for boron neutron capture therapy on cell survival and DNA double-strand breaks in cultured mammalian cells

    PubMed Central

    Okumura, Kakuji; Kinashi, Yuko; Kubota, Yoshihisa; Kitajima, Erika; Okayasu, Ryuichi; Ono, Koji; Takahashi, Sentaro

    2013-01-01

    Understanding the biological effects of neutron mixed-beam irradiation used for boron neutron capture therapy (BNCT) is important in order to improve the efficacy of the therapy and to reduce side effects. In the present study, cell viability and DNA double-strand breaks (DNA-DSBs) were examined in Chinese hamster ovary cells (CHO-K1) and their radiosensitive mutant cells (xrs5, Ku80-deficient), following neutron mixed-beam irradiation for BNCT. Cell viability was significantly impaired in the neutron irradiation groups compared to the reference gamma-ray irradiation group. The relative biological effectiveness for 10% cell survival was 3.3 and 1.2 for CHO-K1 and xrs5 cells, respectively. There were a similar number of 53BP1 foci, indicators of DNA-DSBs, in the neutron mixed-beam and the gamma-ray groups. In addition, the size of the foci did not differ between groups. However, neutron mixed-beam irradiation resulted in foci with different spatial distributions. The foci were more proximal to each other in the neutron mixed-beam groups than the gamma-ray irradiation groups. These findings suggest that neutron beams may induce another type of DNA damage, such as clustered DNA-DSBs, as has been indicated for other high-LET irradiation. PMID:22966174

  9. Boron neutron capture therapy (BNCT) in Finland: technological and physical prospects after 20 years of experiences.

    PubMed

    Savolainen, Sauli; Kortesniemi, Mika; Timonen, Marjut; Reijonen, Vappu; Kuusela, Linda; Uusi-Simola, Jouni; Salli, Eero; Koivunoro, Hanna; Seppälä, Tiina; Lönnroth, Nadja; Välimäki, Petteri; Hyvönen, Heini; Kotiluoto, Petri; Serén, Tom; Kuronen, Antti; Heikkinen, Sami; Kosunen, Antti; Auterinen, Iiro

    2013-05-01

    Boron Neutron Capture Therapy (BNCT) is a binary radiotherapy method developed to treat patients with certain malignant tumours. To date, over 300 treatments have been carried out at the Finnish BNCT facility in various on-going and past clinical trials. In this technical review, we discuss our research work in the field of medical physics to form the groundwork for the Finnish BNCT patient treatments, as well as the possibilities to further develop and optimize the method in the future. Accordingly, the following aspects are described: neutron sources, beam dosimetry, treatment planning, boron imaging and determination, and finally the possibilities to detect the efficacy and effects of BNCT on patients.

  10. Tandem-ESQ for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT)

    SciTech Connect

    Kreiner, A. J.; Kwan, J. W.; Henestroza, E.; Burlon, A. A.; Di Paolo, H.; Minsky, D.; Debray, M.; Valda, A.; Somacal, H. R.

    2007-02-12

    A folded tandem, with 1.25 MV terminal voltage, combined with an ElectroStatic Quadrupole (ESQ) chain is being proposed as a machine for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT). The machine is shown to be capable of accelerating a 30 mA proton beam to 2.5 MeV. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams, based on the on the 7Li(p,n)7Be reaction, to perform BNCT treatment for deep seated tumors in less than an hour.

  11. Experiments to increase the parameters of the vacuum insulation tandem accelerator for boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Kasatov, D. A.; Kolesnikov, J. A.; Koshkarev, A. M.; Kuznetsov, A. S.; Makarov, A. N.; Sokolova, E. O.; Sorokin, I. N.; Sycheva, T. V.; Taskaev, S. Yu.; Shchudlo, I. M.

    2016-12-01

    An epithermal neutron source that is based on a vacuum insulation tandem accelerator (VITA) and lithium target was created in the Budker Institute of Nuclear Physics for the development of boron neutron capture therapy (BNCT). A stationary proton beam with 2 MeV energy and 1.6 mA current has been obtained. To carry out BNCT, it is necessary to increase the beam parameters up to 2.3 MeV and 3 mA. Ways to increase the parameters of the proton beam have been proposed and discussed in this paper. The results of the experiments are presented.

  12. High Energy Density Laboratory Astrophysics

    SciTech Connect

    Remington, B A

    2004-11-11

    High-energy-density (HED) physics refers broadly to the study of macroscopic collections of matter under extreme conditions of temperature and density. The experimental facilities most widely used for these studies are high-power lasers and magnetic-pinch generators. The HED physics pursued on these facilities is still in its infancy, yet new regimes of experimental science are emerging. Examples from astrophysics include work relevant to planetary interiors, supernovae, astrophysical jets, and accreting compact objects (such as neutron stars and black holes). In this paper, we will review a selection of recent results in this new field of HED laboratory astrophysics and provide a brief look ahead to the coming decade.

  13. An irradiation facility for Boron Neutron Capture Therapy application based on a radio frequency driven D-T neutron source and a new beam shaping assembly

    NASA Astrophysics Data System (ADS)

    Cerullo, Nicola; Esposito, Juan; Leung, Ka Ngo; Custodero, Salvatore

    2002-10-01

    A line of the Boron Neutron Capture Therapy (BNCT) research program aimed at the treatment of brain tumors, carried on at the Nuclear Departments of Pisa and Genova Universities (DIMNP and DITEC), is being focused on a new, 3H(d,n)4He (D-T), accelerator-based neutron source concept, developed at Lawrence Berkeley National Laboratory (LBNL). Simple and compact accelerator designs, using mixed D+ T+ ion beam with relatively low energy, ˜100 keV, have been developed which, in turn, can generate high neutron yields. New approaches have thus been started to design an epithermal neutron irradiation facility able to selectively slow the 14.1 MeV D-T neutrons down to the epithermal (1 eV-10 KeV) energy range. New neutron spectrum shifter and filtering materials, as well as different facility layout approaches have been tested. Possible beam shaping assembly models have also been designed. The research demonstrates that a D-T neutron source could be successfully implemented to provide a ˜1×109 n/cm2 s epithermal neutron flux, in spite of its hard spectrum, although a generator device, able to yield ˜1014 n/s is, at present, not yet available. The latest Monte Carlo simulation of an accelerator-based facility, which relies on a single or multiple rf driven DT fusion neutron generator, is presented.

  14. Fast neutron therapy for squamous cell carcinoma in the head and neck region: results of a randomized trial

    SciTech Connect

    Duncan, W.; Orr, J.A.; Arnott, S.J.; Jack, W.J.; Kerr, G.R.; Williams, J.R.

    1987-02-01

    A randomized trial of fast neuron therapy compared with 4MV photons for patients with head and neck cancer is reported. One hundred and sixty-eight patients were recruited between 1977 and 1984. The minimum follow-up is 2 years. Three patients were withdrawn before treatment began. Eighty-five were allocated to neutron therapy and 80 to receive photon therapy. All patients had squamous cell cancers in one of four primary sites: oral cavity, oropharynx, larynx, and hypopharynx. Local tumor control was similar in both groups: 44.7% after neutrons and 45.0% after photons. Salvage surgery was performed on 18 patients in each treatment group for residual or recurrent cancer. Acute radiation reactions of the mucous membranes were significantly more severe after photons. The number of patients with serious late reactions was greater after neutron therapy but the difference was not statistically significant. There were six deaths related to late morbidity after neutron therapy but none after photon therapy. Survival was better after photon therapy but the difference compared with the neutron group failed to reach statistical significance. When intercurrent deaths are excluded, the difference is less marked. Photon therapy was clearly better in terms of disease-free survival giving a 2-year local disease-free rate of 41.3% (s.e. 5.5%) compared with 29.4% (s.e. 4.9%) after neutrons.

  15. Novel technologies and theoretical models in radiation therapy of cancer patients using 6.3 MeV fast neutrons produced by U-120 cyclotron

    NASA Astrophysics Data System (ADS)

    Musabaeva, L. I.; Startseva, Zh. A.; Gribova, O. V.; Velikaya, V. V.; Lisin, V. A.

    2016-08-01

    The analysis of clinical use of neutron therapy with 6 MeV fast neutrons compared to conventional radiation therapy was carried out. The experience of using neutron and mixed neutron and photon therapy in patients with different radio-resistant malignant tumors shows the necessity of further studies and development of the novel approaches to densely-ionizing radiation. The results of dosimetry and radiobiological studies have been the basis for planning clinical programs for neutron therapy. Clinical trials over the past 30 years have shown that neutron therapy successfully destroys radio-resistant cancers, including salivary gland tumors, adenoidcystic carcinoma, inoperable sarcomas, locally advanced head and neck tumors, and locally advanced prostate cancer. Radiation therapy with 6.3 MeV fast neutrons used alone and in combination with photon therapy resulted in improved long-term treatment outcomes in patients with radio-resistant malignant tumors.

  16. Design study of a medical proton linac for neutron therapy

    SciTech Connect

    Machida, S.; Raparia, D.

    1988-08-26

    This paper describes a design study which establishes the physical parameters of the low energy beam transport, radiofrequency quadrupole, and linac, using computer programs available at Fermilab. Beam dynamics studies verify that the desired beam parameters can be achieved. The machine described here meets the aforementioned requirements and can be built using existing technology. Also discussed are other technically feasible options which could be attractive to clinicians, though they would complicate the design of the machine and increase construction costs. One of these options would allow the machine to deliver 2.3 MeV protons to produce epithermal neutrons for treating brain tumors. A second option would provide 15 MeV protons for isotope production. 21 refs., 33 figs.

  17. Gadolinium as an element for neutron capture therapy

    SciTech Connect

    Brugger, R.M.; Liu, H.B.; Laster, B.H.; Gordon, C.R.; Greenberg, D.D.; Warkentien, L.S.

    1992-12-31

    At BNL, preparations are being made to test in vitro compounds containing Gd and compare their response to the response of GD-DTPA to determine if one or several compounds can be located that enter the cells and enhance the Auger effect. Two similar rotators with positions for cell vials that have been constructed for these tests. The first rotator is made of only paraffin which simulates healthy tissue and provides control curves. The second rotator has 135 ppM of Gd-157 in the paraffin to simulate a Gd loaded tumor. Cells are irradiated in vials in the paraffin rotator and in the Gd-paraffin rotator at the epithermal beam of the Brookhaven Medical Research Reactor (BMRR). This produces an irradiation similar to what a patient would receive In an actual treatment. A combination of irradiations are made with both rotators; with no Gd compound or IdUrd In the cell media, with only Gd compound in the cell media and with both Gd compound and IdUrd in the cell media. The first set shows the effects of gamma rays from the H(n,gamma) reaction and the prompt gamma rays from capture of neutrons by Gd. The second set shows if there is any effect of Gd being in the cell media or inside the cells, i.e., an Auger effect. The third set shows the effect of enhancement by the IdUrd produced by the gamma rays from neutrons captured by either H or Gd. The fourth set combines all of the reactions and enhancements. Preliminary calculations and physical measurements of the doses that the cells will receive In these rotators have been made.

  18. Gadolinium as an element for neutron capture therapy

    SciTech Connect

    Brugger, R.M.; Liu, H.B.; Laster, B.H.; Gordon, C.R.; Greenberg, D.D.; Warkentien, L.S.

    1992-01-01

    At BNL, preparations are being made to test in vitro compounds containing Gd and compare their response to the response of GD-DTPA to determine if one or several compounds can be located that enter the cells and enhance the Auger effect. Two similar rotators with positions for cell vials that have been constructed for these tests. The first rotator is made of only paraffin which simulates healthy tissue and provides control curves. The second rotator has 135 ppM of Gd-157 in the paraffin to simulate a Gd loaded tumor. Cells are irradiated in vials in the paraffin rotator and in the Gd-paraffin rotator at the epithermal beam of the Brookhaven Medical Research Reactor (BMRR). This produces an irradiation similar to what a patient would receive In an actual treatment. A combination of irradiations are made with both rotators; with no Gd compound or IdUrd In the cell media, with only Gd compound in the cell media and with both Gd compound and IdUrd in the cell media. The first set shows the effects of gamma rays from the H(n,gamma) reaction and the prompt gamma rays from capture of neutrons by Gd. The second set shows if there is any effect of Gd being in the cell media or inside the cells, i.e., an Auger effect. The third set shows the effect of enhancement by the IdUrd produced by the gamma rays from neutrons captured by either H or Gd. The fourth set combines all of the reactions and enhancements. Preliminary calculations and physical measurements of the doses that the cells will receive In these rotators have been made.

  19. Neutron, proton, and photonuclear cross-sections for radiation therapy and radiation protection.

    PubMed

    Chadwick, M B

    1998-12-01

    I review recent work at Los Alamos undertaken to evaluate neutron, proton, and photonuclear cross-sections up to 150 MeV (to 250 MeV for protons), based on experimental data and nuclear model calculations. These data are represented in the ENDF format and can be used in computer codes to simulate radiation transport. They permit calculations of absorbed dose in the body from therapy beams, and through use of kerma coefficients allow absorbed dose to be estimated for a given neutron energy distribution. In radiation protection, these data can be used to determine shielding requirements in accelerator environments and to calculate neutron, proton, gamma-ray, and radionuclide production. Illustrative comparisons of the evaluated cross-section and kerma coefficient data with measurements are given.

  20. High-energy detector

    DOEpatents

    Bolotnikov, Aleksey E [South Setauket, NY; Camarda, Giuseppe [Farmingville, NY; Cui, Yonggang [Upton, NY; James, Ralph B [Ridge, NY

    2011-11-22

    The preferred embodiments are directed to a high-energy detector that is electrically shielded using an anode, a cathode, and a conducting shield to substantially reduce or eliminate electrically unshielded area. The anode and the cathode are disposed at opposite ends of the detector and the conducting shield substantially surrounds at least a portion of the longitudinal surface of the detector. The conducting shield extends longitudinally to the anode end of the detector and substantially surrounds at least a portion of the detector. Signals read from one or more of the anode, cathode, and conducting shield can be used to determine the number of electrons that are liberated as a result of high-energy particles impinge on the detector. A correction technique can be implemented to correct for liberated electron that become trapped to improve the energy resolution of the high-energy detectors disclosed herein.

  1. High Energy Astrophysics Program

    NASA Technical Reports Server (NTRS)

    1996-01-01

    This report reviews activities performed by members of the USRA (Universities Space Research Association) contract team during the six months during the reporting period (10/95 - 3/96) and projected activities during the coming six months. Activities take place at the Goddard Space Flight Center, within the Laboratory for High Energy Astrophysics. Developments concern instrumentation, observation, data analysis, and theoretical work in Astrophysics. Missions supported include: Advanced Satellite for Cosmology and Astrophysics (ASCA), X-ray Timing Experiment (XTE), X-ray Spectrometer (XRS), Astro-E, High Energy Astrophysics Science, Archive Research Center (HEASARC), and others.

  2. High Energy Astrophysics Program

    NASA Technical Reports Server (NTRS)

    1996-01-01

    This report reviews activities performed-by members of the USRA contract team during the six months of the reporting period and projected activities during the coming six months. Activities take place at the Goddard Space Flight Center, visiting the Laboratory for High Energy Astrophysics. Developments concern instrumentation, observation, data analysis, and theoretical work in Astrophysics. Missions supported include: Advanced Satellite for Cosmology and Astrophysics (ASCA); X-ray Timing Experiment (XTE); X-ray Spectrometer (XRS); Astro-E; High Energy Astrophysics Science Archive Research Center (HEASARC), and others.

  3. Optimum design and criticality safety of a beam-shaping assembly with an accelerator-driven subcritical neutron multiplier for boron neutron capture therapies.

    PubMed

    Hiraga, F

    2015-12-01

    The beam-shaping assembly for boron neutron capture therapies with a compact accelerator-driven subcritical neutron multiplier was designed so that an epithermal neutron flux of 1.9×10(9) cm(-2) s(-1) at the treatment position was generated by 5 MeV protons in a beam current of 2 mA. Changes in the atomic density of (135)Xe in the nuclear fuel due to the operation of the beam-shaping assembly were estimated. The criticality safety of the beam-shaping assembly in terms of Xe poisoning is discussed.

  4. Monte Carlo modeling of proton therapy installations: a global experimental method to validate secondary neutron dose calculations

    NASA Astrophysics Data System (ADS)

    Farah, J.; Martinetti, F.; Sayah, R.; Lacoste, V.; Donadille, L.; Trompier, F.; Nauraye, C.; De Marzi, L.; Vabre, I.; Delacroix, S.; Hérault, J.; Clairand, I.

    2014-06-01

    Monte Carlo calculations are increasingly used to assess stray radiation dose to healthy organs of proton therapy patients and estimate the risk of secondary cancer. Among the secondary particles, neutrons are of primary concern due to their high relative biological effectiveness. The validation of Monte Carlo simulations for out-of-field neutron doses remains however a major challenge to the community. Therefore this work focused on developing a global experimental approach to test the reliability of the MCNPX models of two proton therapy installations operating at 75 and 178 MeV for ocular and intracranial tumor treatments, respectively. The method consists of comparing Monte Carlo calculations against experimental measurements of: (a) neutron spectrometry inside the treatment room, (b) neutron ambient dose equivalent at several points within the treatment room, (c) secondary organ-specific neutron doses inside the Rando-Alderson anthropomorphic phantom. Results have proven that Monte Carlo models correctly reproduce secondary neutrons within the two proton therapy treatment rooms. Sensitive differences between experimental measurements and simulations were nonetheless observed especially with the highest beam energy. The study demonstrated the need for improved measurement tools, especially at the high neutron energy range, and more accurate physical models and cross sections within the Monte Carlo code to correctly assess secondary neutron doses in proton therapy applications.

  5. Monte Carlo modeling of proton therapy installations: a global experimental method to validate secondary neutron dose calculations.

    PubMed

    Farah, J; Martinetti, F; Sayah, R; Lacoste, V; Donadille, L; Trompier, F; Nauraye, C; De Marzi, L; Vabre, I; Delacroix, S; Hérault, J; Clairand, I

    2014-06-07

    Monte Carlo calculations are increasingly used to assess stray radiation dose to healthy organs of proton therapy patients and estimate the risk of secondary cancer. Among the secondary particles, neutrons are of primary concern due to their high relative biological effectiveness. The validation of Monte Carlo simulations for out-of-field neutron doses remains however a major challenge to the community. Therefore this work focused on developing a global experimental approach to test the reliability of the MCNPX models of two proton therapy installations operating at 75 and 178 MeV for ocular and intracranial tumor treatments, respectively. The method consists of comparing Monte Carlo calculations against experimental measurements of: (a) neutron spectrometry inside the treatment room, (b) neutron ambient dose equivalent at several points within the treatment room, (c) secondary organ-specific neutron doses inside the Rando-Alderson anthropomorphic phantom. Results have proven that Monte Carlo models correctly reproduce secondary neutrons within the two proton therapy treatment rooms. Sensitive differences between experimental measurements and simulations were nonetheless observed especially with the highest beam energy. The study demonstrated the need for improved measurement tools, especially at the high neutron energy range, and more accurate physical models and cross sections within the Monte Carlo code to correctly assess secondary neutron doses in proton therapy applications.

  6. Optimization of Boron Neutron Capture Therapy for the Treatment of Undifferentiated Thyroid Cancer

    SciTech Connect

    Dagrosa, Maria Alejandra; Thomasz, Lisa M.Sc.; Longhino, Juan; Perona, Marina; Calzetta, Osvaldo; Blaumann, Herman; Rebagliati, Raul Jimenez; Cabrini, Romulo; Kahl, Steven; Juvenal, Guillermo Juan; Pisarev, Mario Alberto

    2007-11-15

    Purpose: To analyze the possible increase in efficacy of boron neutron capture therapy (BNCT) for undifferentiated thyroid carcinoma (UTC) by using p-boronophenylalanine (BPA) plus 2,4-bis ({alpha},{beta}-dihydroxyethyl)-deutero-porphyrin IX (BOPP) and BPA plus nicotinamide (NA) as a radiosensitizer of the BNCT reaction. Methods and Materials: Nude mice were transplanted with a human UTC cell line (ARO), and after 15 days they were treated as follows: (1) control, (2) NCT (neutrons alone), (3) NCT plus NA (100 mg/kg body weight [bw]/day for 3 days), (4) BPA (350 mg/kg bw) + neutrons, (5) BPA + NA + neutrons, and (6) BPA + BOPP (60 mg/kg bw) + neutrons. The flux of the mixed (thermal + epithermal) neutron beam was 2.8 x 10{sup 8} n/cm{sup 2}/sec for 83.4 min. Results: Neutrons alone or with NA caused some tumor growth delay, whereas in the BPA, BPA + NA, and BPA + BOPP groups a 100% halt of tumor growth was observed in all mice at 26 days after irradiation. When the initial tumor volume was 50 mm{sup 3} or less, complete remission was found with BPA + NA (2 of 2 mice), BPA (1 of 4), and BPA + BOPP (7 of 7). After 90 days of complete regression, recurrence of the tumor was observed in BPA + NA (2 of 2) and BPA + BOPP (1 of 7). The determination of apoptosis in tumor samples by measurements of caspase-3 activity showed an increase in the BNCT (BPA + NA) group at 24 h (p < 0.05 vs. controls) and after the first week after irradiation in the three BNCT groups. Terminal transferase dUTP nick end labeling analysis confirmed these results. Conclusions: Although NA combined with BPA showed an increase of apoptosis at early times, only the group irradiated after the combined administration of BPA and BOPP showed a significantly improved therapeutic response.

  7. Inhibition of human pancreatic cancer growth in nude mice by boron neutron capture therapy.

    PubMed

    Yanagië, H; Tomita, T; Kobayashi, H; Fujii, Y; Nonaka, Y; Saegusa, Y; Hasumi, K; Eriguchi, M; Kobayashi, T; Ono, K

    1997-01-01

    Immunoliposomes were prepared by conjugating anti-carcinoembryonic antigen (CEA) monoclonal antibody with liposomes containing [10B]compound. These immunoliposomes were shown to bind selectively to human pancreatic carcinoma cells (AsPC-1) bearing CEA on their surface. The cytotoxic effects of locally injected [10B]compound, multilamellar liposomes containing [10B]compound or [10B]immunoliposomes (anti-CEA) on human pancreatic carcinoma xenografts in nude mice were evaluated with thermal neutron irradiation. After thermal neutron irradiation of mice injected with [10B]solution, 10B-containing liposomes or [10B]immunoliposomes, AsPC-1 tumour growth was suppressed relative to controls. Injection of [10B]immunoliposomes caused the greatest tumour suppression with thermal neutron irradiation in vivo. Histopathologically, hyalinization and necrosis were found in 10B-treated tumours, while tumour tissue injected with saline or saline-containing immunoliposomes showed neither destruction nor necrosis. These results suggest that intratumoral injection of boronated immunoliposomes can increase the retention of 10B atoms by tumour cells, causing tumour growth suppression in vivo upon thermal neutron irradiation. Boron neutron capture therapy (BNCT) with intratumoral injection of immunoliposomes is able to destroy malignant cells in the marginal portion between normal tissues and cancer tissues from the side of 4He generation.

  8. High Energy Astronomy Observatory

    NASA Technical Reports Server (NTRS)

    1980-01-01

    An overview of the High Energy Astronomy Observatory 2 contributions to X-ray astronomy is presented along with a brief description of the satellite and onboard telescope. Observations relating to galaxies and galactic clusters, black holes, supernova remnants, quasars, and cosmology are discussed.

  9. High energy particle astronomy.

    NASA Technical Reports Server (NTRS)

    Buffington, A.; Muller, R. A.; Smith, L. H.; Smoot, G. F.

    1972-01-01

    Discussion of techniques currently used in high energy particle astronomy for measuring charged and neutral cosmic rays and their isotope and momentum distribution. Derived from methods developed for accelerator experiments in particle physics, these techniques help perform important particle astronomy experiments pertaining to nuclear cosmic ray and gamma ray research, electron and position probes, and antimatter searches.

  10. High energy colliders

    SciTech Connect

    Palmer, R.B.; Gallardo, J.C.

    1997-02-01

    The authors consider the high energy physics advantages, disadvantages and luminosity requirements of hadron (pp, p{anti p}), lepton (e{sup +}e{sup {minus}}, {mu}{sup +}{mu}{sup {minus}}) and photon-photon colliders. Technical problems in obtaining increased energy in each type of machine are presented. The machines relative size are also discussed.

  11. Boron Neutron Capture Therapy (BNCT) Dose Calculation using Geometrical Factors Spherical Interface for Glioblastoma Multiforme

    SciTech Connect

    Zasneda, Sabriani; Widita, Rena

    2010-06-22

    Boron Neutron Capture Therapy (BNCT) is a cancer therapy by utilizing thermal neutron to produce alpha particles and lithium nuclei. The superiority of BNCT is that the radiation effects could be limited only for the tumor cells. BNCT radiation dose depends on the distribution of boron in the tumor. Absorbed dose to the cells from the reaction 10B (n, {alpha}) 7Li was calculated near interface medium containing boron and boron-free region. The method considers the contribution of the alpha particle and recoiled lithium particle to the absorbed dose and the variation of Linear Energy Transfer (LET) charged particles energy. Geometrical factor data of boron distribution for the spherical surface is used to calculate the energy absorbed in the tumor cells, brain and scalp for case Glioblastoma Multiforme. The result shows that the optimal dose in tumor is obtained for boron concentrations of 22.1 mg {sup 10}B/g blood.

  12. Proton linac for hospital-based fast neutron therapy and radioisotope production

    SciTech Connect

    Lennox, A.J.; Hendrickson, F.R.; Swenson, D.A.; Winje, R.A.; Young, D.E.; Rush Univ., Chicago, IL; Science Applications International Corp., Princeton, NJ; Fermi National Accelerator Lab., Batavia, IL )

    1989-09-01

    Recent developments in linac technology have led to the design of a hospital-based proton linac for fast neutron therapy. The 180 microamp average current allows beam to be diverted for radioisotope production during treatments while maintaining an acceptable dose rate. During dedicated operation, dose rates greater than 280 neutron rads per minute are achievable at depth, DMAX = 1.6 cm with source to axis distance, SAD = 190 cm. Maximum machine energy is 70 MeV and several intermediate energies are available for optimizing production of isotopes for Positron Emission Tomography and other medical applications. The linac can be used to produce a horizontal or a gantry can be added to the downstream end of the linac for conventional patient positioning. The 70 MeV protons can also be used for proton therapy for ocular melanomas. 17 refs., 1 fig., 1 tab.

  13. Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT).

    PubMed

    Wittig, Andrea; Michel, Jean; Moss, Raymond L; Stecher-Rasmussen, Finn; Arlinghaus, Heinrich F; Bendel, Peter; Mauri, Pier Luigi; Altieri, Saverio; Hilger, Ralf; Salvadori, Piero A; Menichetti, Luca; Zamenhof, Robert; Sauerwein, Wolfgang A G

    2008-10-01

    Boron Neutron Capture Therapy (BNCT) is based on the ability of the stable isotope 10B to capture neutrons, which leads to a nuclear reaction producing an alpha- and a 7Li-particle, both having a high biological effectiveness and a very short range in tissue, being limited to approximately one cell diameter. This opens the possibility for a highly selective cancer therapy. BNCT strongly depends on the selective uptake of 10B in tumor cells and on its distribution inside the cells. The chemical properties of boron and the need to discriminate different isotopes make the investigation of the concentration and distribution of 10B a challenging task. The most advanced techniques to measure and image boron are described, both invasive and non-invasive. The most promising approach for further investigation will be the complementary use of the different techniques to obtain the information that is mandatory for the future of this innovative treatment modality.

  14. Boron neutron capture therapy for malignant melanoma: first clinical case report in China

    PubMed Central

    Yong, Zhong; Song, Zewen; Zhou, Yongmao; Liu, Tong; Zhang, Zizhu; Zhao, Yanzhong; Chen, Yang; Jin, Congjun; Chen, Xiang; Lu, Jianyun; Han, Rui; Li, Pengzhou; Sun, Xulong; Wang, Guohui; Shi, Guangqing; Zhu, Shaihong

    2016-01-01

    A phase I/II clinical trial for treating malignant melanoma by boron neutron capture therapy (BNCT) was designed to evaluate whether the world’s first in-hospital neutron irradiator (IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography (PET/CT) scan, pathological analysis and gross examination, the patient showed a complete response to BNCT, indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals. PMID:28174492

  15. Synthesis and evaluation of boron compounds for neutron capture therapy of malignant brain tumors

    SciTech Connect

    Soloway, A.H.; Barth, R.F.

    1990-01-01

    Boron neutron capture therapy offers the potentiality for treating brain tumors currently resistant to treatment. The success of this form of therapy is directly dependent upon the delivery of sufficient numbers of thermal-neutrons to tumor cells which possess high concentrations of B-10. The objective of this project is to develop chemical methodology to synthesize boron-containing compounds with the potential for becoming incorporated into rapidly-dividing malignant brain tumor cells and excluded from normal components of the brain and surrounding tissues, to develope biological methods for assessing the potential of the compound by use of cell culture or intratumoral injection, to develop analytical methodology for measuring boron in cells and tissue using direct current plasma atomic emission spectroscopy (DCP-AES) and alpha track autoradiography, to develop biochemical and HPLC procedures for evaluating compound uptake and tissue half-life, and to develop procedures required to assess both in vitro and vivo efficacy of BNCT with selected compounds.

  16. NCTPlan application for neutron capture therapy dosimetric planning at MEPhI nuclear research reactor.

    PubMed

    Elyutina, A S; Kiger, W S; Portnov, A A

    2011-12-01

    The results of modeling of two therapeutic beams HEC-1 and HEC-4 at the NRNU "MEPhI" research nuclear reactor exploitable for preclinical treatments are reported. The exact models of the beams are constructed as an input to the NCTPlan code used for planning Neutron Capture Therapy (NCT) procedure. The computations are purposed to improve the accuracy of prediction of a dose absorbed in tissue with the account of all components of radiation.

  17. Boron neutron capture therapy for oral precancer: proof of principle in an experimental animal model

    SciTech Connect

    A. Monti Hughes; ECC Pozzi; S. Thorp; M. A. Garabalino; R. O. Farias; S. J. Gonzalez; E. M. Heber; M. E. Itoiz; R. F. Aromando; A. J. Molinari; M. Miller; D. W. Nigg; P. Curotto; V. A. Trivillin; A. E. Schwint

    2013-11-01

    Field-cancerized tissue can give rise to second primary tumours, causing therapeutic failure. Boron neutron capture therapy (BNCT) is based on biological targeting and would serve to treat undetectable foci of malignant transformation. The aim of this study was to optimize BNCT for the integral treatment for oral cancer, with particular emphasis on the inhibitory effect on tumour development originating in precancerous conditions, and radiotoxicity of different BNCT protocols in a hamster cheek pouch oral precancer model.

  18. FOREWORD: Neutron metrology Neutron metrology

    NASA Astrophysics Data System (ADS)

    Thomas, David J.; Nolte, Ralf; Gressier, Vincent

    2011-12-01

    industry, from the initial fuel enrichment and fabrication processes right through to storage or reprocessing, and neutron metrology is clearly important in this area. Neutron fields do, however, occur in other areas, for example where neutron sources are used in oil well logging and moisture measurements. They also occur around high energy accelerators, including photon linear accelerators used for cancer therapy, and are expected to be a more serious problem around the new hadron radiation therapy facilities. Roughly 50% of the cosmic ray doses experienced by fliers at the flight altitudes of commercial aircraft are due to neutrons. Current research on fusion presents neutron metrology with a whole new range of challenges because of the very high fluences expected. One of the most significant features of neutron fields is the very wide range of possible neutron energies. In the nuclear industry, for example, neutrons occur with energies from those of thermal neutrons at a few meV to the upper end of the fission spectrum at perhaps 10 MeV. For cosmic ray dosimetry the energy range extends into the GeV region. This enormous range sets a challenge for designing measuring devices and a parallel challenge of developing measurement standards for characterizing these devices. One of the major considerations when deciding on topics for this special issue was agreeing on what not to include. Modelling, i.e. the use of radiation transport codes, is now a very important aspect of neutron measurements. These calculations are vital for shielding and for instrument design; nevertheless, the topic has only been included here where it has a direct bearing on metrology and the development of standards. Neutron spectrometry is an increasingly important technique for unravelling some of the problems of dose equivalent measurements and for plasma diagnostics in fusion research. However, this topic is at least one step removed from primary metrology and so it was felt that it should not be

  19. Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model.

    PubMed

    Andoh, Tooru; Fujimoto, Takuya; Sudo, Tamotsu; Suzuki, Minoru; Sakurai, Yoshinori; Sakuma, Toshiko; Moritake, Hiroshi; Sugimoto, Tohru; Takeuchi, Tamotsu; Sonobe, Hiroshi; Epstein, Alan L; Fukumori, Yoshinobu; Ono, Koji; Ichikawa, Hideki

    2014-06-01

    Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In our previous study, the tumor disappeared under boron neutron capture therapy (BNCT) on subcutaneously-transplanted CCS-bearing animals. In the present study, the tumor disappeared under this therapy on model mice intramuscularly implanted with three different human CCS cells. BNCT led to the suppression of tumor-growth in each of the different model mice, suggesting its potentiality as an alternative to, or integrative option for, the treatment of CCS.

  20. Technical aspects of boron neutron capture therapy at the BNL Medical Research Reactor

    SciTech Connect

    Holden, N.E.; Rorer, D.C.; Patti, F.J.; Liu, H.B.; Reciniello, R.; Chanana, A.D.

    1997-07-01

    The Brookhaven Medical Research Reactor, BMRR, is a 3 MW heterogeneous, tank-type, light water cooled and moderated, graphite reflected reactor, which was designed for biomedical studies. Early BNL work in Boron Neutron Capture Therapy (BNCT) used a beam of thermal neutrons for experimental treatment of brain tumors. Research elsewhere and at BNL indicated that higher energy neutrons would be required to treat deep seated brain tumors. Epithermal neutrons would be thermalized as they penetrated the brain and peak thermal neutron flux densities would occur at the depth of brain tumors. One of the two BMRR thermal port shutters was modified in 1988 to include plates of aluminum and aluminum oxide to provide an epithermal port. Lithium carbonate in polyethylene was added in 1991 around the bismuth port to reduce the neutron flux density coming from outside the port. To enhance the epithermal neutron flux density, the two vertical thimbles A-3 (core edge) and E-3 (in core) were replaced with fuel elements. There are now four fuel elements of 190 grams each and 28 fuel elements of 140 grams each for a total of 4.68 kg of {sup 235}U in the core. The authors have proposed replacing the epithermal shutter with a fission converter plate shutter. It is estimated that the new shutter would increase the epithermal neutron flux density by a factor of seven and the epithermal/fast neutron ratio by a factor of two. The modifications made to the BMRR in the past few years permit BNCT for brain tumors without the need to reflect scalp and bone flaps. Radiation workers are monitored via a TLD badge and a self-reading dosimeter during each experiment. An early concern was raised about whether workers would be subject to a significant dose rate from working with patients who have been irradiated. The gamma ray doses for the representative key personnel involved in the care of the first 12 patients receiving BNCT are listed. These workers did not receive unusually high exposures.

  1. Boron neutron capture therapy of brain tumors: past history, current status, and future potential.

    PubMed

    Barth, R F; Soloway, A H; Brugger, R M

    1996-01-01

    Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield alpha particles and recoiling lithium-7 nuclei. High-grade astrocytomas, glioblastoma multiforme, and metastatic brain tumors constitute a major group of neoplasms for which there is no effective treatment. There is growing interest in using BNCT in combination with surgery to treat patients with primary, and possibly metastatic brain tumors. For BNCT to be successful, a large number of 10B atoms must be localized on or preferably within neoplastic cells, and a sufficient number of thermal neutrons must reach and be absorbed by the 10B atoms to sustain a lethal 10B(n, alpha)7 Li reaction. Two major questions will be addressed in this review. First, how can a large number of 10B atoms be delivered selectively to cancer cells? Second, how can a high fluence of neutrons be delivered to the tumor? Two boron compounds currently are being used clinically, sodium borocaptate (BSH) and boronophenylalanine (BPA), and a number of new delivery agents are under investigation, including boronated porphyrins, nucleosides, amino acids, polyamines, monoclonal and bispecific antibodies, liposomes, and epidermal growth factor. These will be discussed, and potential problems associated with their use as boron delivery agents will be considered. Nuclear reactors, currently, are the only source of neutrons for BNCT, and the fission process within the core produces a mixture of lower-energy thermal and epithermal neutrons, fast or high (> 10,000 eV) energy neutrons, and gamma rays. Although thermal neutron beams have been used clinically in Japan to treat patients with brain tumors and cutaneous melanomas, epithermal neutron beams should be more useful because of their superior tissue-penetrating properties. Beam sources and characteristics will be discussed in the context of current and future BNCT trials. Finally, the past and present

  2. DNA damage induced by boron neutron capture therapy is partially repaired by DNA ligase IV.

    PubMed

    Kondo, Natsuko; Sakurai, Yoshinori; Hirota, Yuki; Tanaka, Hiroki; Watanabe, Tsubasa; Nakagawa, Yosuke; Narabayashi, Masaru; Kinashi, Yuko; Miyatake, Shin-ichi; Hasegawa, Masatoshi; Suzuki, Minoru; Masunaga, Shin-ichiro; Ohnishi, Takeo; Ono, Koji

    2016-03-01

    Boron neutron capture therapy (BNCT) is a particle radiation therapy that involves the use of a thermal or epithermal neutron beam in combination with a boron ((10)B)-containing compound that specifically accumulates in tumor. (10)B captures neutrons and the resultant fission reaction produces an alpha ((4)He) particle and a recoiled lithium nucleus ((7)Li). These particles have the characteristics of high linear energy transfer (LET) radiation and therefore have marked biological effects. High-LET radiation is a potent inducer of DNA damage, specifically of DNA double-strand breaks (DSBs). The aim of the present study was to clarify the role of DNA ligase IV, a key player in the non-homologous end-joining repair pathway, in the repair of BNCT-induced DSBs. We analyzed the cellular sensitivity of the mouse embryonic fibroblast cell lines Lig4-/- p53-/- and Lig4+/+ p53-/- to irradiation using a thermal neutron beam in the presence or absence of (10)B-para-boronophenylalanine (BPA). The Lig4-/- p53-/- cell line had a higher sensitivity than the Lig4+/+ p53-/-cell line to irradiation with the beam alone or the beam in combination with BPA. In BNCT (with BPA), both cell lines exhibited a reduction of the 50 % survival dose (D 50) by a factor of 1.4 compared with gamma-ray and neutron mixed beam (without BPA). Although it was found that (10)B uptake was higher in the Lig4+/+ p53-/- than in the Lig4-/- p53-/- cell line, the latter showed higher sensitivity than the former, even when compared at an equivalent (10)B concentration. These results indicate that BNCT-induced DNA damage is partially repaired using DNA ligase IV.

  3. High energy from space

    NASA Technical Reports Server (NTRS)

    Margon, Bruce; Canizares, Claude; Catura, Richard C.; Clark, George W.; Fichtel, Carl E.; Friedman, Herbert; Giacconi, Riccardo; Grindlay, Jonathan E.; Helfand, David J.; Holt, Stephen S.

    1991-01-01

    The following subject areas are covered: (1) important scientific problems for high energy astrophysics (stellar activity, the interstellar medium in galaxies, supernovae and endpoints of stellar evolution, nucleosynthesis, relativistic plasmas and matter under extreme conditions, nature of gamma-bursts, identification of black holes, active nuclei, accretion physics, large-scale structures, intracluster medium, nature of dark matter, and the X- and gamma-ray background); (2) the existing experimental programs (Advanced X-Ray Astrophysics Facility (AXAF), Gamma Ray Observatory (GRO), X-Ray Timing Explorer (XTE), High Energy Transient Experiment (HETE), U.S. participation in foreign missions, and attached Shuttle and Space Station Freedom payloads); (3) major missions for the 1990's; (4) a new program of moderate missions; (5) new opportunities for small missions; (6) technology development issues; and (7) policy issues.

  4. High energy transients

    NASA Technical Reports Server (NTRS)

    Woosley, S. E.

    1984-01-01

    A meeting was convened on the campus of the University of California at Santa Cruz during the two-week interval July 11 through July 22, 1983. Roughly 100 participants were chosen so as to give broad representation to all aspects of high energy transients. Ten morning review sessions were held in which invited speakers discussed the current status of observations and theory of the above subjects. Afternoon workshops were also held, usually more than one per day, to informally review various technical aspects of transients, confront shortcomings in theoretical models, and to propose productive courses for future research. Special attention was also given to the instrumentation used to study high energy transient and the characteristics and goals of a dedicated space mission to study transients in the next decade were determined. A listing of articles written by various members of the workshop is included.

  5. High energy beam lines

    NASA Astrophysics Data System (ADS)

    Marchetto, M.; Laxdal, R. E.

    2014-01-01

    The ISAC post accelerator comprises an RFQ, DTL and SC-linac. The high energy beam lines connect the linear accelerators as well as deliver the accelerated beams to two different experimental areas. The medium energy beam transport (MEBT) line connects the RFQ to the DTL. The high energy beam transport (HEBT) line connects the DTL to the ISAC-I experimental stations (DRAGON, TUDA-I, GPS). The DTL to superconducting beam (DSB) transport line connects the ISAC-I and ISAC-II linacs. The superconducting energy beam transport (SEBT) line connects the SC linac to the ISAC-II experimental station (TUDA-II, HERACLES, TIGRESS, EMMA and GPS). All these lines have the function of transporting and matching the beams to the downstream sections by manipulating the transverse and longitudinal phase space. They also contain diagnostic devices to measure the beam properties.

  6. Neutron capture therapy (NCT) enhancement of fast neutron radiotherapy: Application to non-small cell lung cancer

    NASA Astrophysics Data System (ADS)

    Laramore, G. E.; Stelzer, K. J.; Risler, R.; Schwartz, J. L.; Douglas, J. J.; Einck, J. P.; Nigg, D. W.; Wemple, C. A.; Hartwell, J. K.; Harker, Y. D.; Gavin, P. R.; Hawthorne, M. F.

    2001-07-01

    Fast neutron radiotherapy utilizes neutrons in the energy range of several millions to several tens of millions of eV to treat human malignancies. These fast neutron beams produce a small cloud of "slow" neutrons as they penetrate the body. If one can selectively attach isotopes having large neutron capture cross sections (such as 10B) to cancer cells, these "slow" neutrons can be used to enhance the killing of tumors. We describe a multidisciplinary effort to apply this technique to the treatment of patients with inoperable, non-small cell lung cancers. Problems in target design, compound development, beam optimization, and radiobiological experiments are discussed.

  7. Compact multileaf collimator for conformal and intensity modulated fast neutron therapy: Electromechanical design and validation

    SciTech Connect

    Farr, J. B.; Maughan, R. L.; Yudelev, M.; Blosser, E.; Brandon, J.; Horste, T.; Forman, J. D.

    2006-09-15

    The electromechanical properties of a 120-leaf, high-resolution, computer-controlled, fast neutron multileaf collimator (MLC) are presented. The MLC replaces an aging, manually operated multirod collimator. The MLC leaves project 5 mm in the isocentric plane perpendicular to the beam axis. A taper is included on the leaves matching beam divergence along one axis. The 5-mm leaf projection width is chosen to give high-resolution conformality across the entire field. The maximum field size provided is 30x30 cm{sup 2}. To reduce the interleaf transmission a 0.254-mm blocking step is included. End-leaf steps totaling 0.762 mm are also provided allowing opposing leaves to close off within the primary radiation beam. The neutron MLC also includes individual 45 deg. and 60 deg. automated universal tungsten wedges. The automated high-resolution neutron collimation provides an increase in patient throughput capacity, enables a new modality, intensity modulated neutron therapy, and limits occupational radiation exposure by providing remote operation from a shielded console area.

  8. Neutron dose in and out of 18MV photon fields.

    PubMed

    Ezzati, A O; Studenski, M T

    2017-04-01

    In radiation therapy, neutron contamination is an undesirable side effect of using high energy photons to treat patients. Neutron contamination requires adjustments to the shielding requirements of the linear accelerator vault and contributes to the risk of secondary malignancies in patients by delivering dose outside of the primary treatment field. Using MCNPX, an established Monte Carlo code, manufacturer blueprints, and the most up to date ICRP neutron dose conversion factors, the neutron spectra, neutron/photon dose ratio, and the neutron capture gamma ray dose were calculated at different depths and off axis distances in a tissue equivalent phantom. Results demonstrated that the neutron spectra and dose are dependent on field size, depth in the phantom, and off-axis distance. Simulations showed that because of the low neutron absorption cross section of the linear accelerator head materials, the contribution to overall patient dose from neutrons can be up to 1000 times the photon dose out of the treatment field and is also dependent on field size and depth. Beyond 45cm off-axis, the dependence of the neutron dose on field size is minimal. Neutron capture gamma ray dose is also field size dependent and is at a maximum at a depth of about 7cm. It is important to remember that when treating with high energy photons, the dose from contamination neutrons must be considered as it is much greater than the photon dose.

  9. D-T neutron generator development for cancer therapy. 1980 annual progress report

    SciTech Connect

    Bacon, F.M.; Walko, R.J.; Bickes, R.W. Jr.; Cowgill, D.F.; Riedel, A.A.; O'Hagan, J.B.

    1980-05-01

    This report summarizes the work completed during the first year of a two-year grant by NCI/HEW to investigate the feasibility of developing a D-T neutron generator for use in cancer therapy. Experiments have continued on the Target Test Facility (TTF) developed during a previous grant to investigate high-temperature metal hydrides for use as target materials. The high voltage reliability of the TTF has been improved so that 200 kV, 200 mA operation is now routine. In recent target tests, the D-D neutron production rate was measured to be > 1 x 10/sup 11//s, a rate that corresponds to a D-T neutron production rate of > 1 x 10/sup 13//s - the desired rate for use in cancer therapy. Deuterium concentration depth profiles in the target, measured during intense ion beam bombardment, show that deuterium is depleted near the surface of the target due to impurities implanted by the ion beam. Recent modifications of the duopigatron ion source to reduce secondary electron damage to the electrodes also improved the ion source efficiency by about 40%. An ultra high vacuum version of the TTF is now being constructed to determine if improved vacuum conditions will reduce ion source impurities to a sufficiently low level that the deuterium near the surface of the target is not depleted. Testing will begin in June 1980.

  10. Theoretical High Energy Physics

    SciTech Connect

    Christ, Norman H.; Weinberg, Erick J.

    2014-07-14

    we provide reports from each of the six faculty supported by the Department of Energy High Energy Physics Theory grant at Columbia University. Each is followed by a bibliography of the references cited. A complete list of all of the publications in the 12/1/2010-04/30/2014 period resulting from research supported by this grant is provided in the following section. The final section lists the Ph.D. dissertations based on research supported by the grant that were submitted during this period.

  11. High energy electron cooling

    SciTech Connect

    Parkhomchuk, V.

    1997-09-01

    High energy electron cooling requires a very cold electron beam. The questions of using electron cooling with and without a magnetic field are presented for discussion at this workshop. The electron cooling method was suggested by G. Budker in the middle sixties. The original idea of the electron cooling was published in 1966. The design activities for the NAP-M project was started in November 1971 and the first run using a proton beam occurred in September 1973. The first experiment with both electron and proton beams was started in May 1974. In this experiment good result was achieved very close to theoretical prediction for a usual two component plasma heat exchange.

  12. SU-E-T-21: A D-D Based Neutron Generator System for Boron Neutron Capture Therapy: A Feasibility Study

    SciTech Connect

    Hsieh, M; Liu, Y; Nie, L

    2015-06-15

    Purpose: To investigate the feasibility of a deuterium-deuterium (DD) neutron generator for application in boron neutron capture therapy (BNCT) of brain cancer Methods: MCNP simulations were performed using a head phantom and a monoenergetic neutron source, which resembles the point source in a DD generator that emits 2.45-MeV neutrons. Source energies ranging from 5eV to 2.45MeV were simulated to determine the optimal treatment energy. The phantom consisted of soft tissue, brain tissue, skull, skin layer, and a brain tumor of 5 cm in diameter. Tumor depth was varied from 5–10 cm. Boron-10 concentrations of 10 ppm, 15 ppm, and 30 ppm were used in the soft/brain tissues, skin, and tumor, respectively. The neutron flux required to deliver 60 Gy to the tumor as well as the normal tissue doses were determined. Results: Beam energies between 5eV and 10keV obtained doses with the highest dose ratios (3.3–25.9) between the tumor and the brain at various depths. The dose ratio with 2.45-MeV neutrons ranged from 0.8–6.6. To achieve the desired tumor dose in 40 minutes, the required neutron flux for a DD generator was between 8.8E10 and 5.2E11 n/s and the resulting brain dose was between 2.3 and 18 Gy, depending on the tumor depth. The skin and soft tissue doses were within acceptable tolerances. The boron-neutron interaction accounted for 54–58% of the total dose. Conclusion: This study shows that the DD neutron generator can be a feasible neutron source for BNCT. The required neutron flux for treatment is achievable with the current DD neutron technology. With a well-designed beam shaping assembly and treatment geometry, the neutron flux can be further improved and a 60-Gy prescription can be accurately delivered to the target while maintaining tolerable normal tissue doses. Further experimental studies will be developed and conducted to validate the simulation results.

  13. Radiation dose measurements and Monte Carlo calculations for neutron and photon reactions in a human head phantom for accelerator-based boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Kim, Don-Soo

    Dose measurements and radiation transport calculations were investigated for the interactions within the human brain of fast neutrons, slow neutrons, thermal neutrons, and photons associated with accelerator-based boron neutron capture therapy (ABNCT). To estimate the overall dose to the human brain, it is necessary to distinguish the doses from the different radiation sources. Using organic scintillators, human head phantom and detector assemblies were designed, constructed, and tested to determine the most appropriate dose estimation system to discriminate dose due to the different radiation sources that will ultimately be incorporated into a human head phantom to be used for dose measurements in ABNCT. Monoenergetic and continuous energy neutrons were generated via the 7Li(p,n)7Be reaction in a metallic lithium target near the reaction threshold using the 5.5 MV Van de Graaff accelerator at the University of Massachusetts Lowell. A human head phantom was built to measure and to distinguish the doses which result from proton recoils induced by fast neutrons, alpha particles and recoil lithium nuclei from the 10B(n,alpha)7Li reaction, and photons generated in the 7Li accelerator target as well as those generated inside the head phantom through various nuclear reactions at the same time during neutron irradiation procedures. The phantom consists of two main parts to estimate dose to tumor and dose to healthy tissue as well: a 3.22 cm3 boron loaded plastic scintillator which simulates a boron containing tumor inside the brain and a 2664 cm3 cylindrical liquid scintillator which represents the surrounding healthy tissue in the head. The Monte Carlo code MCNPX(TM) was used for the simulation of radiation transport due to neutrons and photons and extended to investigate the effects of neutrons and other radiation on the brain at various depths.

  14. Boron analysis for neutron capture therapy using particle-induced gamma-ray emission.

    PubMed

    Nakai, Kei; Yamamoto, Yohei; Okamoto, Emiko; Yamamoto, Tetsuya; Yoshida, Fumiyo; Matsumura, Akira; Yamada, Naoto; Kitamura, Akane; Koka, Masashi; Satoh, Takahiro

    2015-12-01

    The neutron source of BNCT is currently changing from reactor to accelerator, but peripheral facilities such as a dose-planning system and blood boron analysis have still not been established. To evaluate the potential application of particle-induced gamma-ray emission (PIGE) for boron measurement in clinical boron neutron capture therapy, boronophenylalanine dissolved within a cell culture medium was measured using PIGE. PIGE detected 18 μgB/mL f-BPA in the culture medium, and all measurements of any given sample were taken within 20 min. Two hours of f-BPA exposure was required to create a boron distribution image. However, even though boron remained in the cells, the boron on the cell membrane could not be distinguished from the boron in the cytoplasm.

  15. [Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy].

    PubMed

    Nakamura, Hiroyuki

    2013-01-01

      High accumulation and selective delivery of boron into tumor tissue are the most important requirements to achieve the efficient cell-killing effect of boron neutron capture therapy (BNCT) that relies on the nuclear reaction of two essentially nontoxic species, boron-10 ((10)B) and thermal neutrons in boron-loaded tissues. Recent development of boron cluster lipids and their liposomal boron delivery system (BDS) are summarized in this article. Boron compounds that have no affinity to tumor can potentially be delivered to tumor tissues by liposomes, therefore, liposomal BDS would be one of the most attractive approaches for efficient BNCT of various cancers. There are two approaches for BDS: encapsulation of boron compounds into liposomes and incorporation of boron-conjugated lipids into the liposomal bilayer. The combination of both approaches has a potential for reduction of the total dose of liposomes without reducing the efficacy of BNCT.

  16. Numerical characterization of a tomographic system for online dose measurements in Boron Neutron Capture Therapy

    SciTech Connect

    Minsky, D. M.; Valda, A. A.; Somacal, H.; Burlon, A. A.; Kreiner, A. J.

    2007-02-12

    A tomographic system for online dose measurements in Boron Neutron Capture Therapy (BNCT) based on the measurement of a specific 478 keV {gamma}-ray emitted after the neutron capture in boron is being developed. In the present work we study by means of Monte Carlo numerical simulations the effects of the finite spatial resolution and the limited number of counts, i. e. the statistical noise, on the reconstructed image contrast of numerical phantoms. These phantoms, of simple geometry, mimic the tumor (specific) and the normal tissue (non specific) boron concentrations. The simulated projection data were reconstructed using the expectation-maximization maximum-likelihood algorithm. These studies will help in the improvement of BNCT dosimetry.

  17. Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden.

    PubMed

    Capala, Jacek; Stenstam, Britta H; Sköld, Kurt; Munck af Rosenschöld, Per; Giusti, Valerio; Persson, Charlotta; Wallin, Eva; Brun, Arne; Franzen, Lars; Carlsson, Jörgen; Salford, Leif; Ceberg, Crister; Persson, Bertil; Pellettieri, Luigi; Henriksson, Roger

    2003-01-01

    A boron neutron capture therapy (BNCT) facility has been constructed at Studsvik, Sweden. It includes two filter/moderator configurations. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range. The other beam has been designed to produce a large uniform field of thermal neutrons for radiobiological research. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia. The clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, presently, involve a protocol for BNCT treatment of glioblastoma patients who have not received any therapy other than surgery. In this protocol, p-boronophenylalanine (BPA), administered as a 6-h intravenous infusion, is used as the boron delivery agent. As of January 2002, 17 patients were treated. The 6-h infusion of 900 mg BPA/kg body weight was shown to be safe and resulted in the average blood-boron concentration of 24 microg/g (range: 15-32 microg/g) at the time of irradiation (approximately 2-3 h post-infusion). Peak and average weighted radiation doses to the brain were in the ranges of 8.0-15.5 Gy(W) and 3.3-6.1 Gy(W), respectively. So far, no severe BNCT-related acute toxicities have been observed. Due to the short follow-up time, it is too early to evaluate the efficacy of these studies.

  18. Monte Carlo and analytical model predictions of leakage neutron exposures from passively scattered proton therapy

    SciTech Connect

    Pérez-Andújar, Angélica; Zhang, Rui; Newhauser, Wayne

    2013-12-15

    Purpose: Stray neutron radiation is of concern after radiation therapy, especially in children, because of the high risk it might carry for secondary cancers. Several previous studies predicted the stray neutron exposure from proton therapy, mostly using Monte Carlo simulations. Promising attempts to develop analytical models have also been reported, but these were limited to only a few proton beam energies. The purpose of this study was to develop an analytical model to predict leakage neutron equivalent dose from passively scattered proton beams in the 100-250-MeV interval.Methods: To develop and validate the analytical model, the authors used values of equivalent dose per therapeutic absorbed dose (H/D) predicted with Monte Carlo simulations. The authors also characterized the behavior of the mean neutron radiation-weighting factor, w{sub R}, as a function of depth in a water phantom and distance from the beam central axis.Results: The simulated and analytical predictions agreed well. On average, the percentage difference between the analytical model and the Monte Carlo simulations was 10% for the energies and positions studied. The authors found that w{sub R} was highest at the shallowest depth and decreased with depth until around 10 cm, where it started to increase slowly with depth. This was consistent among all energies.Conclusion: Simple analytical methods are promising alternatives to complex and slow Monte Carlo simulations to predict H/D values. The authors' results also provide improved understanding of the behavior of w{sub R} which strongly depends on depth, but is nearly independent of lateral distance from the beam central axis.

  19. Radiation transport requirements for clinical applications of neutron capture therapy: The rtt-MC Monte Carlo module

    SciTech Connect

    Wheeler, F.J.; Wessol, D.E.

    1995-12-31

    The rtt-MC dose calculation module of the BNCT-Rtpe treatment planning system has been developed specifically for boron neutron cancer therapy. Due to the complicated nature of combined gamma, fast-, epithermal- and thermal-energy neutron transport in tissue, all approaches to treatment planning to date for this treatment modality rely on Monte Carlo or three-dimensional discrete ordinates methods. Simple, fast and accurate methods for this modality have simply not been developed. In this paper the authors discuss some of the unique attributes of this therapy and the approaches they have used to begin to merge into clinical applications. As this paper is under draft, the modern implementation of boron neutron cancer therapy in the US is being realized. Research of skin and tumor effect for superficial melanoma of the extremities has been initiated at the Massachusetts Institute of Technology and brain cancer therapy (using this planning system) has begun at Brookhaven National Laboratory.

  20. A coupled deterministic/stochastic method for computing neutron capture therapy dose rates

    NASA Astrophysics Data System (ADS)

    Hubbard, Thomas Richard

    Neutron capture therapy (NCT) is an experimental method of treating brain tumors and other cancers by: (1) injecting or infusing the patient with a tumor-seeking, neutron target-labeled drug; and (2) irradiating the patient in an intense epithermal neutron fluence. The nuclear reaction between the neutrons and the target nuclei (e.g. sp{10}B(n,alpha)sp7Lirbrack releases energy in the form of high-LET (i.e. energy deposited within the range of a cell diameter) reaction particles which selectively kill the tumor cell. The efficacy of NCT is partly dependent on the delivery of maximum thermal neutron fluence to the tumor and the minimization of radiation dose to healthy tissue. Since the filtered neutron source (e.g. research reactor) usually provides a broad energy spectrum of highly-penetrating neutron and gamma-photon radiation, detailed transport calculations are necessary in order to plan treatments that use optimal treatment facility configurations and patient positioning. Current computational methods for NCT use either discrete ordinates calculation or, more often, Monte Carlo simulation to predict neutron fluences in the vicinity of the tumor. These methods do not, however, accurately calculate the transport of radiation throughout the entire facility or the deposition of dose in all the various parts of the body due to shortcomings of using either method alone. A computational method, specifically designed for NCT problems, has been adapted from the MASH methodology and couples a forward discrete ordinates (Ssb{n}) calculation with an adjoint Monte Carlo run to predict the dose at any point within the patient. The transport from the source through the filter/collimator is performed with a forward DORT run, and this is then coupled to adjoint MORSE results at a selected coupling parallelepiped which surrounds human phantom. Another routine was written to allow the user to generate the MORSE models at various angles and positions within the treatment room. The

  1. Introduction to High-Energy Astrophysics

    NASA Astrophysics Data System (ADS)

    Rosswog, Stephan; Bruggen, Marcus

    2003-04-01

    High-energy astrophysics covers cosmic phenomena that occur under the most extreme physical conditions. It explores the most violent events in the Universe: the explosion of stars, matter falling into black holes, and gamma-ray bursts - the most luminous explosions since the Big Bang. Driven by a wealth of new observations, the last decade has seen a large leap forward in our understanding of these phenomena. Exploring modern topics of high-energy astrophysics, such as supernovae, neutron stars, compact binary systems, gamma-ray bursts, and active galactic nuclei, this textbook is ideal for undergraduate students in high-energy astrophysics. It is a self-supporting, timely overview of this exciting field of research. Assuming a familiarity with basic physics, it introduces all other concepts, such as gas dynamics or radiation processes, in an instructive way. An extended appendix gives an overview of some of the most important high-energy astrophysics instruments, and each chapter ends with exercises.• New, up-to-date, introductory textbook providing a broad overview of high-energy phenomena and the many advances in our knowledge gained over the last decade • Written especially for undergraduate teaching use, it introduces the necessary physics and includes many exercises • This book fills a valuable niche at the advanced undergraduate level, providing professors with a new modern introduction to the subject

  2. Clinical application of in vivo treatment delivery verification based on PET/CT imaging of positron activity induced at high energy photon therapy

    NASA Astrophysics Data System (ADS)

    Janek Strååt, Sara; Andreassen, Björn; Jonsson, Cathrine; Noz, Marilyn E.; Maguire, Gerald Q., Jr.; Näfstadius, Peder; Näslund, Ingemar; Schoenahl, Frederic; Brahme, Anders

    2013-08-01

    The purpose of this study was to investigate in vivo verification of radiation treatment with high energy photon beams using PET/CT to image the induced positron activity. The measurements of the positron activation induced in a preoperative rectal cancer patient and a prostate cancer patient following 50 MV photon treatments are presented. A total dose of 5 and 8 Gy, respectively, were delivered to the tumors. Imaging was performed with a 64-slice PET/CT scanner for 30 min, starting 7 min after the end of the treatment. The CT volume from the PET/CT and the treatment planning CT were coregistered by matching anatomical reference points in the patient. The treatment delivery was imaged in vivo based on the distribution of the induced positron emitters produced by photonuclear reactions in tissue mapped on to the associated dose distribution of the treatment plan. The results showed that spatial distribution of induced activity in both patients agreed well with the delivered beam portals of the treatment plans in the entrance subcutaneous fat regions but less so in blood and oxygen rich soft tissues. For the preoperative rectal cancer patient however, a 2 ± (0.5) cm misalignment was observed in the cranial-caudal direction of the patient between the induced activity distribution and treatment plan, indicating a beam patient setup error. No misalignment of this kind was seen in the prostate cancer patient. However, due to a fast patient setup error in the PET/CT scanner a slight mis-position of the patient in the PET/CT was observed in all three planes, resulting in a deformed activity distribution compared to the treatment plan. The present study indicates that the induced positron emitters by high energy photon beams can be measured quite accurately using PET imaging of subcutaneous fat to allow portal verification of the delivered treatment beams. Measurement of the induced activity in the patient 7 min after receiving 5 Gy involved count rates which were about

  3. Prospects at high energies

    SciTech Connect

    Quigg, C.

    1988-11-01

    I discuss some possibilities for neutrino experiments in the fixed-target environment of the SPS, Tevatron, and UNK, with their primary proton beams of 0.4, 0.9, and 3.0 TeV. The emphasis is on unfinished business: issues that have been recognized for some time, but not yet resolved. Then I turn to prospects for proton-proton colliders to explore the 1-TeV scale. I review the motivation for new physics in the neighborhood of 1 TeV and mention some discovery possibilities for high-energy, high-luminosity hadron colliders and the implications they would have for neutrino physics. I raise the possibility of the direct study of neutrino interactions in hadron colliders. I close with a report on the status of the SSC project. 38 refs., 17 figs.

  4. Treatment of stage IIIB cervical cancer with Californium-252 fast-neutron brachytherapy and external photon therapy

    SciTech Connect

    Gallion, H.H.; Maruyama, Y.; van Nagell, J.R. Jr.; Donaldson, E.S.; Rowley, K.C.; Yoneda, J.; Beach, J.L.; Powell, D.E.; Kryscio, R.J.

    1987-05-15

    From January 1977 to July 1984, 32 patients with Stage IIIB cervical cancer were treated at the University of Kentucky Medical Center by a combination of outpatient neutron brachytherapy and external pelvic radiation. These patients received 4500 to 5000 rad external photon therapy and two or three outpatient Californium-252 (252Cf) implants, plus sidewall boost irradiation. Treatment results were compared retrospectively to those obtained in a historical control group of patients with Stage IIIB cervical cancer treated with external radiation and conventional photon brachytherapy from 1972 to 1976. Local or regional tumor recurrence developed in 53% of patients treated with neutron therapy and an additional 9% experienced distant metastases. Thirty-eight percent of patients remain free of disease 12 to 96 months (mean, 51 months) after therapy. The 2-year and 5-year survival rates of patients treated with neutron therapy were 53% and 36%, which were not significantly different than those obtained with photon brachytherapy (2-year survival, 61%; 5-year survival, 34%). Complications of neutron therapy were minimal and included proctitis (19%) and vaginal stenosis (9%). There were no cases of enteric fistulae. Outpatient neutron brachytherapy was cost effective and was well tolerated by patients.

  5. Treatment of stage IIIB cervical cancer with Californium-252 fast-neutron brachytherapy and external photon therapy.

    PubMed

    Gallion, H H; Maruyama, Y; van Nagell, J R; Donaldson, E S; Rowley, K C; Yoneda, J; Beach, J L; Powell, D E; Kryscio, R J

    1987-05-15

    From January 1977 to July 1984, 32 patients with Stage IIIB cervical cancer were treated at the University of Kentucky Medical Center by a combination of outpatient neutron brachytherapy and external pelvic radiation. These patients received 4500 to 5000 rad external photon therapy and two or three outpatient Californium-252 (252Cf) implants, plus sidewall boost irradiation. Treatment results were compared retrospectively to those obtained in a historical control group of patients with Stage IIIB cervical cancer treated with external radiation and conventional photon brachytherapy from 1972 to 1976. Local or regional tumor recurrence developed in 53% of patients treated with neutron therapy and an additional 9% experienced distant metastases. Thirty-eight percent of patients remain free of disease 12 to 96 months (mean, 51 months) after therapy. The 2-year and 5-year survival rates of patients treated with neutron therapy were 53% and 36%, which were not significantly different than those obtained with photon brachytherapy (2-year survival, 61%; 5-year survival, 34%). Complications of neutron therapy were minimal and included proctitis (19%) and vaginal stenosis (9%). There were no cases of enteric fistulae. Outpatient neutron brachytherapy was cost effective and was well tolerated by patients.

  6. Boron containing magnetic nanoparticles for neutron capture therapy--an innovative approach for specifically targeting tumors.

    PubMed

    Tietze, Rainer; Unterweger, Harald; Dürr, Stephan; Lyer, Stefan; Canella, Lea; Kudejova, Petra; Wagner, Franz M; Petry, Winfried; Taccardi, Nicola; Alexiou, Christoph

    2015-12-01

    The selective delivery of (10)B into the tumor tissue remains to be further improved for successful and reliable Boron Neutron Capture Therapy applications. Magnetic Drug Targeting using intraarterially administered superparamagnetic nanoparticles and external magnetic fields already exhibited convincing results in terms of highly efficient and selective drug deposition. Using the same technique for the targeted (10)B delivery is a promising new approach. Here, systematic irradiation experiments of phantom cubes containing different concentrations of boron and nanoparticles as well as varying three-dimensional arrangements have been performed.

  7. Tomographic image of prompt gamma ray from boron neutron capture therapy: A Monte Carlo simulation study

    SciTech Connect

    Yoon, Do-Kun; Jung, Joo-Young; Suk Suh, Tae; Jo Hong, Key

    2014-02-24

    Purpose of paper is to confirm the feasibility of acquisition of three dimensional single photon emission computed tomography image from boron neutron capture therapy using Monte Carlo simulation. Prompt gamma ray (478 keV) was used to reconstruct image with ordered subsets expectation maximization method. From analysis of receiver operating characteristic curve, area under curve values of three boron regions were 0.738, 0.623, and 0.817. The differences between length of centers of two boron regions and distance of maximum count points were 0.3 cm, 1.6 cm, and 1.4 cm.

  8. Drug delivery system design and development for boron neutron capture therapy on cancer treatment.

    PubMed

    Sherlock Huang, Lin-Chiang; Hsieh, Wen-Yuan; Chen, Jiun-Yu; Huang, Su-Chin; Chen, Jen-Kun; Hsu, Ming-Hua

    2014-06-01

    We have already synthesized a boron-containing polymeric micellar drug delivery system for boron neutron capture therapy (BNCT). The synthesized diblock copolymer, boron-terminated copolymers (Bpin-PLA-PEOz), consisted of biodegradable poly(D,l-lactide) (PLA) block and water-soluble polyelectrolyte poly(2-ethyl-2-oxazoline) (PEOz) block, and a cap of pinacol boronate ester (Bpin). In this study, we have demonstrated that synthesized Bpin-PLA-PEOz micelle has great potential to be boron drug delivery system with preliminary evaluation of biocompatibility and boron content.

  9. Dose estimation for internal organs during boron neutron capture therapy for body-trunk tumors.

    PubMed

    Sakurai, Y; Tanaka, H; Suzuki, M; Masunaga, S; Kinashi, Y; Kondo, N; Ono, K; Maruhashi, A

    2014-06-01

    Radiation doses during boron neutron capture therapy for body-trunk tumors were estimated for various internal organs, using data from patients treated at Kyoto University Research Reactor Institute. Dose-volume histograms were constructed for tissues of the lung, liver, kidney, pancreas, and bowel. For pleural mesothelioma, the target total dose to the normal lung tissues on the diseased side is 5Gy-Eq in average for the whole lung. It was confirmed that the dose to the liver should be carefully considered in cases of right lung disease.

  10. The formulation of polyhedral boranes for the boron neutron capture therapy of cancer.

    PubMed

    Calabrese, Gianpiero; Nesnas, John J; Barbu, Eugen; Fatouros, Dimitris; Tsibouklis, John

    2012-02-01

    The early promise of boron neutron capture therapy as a method for the treatment of cancer has been inhibited by the inherent toxicity associated with therapeutically useful doses of ¹⁰B-containing pharmacophores, the need for target-tissue specificity and the challenges imposed by biological barriers. Although developments in the synthetic chemistry of polyhedral boranes have addressed issues of toxicity to a considerable extent, the optimisation of the transport and the delivery of boronated agents to the site of action--the subject of this review--is a challenge that is addressed by the development of innovative formulation strategies.

  11. Single step synthesis of nanostructured boron nitride for boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Singh, Bikramjeet; Singh, Paviter; Kumar, Manjeet; Thakur, Anup; Kumar, Akshay

    2015-05-01

    Nanostructured Boron Nitride (BN) has been successfully synthesized by carbo-thermic reduction of Boric Acid (H3BO3). This method is a relatively low temperature synthesis route and it can be used for large scale production of nanostructured BN. The synthesized nanoparticles have been characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM) and differential thermal analyzer (DTA). XRD analysis confirmed the formation of single phase nanostructured Boron Nitride. SEM analysis showed that the particles are spherical in shape. DTA analysis showed that the phase is stable upto 900 °C and the material can be used for high temperature applications as well boron neutron capture therapy (BNCT).

  12. [Thymus endocrine function and the immune system indices of cancer patients after neutron and gamma therapy].

    PubMed

    Grinevich, Iu A; Martynenko, S V; Baraboĭ, V A; Monich, A Iu; Tolstopiatov, B A; Konovalenko, V F; Protsyk, V S

    1992-01-01

    Patients with head and neck and locomotor system tumors received neutron therapy in the total doses of 4-8 and 12-14 Gy which was followed by a pronounced dose-dependent decrease in the serum thymus factor and total blood-lymphocyte levels. The latter changes were predominantly due to a decrease in the non-T-non-B cell concentration. Following the treatment, a rise in the level of circulating immune complexes and those of IgA and IgG was observed. Changes in the immune system proved less apparent in patients with locomotor system cancer who had been given 20 Gy of gamma-ray radiation.

  13. Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST).

    PubMed

    Fujimoto, Takuya; Andoh, Tooru; Sudo, Tamotsu; Fujita, Ikuo; Fukase, Naomasa; Takeuchi, Tamotsu; Sonobe, Hiroshi; Inoue, Masayoshi; Hirose, Tkanori; Sakuma, Toshiko; Moritake, Hiroshi; Sugimoto, Tohru; Kawamoto, Teruya; Fukumori, Yoshinobu; Yamamoto, Satomi; Atagi, Shinji; Sakurai, Yoshinori; Kurosaka, Masahiro; Ono, Koji; Ichikawa, Hideki; Suzuki, Minoru

    2015-12-01

    Malignant peripheral nerve sheath tumors (MPNST) are relatively rare neoplasms with poor prognosis. At present there is no effective treatment for MPNST other than surgical resection. Nonetheless, the anti-tumor effect of boron neutron capture therapy (BNCT) was recently demonstrated in two patients with MPNST. Subsequently, tumor-bearing nude mice subcutaneously transplanted with a human MPNST cell line were injected with p-borono-L-phenylalanine (L-BPA) and subjected to BNCT. Pathological studies then revealed that the MPNST cells were selectively destroyed by BNCT.

  14. Influence of Neutron Sources and 10B Concentration on Boron Neutron Capture Therapy for Shallow and Deeper Non-small Cell Lung Cancer.

    PubMed

    Yu, Haiyan; Tang, Xiaobin; Shu, Diyun; Liu, Yuanhao; Geng, Changran; Gong, Chunhui; Hang, Shuang; Chen, Da

    2017-03-01

    Boron Neutron Capture Therapy (BNCT) is a radiotherapy that combines biological targeting and high Linear Energy Transfer (LET). It is considered a potential therapeutic approach for non-small cell lung cancer (NSCLC). It could avoid the inaccurate treatment caused by the lung motion during radiotherapy, because the dose deposition mainly depends on the boron localization and neutron source. Thus, B concentration and neutron sources are both principal factors of BNCT, and they play significant roles in the curative effect of BNCT for different cases. The purpose was to explore the feasibility of BNCT treatment for NSCLC with either of two neutron sources (the epithermal reactor at the Massachusetts Institute of Technology named "MIT source" and the accelerator neutron source designed in Argentina named "MEC source") and various boron concentrations. Shallow and deeper lung tumors were defined in the Chinese hybrid radiation phantom, and the Monte Carlo method was used to calculate the dose to tumors and healthy organs. The MEC source was more appropriate to treat the shallow tumor (depth of 6 cm) with a shorter treatment time. However, the MIT source was more suitable for deep lung tumor (depth of 9 cm) treatment, as the MEC source is more likely to exceed the skin dose limit. Thus, a neutron source consisting of more fast neutrons is not necessarily suitable for deep treatment of lung tumors. Theoretical distribution of B in tumors and organs at risk (especially skin) was obtained to meet the treatable requirement of BNCT, which may provide the references to identify the feasibility of BNCT for the treatment of lung cancer using these two neutron sources in future clinical applications.

  15. Therapy and treatment with a high-energy laser in case of a periodontal disease treatment instead of physiotherapy or low-level laser treatment

    NASA Astrophysics Data System (ADS)

    Buerger, Friedhelm R.

    1996-12-01

    Since intensive efforts ofprophylaxis including fluoridisation, better oral hygiene, eating ofless sugar containing foods, reduced the risk ofcaries and the problems ofcaries lesions significantly. But, especially beginning at the age of3O years more than 80 % ofthe population in almost every nation shows signs of periodontal defects. This you can call an epidemic disease. Because people get older and expect a lot concerning their outlook, their esthetic, their phonetic, they have great expectations towards their natural dentition and keep their own teeth. This is a great challenge to periodontal prophylaxis and periodontal therapy. According to the progress ofthe disease different therapies are indicated. Starting with oral hygiene instructions to establish better oral hygiene with all the modem technologies ofmicrobiological investigations, pharmaceutical therapy, physiotherapy, low level laser treatment, periodontal-surgery, like curettage, deepscaling and rootplaning but also more sophisticated teatmentplans with gingivoplasty, gingivectomy, flap-procedures and mucogingival surgeiy including bone fillings, regenerativ technics the whole spectrum oftreatment options has widely expanded during the last years.

  16. Performance of a New Composite Single-Crystal Filtered Thermal Neutron Beam for Neutron Capture Therapy Research at the University of Missouri

    SciTech Connect

    John D. Brockman; David W. Nigg; M. Frederick Hawthorne; Charles McKibben

    2008-11-01

    The University of Missouri (MU) Institute for Nano and Molecular Medicine, the Idaho National Laboratory (INL) and the University of Missouri Research Reactor (MURR) have undertaken a new collaborative research initiative to further the development of improved boron delivery agents for BNCT. The first step of this effort has involved the design and construction of a new thermal neutron beam irradiation facility for cell and small-animal radiobological research at the MURR. In this paper we present the beamline design with the results of pertinent neutronic design calculations. Results of neutronic performance measurements, initiated in February 2008, will also be available for inclusion in the final paper. The new beam will be located in an existing 152.4 mm (6’) diameter MURR beam tube extending from the core to the right in Figure 1. The neutron beam that emanates from the berylium reflector around the reactor is filtered with single-crystal silicon and single-crystal bismuth segments to remove high energy, fission spectrum neutrons and reactor gamma ray contamination. The irradiation chamber is downstream of the bismuth filter section, and approximately 3.95 m from the central axis of the reactor. There is sufficient neutron flux available from the MURR at its rated power of 10 MW to avoid the need for cryogenic cooling of the crystals. The MURR operates on average 150 hours per week, 52 weeks a year. In order to take advantage of 7800 hours of operation time per year the small animal BNCT facility will incorparate a shutter constucuted of boral, lead, steel and polyethylene that will allow experimenters to access the irradiation chamber a few minutes after irradiation. Independent deterministic and stochastic models of the coupled reactor core and beamline were developed using the DORT two-dimensional radiation transport code and the MCNP-5 Monte Carlo code, respectively. The BUGLE-80 47-neutron, 20-gamma group cross section library was employed for the DORT

  17. On achieving a clinically useful D-T neutron isocentric therapy system

    SciTech Connect

    Hilton, J.L.; Hendry, G.O.

    1981-04-01

    The Cyclotron Corporation's Model 4100 Neutron Cancer Therapy System with its output of 8 x 10/sup 12/ (14 MeV) neutron/sec designed for 500 hours is made up of: a factory recyclable miniature 200 kV sealed tube which radially accelerates up to 450 mA of deuterium and tritium ions from four duoplasmatron-type ion sources onto a central target; hand changeable radiation collimators; boronated hydrogenous shielding; isocentric gantry mounting; clinical diagnostics; and controls. The self-contained gas handling system which provides the needed differential gas pressure also stores, pumps, cleans, and recycles the D-T inventory. It is composed of a reversible getter high vacuum pump, a selective noble gas sputter ion pump, and a specialized uranium trap which, by controlled thermal decomposition of uranium hydride, regulates the ion source pressure. A D-T gas inventory of 3.7 k curies provides beam-on time of about three hours, while the gas recycle requires one to two hours. The four-sided target is made up from an array of heat transfer-optimized small copper tubes and their metal surface cladding which results in relatively high neutron output and long target life. The double vacuum walls, providing redundant tritium containment, are combined with other safety features.

  18. Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model

    SciTech Connect

    David W. Nigg

    2012-08-01

    Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA–BNCT, boronophenylalanine (BPA) ? neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA–BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks posttreatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA–BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mgfell significantly to 19 ± 16 mg for BPA–BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA–BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA– BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.

  19. Characterization of high-energy quasi-monoenergetic neutron energy spectra and ambient dose equivalents of 80-389 MeV 7Li(p,n) reactions using a time-of-flight method

    NASA Astrophysics Data System (ADS)

    Iwamoto, Yosuke; Hagiwara, Masayuki; Satoh, Daiki; Araki, Shouhei; Yashima, Hiroshi; Sato, Tatsuhiko; Masuda, Akihiko; Matsumoto, Tetsuro; Nakao, Noriaki; Shima, Tatsushi; Kin, Tadahiro; Watanabe, Yukinobu; Iwase, Hiroshi; Nakamura, Takashi

    2015-12-01

    We completed a series of measurements on mono-energetic neutron energy spectra of the 7Li(p,n) reaction with 80-389-MeV protons in the 100-m time-of-flight (TOF) tunnel at the Research Center for Nuclear Physics cyclotron facility. For that purpose, we measured neutron energy spectra of the 80-, 100- and 296-MeV proton incident reactions, which had not been investigated in our previous studies. The neutron peak intensity was 0.9-1.1×1010 neutrons/sr/μC in the incident proton energy region of 80-389 MeV, and it was almost independent of the incident proton energy. The contribution of peak intensity of the spectrum to the total intensity integrated with energies above 3 MeV varied between 0.38 and 0.48 in the incident proton energy range of 80-389 MeV. To consider the correction required to derive a response in the peak region from the measured total responses of neutron monitors in the 100-m TOF tunnel, we proposed the subtraction method using energy spectra between 0° and 25°. The normalizing factor k against 25° neutron fluence to equalize it to 0° neutron fluence in the continuum region ranges from 0.74 to 1.02 depending on the incident proton energy and angle measured. Even without the TOF method, the subtraction method with the k factor almost decreases the response in the continuum region of a neutron spectrum against the total response of neutron monitors.

  20. FSU High Energy Physics

    SciTech Connect

    Prosper, Harrison B.; Adams, Todd; Askew, Andrew; Berg, Bernd; Blessing, Susan K.; Okui, Takemichi; Owens, Joseph F.; Reina, Laura; Wahl, Horst D.

    2014-12-01

    The High Energy Physics group at Florida State University (FSU), which was established in 1958, is engaged in the study of the fundamental constituents of matter and the laws by which they interact. The group comprises theoretical and experimental physicists, who sometimes collaborate on projects of mutual interest. The report highlights the main recent achievements of the group. Significant, recent, achievements of the group’s theoretical physicists include progress in making precise predictions in the theory of the Higgs boson and its associated processes, and in the theoretical understanding of mathematical quantities called parton distribution functions that are related to the structure of composite particles such as the proton. These functions are needed to compare data from particle collisions, such as the proton-proton collisions at the CERN Large Hadron Collider (LHC), with theoretical predictions. The report also describes the progress in providing analogous functions for heavy nuclei, which find application in neutrino physics. The report highlights progress in understanding quantum field theory on a lattice of points in space and time (an area of study called lattice field theory), the progress in constructing several theories of potential new physics that can be tested at the LHC, and interesting new ideas in the theory of the inflationary expansion of the very early universe. The focus of the experimental physicists is the Compact Muon Solenoid (CMS) experiment at CERN. The report, however, also includes results from the D0 experiment at Fermilab to which the group made numerous contributions over a period of many years. The experimental group is particularly interested in looking for new physics at the LHC that may provide the necessary insight to extend the standard model (SM) of particle physics. Indeed, the search for new physics is the primary task of contemporary particle physics, one motivated by the need to explain certain facts, such as the

  1. Boron neutron capture therapy and radiation synovectomy research at the Massachusetts Institute of Technology Research Reactor

    SciTech Connect

    Zamenhof, R.G.; Nwanguma, C.I.; Wazer, D.E.; Saris, S.; Madoc-Jones, H. ); Sledge, C.B.; Shortkroff, S. )

    1992-04-01

    In this paper, current research in boron neutron capture therapy (BNCT) and radiation synovectomy at the Massachusetts Institute of Technology Research Reactor is reviewed. In the last few years, major emphasis has been placed on the development of BNCT primarily for treatment of brain tumors. This has required a concerted effort in epithermal beam design and construction as well as the development of analytical capabilities for {sup 10}B analysis and patient treatment planning. Prompt gamma analysis and high-resolution track-etch autoradiography have been developed to meet the needs, respectively, for accurate bulk analysis and for quantitative imaging of {sup 10}B in tissue at subcellular resolutions. Monte Carlo-based treatment planning codes have been developed to ensure optimized and individualized patient treatments. In addition, the development of radiation synovectomy as an alternative therapy to surgical intervention is joints that are affected by rheumatoid arthritis is described.

  2. A conceptual design of a beam-shaping assembly for boron neutron capture therapy based on deuterium-tritium neutron generators.

    PubMed

    Martín, Guido; Abrahantes, Arian

    2004-05-01

    A conceptual design of a beam-shaping assembly for boron neutron capture therapy using deuterium-tritium accelerator based neutrons source is developed. Calculations based on a simple geometry model for the radiation transport are initially performed to estimate the assembly materials and their linear dimensions. Afterward, the assembly geometry is produced, optimized and verified. In order to perform these calculations the general-purpose MCNP code is used. Irradiation time and therapeutic gain are utilized as beam assessment parameters. Metallic uranium and manganese are successfully tested for fast-to-epithermal neutron moderation. In the present beam-shaping assembly proposal, the therapeutic gain is improved by 23% and the accelerator current required for a fixed irradiation period is reduced by six times compared to previous proposals based on the same D-T reaction.

  3. Studies on depth-dose-distribution controls by deuteration and void formation in boron neutron capture therapy.

    PubMed

    Sakurai, Yoshinori

    2004-08-07

    Physical studies on (i) replacement of heavy water for body water (deuteration), and (ii) formation of a void in human body (void formation) were performed as control techniques for dose distribution in a human head under neutron capture therapy. Simulation calculations were performed for a human-head-size cylindrical phantom using a two-dimensional transport calculation code for mono-energetic incidences of higher-energy epi-thermal neutrons (1.2-10 keV), lower-energy epi-thermal neutrons (3.1-23 eV) and thermal neutrons (1 meV to 0.5 eV). The deuteration was confirmed to be effective both in thermal neutron incidence and in epi-thermal neutron incidence from the viewpoints of improvement of the thermal neutron flux distribution and elimination of the secondary gamma rays. For the void formation, a void was assumed to be 4 cm in diameter and 3 cm in depth at the surface part in this study. It was confirmed that the treatable depth was improved almost 2 cm for any incident neutron energy in the case of the 10 cm irradiation field diameter. It was made clear that the improvement effect was larger in isotropic incidence than in parallel incidence, in the case that an irradiation field size was delimited fitting into a void diameter.

  4. Exploring Boron Neutron Capture Therapy for non-small cell lung cancer.

    PubMed

    Farías, Rubén O; Bortolussi, Silva; Menéndez, Pablo R; González, Sara J

    2014-12-01

    Boron Neutron Capture Therapy (BNCT) is a radiotherapy that combines biological targeting and high LET radiation. It consists in the enrichment of tumour with (10)B and in the successive irradiation of the target with low energy neutrons producing charged particles that mainly cause non-repairable damages to the cells. The feasibility to treat Non Small Cells Lung Cancer (NSCLC) with BNCT was explored. This paper proposes a new approach to determine treatment plans, introducing the possibility to choose the irradiation start and duration to maximize the tumour dose. A Tumour Control Probability (TCP) suited for lung BNCT as well as other high dose radiotherapy schemes was also introduced. Treatment plans were evaluated in localized and disseminated lung tumours. Semi-ideal and real energy spectra beams were employed to assess the best energy range and the performance of non-tailored neutron sources for lung tumour treatments. The optimal neutron energy is within [500 eV-3 keV], lower than the 10 keV suggested for the treatment of deep-seated tumours in the brain. TCPs higher than 0.6 and up to 0.95 are obtained for all cases. Conclusions drawn from [Suzuki et al., Int Canc Conf J 1 (4) (2012) 235-238] supporting the feasibility of BNCT for shallow lung tumours are confirmed, however discussions favouring the treatment of deeper lesions and disseminated disease are also opened. Since BNCT gives the possibility to deliver a safe and potentially effective treatment for NSCLC, it can be considered a suitable alternative for patients with few or no treatment options.

  5. High Energy Astrophysics Mission

    NASA Technical Reports Server (NTRS)

    White, Nicholas E.; Ormes, Jonathan F. (Technical Monitor)

    2000-01-01

    The nature of gravity and its relationship to the other three forces and to quantum theory is one of the major challenges facing us as we begin the new century. In order to make progress we must challenge the current theories by observing the effects of gravity under the most extreme conditions possible. Black holes represent one extreme, where the laws of physics as we understand them break down. The Universe as whole is another extreme, where its evolution and fate is dominated by the gravitational influence of dark matter and the nature of the Cosmological constant. The early universe represents a third extreme, where it is thought that gravity may somehow be unified with the other forces. NASA's "Cosmic Journeys" program is part of a NASA/NSF/DoE tri-agency initiative designed to observe the extremes of gravity throughout the universe. This program will probe the nature of black holes, ultimately obtaining a direct image of the event horizon. It will investigate the large scale structure of the Universe to constrain the location and nature of dark matter and the nature of the cosmological constant. Finally it will search for and study the highest energy processes, that approach those found in the early universe. I will outline the High Energy Astrophysics part of this program.

  6. High energy physics

    SciTech Connect

    Kernan, A.; Shen, B.C.; Ma, E.

    1997-07-01

    This proposal is for the continuation of the High Energy Physics Program at the University of California, Riverside. In 1990, we will concentrate on analysis of LEP data from the OPAL detector. We expect to record 10{sup 5} Z`s by the end of 1989 and 10{sup 6} in 1990. This data will be used to measure the number of quark-lepton families in the universe. In the second half of 1990 we will also be occupied with the installation of the D-Zero detector in the Tevatron Collider and the preparation of software for the 1991 run. A new initiative made possible by generous university support is a laboratory for detector development at UCR. The focus will be on silicon strip tracking detectors both for the D-Zero upgrade and for SSC physics. The theory program will pursue further various mass-generating radiative mechanisms for understanding small quark and lepton masses as well as some novel phenomenological aspects of supersymmetry.

  7. High energy physics

    SciTech Connect

    Kernan, A.; Shen, B.C.; Ma, E.

    1997-07-01

    This proposal is for the continuation of the High Energy Physics program at the University of California at Riverside. In hadron collider physics the authors will complete their transition from experiment UA1 at CERN to the DZERO experiment at Fermilab. On experiment UA1 their effort will concentrate on data analysis at Riverside. At Fermilab they will coordinate the high voltage system for all detector elements. They will also carry out hardware/software development for the D0 muon detector. The TPC/Two-Gamma experiment has completed its present phase of data-taking after accumulating 160 pb{sup {minus}}1 of luminosity. The UC Riverside group will continue data and physics analysis and make minor hardware improvement for the high luminosity run. The UC Riverside group is participating in design and implementation of the data acquisition system for the OPAL experiment at LEP. Mechanical and electronics construction of the OPAL hadron calorimeter strip readout system is proceeding on schedule. Data analysis and Monte Carlo detector simulation efforts are proceeding in preparation for the first physics run when IEP operation comenses in fall 1989.

  8. Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy.

    PubMed

    Schaffran, Tanja; Jiang, Nan; Bergmann, Markus; Küstermann, Ekkehard; Süss, Regine; Schubert, Rolf; Wagner, Franz M; Awad, Doaa; Gabel, Detlef

    2014-01-01

    The potential of boron-containing lipids with three different structures, which were intended for use in boron neutron capture therapy, was investigated. All three types of boron lipids contained the anionic dodecaborate cluster as the headgroup. Their effects on two different tumor models in mice following intravenous injection were tested; for this, liposomes with boron lipid, distearoyl phosphatidylcholine, and cholesterol as helper lipids, and containing a polyethylene glycol lipid for steric protection, were administered intravenously into tumor-bearing mice (C3H mice for SCCVII squamous cell carcinoma and BALB/c mice for CT26/WT colon carcinoma). With the exception of one lipid (B-THF-14), the lipids were well tolerated, and no other animal was lost due to systemic toxicity. The lipid which led to death was not found to be much more toxic in cell culture than the other boron lipids. All of the lipids that were well tolerated showed hemorrhage in both tumor models within a few hours after administration. The hemorrhage could be seen by in vivo magnetic resonance and histology, and was found to occur within a few hours. The degree of hemorrhage depended on the amount of boron administered and on the tumor model. The observed unwanted effect of the lipids precludes their use in boron neutron capture therapy.

  9. Dermal Fenestration With Negative Pressure Wound Therapy: A Technique for Managing Soft Tissue Injuries Associated With High-Energy Complex Foot Fractures.

    PubMed

    Poon, Henrietta; Le Cocq, Heather; Mountain, Alistair J; Sargeant, Ian D

    2016-01-01

    Military casualties can sustain complex foot fractures from blast incidents. This frequently involves the calcaneum and is commonly associated with mid-foot fracture dislocations. The foot is at risk of both compartment syndrome and the development of fracture blisters after such injuries. The amount of energy transfer and the environment in which the injury was sustained also predispose patients to potential skin necrosis and deep infection. Decompression of the compartments is a part of accepted practice in civilian trauma to reduce the risk of complications associated with significant soft tissue swelling. The traditional methods of foot fasciotomy, however, are not without significant complications. We report a simple technique of dermal fenestration combined with the use of negative pressure wound therapy, which aims to preserve the skin integrity of the foot without resorting to formal fasciotomy.

  10. Fission foil detector calibrations with high energy protons

    NASA Technical Reports Server (NTRS)

    Benton, E. V.; Frank, A. L.

    1995-01-01

    Fission foil detectors (FFD's) are passive devices composed of heavy metal foils in contact with muscovite mica films. The heavy metal nuclei have significant cross sections for fission when irradiated with neutrons and protons. Each isotope is characterized by threshold energies for the fission reactions and particular energy-dependent cross sections. In the FFD's, fission fragments produced by the reactions are emitted from the foils and create latent particle tracks in the adjacent mica films. When the films are processed surface tracks are formed which can be optically counted. The track densities are indications of the fluences and spectra of neutrons and/or protons. In the past, detection efficiencies have been calculated using the low energy neutron calibrated dosimeters and published fission cross sections for neutrons and protons. The problem is that the addition of a large kinetic energy to the (n,nucleus) or (p,nucleus) reaction could increase the energies and ranges of emitted fission fragments and increase the detector sensitivity as compared with lower energy neutron calibrations. High energy calibrations are the only method of resolving the uncertainties in detector efficiencies. At high energies, either proton or neutron calibrations are sufficient since the cross section data show that the proton and neutron fission cross sections are approximately equal. High energy proton beams have been utilized (1.8 and 4.9 GeV, 80 and 140 MeV) for measuring the tracks of fission fragments emitted backward and forward.

  11. Fission foil detector calibrations with high energy protons

    SciTech Connect

    Benton, E.V.; Frank, A.L.

    1995-03-01

    Fission foil detectors (FFD`s) are passive devices composed of heavy metal foils in contact with muscovite mica films. The heavy metal nuclei have significant cross sections for fission when irradiated with neutrons and protons. Each isotope is characterized by threshold energies for the fission reactions and particular energy-dependent cross sections. In the FFD`s, fission fragments produced by the reactions are emitted from the foils and create latent particle tracks in the adjacent mica films. When the films are processed surface tracks are formed which can be optically counted. The track densities are indications of the fluences and spectra of neutrons and/or protons. In the past, detection efficiencies have been calculated using the low energy neutron calibrated dosimeters and published fission cross sections for neutrons and protons. The problem is that the addition of a large kinetic energy to the (n,nucleus) or (p,nucleus) reaction could increase the energies and ranges of emitted fission fragments and increase the detector sensitivity as compared with lower energy neutron calibrations. High energy calibrations are the only method of resolving the uncertainties in detector efficiencies. At high energies, either proton or neutron calibrations are sufficient since the cross section data show that the proton and neutron fission cross sections are approximately equal. High energy proton beams have been utilized (1.8 and 4.9 GeV, 80 and 140 MeV) for measuring the tracks of fission fragments emitted backward and forward.

  12. (High energy physics)

    SciTech Connect

    Bonner, B.E.; Roberts, J.B. Jr.

    1991-09-01

    An intense analysis effort on the data we obtained in a seven month run on E704 last year has produced a flood of new results on polarization effects in particle production at 200 GeV/c. We are fortunate to be able to report in detail on those results. Our other Fermilab experiment, E683 (photoproduction of jets) has been delayed an unbelievable amount of time by Fermilab schedule slippages. It was scheduled and ready for beam two years ago As this report is being written, we have been running for two months and are expecting four months of production data taking. In this report we show some of our preliminary results. In addition we are near the end of a six month run on our CERN experiment, NA47 (SMC) which will measure the spin dependent structure functions for the proton and neutron. It is with a sense of relief, mixed with pride, that we report that all the equipment which we constructed for that experiment is currently working as designed. The random coincidence of accelerator schedules has left us slightly dazed, but all experiments are getting done and analyzed in a timely fashion. As members of the Solenoidal Detector Collaboration, we have been preparing for the only currently approved experiment at the SSC. Here we report on our scintillating fiber tracker design and simulation activities. In addition we report the results of our investigation of the detector response to heavy Z particles. Since our last report, we have joined the D0 collaboration with the primary aim of contributing to the D0 upgrade over the next few years. It is also important for us to gain experience in collider physics during the period leading up to the SDC turn-on.

  13. SU-D-BRF-02: In Situ Verification of Radiation Therapy Dose Distributions From High-Energy X-Rays Using PET Imaging

    SciTech Connect

    Zhang, Q; Kai, L; Wang, X; Hua, B; Chui, L; Wang, Q; Ma, C

    2014-06-01

    Purpose: To study the possibility of in situ verification of radiation therapy dose distributions using PET imaging based on the activity distribution of 11C and 15O produced via photonuclear reactions in patient irradiated by 45MV x-rays. Methods: The method is based on the photonuclear reactions in the most elemental composition {sup 12}C and {sup 16}O in body tissues irradiated by bremsstrahlung photons with energies up to 45 MeV, resulting primarily in {sup 11}C and {sup 15}O, which are positron-emitting nuclei. The induced positron activity distributions were obtained with a PET scanner in the same room of a LA45 accelerator (Top Grade Medical, Beijing, China). The experiments were performed with a brain phantom using realistic treatment plans. The phantom was scanned at 20min and 2-5min after irradiation for {sup 11}C and {sup 15}, respectively. The interval between the two scans was 20 minutes. The activity distributions of {sup 11}C and {sup 15}O within the irradiated volume can be separated from each other because the half-life is 20min and 2min for {sup 11}C and {sup 15}O, respectively. Three x-ray energies were used including 10MV, 25MV and 45MV. The radiation dose ranged from 1.0Gy to 10.0Gy per treatment. Results: It was confirmed that no activity was detected at 10 MV beam energy, which was far below the energy threshold for photonuclear reactions. At 25 MV x-ray activity distribution images were observed on PET, which needed much higher radiation dose in order to obtain good quality. For 45 MV photon beams, good quality activation images were obtained with 2-3Gy radiation dose, which is the typical daily dose for radiation therapy. Conclusion: The activity distribution of {sup 15}O and {sup 11}C could be used to derive the dose distribution of 45MV x-rays at the regular daily dose level. This method can potentially be used to verify in situ dose distributions of patients treated on the LA45 accelerator.

  14. GEM Applications Outside High Energy Physics

    NASA Astrophysics Data System (ADS)

    Pinto, Serge Duarte

    2013-04-01

    From its invention in 1997, the Gas Electron Multiplier (GEM) has been applied in nuclear and high energy physics experiments. Over time however, other applications have also exploited the favorable properties of GEMs. The use of GEMs in these applications will be explained in principle and practice. This paper reviews applications in research, beam instrumentation and homeland security. The detectors described measure neutral radiations such as photons, x-rays, gamma rays and neutrons, as well as all kinds of charged radiation. This paper provides an overview of the still expanding range of possibilities of this versatile detector concept.

  15. High-energy proton radiation belt.

    NASA Technical Reports Server (NTRS)

    White, R. S.

    1973-01-01

    The experiments and theories to explain the high-energy protons trapped in the earth's radiation belt are reviewed. The theory of cosmic ray albedo neutron decay injection of protons into the radiation belt is discussed. Radial diffusion and change in the earth's dipole moment are considered along with losses of protons by ionization and nuclear collision. It is found that the measured albedo neutron escape current is sufficient to supply trapped protons above 30 MeV. The theoretical calculations of the trapped protons are in agreement with the measurements for L less than or equal to 1.7 both on and off the equator. For L greater than or equal to 1.7, additional trapped proton differential energy measurements should be made before the theory can be adequately tested. It appears that an additional loss mechanism such as pitch angle scattering may be required.

  16. Monte Carlo and analytical model predictions of leakage neutron exposures from passively scattered proton therapy

    PubMed Central

    Pérez-Andújar, Angélica; Zhang, Rui; Newhauser, Wayne

    2013-01-01

    Purpose: Stray neutron radiation is of concern after radiation therapy, especially in children, because of the high risk it might carry for secondary cancers. Several previous studies predicted the stray neutron exposure from proton therapy, mostly using Monte Carlo simulations. Promising attempts to develop analytical models have also been reported, but these were limited to only a few proton beam energies. The purpose of this study was to develop an analytical model to predict leakage neutron equivalent dose from passively scattered proton beams in the 100-250-MeV interval. Methods: To develop and validate the analytical model, the authors used values of equivalent dose per therapeutic absorbed dose (H/D) predicted with Monte Carlo simulations. The authors also characterized the behavior of the mean neutron radiation-weighting factor, \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{upgreek} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document} \\overline {w_R }\\end{document}wR¯, as a function of depth in a water phantom and distance from the beam central axis. Results: The simulated and analytical predictions agreed well. On average, the percentage difference between the analytical model and the Monte Carlo simulations was 10% for the energies and positions studied. The authors found that \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{upgreek} \\usepackage{mathrsfs} \\setlength{\\oddsidemargin}{-69pt} \\begin{document} \\overline {w_R }\\end{document}wR¯ was highest at the shallowest depth and decreased with depth until around 10 cm, where it started to increase slowly with depth. This was consistent among all energies. Conclusion: Simple analytical methods are promising alternatives to complex and slow Monte Carlo simulations

  17. MCNP6 model of the University of Washington clinical neutron therapy system (CNTS)

    NASA Astrophysics Data System (ADS)

    Moffitt, Gregory B.; Stewart, Robert D.; Sandison, George A.; Goorley, John T.; Argento, David C.; Jevremovic, Tatjana

    2016-01-01

    A MCNP6 dosimetry model is presented for the Clinical Neutron Therapy System (CNTS) at the University of Washington. In the CNTS, fast neutrons are generated by a 50.5 MeV proton beam incident on a 10.5 mm thick Be target. The production, scattering and absorption of neutrons, photons, and other particles are explicitly tracked throughout the key components of the CNTS, including the target, primary collimator, flattening filter, monitor unit ionization chamber, and multi-leaf collimator. Simulations of the open field tissue maximum ratio (TMR), percentage depth dose profiles, and lateral dose profiles in a 40 cm  ×  40 cm  ×  40 cm water phantom are in good agreement with ionization chamber measurements. For a nominal 10  ×  10 field, the measured and calculated TMR values for depths of 1.5 cm, 5 cm, 10 cm, and 20 cm (compared to the dose at 1.7 cm) are within 0.22%, 2.23%, 4.30%, and 6.27%, respectively. For the three field sizes studied, 2.8 cm  ×  2.8 cm, 10.4 cm  ×  10.3 cm, and 28.8 cm  ×  28.8 cm, a gamma test comparing the measured and simulated percent depth dose curves have pass rates of 96.4%, 100.0%, and 78.6% (depth from 1.5 to 15 cm), respectively, using a 3% or 3 mm agreement criterion. At a representative depth of 10 cm, simulated lateral dose profiles have in-field (⩾10% of central axis dose) pass rates of 89.7% (2.8 cm  ×  2.8 cm), 89.6% (10.4 cm  ×  10.3 cm), and 100.0% (28.8 cm  ×  28.8 cm) using a 3% and 3 mm criterion. The MCNP6 model of the CNTS meets the minimum requirements for use as a quality assurance tool for treatment planning and provides useful insights and information to aid in the advancement of fast neutron therapy.

  18. Monte Carlo based treatment planning systems for Boron Neutron Capture Therapy in Petten, The Netherlands

    NASA Astrophysics Data System (ADS)

    Nievaart, V. A.; Daquino, G. G.; Moss, R. L.

    2007-06-01

    Boron Neutron Capture Therapy (BNCT) is a bimodal form of radiotherapy for the treatment of tumour lesions. Since the cancer cells in the treatment volume are targeted with 10B, a higher dose is given to these cancer cells due to the 10B(n,α)7Li reaction, in comparison with the surrounding healthy cells. In Petten (The Netherlands), at the High Flux Reactor, a specially tailored neutron beam has been designed and installed. Over 30 patients have been treated with BNCT in 2 clinical protocols: a phase I study for the treatment of glioblastoma multiforme and a phase II study on the treatment of malignant melanoma. Furthermore, activities concerning the extra-corporal treatment of metastasis in the liver (from colorectal cancer) are in progress. The irradiation beam at the HFR contains both neutrons and gammas that, together with the complex geometries of both patient and beam set-up, demands for very detailed treatment planning calculations. A well designed Treatment Planning System (TPS) should obey the following general scheme: (1) a pre-processing phase (CT and/or MRI scans to create the geometric solid model, cross-section files for neutrons and/or gammas); (2) calculations (3D radiation transport, estimation of neutron and gamma fluences, macroscopic and microscopic dose); (3) post-processing phase (displaying of the results, iso-doses and -fluences). Treatment planning in BNCT is performed making use of Monte Carlo codes incorporated in a framework, which includes also the pre- and post-processing phases. In particular, the glioblastoma multiforme protocol used BNCT_rtpe, while the melanoma metastases protocol uses NCTPlan. In addition, an ad hoc Positron Emission Tomography (PET) based treatment planning system (BDTPS) has been implemented in order to integrate the real macroscopic boron distribution obtained from PET scanning. BDTPS is patented and uses MCNP as the calculation engine. The precision obtained by the Monte Carlo based TPSs exploited at Petten

  19. Risk of Developing Second Cancer From Neutron Dose in Proton Therapy as Function of Field Characteristics, Organ, and Patient Age

    SciTech Connect

    Zacharatou Jarlskog, Christina; Paganetti, Harald

    2008-09-01

    Purpose: To estimate the risk of a second malignancy after treatment of a primary brain cancer using passive scattered proton beam therapy. The focus was on the cancer risk caused by neutrons outside the treatment volume and the dependency on the patient's age. Methods and Materials: Organ-specific neutron-equivalent doses previously calculated for eight different proton therapy brain fields were considered. Organ-specific models were applied to assess the risk of developing solid cancers and leukemia. Results: The main contributors (>80%) to the neutron-induced risk are neutrons generated in the treatment head. Treatment volume can influence the risk by up to a factor of {approx}2. Young patients are subject to significantly greater risks than are adult patients because of the geometric differences and age dependency of the risk models. Breast cancer should be the main concern for females. For males, the risks of lung cancer, leukemia, and thyroid cancer were significant for pediatric patients. In contrast, leukemia was the leading risk for an adult. Most lifetime risks were <1% (70-Gy treatment). The only exceptions were breast, thyroid, and lung cancer for females. For female thyroid cancer, the treatment risk can exceed the baseline risk. Conclusion: The risk of developing a second malignancy from neutrons from proton beam therapy of a brain lesion is small (i.e., presumably outweighed by the therapeutic benefit) but not negligible (i.e., potentially greater than the baseline risk). The patient's age at treatment plays a major role.

  20. Development of beryllium-based neutron target system with three-layer structure for accelerator-based neutron source for boron neutron capture therapy.

    PubMed

    Kumada, Hiroaki; Kurihara, Toshikazu; Yoshioka, Masakazu; Kobayashi, Hitoshi; Matsumoto, Hiroshi; Sugano, Tomei; Sakurai, Hideyuki; Sakae, Takeji; Matsumura, Akira

    2015-12-01

    The iBNCT project team with University of Tsukuba is developing an accelerator-based neutron source. Regarding neutron target material, our project has applied beryllium. To deal with large heat load and blistering of the target system, we developed a three-layer structure for the target system that includes a blistering mitigation material between the beryllium used as the neutron generator and the copper heat sink. The three materials were bonded through diffusion bonding using a hot isostatic pressing method. Based on several verifications, our project chose palladium as the intermediate layer. A prototype of the neutron target system was produced. We will verify that sufficient neutrons for BNCT treatment are generated by the device in the near future.

  1. SU-E-T-567: Neutron Dose Equivalent Evaluation for Pencil Beam Scanning Proton Therapy with Apertures

    SciTech Connect

    Geng, C; Schuemann, J; Moteabbed, M; Paganetti, H

    2015-06-15

    Purpose: To determine the neutron contamination from the aperture in pencil beam scanning during proton therapy. Methods: A Monte Carlo based proton therapy research platform TOPAS and the UF-series hybrid pediatric phantoms were used to perform this study. First, pencil beam scanning (PBS) treatment pediatric plans with average spot size of 10 mm at iso-center were created and optimized for three patients with and without apertures. Then, the plans were imported into TOPAS. A scripting method was developed to automatically replace the patient CT with a whole body phantom positioned according to the original plan iso-center. The neutron dose equivalent was calculated using organ specific quality factors for two phantoms resembling a 4- and 14-years old patient. Results: The neutron dose equivalent generated by the apertures in PBS is 4–10% of the total neutron dose equivalent for organs near the target, while roughly 40% for organs far from the target. Compared to the neutron dose equivalent caused by PBS without aperture, the results show that the neutron dose equivalent with aperture is reduced in the organs near the target, and moderately increased for those organs located further from the target. This is due to the reduction of the proton dose around the edge of the CTV, which causes fewer neutrons generated in the patient. Conclusion: Clinically, for pediatric patients, one might consider adding an aperture to get a more conformal treatment plan if the spot size is too large. This work shows the somewhat surprising fact that adding an aperture for beam scanning for facilities with large spot sizes reduces instead of increases a potential neutron background in regions near target. Changran Geng is supported by the Chinese Scholarship Council (CSC) and the National Natural Science Foundation of China (Grant No. 11475087)

  2. Advances in boron neutron capture therapy (BNCT) at kyoto university - From reactor-based BNCT to accelerator-based BNCT

    NASA Astrophysics Data System (ADS)

    Sakurai, Yoshinori; Tanaka, Hiroki; Takata, Takushi; Fujimoto, Nozomi; Suzuki, Minoru; Masunaga, Shinichiro; Kinashi, Yuko; Kondo, Natsuko; Narabayashi, Masaru; Nakagawa, Yosuke; Watanabe, Tsubasa; Ono, Koji; Maruhashi, Akira

    2015-07-01

    At the Kyoto University Research Reactor Institute (KURRI), a clinical study of boron neutron capture therapy (BNCT) using a neutron irradiation facility installed at the research nuclear reactor has been regularly performed since February 1990. As of November 2014, 510 clinical irradiations were carried out using the reactor-based system. The world's first accelerator-based neutron irradiation system for BNCT clinical irradiation was completed at this institute in early 2009, and the clinical trial using this system was started in 2012. A shift of BCNT from special particle therapy to a general one is now in progress. To promote and support this shift, improvements to the irradiation system, as well as its preparation, and improvements in the physical engineering and the medical physics processes, such as dosimetry systems and quality assurance programs, must be considered. The recent advances in BNCT at KURRI are reported here with a focus on physical engineering and medical physics topics.

  3. Boron uptake measurements in a rat model for Boron Neutron Capture Therapy of lung tumours.

    PubMed

    Bortolussi, S; Bakeine, J G; Ballarini, F; Bruschi, P; Gadan, M A; Protti, N; Stella, S; Clerici, A; Ferrari, C; Cansolino, L; Zonta, C; Zonta, A; Nano, R; Altieri, S

    2011-02-01

    Lung carcinoma is the leading cause of cancer mortality in the Western countries. Despite the introduction over the last few years of new therapeutic agents, survival from lung cancer has shown no discernible improvement in the last 20 years. For these reasons any efforts to find and validate new effective therapeutic procedures for lung cancer are very timely. The selective boron uptake in the tumour with respect to healthy tissues makes Boron Neutron Capture Therapy a potentially advantageous option in the treatment of tumours that affect whole vital organs, and that are surgically inoperable. To study the possibility of applying BNCT to the treatment of diffuse pulmonary tumours, an animal model for boron uptake measurements in lung metastases was developed. Both healthy and tumour-bearing rats were infused with Boronophenylalanine (BPA) and sacrificed at different time intervals after drug administration. The lungs were extracted, and prepared for boron analysis by neutron autoradiography and α-spectroscopy. The boron concentrations in tumour and normal lung were plotted as a function of the time elapsed after BPA administration. The concentration in tumour is almost constant within the error bars for all the time intervals of the experiment (1-8 h), while the curve in normal lung decreases after 4 h from BPA infusion. At 4 h, the ratio of boron concentration in tumour to boron concentration in healthy lung is higher than 3, and it stays above this level up to 8 h. Also the images of boron distribution in the samples, obtained by neutron autoradiography, show a selective absorption in the metastases.

  4. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model.

    PubMed

    Garabalino, Marcela A; Heber, Elisa M; Monti Hughes, Andrea; González, Sara J; Molinari, Ana J; Pozzi, Emiliano C C; Nievas, Susana; Itoiz, Maria E; Aromando, Romina F; Nigg, David W; Bauer, William; Trivillin, Verónica A; Schwint, Amanda E

    2013-08-01

    Boron neutron capture therapy (BNCT) is based on selective accumulation of ¹⁰B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg ¹⁰B/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.

  5. Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma-seeking compound

    SciTech Connect

    Mishima, Y.; Ichihashi, M.; Tsuji, M.; Hatta, S.; Ueda, M.; Honda, C.; Suzuki, T.

    1989-05-01

    As pigment cells undergo melanoma genesis, accentuated melanogenesis concurrently occurs in principle. Subsequent to the understanding of intrinsic factors controlling both processes, we found our selective melanoma neutron capture therapy (NCT) using 10B-dopa (melanin substrate) analogue, 10B1-p-boronophenylalanine (10B1-BPA), followed by 10B(n, alpha)7Li reaction, induced by essentially harmless thermal neutrons, which releases energy of 2.33 MeV to 14 mu, the diameter of melanoma cells. In vitro/in vivo radiobiological analysis revealed the highly enhanced melanoma killing effect of 10B1-BPA. Chemical and prompt gamma ray spectrometry assays of 10B accumulated within melanoma cells after 10B1-BPA administration in vitro and in vivo show high affinity, e.g., 10B melanoma/blood ratio of 11.5. After successfully eradicating melanoma transplanted into hamsters with NCT, we advanced to preclinical studies using spontaneously occurring melanoma in Duroc pig skin. We cured three melanoma cases, 4.6 to 12 cm in diameter, by single neutron capture treatment. Complete disappearance of melanoma was obtained without substantial side effects. Acute and subacute toxicity as well as pharmacodynamics of 10B1-BPA have been studied in relation to therapeutic dosage requirements. Clinical radiation dosimetry using human phantom has been carried out. Further preclinical studies using human melanoma transplanted into nude mouse have been a useful model for obtaining optimal results for each melanoma type. We recently treated the first human melanoma patient with our NCT, using essentially the method for Duroc pig melanoma, and obtained similar regression time course leading to cure.

  6. An international dosimetry exchange for boron neutron capture therapy. Part I: Absorbed dose measurements.

    PubMed

    Binns, P J; Riley, K J; Harling, O K; Kiger, W S; Munck af Rosenschöld, P M; Giusti, V; Capala, J; Sköld, K; Auterinen, I; Serén, T; Kotiluoto, P; Uusi-Simola, J; Marek, M; Viererbl, L; Spurny, F

    2005-12-01

    An international collaboration was organized to undertake a dosimetry exchange to enable the future combination of clinical data from different centers conducting neutron capture therapy trials. As a first step (Part I) the dosimetry group from the Americas, represented by MIT, visited the clinical centers at Studsvik (Sweden), VTT Espoo (Finland), and the Nuclear Research Institute (NRI) at Rez (Czech Republic). A combined VTT/NRI group reciprocated with a visit to MIT. Each participant performed a series of dosimetry measurements under equivalent irradiation conditions using methods appropriate to their clinical protocols. This entailed in-air measurements and dose versus depth measurements in a large water phantom. Thermal neutron flux as well as fast neutron and photon absorbed dose rates were measured. Satisfactory agreement in determining absorbed dose within the experimental uncertainties was obtained between the different groups although the measurement uncertainties are large, ranging between 3% and 30% depending upon the dose component and the depth of measurement. To improve the precision in the specification of absorbed dose amongst the participants, the individually measured dose components were normalized to the results from a single method. Assuming a boron concentration of 15 microg g(-1) that is typical of concentrations realized clinically with the boron delivery compound boronophenylalanine-fructose, systematic discrepancies in the specification of the total biologically weighted dose of up to 10% were apparent between the different groups. The results from these measurements will be used in future to normalize treatment plan calculations between the different clinical dosimetry protocols as Part II of this study.

  7. Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer.

    PubMed

    Lim, Diana; Quah, Daniel S C; Leech, Michelle; Marignol, Laure

    2015-12-01

    This review compares the safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of previously irradiated, inoperable locoregional recurrent HNC patients and compares BNCT against the standard treatment of platinum-based chemotherapy. Our analysis of published clinical trials highlights efficacy of BNCT associated with mild side effects. However, the use of BNCT should be explored in stratified randomised trials.

  8. Quinolone and Glycopeptide Therapy for Infection in Mouse Following Exposure to Mixed-Field Neutron-Gamma-Photon Radiation

    DTIC Science & Technology

    1993-01-01

    gamma-hemolytic streptococcus, HeN mouse treated with L-ofloxacin and vancomycin. five E. faecalis and four S. aureus) (Table 4). More...S’nierworca faecalis resistant to vancomycin (3 of 5). ’Exteroeacusfaecalis resistant to vancomycin (2 of 7). Therapy of infection after neutron irradiation 777

  9. Development of JCDS, a computational dosimetry system at JAEA for boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Kumada, H.; Yamamoto, K.; Matsumura, A.; Yamamoto, T.; Nakagawa, Y.

    2007-06-01

    Clinical trials of boron neutron capture therapy (BNCT) are being carried out using several research reactors throughout the world. In Japan, many medical groups perform clinical trials of BNCT using Japan Research Reactor No.4 (JRR-4) in Japan Atomic Energy Agency (JAEA). JAEA has developed a treatment planning system, JCDS, in order to evaluate radiation dose given to a patient in the BNCT. JCDS employs a voxel calculation method to compute the radiation dose given to a patient. An initial version of JCDS created a voxel model, dividing a space into 1 × 1 × 1 cm3voxel cells. JCDS was improved to create a detailed voxel model consisting of minute voxel cells such as 2 × 2 × 2 mm3voxel cells. Verification of accuracy of calculations with the detailed voxel mode demonstrated that the detailed voxel model enables JCDS to evaluate more accurately the radiation doses to a patient undergoing BNCT. Furthermore, the calculation code of JCDS is being incorporated into the PHITS system as a Monte-Carlo transport code. By employing the PHITS system in the dose evaluation, total doses given to a patient by combined modality therapy such as BNCT and X-ray therapy can be estimated accurately. Here, an outline and the performances of the latest version of JCDS are presented, and a future system integrated with JCDS is introduced.

  10. Spectromicroscopy of boron for the optimization of boron neutron capture therapy (BNCT) for cancer

    NASA Astrophysics Data System (ADS)

    Gilbert, B.; Redondo, J.; Baudat, P.-A.; Lorusso, G. F.; Andres, R.; Van Meir, E. G.; Brunet, J.-F.; Hamou, M.-F.; Suda, T.; Mercanti, Delio; Ciotti, M. Teresa; Droubay, T. C.; Tonner, B. P.; Perfetti, P.; Margaritondo, M.; DeStasio, Gelsomina

    1998-10-01

    We used synchrotron spectromicroscopy to study the microscopic distribution of boron in rat brain tumour and healthy tissue in the field of boron neutron capture therapy (BNCT). The success of this experimental cancer therapy depends on the preferential uptake of ? in tumour cells after injection of a boron compound (in our case ?, or BSH). With the Mephisto (microscope à emission de photoélectrons par illumination synchrotronique de type onduleur) spectromicroscope, high-magnification imaging and chemical analysis was performed on brain tissue sections from a rat carrying an implanted brain tumour and the results were compared with inductively coupled plasma-atomic emission spectroscopy (ICP-AES) detection of boron in bulk tissue. Boron was found to have been taken up more favourably by regions of tumour rather than healthy tissue, but the resulting boron distribution in the tumour was inhomogeneous. The results demonstrate that Mephisto can perform microchemical analysis of tissue sections, detect and localize the presence of boron with submicron spatial resolution. The application of this technique to boron in brain tissue can therefore be used to evaluate the current efforts to optimize BNC therapy.

  11. A facility for measurements of nuclear cross sections for fast neutron cancer therapy

    NASA Astrophysics Data System (ADS)

    Dangtip, S.; Ataç, A.; Bergenwall, B.; Blomgren, J.; Elmgren, K.; Johansson, C.; Klug, J.; Olsson, N.; Carlsson, G. A.; Söderberg, J.; Jonsson, O.; Nilsson, L.; Renberg, P.-U.; Nadel-Turonski, P.; Brun, C. L.; Lecolley, F.-R.; Lecolley, J.-F.; Varignon, C.; Eudes, P.; Haddad, F.; Kerveno, M.; Kirchner, T.; Lebrun, C.

    2000-10-01

    A facility for measurements of neutron-induced double-differential light-ion production cross-sections, for application within, e.g., fast neutron cancer therapy, is described. The central detection elements are three-detector telescopes consisting of two silicon detectors and a CsI crystal. Use of /ΔE-ΔE-E techniques allows good particle identification for p, d, t, 3He and alpha particles over an energy range from a few MeV up to 100 MeV. Active plastic scintillator collimators are used to define the telescope solid angle. Measurements can be performed using up to eight telescopes at /20° intervals simultaneously, thus covering a wide angular range. The performance of the equipment is illustrated using experimental data taken with a carbon target at En=95 MeV. Distortions of the measured charged-particle spectra due to energy and particle losses in the target are corrected using a newly developed computer code. Results from such correction calculations are presented.

  12. Dynamic infrared imaging for biological and medical applications in Boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Santa Cruz, Gustavo A.; González, Sara J.; Dagrosa, Alejandra; Schwint, Amanda E.; Carpano, Marina; Trivillin, Verónica A.; Boggio, Esteban F.; Bertotti, José; Marín, Julio; Monti Hughes, Andrea; Molinari, Ana J.; Albero, Miguel

    2011-05-01

    Boron Neutron Capture Therapy (BNCT) is a treatment modality, currently focused on the treatment of cancer, which involves a tumor selective 10B compound and a specially tuned neutron beam to produce a lethal nuclear reaction. BNCT kills target cells with microscopic selectivity while sparing normal tissues from potentially lethal doses of radiation. In the context of the Argentine clinical and research BNCT projects at the National Atomic Energy Commission and in a strong collaboration with INVAP SE, we successfully implemented Dynamic Infrared Imaging (DIRI) in the clinical setting for the observation of cutaneous melanoma patients and included DIRI as a non invasive methodology in several research protocols involving small animals. We were able to characterize melanoma lesions in terms of temperature and temperature rate-of-recovery after applying a mild cold thermal stress, distinguishing melanoma from other skin pigmented lesions. We observed a spatial and temporal correlation between skin acute reactions after irradiation, the temperature pattern and the dose distribution. We studied temperature distribution as a function of tumor growth in mouse xenografts, observing a significant correlation between tumor temperature and drug uptake; we investigated temperature evolution in the limbs of Wistar rats for a protocol of induced rheumatoid arthritis (RA), DIRI being especially sensitive to RA induction even before the development of clinical signs and studied surface characteristics of tumors, precancerous and normal tissues in a model of oral cancer in the hamster cheek pouch.

  13. Verification of the computational dosimetry system in JAERI (JCDS) for boron neutron capture therapy

    NASA Astrophysics Data System (ADS)

    Kumada, H.; Yamamoto, K.; Matsumura, A.; Yamamoto, T.; Nakagawa, Y.; Nakai, K.; Kageji, T.

    2004-08-01

    Clinical trials for boron neutron capture therapy (BNCT) by using the medical irradiation facility installed in Japan Research Reactor No. 4 (JRR-4) at Japan Atomic Energy Research Institute (JAERI) have been performed since 1999. To carry out the BNCT procedure based on proper treatment planning and its precise implementation, the JAERI computational dosimetry system (JCDS) which is applicable to dose planning has been developed in JAERI. The aim of this study was to verify the performance of JCDS. The experimental data with a cylindrical water phantom were compared with the calculation results using JCDS. Data of measurements obtained from IOBNCT cases at JRR-4 were also compared with retrospective evaluation data with JCDS. In comparison with phantom experiments, the calculations and the measurements for thermal neutron flux and gamma-ray dose were in a good agreement, except at the surface of the phantom. Against the measurements of clinical cases, the discrepancy of JCDS's calculations was approximately 10%. These basic and clinical verifications demonstrated that JCDS has enough performance for the BNCT dosimetry. Further investigations are recommended for precise dose distribution and faster calculation environment.

  14. Induced radioactivity in the blood of cancer patients following Boron Neutron Capture Therapy.

    PubMed

    Fujiwara, Keiko; Kinashi, Yuko; Takahashi, Tomoyuki; Yashima, Hiroshi; Kurihara, Kouta; Sakurai, Yoshinori; Tanaka, Hiroki; Ono, Koji; Takahashi, Sentaro

    2013-07-01

    Since 1990, Boron Neutron Capture Therapy (BNCT) has been used for over 400 cancer patients at the Kyoto University Research Reactor Institute (KURRI). After BNCT, the patients are radioactive and their (24)Na and (38)Cl levels can be detected via a Na-I scintillation counter. This activity is predominantly due to (24)Na, which has a half-life of 14.96 h and thus remains in the body for extended time periods. Radioactive (24)Na is mainly generated from (23)Na in the target tissue that is exposed to the neutron beam in BNCT. The purpose of this study is to evaluate the relationship between the radioactivity of blood (24)Na following BNCT and the absorbed gamma ray dose in the irradiated field. To assess blood (24)Na, 1 ml of peripheral blood was collected from 30 patients immediately after the exposure, and the radioactivity of blood (24)Na was determined using a germanium counter. The activity of (24)Na in the blood correlated with the absorbed gamma ray doses in the irradiated field. For the same absorbed gamma ray dose in the irradiated field, the activity of blood (24)Na was higher in patients with neck or lung tumors than in patients with brain or skin tumors. The reasons for these findings are not readily apparent, but the difference in the blood volume and the ratio of bone to soft tissue in the irradiated field, as well as the dose that leaked through the clinical collimator, may be responsible.

  15. Boron neutron capture therapy of a murine mammary carcinoma using a lipophilic carboranyltetraphenylporphyrin.

    PubMed

    Miura, M; Morris, G M; Micca, P L; Lombardo, D T; Youngs, K M; Kalef-Ezra, J A; Hoch, D A; Slatkin, D N; Ma, R; Coderre, J A

    2001-04-01

    The first control of a malignant tumor in vivo by porphyrin- mediated boron neutron capture therapy (BNCT) is described. In mice bearing implanted EMT-6 mammary carcinomas, boron uptake using a single injection of either p-boronophenylalanine (BPA) or mercaptoundecahydrododecaborane (BSH) was compared with either a single injection or multiple injections of the carboranylporphyrin CuTCPH. The BSH and BPA doses used were comparable to the highest doses of these compounds previously administered in a single injection to rodents. For BNCT, boron concentrations averaged 85 microg (10)B/g in the tumor and 4 microg (10)B/g in blood 2 days after the last of six injections (over 32 h) that delivered a total of 190 microg CuTCPH/g body weight. During a single 15, 20, 25 or 30 MW-min exposure to the thermalized neutron beam of the Brookhaven Medical Research Reactor, a tumor received average absorbed doses of approximately 39, 52, 66 or 79 Gy, respectively. A long-term (>200 days) tumor control rate of 71% was achieved at a dose of 66 Gy with minimal damage to the leg. Equivalent long-term tumor control by a single exposure to 42 Gy X rays was achieved, but with greater damage to the irradiated leg.

  16. Verification of the computational dosimetry system in JAERI (JCDS) for boron neutron capture therapy.

    PubMed

    Kumada, H; Yamamoto, K; Matsumura, A; Yamamoto, T; Nakagawa, Y; Nakai, K; Kageji, T

    2004-08-07

    Clinical trials for boron neutron capture therapy (BNCT) by using the medical irradiation facility installed in Japan Research Reactor No. 4 (JRR-4) at Japan Atomic Energy Research Institute (JAERI) have been performed since 1999. To carry out the BNCT procedure based on proper treatment planning and its precise implementation, the JAERI computational dosimetry system (JCDS) which is applicable to dose planning has been developed in JAERI. The aim of this study was to verify the performance of JCDS. The experimental data with a cylindrical water phantom were compared with the calculation results using JCDS. Data of measurements obtained from IOBNCT cases at JRR-4 were also compared with retrospective evaluation data with JCDS. In comparison with phantom experiments, the calculations and the measurements for thermal neutron flux and gamma-ray dose were in a good agreement, except at the surface of the phantom. Against the measurements of clinical cases, the discrepancy of JCDS's calculations was approximately 10%. These basic and clinical verifications demonstrated that JCDS has enough performance for the BNCT dosimetry. Further investigations are recommended for precise dose distribution and faster calculation environment.

  17. Brain tumour and infiltrations dosimetry of boron neutron capture therapy combined with 252Cf brachytherapy.

    PubMed

    Brandão, Sâmia F; Campos, Tarcísio P R

    2012-04-01

    This article presents a dosimetric investigation of boron neutron capture therapy (BNCT) combined with (252)Cf brachytherapy for brain tumour control. The study was conducted through computational simulation in MCNP5 code, using a precise and discrete voxel model of a human head, in which a hypothetical brain tumour was incorporated. A boron concentration ratio of 1:5 for healthy-tissue: tumour was considered. Absorbed and biologically weighted dose rates and neutron fluency in the voxel model were evaluated. The absorbed dose rate results were exported to SISCODES software, which generates the isodose surfaces on the brain. Analyses were performed to clarify the relevance of boron concentrations in occult infiltrations far from the target tumour, with boron concentration ratios of 1:1 up to 1:50 for healthy-tissue:infiltrations and healthy-tissue:tumour. The average biologically weighted dose rates at tumour area exceed up to 40 times the surrounding healthy tissue dose rates. In addition, the biologically weighted dose rates from boron have the main contribution at the infiltrations, especially far from primary tumour. In conclusion, BNCT combined with (252)Cf brachytherapy is an alternative technique for brain tumour treatment because it intensifies dose deposition at the tumour and at infiltrations, sparing healthy brain tissue.

  18. Induced radioactivity in the blood of cancer patients following Boron Neutron Capture Therapy

    PubMed Central

    Fujiwara, Keiko; Kinashi, Yuko; Takahashi, Tomoyuki; Yashima, Hiroshi; Kurihara, Kouta; Sakurai, Yoshinori; Tanaka, Hiroki; Ono, Koji; Takahashi, Sentaro

    2013-01-01

    Since 1990, Boron Neutron Capture Therapy (BNCT) has been used for over 400 cancer patients at the Kyoto University Research Reactor Institute (KURRI). After BNCT, the patients are radioactive and their 24Na and 38Cl levels can be detected via a Na-I scintillation counter. This activity is predominantly due to 24Na, which has a half-life of 14.96 h and thus remains in the body for extended time periods. Radioactive 24Na is mainly generated from 23Na in the target tissue that is exposed to the neutron beam in BNCT. The purpose of this study is to evaluate the relationship between the radioactivity of blood 24Na following BNCT and the absorbed gamma ray dose in the irradiated field. To assess blood 24Na, 1 ml of peripheral blood was collected from 30 patients immediately after the exposure, and the radioactivity of blood 24Na was determined using a germanium counter. The activity of 24Na in the blood correlated with the absorbed gamma ray doses in the irradiated field. For the same absorbed gamma ray dose in the irradiated field, the activity of blood 24Na was higher in patients with neck or lung tumors than in patients with brain or skin tumors. The reasons for these findings are not readily apparent, but the difference in the blood volume and the ratio of bone to soft tissue in the irradiated field, as well as the dose that leaked through the clinical collimator, may be responsible. PMID:23392825

  19. New challenges in high-energy particle radiobiology.

    PubMed

    Durante, M

    2014-03-01

    Densely ionizing radiation has always been a main topic in radiobiology. In fact, α-particles and neutrons are sources of radiation exposure for the general population and workers in nuclear power plants. More recently, high-energy protons and heavy ions attracted a large interest for two applications: hadrontherapy in oncology and space radiation protection in manned space missions. For many years, studies concentrated on measurements of the relative biological effectiveness (RBE) of the energetic particles for different end points, especially cell killing (for radiotherapy) and carcinogenesis (for late effects). Although more recently, it has been shown that densely ionizing radiation elicits signalling pathways quite distinct from those involved in the cell and tissue response to photons. The response of the microenvironment to charged particles is therefore under scrutiny, and both the damage in the target and non-target tissues are relevant. The role of individual susceptibility in therapy and risk is obviously a major topic in radiation research in general, and for ion radiobiology as well. Particle radiobiology is therefore now entering into a new phase, where beyond RBE, the tissue response is considered. These results may open new applications for both cancer therapy and protection in deep space.

  20. New challenges in high-energy particle radiobiology

    PubMed Central

    2014-01-01

    Densely ionizing radiation has always been a main topic in radiobiology. In fact, α-particles and neutrons are sources of radiation exposure for the general population and workers in nuclear power plants. More recently, high-energy protons and heavy ions attracted a large interest for two applications: hadrontherapy in oncology and space radiation protection in manned space missions. For many years, studies concentrated on measurements of the relative biological effectiveness (RBE) of the energetic particles for different end points, especially cell killing (for radiotherapy) and carcinogenesis (for late effects). Although more recently, it has been shown that densely ionizing radiation elicits signalling pathways quite distinct from those involved in the cell and tissue response to photons. The response of the microenvironment to charged particles is therefore under scrutiny, and both the damage in the target and non-target tissues are relevant. The role of individual susceptibility in therapy and risk is obviously a major topic in radiation research in general, and for ion radiobiology as well. Particle radiobiology is therefore now entering into a new phase, where beyond RBE, the tissue response is considered. These results may open new applications for both cancer therapy and protection in deep space. PMID:24198199

  1. Rational design of gold nanoparticles functionalized with carboranes for application in Boron Neutron Capture Therapy.

    PubMed

    Ciani, Laura; Bortolussi, Silva; Postuma, Ian; Cansolino, Laura; Ferrari, Cinzia; Panza, Luigi; Altieri, Saverio; Ristori, Sandra

    2013-12-31

    In this paper we propose a bottom-up approach to obtain new boron carriers built with ortho-carborane functionalized gold nanoparticles (GNPs) for applications in Boron Neutron Capture Therapy. The interaction between carboranes and the gold surface was assured by one or two SH-groups directly linked to the boron atoms of the B10C2 cage. This allowed obtaining stable, nontoxic systems, though optimal biological performance was hampered by low solubility in aqueous media. To improve cell uptake, the hydrophilic character of carborane functionalized GNPs was enhanced by further coverage with an appropriately tailored diblock copolymer (PEO-b-PCL). This polymer also contained pendant carboranes to provide anchoring to the pre-functionalized GNPs. In vitro tests, carried out on osteosarcoma cells, showed that the final vectors possessed excellent biocompatibility joint to the capacity of concentrating boron atoms in the target, which is encouraging evidenced to pursue applications in vivo.

  2. Carborane-conjugated 2-quinolinecarboxamide ligands of the translocator protein for boron neutron capture therapy.

    PubMed

    Cappelli, Andrea; Valenti, Salvatore; Mancini, Alessandra; Giuliani, Germano; Anzini, Maurizio; Altieri, Saverio; Bortolussi, Silva; Ferrari, Cinzia; Clerici, Anna Maria; Zonta, Cecilia; Carraro, Fabio; Filippi, Irene; Giorgi, Gianluca; Donati, Alessandro; Ristori, Sandra; Vomero, Salvatore; Concas, Alessandra; Biggio, Giovanni

    2010-12-15

    Potential boron neutron capture therapy (BNCT) agents have been designed on the basis of the evidence about translocator protein (TSPO) overexpression on the outer mitochondrial membrane of tumor cells. The structure of the first TSPO ligand bearing a carborane cage (compound 2d) has been modified in order to find a suitable candidate for in vivo studies. The designed compounds were synthesized and evaluated for their potential interaction with TSPO and tumor cells. In vitro biological evaluation showed in the case of fluoromethyl derivative 4b a nanomolar TSPO affinity very similar to that of 2d, a significantly lower cytotoxicity, and a slightly superior performance as boron carrier toward breast cancer cells. Moreover, compound 4b could be used as a ¹⁹F magnetic resonance imaging (MRI) agent as well as labeled with ¹¹C or ¹⁸F to obtain positron emission tomography (PET) radiotracers in order to apply the "see and treat" strategy in BNCT.

  3. Cell cycle dependence of boron uptake from two boron compounds used for clinical neutron capture therapy.

    PubMed

    Yoshida, F; Matsumura, A; Shibata, Y; Yamamoto, T; Nakauchi, H; Okumura, M; Nose, T

    2002-12-10

    In neutron capture therapy, it is important that the boron is selectively uptaken by tumor cells. In the present study, we used flow cytometry to sort the cells in the G0/G1 phase and those in the G2/M phase, and the boron concentration in each fraction was measured with inductively coupled plasma atomic emission spectroscopy. The results revealed that sodium borocaptate and boronophenylalanine (BPA), were associated with higher rates of boron uptake in the G2/M than in the G0/G1 phase. However, the difference was more prominent in the case of BPA. The G2/M:G0/G1 ratio decreased as a function of exposure time in BPA containing culture medium, thereby indicating the cell cycle dependency of BPA uptake. Such heterogeneity of boron uptake by tumor cells should be considered for microdosimetry.

  4. Single step synthesis of nanostructured boron nitride for boron neutron capture therapy

    SciTech Connect

    Singh, Bikramjeet; Singh, Paviter; Kumar, Akshay; Kumar, Manjeet; Thakur, Anup

    2015-05-15

    Nanostructured Boron Nitride (BN) has been successfully synthesized by carbo-thermic reduction of Boric Acid (H{sub 3}BO{sub 3}). This method is a relatively low temperature synthesis route and it can be used for large scale production of nanostructured BN. The synthesized nanoparticles have been characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM) and differential thermal analyzer (DTA). XRD analysis confirmed the formation of single phase nanostructured Boron Nitride. SEM analysis showed that the particles are spherical in shape. DTA analysis showed that the phase is stable upto 900 °C and the material can be used for high temperature applications as well boron neutron capture therapy (BNCT)

  5. Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine

    SciTech Connect

    Coderre, J.A.; Greenberg, D.; Micca, P.L.; Joel, D.D.; Saraf, S. ); Packer, S. . Div. of Ophthalmology)

    1990-01-01

    During conventional radiotherapy, the dose that can be delivered to the tumor is limited by the tolerance of the surrounding normal tissue within the treatment volume. Boron Neutron Capture Therapy (BNCT) represents a promising modality for selective tumor irradiation. The key to effective BNCT is selective localization of {sup 10}B in the tumor. We have shown that the synthetic amino acid p-boronophenylalanine (BPA) will selectively deliver boron to melanomas and other tumors such as gliosarcomas and mammary carcinomas. Systemically delivered BPA may have general utility as a boron delivery agent for BNCT. In this paper, BNCT with BPA is used in treatment of experimentally induced gliosarcoma in rats and nonpigmented melanoma in rabbits. The tissue distribution of boron is described, as is response to the BNCT. 6 refs., 4 figs., 1 tab.

  6. The Anti-Proliferative Effect of Boron Neutron Capture Therapy in a Prostate Cancer Xenograft Model

    PubMed Central

    Yoshikawa, Yuki; Takai, Tomoaki; Ibuki, Naokazu; Hirano, Hajime; Nomi, Hayahito; Kawabata, Shinji; Kiyama, Satoshi; Miyatake, Shin-Ichi; Kuroiwa, Toshihiko; Suzuki, Minoru; Kirihata, Mitsunori; Azuma, Haruhito

    2015-01-01

    Purpose Boron neutron capture therapy (BNCT) is a selective radiation treatment for tumors that preferentially accumulate drugs carrying the stable boron isotope, 10B. BNCT has been evaluated clinically as an alternative to conventional radiation therapy for the treatment of brain tumors, and more recently, recurrent advanced head and neck cancer. Here we investigated the effect of BNCT on prostate cancer (PCa) using an in vivo mouse xenograft model that we have developed. Materials and Methods Mice bearing the xenotransplanted androgen-independent human PCa cell line, PC3, were divided into four groups: Group 1: untreated controls; Group 2: Boronophenylalanine (BPA); Group 3: neutron; Group 4: BPA-mediated BNCT. We compared xenograft growth among these groups, and the body weight and any motility disturbance were recorded. Immunohistochemical (IHC) studies of the proliferation marker, Ki-67, and TUNEL staining were performed 9 weeks after treatment. Results The in vivo studies demonstrated that BPA-mediated BNCT significantly delayed tumor growth in comparison with the other groups, without any severe adverse events. There was a significant difference in the rate of freedom from gait abnormalities between the BPA-mediated BNCT group and the other groups. The IHC studies revealed that BNCT treatment significantly reduced the number of Ki-67-positive cells in comparison with the controls (mean±SD 6.9±1.5 vs 12.7±4.0, p<0.05), while there was no difference in the number of apoptotic cells, suggesting that BPA-mediated BNCT reduced PCa progression without affecting apoptosis at 9 weeks post-treatment. Conclusions This study has provided the first preclinical proof-of-principle data to indicate that BPA-mediated BNCT reduces the in vivo growth of PCa. Although further studies will be necessary, BNCT might be a novel potential treatment for PCa. PMID:26325195

  7. Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer

    SciTech Connect

    Kankaanranta, Leena; Seppaelae, Tiina; Koivunoro, Hanna; Saarilahti, Kauko; Atula, Timo; Collan, Juhani; Salli, Eero; Kortesniemi, Mika; Uusi-Simola, Jouni; Maekitie, Antti; Seppaenen, Marko; Minn, Heikki; Kotiluoto, Petri; Auterinen, Iiro; Savolainen, Sauli; Kouri, Mauri; Joensuu, Heikki

    2007-10-01

    Purpose: Head and neck carcinomas that recur locally after conventional irradiation pose a difficult therapeutic problem. We evaluated safety and efficacy of boron neutron capture therapy (BNCT) in the treatment of such cancers. Methods and Materials: Twelve patients with inoperable, recurred, locally advanced (rT3, rT4, or rN2) head and neck cancer were treated with BNCT in a prospective, single-center Phase I-II study. Prior treatments consisted of surgery and conventionally fractionated photon irradiation to a cumulative dose of 56-74 Gy administered with or without concomitant chemotherapy. Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0. Intravenously administered boronophenylalanine-fructose (BPA-F, 400 mg/kg) was used as the boron carrier. Each patient was scheduled to be treated twice with BNCT. Results: Ten patients received BNCT twice; 2 were treated once. Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months. The median duration of response was 12.1 months; six responses were ongoing at the time of analysis or death (range, 4.9-19.2 months). Four (33%) patients were alive without recurrence with a median follow-up of 14.0 months (range, 12.8-19.2 months). The most common acute adverse effects were mucositis, fatigue, and local pain; 2 patients had a severe (Grade 3) late adverse effect (xerostomia, 1; dysphagia, 1). Conclusions: Boron neutron capture therapy is effective and safe in the treatment of inoperable, locally advanced head and neck carcinomas that recur at previously irradiated sites.

  8. Neutron shielding for a new projected proton therapy facility: A Geant4 simulation study.

    PubMed

    Cadini, Francesco; Bolst, David; Guatelli, Susanna; Beltran, Chris; Jackson, Michael; Rosenfeld, Anatoly B

    2016-12-01

    In this work, we used the Monte Carlo-based Geant4 simulation toolkit to calculate the ambient dose equivalents due to the secondary neutron field produced in a new projected proton therapy facility. In particular the facility geometry was modeled in Geant4 based on the CAD design. Proton beams were originated with an energy of 250MeV in the gantry rooms with different angles with respect to the patient; a fixed 250MeV proton beam was also modeled. The ambient dose equivalent was calculated in several locations of interest inside and outside the facility, for different scenarios. The simulation results were compared qualitatively to previous work on an existing facility bearing some similarities with the design under study, showing that the ambient dose equivalent ranges obtained are reasonable. The ambient dose equivalents, calculated by means of the Geant4 simulation, were compared to the Australian regulatory limits and showed that the new facility will not pose health risks for the public or staff, with a maximum equivalent dose rate equal to 7.9mSv/y in the control rooms and maze exit areas and 1.3·10(-1)mSv/y close to the walls, outside the facility, under very conservative assumptions. This work represents the first neutron shielding verification analysis of a new projected proton therapy facility and, as such, it may serve as a new source of comparison and validation for the international community, besides confirming the viability of the project from a radioprotection point of view.

  9. Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent.

    PubMed

    Dewi, Novriana; Yanagie, Hironobu; Zhu, Haito; Demachi, Kazuyuki; Shinohara, Atsuko; Yokoyama, Kazuhito; Sekino, Masaki; Sakurai, Yuriko; Morishita, Yasuyuki; Iyomoto, Naoko; Nagasaki, Takeshi; Horiguchi, Yukichi; Nagasaki, Yukio; Nakajima, Jun; Ono, Minoru; Kakimi, Kazuhiro; Takahashi, Hiroyuki

    2013-07-01

    Neutron capture therapy (NCT) is a promising non-invasive cancer therapy approach and some recent NCT research has focused on using compounds containing gadolinium as an alternative to currently used boron-10 considering several advantages that gadolinium offers compared to those of boron. In this study, we evaluated gadolinium-entrapped liposome compound as neutron capture therapy agent by in vivo experiment on colon-26 tumor-bearing mice. Gadolinium compound were injected intravenously via tail vein and allowed to accumulate into tumor site. Tumor samples were taken for quantitative analysis by ICP-MS at 2, 12, and 24 h after gadolinium compound injection. Highest gadolinium concentration was observed at about 2 h after gadolinium compound injection with an average of 40.3 μg/g of wet tumor tissue. We performed neutron irradiation at JRR-4 reactor facility of Japan Atomic Energy Research Institute in Tokaimura with average neutron fluence of 2×10¹² n/cm². The experimental results showed that the tumor growth suppression of gadolinium-injected irradiated group was revealed until about four times higher compared to the control group, and no significant weight loss were observed after treatment suggesting low systemic toxicity of this compound. The gadolinium-entrapped liposome will become one of the candidates for Gd delivery system on NCT.

  10. Biological efficacy of boronated low-density lipoprotein for boron neutron capture therapy as measured in cell culture.

    PubMed

    Laster, B H; Kahl, S B; Popenoe, E A; Pate, D W; Fairchild, R G

    1991-09-01

    Low-density lipoproteins (LDLs) are known to be internalized by the cell through receptor-mediated mechanisms. There is evidence that LDLs may be taken up avidly by tumor cells to provide cholesterol for the synthesis of cell membranes. Thus, the possibility exists that LDLs may provide an ideal vehicle for the transport of boron to tumor cells for boron neutron capture therapy. A boronated analogue of LDL has recently been synthesized for possible application in boron neutron capture therapy. The analogue was tested in cell culture for uptake and biological efficacy in the thermal neutron beam at the Brookhaven Medical Research Reactor. It was found that boron concentrations 10 times higher than that required in tumors for boron neutron capture therapy were easily obtained and that the amount of uptake was consistent with a receptor-mediated binding mechanism. The measured intracellular concentration of approximately 240 micrograms 10B/g cells is significantly higher than that obtained with any other boron compound previously evaluated for possible clinical application.

  11. Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma.

    PubMed

    Hsu, C F; Lin, S Y; Peir, J J; Liao, J W; Lin, Y C; Chou, F I

    2011-12-01

    Osteosarcoma is a malignant tumor commonly found in human and animals. The ability of boric acid (BA) to accumulate in osteosarcoma due to the mechanism of the bone formation of cancer cells would make boron neutron capture therapy (BNCT) an alternative therapy for osteosarcoma. This study evaluated the feasibility of using BA as the boron drug for BNCT of bone cancer. The cytotoxicity of BA to L929 cells exceeded that of UMR-106 cells. With 25 μg (10)B/mL medium of BA treatment, the boron concentration in UMR-106 cells was higher than that in L929 cells. The biodistribution and pharmacokinetics of BA in Sprague-Dawley (SD) rats were studied by administrating 25 mg (10)B/kg body weight to SD rats. Blood boron level decreased rapidly within one hour after BA injection. Boron concentration in the long bone was 4-6 time higher than that of blood. Results of this study suggest that BA may be a potential drug for BNCT for osteosarcoma.

  12. [A clinical trial of neutron capture therapy for brain tumors]. Technical progress report 1988

    SciTech Connect

    Zamenhof, R.G.

    1988-12-31

    This report describes progress made in refining of neutron-induced alpha tract autoradiography, in designing epithermal neutron bean at MITR-II and in planning treatment dosimetry using Monte Carlo techniques.

  13. Optical polarizing neutron devices designed for pulsed neutron sources

    SciTech Connect

    Takeda, M.; Kurahashi, K.; Endoh, Y.; Itoh, S.

    1997-09-01

    We have designed two polarizing neutron devices for pulsed cold neutrons. The devices have been tested at the pulsed neutron source at the Booster Synchrotron Utilization Facility of the National Laboratory for High Energy Physics. These two devices proved to have a practical use for experiments to investigate condensed matter physics using pulsed cold polarized neutrons.

  14. High-energy spectroscopic astrophysics

    NASA Astrophysics Data System (ADS)

    Güdel, Manuel; Walter, Roland

    After three decades of intense research in X-ray and gamma-ray astronomy, the time was ripe to summarize basic knowledge on X-ray and gamma-ray spectroscopy for interested students and researchers ready to become involved in new high-energy missions. This volume exposes both the scientific basics and modern methods of high-energy spectroscopic astrophysics. The emphasis is on physical principles and observing methods rather than a discussion of particular classes of high-energy objects, but many examples and new results are included in the three chapters as well.

  15. Experimental High Energy Neutrino Astrophysics

    SciTech Connect

    Distefano, Carla

    2005-10-12

    Neutrinos are considered promising probes for high energy astrophysics. More than four decades after deep water Cerenkov technique was proposed to detect high energy neutrinos. Two detectors of this type are successfully taking data: BAIKAL and AMANDA. They have demonstrated the feasibility of the high energy neutrino detection and have set first constraints on TeV neutrino production astrophysical models. The quest for the construction of km3 size detectors have already started: in the South Pole, the IceCube neutrino telescope is under construction; the ANTARES, NEMO and NESTOR Collaborations are working towards the installation of a neutrino telescope in the Mediterranean Sea.

  16. Flux and Spectrum of Neutrons Generated from 25 Mv Medical X-Ray Therapy Machine

    DTIC Science & Technology

    1989-05-01

    neutron absorption cross section at t. By using this relation in equation (1) the integration is possible over...0 n td f dat) n (it, rpLthprmQJ where 000 is defined as the microscopic neutron absorption cross - section at 2200 m/s, the most probable speed of a... neutron - absorption cross - section of the target as a function of energy O(E) is neutron flux per unit of energy as a function of energy. 1,d is

  17. Macroscopic geometric heterogeneity effects in radiation dose distribution analysis for boron neutron capture therapy.

    PubMed

    Moran, J M; Nigg, D W; Wheeler, F J; Bauer, W F

    1992-01-01

    Calculations of radiation flux and dose distributions for boron neutron capture therapy (BNCT) of brain tumors are typically performed using sophisticated three-dimensional analytical models based on either a homogeneous approximation or a simplified few-region approximation to the actual highly heterogeneous geometry of the irradiation volume. Such models should be validated by comparison with calculations using detailed models in which all significant macroscopic tissue heterogeneities and geometric structures are explicitly represented as faithfully as possible. This paper describes such a validation exercise for BNCT of canine brain tumors. Geometric measurements of the canine anatomical structures of interest for this work were performed by dissecting and examining two essentially identical Labrador retriever heads. Chemical analyses of various tissue samples taken during the dissections were conducted to obtain measurements of elemental compositions for the tissues of interest. The resulting geometry and tissue composition data were then used to construct a detailed heterogeneous calculational model of the Labrador head. Calculations of three-dimensional radiation flux distributions pertinent to BNCT were performed for this model using the TORT discrete-ordinates radiation transport code. The calculations were repeated for a corresponding volume-weighted homogeneous-tissue model. Comparison of the results showed that peak neutron and photon flux magnitudes were quite similar for the two models (within 5%), but that the spatial flux profiles were shifted in the heterogeneous model such that the fluxes in some locations away from the peak differed from the corresponding fluxes in the homogeneous model by as much as 10%-20%. Differences of this magnitude can be therapeutically significant, emphasizing the need for proper validation of simplified treatment planning models.

  18. A benchmark analysis of radiation flux distribution for Boron Neutron Capture Therapy of canine brain tumors

    SciTech Connect

    Moran, J.M.

    1992-02-01

    Calculations of radiation flux and dose distributions for Boron Neutron Capture Therapy (BNCT) of brain tumors are typically performed using sophisticated three-dimensional analytical models based on either a homogeneous approximation or a simplified few-region approximation to the actual highly-heterogeneous geometry of the irradiation volume. Such models should be validated by comparison with calculations using detailed models in which all significant macroscopic tissue heterogeneities and geometric structures are explicitly represented as faithfully as possible. This work describes a validation exercise for BNCT of canine brain tumors. Geometric measurements of the canine anatomical structures of interest for this work were performed by dissecting and examining two essentially identical Labrador Retriever heads. Chemical analyses of various tissue samples taken during the dissections were conducted to obtain measurements of elemental compositions for tissues of interest. The resulting geometry and tissue composition data were then used to construct a detailed heterogeneous calculational model of the Labrador Retriever head. Calculations of three-dimensional radiation flux distributions pertinent to BNCT were performed for the model using the TORT discrete-ordinates radiation transport code. The calculations were repeated for a corresponding volume-weighted homogeneous tissue model. Comparison of the results showed that the peak neutron and photon flux magnitudes were quite similar for the two models (within 5%), but that the spatial flux profiles were shifted in the heterogeneous model such that the fluxes in some locations away from the peak differed from the corresponding fluxes in the homogeneous model by as much as 10-20%. Differences of this magnitude can be therapeutically significant, emphasizing the need for proper validation of simplified treatment planning models.

  19. Experimental and Simulated Characterization of a Beam Shaping Assembly for Accelerator- Based Boron Neutron Capture Therapy (AB-BNCT)

    SciTech Connect

    Burlon, Alejandro A.; Valda, Alejandro A.; Girola, Santiago; Minsky, Daniel M.; Kreiner, Andres J.

    2010-08-04

    In the frame of the construction of a Tandem Electrostatic Quadrupole Accelerator facility devoted to the Accelerator-Based Boron Neutron Capture Therapy, a Beam Shaping Assembly has been characterized by means of Monte-Carlo simulations and measurements. The neutrons were generated via the {sup 7}Li(p, n){sup 7}Be reaction by irradiating a thick LiF target with a 2.3 MeV proton beam delivered by the TANDAR accelerator at CNEA. The emerging neutron flux was measured by means of activation foils while the beam quality and directionality was evaluated by means of Monte Carlo simulations. The parameters show compliance with those suggested by IAEA. Finally, an improvement adding a beam collimator has been evaluated.

  20. A Small-Animal Irradiation Facility for Neutron Capture Therapy Research at the RA-3 Research Reactor

    SciTech Connect

    Emiliano Pozzi; David W. Nigg; Marcelo Miller; Silvia I. Thorp; Amanda E. Schwint; Elisa M. Heber; Veronica A. Trivillin; Leandro Zarza; Guillermo Estryk

    2007-11-01

    The National Atomic Energy Commission of Argentina (CNEA) has constructed a thermal neutron source for use in Boron Neutron Capture Therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The Idaho National Laboratory (INL) and CNEA have jointly conducted some initial neutronic characterization measurements for one particular configuration of this source. The RA-3 reactor (Figure 1) is an open pool type reactor, with 20% enriched uranium plate-type fuel and light water coolant. A graphite thermal column is situated on one side of the reactor as shown. A tunnel penetrating the graphite structure enables the insertion of samples while the reactor is in normal operation. Samples up to 14 cm height and 15 cm width are accommodated.

  1. A Bystander Effect Observed in Boron Neutron Capture Therapy: A Study of the Induction of Mutations in the HPRT Locus

    SciTech Connect

    Kinashi, Yuko . E-mail: kinashi@rri.kyoto-u.ac.jp; Masunaga, Shinichiro; Nagata, Kenji; Suzuki, Minoru; Takahashi, Sentaro; Ono, Koji

    2007-06-01

    Purpose: To investigate bystander mutagenic effects induced by {alpha}-particles during boron neutron capture therapy, we mixed cells that were electroporated with borocaptate sodium (BSH), which led to the accumulation of {sup 10}B inside the cells, and cells that did not contain the boron compound. The BSH-containing cells were irradiated with {alpha}-particles produced by the {sup 10}B(n,{alpha}){sup 7}Li reaction, whereas cells without boron were affected only by the {sup 1}H(n,{gamma}){sup 2}H and {sup 14}N(n,{rho}){sup 14}C reactions. Methods and Materials: The lethality and mutagenicity measured by the frequency of mutations induced in the hypoxanthine-guanine phosphoribosyltransferase locus were examined in Chinese hamster ovary cells irradiated with neutrons (Kyoto University Research Reactor: 5 MW). Neutron irradiation of 1:1 mixtures of cells with and without BSH resulted in a survival fraction of 0.1, and the cells that did not contain BSH made up 99.4% of the resulting cell population. The molecular structures of the mutations were determined using multiplex polymerase chain reactions. Results: Because of the bystander effect, the frequency of mutations increased in the cells located nearby the BSH-containing cells compared with control cells. Molecular structural analysis indicated that most of the mutations induced by the bystander effect were point mutations and that the frequencies of total and partial deletions induced by the bystander effect were less than those induced by the original neutron irradiation. Conclusion: These results suggested that in boron neutron capture therapy, the mutations caused by the bystander effect and those caused by the original neutron irradiation are induced by different mechanisms.

  2. Demonstration of a high-intensity neutron source based on a liquid-lithium target for Accelerator based Boron Neutron Capture Therapy.

    PubMed

    Halfon, S; Arenshtam, A; Kijel, D; Paul, M; Weissman, L; Berkovits, D; Eliyahu, I; Feinberg, G; Kreisel, A; Mardor, I; Shimel, G; Shor, A; Silverman, I; Tessler, M

    2015-12-01

    A free surface liquid-lithium jet target is operating routinely at Soreq Applied Research Accelerator Facility (SARAF), bombarded with a ~1.91 MeV, ~1.2 mA continuous-wave narrow proton beam. The experiments demonstrate the liquid lithium target (LiLiT) capability to constitute an intense source of epithermal neutrons, for Accelerator based Boron Neutron Capture Therapy (BNCT). The target dissipates extremely high ion beam power densities (>3 kW/cm(2), >0.5 MW/cm(3)) for long periods of time, while maintaining stable conditions and localized residual activity. LiLiT generates ~3×10(10) n/s, which is more than one order of magnitude larger than conventional (7)Li(p,n)-based near threshold neutron sources. A shield and moderator assembly for BNCT, with LiLiT irradiated with protons at 1.91 MeV, was designed based on Monte Carlo (MCNP) simulations of BNCT-doses produced in a phantom. According to these simulations it was found that a ~15 mA near threshold proton current will apply the therapeutic doses in ~1h treatment duration. According to our present results, such high current beams can be dissipated in a liquid-lithium target, hence the target design is readily applicable for accelerator-based BNCT.

  3. Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.

    PubMed

    Kawabata, Shinji; Yang, Weilian; Barth, Rolf F; Wu, Gong; Huo, Tianyao; Binns, Peter J; Riley, Kent J; Ongayi, Owendi; Gottumukkala, Vijay; Vicente, M Graça H

    2011-06-01

    Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive 10B is irradiated with low energy thermal neutrons to produce α-particles (10B[n,α] Li). Carboranylporphyrins are a class of substituted porphyrins containing multiple carborane clusters. Three of these compounds, designated H2TBP, H2TCP, and H2DCP, have been evaluated in the present study. The goals were two-fold. First, to determine their biodistribution following intracerebral (i.c.) administration by short term (30 min) convection enhanced delivery (CED) or sustained delivery over 24 h by Alzet™ osmotic pumps to F98 glioma bearing rats. Second, to determine the efficacy of H2TCP and H2TBP as boron delivery agents for BNCT in F98 glioma bearing rats. Tumor boron concentrations immediately after i.c. pump delivery were high and they remained so at 24 h. The corresponding normal brain concentrations were low and the blood and liver concentrations were undetectable. Based on these data, therapy studies were initiated at the Massachusetts Institute of Technology (MIT) Research Reactor (MITR) with H2TCP and H2TBP 24 h after CED or pump delivery. Mean survival times (MST) ± standard deviations of animals that had received H2TCP or H2TBP, followed by BNCT, were of 35 ± 4 and 44 ± 10 days, compared to 23 ± 3 and 27 ± 3 days, respectively, for untreated and irradiated controls. However, since the tumor boron concentrations of the carboranylporphyrins were 3-5× higher than intravenous (i.v.) boronophenylalanine (BPA), we had expected that the MSTs would have been greater. Histopathologic examination of brains of BNCT treated rats revealed that there were large numbers of porphyrin-laden macrophages, as well as extracellular accumulations of porphyrins, indicating that the seemingly high tumor boron concentrations did not represent the true tumor cellular uptake. Nevertheless, our data are the first to show that carboranyl porphyrins can be

  4. Activation of hip prostheses in high energy radiotherapy and resultant dose to nearby tissue.

    PubMed

    Keehan, Stephanie; Smith, Ryan L; Millar, Jeremy; Esser, Max; Taylor, Michael L; Lonski, Peta; Kron, Tomas; Franich, Rick D

    2017-03-01

    High energy radiotherapy can produce contaminant neutrons through the photonuclear effect. Patients receiving external beam radiation therapy to the pelvis may have high-density hip prostheses. Metallic materials such as those in hip prostheses, often have high cross-sections for neutron interaction. In this study, Thackray (UK) prosthetic hips have been irradiated by 18 MV radiotherapy beams to evaluate the additional dose to patients from the activation products. Hips were irradiated in- and out-of field at various distances from the beam isocenter to assess activation caused in-field by photo-activation, and neutron activation which occurs both in and out-of-field. NaI(Tl) scintillator detectors were used to measure the subsequent gamma-ray emissions and their half-lives. High sensitivity Mg, Cu, P doped LiF thermoluminescence dosimeter chips (TLD-100H) were used to measure the subsequent dose at the surface of a prosthesis over the 12 h following an in-field irradiation of 10,000 MU to a hip prosthesis located at the beam isocenter in a water phantom. (53) Fe, (56) Mn, and (52) V were identified within the hip following irradiation by radiotherapy beams. The dose measured at the surface of a prosthesis following irradiation in a water phantom was 0.20 mGy over 12 h. The dose at the surface of prostheses irradiated to 200 MU was below the limit of detection (0.05 mGy) of the TLD100H. Prosthetic hips are activated by incident photons and neutrons in high energy radiotherapy, however, the dose resulting from activation is very small.

  5. Effect of diameter of nanoparticles and capture cross-section library on macroscopic dose enhancement in boron neutron capture therapy

    PubMed Central

    Farhood, Bagher

    2014-01-01

    Purpose The aim of this study is evaluation of the effect of diameter of 10B nanoparticles and various neutron capture cross-section libraries on macroscopic dose enhancement in boron neutron capture therapy (BNCT). Material and methods MCNPX Monte Carlo code was used for simulation of a 252Cf source, a soft tissue phantom and a tumor containing 10B nanoparticles. Using 252Cf as a neutron source, macroscopic dose enhancement factor (MDEF) and total dose rate in tumor in the presence of 100, 200, and 500 ppm of 10B nanoparticles with 25 nm, 50 nm, and 100 nm diameters were calculated. Additionally, the effect of ENDF, JEFF, JENDL, and CENDL neutron capture cross-section libraries on MDEF was evaluated. Results There is not a linear relationship between the average MDEF value and nanoparticles’ diameter but the average MDEF grows with increased concentration of 10B nanoparticles. There is an increasing trend for average MDEF with the tumor distance. The average MDEF values were obtained the same for various neutron capture cross-section libraries. The maximum and minimum doses that effect on the total dose in tumor were neutron and secondary photon doses, respectively. Furthermore, the boron capture related dose component reduced in some extent with increase of diameter of 10B nanoparticles. Conclusions Based on the results of this study, it can be concluded that from physical point of view, various nanoparticle diameters have no dominant effect on average MDEF value in tumor. Furthermore, it is concluded that various neutron capture cross-section libraries are resulted to the same macroscopic dose enhancements. However, it is predicted that taking into account the biological effects for various nanoparticle diameters will result in different dose enhancements. PMID:25834582

  6. Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers.

    PubMed

    Koganei, Hayato; Ueno, Manabu; Tachikawa, Shoji; Tasaki, Lisa; Ban, Hyun Seung; Suzuki, Minoru; Shiraishi, Kouichi; Kawano, Kumi; Yokoyama, Masayuki; Maitani, Yoshie; Ono, Koji; Nakamura, Hiroyuki

    2013-01-16

    Mercaptoundecahydrododecaborate (BSH)-encapsulating 10% distearoyl boron lipid (DSBL) liposomes were developed as a boron delivery vehicle for neutron capture therapy. The current approach is unique because the liposome shell itself possesses cytocidal potential in addition to its encapsulated agents. BSH-encapsulating 10% DSBL liposomes have high boron content (B/P ratio: 2.6) that enables us to prepare liposome solution with 5000 ppm boron concentration. BSH-encapsulating 10% DSBL liposomes displayed excellent boron delivery efficacy to tumor: boron concentrations reached 174, 93, and 32 ppm at doses of 50, 30, and 15 mg B/kg, respectively. Magnescope was also encapsulated in the 10% DSBL liposomes and the real-time biodistribution of the Magnescope-encapsulating DSBL liposomes was measured in a living body using MRI. Significant antitumor effect was observed in mice injected with BSH-encapsulating 10% DSBL liposomes even at the dose of 15 mg B/kg; the tumor completely disappeared three weeks after thermal neutron irradiation ((1.5-1.8) × 10(12) neutrons/cm(2)). The current results enabled us to reduce the total dose of liposomes to less than one-fifth compared with that of the BSH-encapsulating liposomes without reducing the efficacy of boron neutron capture therapy (BNCT).

  7. Synthesis of Sugar-Boronic Acid Derivatives: A Class of Potential Agents for Boron Neutron Capture Therapy.

    PubMed

    Imperio, Daniela; Del Grosso, Erika; Fallarini, Silvia; Lombardi, Grazia; Panza, Luigi

    2017-04-07

    To date, sugar analogues that contain boronic acids as substitutes for hydroxyl groups are a class of compounds nearly unknown in the literature. The challenging synthesis of two sugar-boronic acid analogues is described, and data are retrieved on their solution behavior, stability, and toxicity. As these compounds were expected to mimic the behavior of carbohydrates, they were tested in regards to their future development as potential boron neutron capture therapy agents.

  8. Clinical trials of boron neutron capture therapy [in humans] [at Beth Israel Deaconess Medical Center][at Brookhaven National Laboratory

    SciTech Connect

    Wallace, Christine

    2001-05-29

    Assessment of research records of Boron Neutron Capture Therapy was conducted at Brookhaven National Laboratory and Beth Israel Deaconess Medical Center using the Code of Federal Regulations, FDA Regulations and Good Clinical Practice Guidelines. Clinical data were collected from subjects' research charts, and differences in conduct of studies at both centers were examined. Records maintained at Brookhaven National Laboratory were not in compliance with regulatory standards. Beth Israel's records followed federal regulations. Deficiencies discovered at both sites are discussed in the reports.

  9. Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome

    SciTech Connect

    Kageji, Teruyoshi . E-mail: kageji@clin.med.tokushima-u.ac.jp; Nagahiro, Shinji; Matsuzaki, Kazuhito; Mizobuchi, Yoshifumi; Toi, Hiroyuki; Nakagawa, Yoshinobu; Kumada, Hiroaki

    2006-08-01

    Purpose: To clarify the correlation between the radiation dose and clinical outcome of sodium borocaptate-based intraoperative boron neutron capture therapy in patients with malignant glioma. Methods and Materials: The first protocol (P1998, n = 8) prescribed a maximal gross tumor volume (GTV) dose of 15 Gy. In 2001, a dose-escalated protocol was introduced (P2001, n 11), which prescribed a maximal vascular volume dose of 15 Gy or, alternatively, a clinical target volume (CTV) dose of 18 Gy. Results: The GTV and CTV doses in P2001 were 1.1-1.3 times greater than those in P1998. The maximal vascular volume dose of those with acute radiation injury was 15.8 Gy. The mean GTV and CTV dose in long-term survivors with glioblastoma was 26.4 and 16.5 Gy, respectively. A statistically significant correlation between the GTV dose and median survival time was found. In the 11 glioblastoma patients in P2001, the median survival time was 19.5 months and 1- and 2-year survival rate was 60.6% and 37.9%, respectively. Conclusion: Dose escalation contributed to the improvement in clinical outcome. To avoid radiation injury, the maximal vascular volume dose should be <12 Gy. For long-term survival in patients with glioblastoma after boron neutron capture therapy, the optimal mean dose of the GTV and CTV was 26 and 16 Gy, respectively.

  10. Effect of Boron Neutron Capture Therapy (BNCT) on Normal Liver Regeneration: Towards a Novel Therapy for Liver Metastases

    SciTech Connect

    Jorge E. Cardoso; Elisa M. Heber; David W. Nigg; Osvaldo Calzetta; Herman Blaumann; Juan Longhino; Maria E. Itoiz; Eduardo Bumaschny; Emiliano Pozzi; Amanda E.Schwint; Verónica A. Trivillin

    2007-10-01

    The “TAORMINA project” developed a new method for Boron Neutron Capture Therapy (BNCT) of human multifocal unresectable liver metastases based on whole liver ex-situ BNCT mediated by boronophenylalanine (BPA), followed by whole liver autograft. This technique involved a high risk, prolonged anhepatic phase. The Roffo Institute liver surgeons (JEC) herein propose a novel technique to pursue ex-situ liver BNCT studies with a drastically lower surgical risk for the patient. The technique would involve, sequentially, ex-situ BNCT of left liver segments II and III, partial liver autograft, and induction of partial atrophy of the untreated right liver. The working hypothesis is that the atrophy of the right, untreated, diseased liver would stimulate regeneration of the left, treated, “cured” liver to yield a healthy liver mass, allowing for the resection of the remaining portion of diseased liver. This technique does not involve an anhepatic phase and would thus pose a drastically lower surgical risk to the patient but requires sine qua non that BNCT should not impair the regenerative capacity of normal hepatocytes. The aim of the present study was to assess the effect of therapeutic doses of BNCT mediated by BPA, GB-10 (Na2 10B10H10) or (GB- 10 + BPA) on normal liver regeneration in the Wistar rat employing partial hepatectomy as a regenerative stimulus. BNCT did not cause alterations in the outcome of normal liver regeneration, regenerated liver function or histology. We provide proof of principle to support the development of a novel, promising BNCT technique for the treatment of liver metastases.

  11. High Energy Astronomy Observatory (HEAO)-1

    NASA Technical Reports Server (NTRS)

    1978-01-01

    This drawing is a schematic of the High Energy Astronomy Observatory (HEAO)-1. The first observatory, designated HEAO-1, was launched on August 12, 1977 aboard an Atlas/Centaur launch vehicle and was designed to survey the sky for additional x-ray and gamma-ray sources as well as pinpointing their positions. The HEAO-1 was originally identified as HEAO-A but the designation was changed once the spacecraft achieved orbit. The HEAO project involved the launching of three unmarned scientific observatories into low Earth orbit between 1977 and 1979 to study some of the most intriguing mysteries of the universe; pulsars, black holes, neutron stars, and super nova. Hardware support for the imaging instruments was provided by American Science and Engineeing. The HEAO spacecraft were built by TRW, Inc. under project management of the Marshall Space Flight Center.

  12. High Energy Astronomy Observatory (HEAO)-1

    NASA Technical Reports Server (NTRS)

    1982-01-01

    This artist's conception depicts the High Energy Astronomy Observatory (HEAO)-1 in orbit. The first observatory, designated HEAO-1, was launched on August 12, 1977 aboard an Atlas/Centaur launch vehicle and was designed to survey the sky for additional x-ray and gamma-ray sources as well as pinpointing their positions. The HEAO-1 was originally identified as HEAO-A but the designation was changed once the spacecraft achieved orbit. The HEAO project involved the launching of three unmarned scientific observatories into low Earth orbit between 1977 and 1979 to study some of the most intriguing mysteries of the universe; pulsars, black holes, neutron stars, and super nova. Hardware support for the imaging instruments was provided by American Science and Engineeing. The HEAO spacecraft were built by TRW, Inc. under project management of the Marshall Space Flight Center.

  13. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

    PubMed

    Sköld, K; Gorlia, T; Pellettieri, L; Giusti, V; H-Stenstam, B; Hopewell, J W

    2010-07-01

    The purpose of this study was to assess the potential of boron neutron capture therapy (BNCT), with a 6-h infusion of the boron carrier l-boronophenylalanine as a fructose preparation (BPA-f), as first-line radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Patient survival data from a Phase II study using BNCT were compared with retrospective data from the two arms of a Phase III study using conventional radiotherapy (RT) in the reference arm and using RT plus concomitant and adjuvant medication with temozolomide (TMZ) in the experimental arm, and were also compared with small subgroups of these patients for whom the methylation status of the MGMT (O(6)-methylguanine-DNA methyltransferase) DNA repair gene was known. Differences in the baseline characteristics, salvage therapy after recurrence and levels of severe adverse events were also considered. The results indicate that BNCT offers a treatment that is at least as effective as conventional RT alone. For patients with an unmethylated MGMT DNA repair gene, a possible clinical advantage of BNCT over RT/TMZ was suggested. BNCT is a single-day treatment, which is of convenience to patients, with mild side effects, which would offer an initial 6 weeks of good-quality life during the time when patients would otherwise be undergoing daily treatments with RT and TMZ. It is suggested that the use of BNCT with a 6-h infusion of BPA-f should be explored in a stratified randomised Phase II trial in which patients with the unmethylated MGMT DNA repair gene are offered BNCT in the experimental arm and RT plus TMZ in the reference arm.

  14. Advantage and limitations of weighting factors and weighted dose quantities and their units in boron neutron capture therapy.

    PubMed

    Rassow, J; Sauerwein, W; Wittig, A; Bourhis-Martin, E; Hideghéty, K; Moss, R

    2004-05-01

    Defining the parameters influencing the biological reaction due to absorbed dose is a continuous topic of research. The main goal of radiobiological research is to translate the measurable dose of ionizing radiation to a quantitative expression of biological effect. Mathematical models based on different biological approaches (e.g., skin reaction, cell culture) provide some estimations that are often misleading and, to some extent, dangerous. Conventional radiotherapy is the simplest case because the primary radiation and secondary radiation are both low linear energy transfer (LET) radiation and have about the same relative biological effectiveness (RBE). Nevertheless, for this one-dose-component case, the dose-effect curves are not linear. In fact, the total absorbed dose and the absorbed dose per fraction as well as the time schedule of the fractionation scheme influence the biological effects. Mathematical models such as the linear-quadratic model can only approximate biological effects. With regard to biological effects, fast neutron therapy is more complex than conventional radiotherapy. Fast neutron beams are always contaminated by gamma rays. As a consequence, biological effects are due to two components, a high-LET component (neutrons) and a low-LET component (photons). A straight transfer of knowledge from conventional radiotherapy to fast neutron therapy is, therefore, not possible: RBE depends on the delivered dose and several other parameters. For dose reporting, the European protocol for fast neutron dosimetry recommends that the total absorbed dose with gamma-ray absorbed dose in brackets is stated. However, boron neutron capture therapy (BNCT) is an even more complex case, because the total absorbed dose is due to four dose components with different LET and RBE. In addition, the terminology and units used by the different BNCT groups is confusing: absorbed dose and weighted dose are both to be stated in grays and are never "photon equivalent." The

  15. Borocaptate sodium: a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors.

    PubMed Central

    Kraft, S L; Gavin, P R; DeHaan, C E; Leathers, C W; Bauer, W F; Miller, D L; Dorn, R V

    1992-01-01

    Borocaptate sodium (Na2B12H11SH) is a boron-carrying compound under consideration for use in boron neutron capture therapy. The biodistribution of boron from borocaptate sodium administration will partly determine boron neutron capture therapy efficacy and normal tissue radiation tolerance. The biodistribution of boron was determined in 30 dogs with spontaneous intracranial tumors at 2, 6, or 12 hr after intravenous borocaptate sodium infusion. Blood and tissue boron concentrations were measured using inductively coupled plasma atomic emission spectroscopy. Mean tumor boron concentration (mean +/- standard error) was 35.9 +/- 4.6 (n = 15), 22.5 +/- 6.0 (n = 9), and 7.0 +/- 1.1 micrograms of boron per g (n = 6) at 2, 6, and 12 hr, respectively, after borocaptate sodium infusion. Peritumor boron concentrations were elevated above that of normal brain in half of the dogs. Normal brain boron concentration (mean +/- standard error) was 4.0 +/- 0.5, 2.0 +/- 0.4, and 2.0 +/- 0.3 micrograms of boron per g at 2, 6, and 12 hr after infusion, respectively. Some cranial and systemic tissues, and blood, had high boron concentration relative to tumor tissue. Geometric dose sparing should partly offset these relatively high normal tissue and blood concentrations. Borocaptate sodium biodistribution is favorable because tumor boron concentrations of recommended magnitude for boron neutron capture therapy were obtained and there was a high tumor-to-normal brain boron concentration ratio. PMID:1465427

  16. Nanostructured Boron Nitride With High Water Dispersibility For Boron Neutron Capture Therapy

    NASA Astrophysics Data System (ADS)

    Singh, Bikramjeet; Kaur, Gurpreet; Singh, Paviter; Singh, Kulwinder; Kumar, Baban; Vij, Ankush; Kumar, Manjeet; Bala, Rajni; Meena, Ramovatar; Singh, Ajay; Thakur, Anup; Kumar, Akshay

    2016-10-01

    Highly water dispersible boron based compounds are innovative and advanced materials which can be used in Boron Neutron Capture Therapy for cancer treatment (BNCT). Present study deals with the synthesis of highly water dispersible nanostructured Boron Nitride (BN). Unique and relatively low temperature synthesis route is the soul of present study. The morphological examinations (Scanning/transmission electron microscopy) of synthesized nanostructures showed that they are in transient phase from two dimensional hexagonal sheets to nanotubes. It is also supported by dual energy band gap of these materials calculated from UV- visible spectrum of the material. The theoretically calculated band gap also supports the same (calculated by virtual nano lab Software). X-ray diffraction (XRD) analysis shows that the synthesized material has deformed structure which is further supported by Raman spectroscopy. The structural aspect of high water disperse ability of BN is also studied. The ultra-high disperse ability which is a result of structural deformation make these nanostructures very useful in BNCT. Cytotoxicity studies on various cell lines (Hela(cervical cancer), human embryonic kidney (HEK-293) and human breast adenocarcinoma (MCF-7)) show that the synthesized nanostructures can be used for BNCT.

  17. GPU-based prompt gamma ray imaging from boron neutron capture therapy

    SciTech Connect

    Yoon, Do-Kun; Jung, Joo-Young; Suk Suh, Tae; Jo Hong, Key; Sil Lee, Keum

    2015-01-15

    Purpose: The purpose of this research is to perform the fast reconstruction of a prompt gamma ray image using a graphics processing unit (GPU) computation from boron neutron capture therapy (BNCT) simulations. Methods: To evaluate the accuracy of the reconstructed image, a phantom including four boron uptake regions (BURs) was used in the simulation. After the Monte Carlo simulation of the BNCT, the modified ordered subset expectation maximization reconstruction algorithm using the GPU computation was used to reconstruct the images with fewer projections. The computation times for image reconstruction were compared between the GPU and the central processing unit (CPU). Also, the accuracy of the reconstructed image was evaluated by a receiver operating characteristic (ROC) curve analysis. Results: The image reconstruction time using the GPU was 196 times faster than the conventional reconstruction time using the CPU. For the four BURs, the area under curve values from the ROC curve were 0.6726 (A-region), 0.6890 (B-region), 0.7384 (C-region), and 0.8009 (D-region). Conclusions: The tomographic image using the prompt gamma ray event from the BNCT simulation was acquired using the GPU computation in order to perform a fast reconstruction during treatment. The authors verified the feasibility of the prompt gamma ray image reconstruction using the GPU computation for BNCT simulations.

  18. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer.

    PubMed

    Suzuki, Minoru; Kato, Ituro; Aihara, Teruhito; Hiratsuka, Junichi; Yoshimura, Kenichi; Niimi, Miyuki; Kimura, Yoshihiro; Ariyoshi, Yasunori; Haginomori, Shin-Ichi; Sakurai, Yoshinori; Kinashi, Yuko; Masunaga, Shin-Ichiro; Fukushima, Masanori; Ono, Koji; Maruhashi, Akira

    2014-01-01

    We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records. Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10-12 Gy-eq to the skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range, 0.7-40.8). A total of 87 BNCT procedures were performed. The overall response rate was 58% within 6 months after BNCT. The median survival time was 10.1 months from the time of BNCT. The 1- and 2-year overall survival (OS) rates were 43.1% and 24.2%, respectively. The major acute Grade 3 or 4 toxicities were hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stomatitis (9.7%) and pain (9.7%), all of which were manageable. Three patients died of treatment-related toxicity. Three patients experienced carotid artery hemorrhage, two of whom had coexistent infection of the carotid artery. This study confirmed the feasibility of our dose-estimation method and that controlled trials are warranted.

  19. Inborn errors in metabolism and 4-boronophenylalanine-fructose-based boron neutron capture therapy.

    PubMed

    Laakso, Juha; Ruokonen, Inkeri; Lapatto, Risto; Kallio, Merja

    2003-11-01

    Infusions of boronophenylalanine-fructose complex (BPA-F), at doses up to 900 mg/kg of BPA and 860 mg/kg of fructose, have been used to deliver boron to cancer tissue for boron neutron capture therapy (BNCT). In patients with phenylketonuria (PKU), phenylalanine accumulates, which is harmful in the long run. PKU has been an exclusion criterion for BPA-F-mediated BNCT. Fructose is harmful to individuals with hereditary fructose intolerance (HFI) in amounts currently used in BNCT. The harmful effects are mediated through induction of hypoglycemia and acidosis, which may lead to irreversible organ damage or even death. Consequently, HFI should be added as an exclusion criterion for BNCT if fructose-containing solutions are used in boron carriers. Non-HFI subjects may also develop symptoms, such as gastrointestinal pain, if the fructose infusion rate is high. We therefore recommend monitoring of glucose levels and correcting possible hypoglycemia promptly. Except for some populations with extremely low PKU prevalence, HFI and PKU prevalences are similar, approximately 1 or 2 per 20,000.

  20. Nanostructured Boron Nitride With High Water Dispersibility For Boron Neutron Capture Therapy

    PubMed Central

    Singh, Bikramjeet; Kaur, Gurpreet; Singh, Paviter; Singh, Kulwinder; Kumar, Baban; Vij, Ankush; Kumar, Manjeet; Bala, Rajni; Meena, Ramovatar; Singh, Ajay; Thakur, Anup; Kumar, Akshay

    2016-01-01

    Highly water dispersible boron based compounds are innovative and advanced materials which can be used in Boron Neutron Capture Therapy for cancer treatment (BNCT). Present study deals with the synthesis of highly water dispersible nanostructured Boron Nitride (BN). Unique and relatively low temperature synthesis route is the soul of present study. The morphological examinations (Scanning/transmission electron microscopy) of synthesized nanostructures showed that they are in transient phase from two dimensional hexagonal sheets to nanotubes. It is also supported by dual energy band gap of these materials calculated from UV- visible spectrum of the material. The theoretically calculated band gap also supports the same (calculated by virtual nano lab Software). X-ray diffraction (XRD) analysis shows that the synthesized material has deformed structure which is further supported by Raman spectroscopy. The structural aspect of high water disperse ability of BN is also studied. The ultra-high disperse ability which is a result of structural deformation make these nanostructures very useful in BNCT. Cytotoxicity studies on various cell lines (Hela(cervical cancer), human embryonic kidney (HEK-293) and human breast adenocarcinoma (MCF-7)) show that the synthesized nanostructures can be used for BNCT. PMID:27759052

  1. Lithium Nitride Synthesized by in situ Lithium Deposition and Ion Implantation for Boron Neutron Capture Therapy

    NASA Astrophysics Data System (ADS)

    Ishitama, Shintaro; Baba, Yuji; Fujii, Ryo; Nakamura, Masaru; Imahori, Yoshio

    Li3N synthesis on Li deposition layer was conducted without H2O and O2 by in situ lithium deposition in high vacuum chamber of 10-6 Pa and ion implantation techniques and the thermo-chemical stability of the Li3N/Li/Cu tri-layered target for Boron Neutron Capture Therapy (BNCT) under laser heating and air exposure was characterized by X-ray photoelectron spectroscopy (XPS). Following conclusions were derived; (1) Li3N/Li/Cu tri-layered target with very low oxide and carbon contamination was synthesized by in situ lithium vacuum deposition and N2+ ion implantation without H2O and O2 additions, (2) The starting temperature of evaporation of Li3N/Li/Cu tri-layered target increased by 120K compared to that of the Li/Cu target and (3) Remarkable oxidation and carbon contamination were observed on the surface of Li3N/Li/Cu after air exposure and these contaminated compositions was not removed by Ar+ heavy sputtering.

  2. Nanostructured Boron Nitride With High Water Dispersibility For Boron Neutron Capture Therapy.

    PubMed

    Singh, Bikramjeet; Kaur, Gurpreet; Singh, Paviter; Singh, Kulwinder; Kumar, Baban; Vij, Ankush; Kumar, Manjeet; Bala, Rajni; Meena, Ramovatar; Singh, Ajay; Thakur, Anup; Kumar, Akshay

    2016-10-19

    Highly water dispersible boron based compounds are innovative and advanced materials which can be used in Boron Neutron Capture Therapy for cancer treatment (BNCT). Present study deals with the synthesis of highly water dispersible nanostructured Boron Nitride (BN). Unique and relatively low temperature synthesis route is the soul of present study. The morphological examinations (Scanning/transmission electron microscopy) of synthesized nanostructures showed that they are in transient phase from two dimensional hexagonal sheets to nanotubes. It is also supported by dual energy band gap of these materials calculated from UV- visible spectrum of the material. The theoretically calculated band gap also supports the same (calculated by virtual nano lab Software). X-ray diffraction (XRD) analysis shows that the synthesized material has deformed structure which is further supported by Raman spectroscopy. The structural aspect of high water disperse ability of BN is also studied. The ultra-high disperse ability which is a result of structural deformation make these nanostructures very useful in BNCT. Cytotoxicity studies on various cell lines (Hela(cervical cancer), human embryonic kidney (HEK-293) and human breast adenocarcinoma (MCF-7)) show that the synthesized nanostructures can be used for BNCT.

  3. First Evaluation of the Biologic Effectiveness Factors of Boron Neutron Capture Therapy (BNCT) in a Human Colon Carcinoma Cell Line

    SciTech Connect

    Dagrosa, Maria Alejandra; Crivello, Martin; Perona, Marina; Thorp, Silvia; Santa Cruz, Gustavo Alberto; Pozzi, Emiliano; Casal, Mariana; Thomasz, Lisa; Cabrini, Romulo; Kahl, Steven; Juvenal, Guillermo Juan; Pisarev, Mario Alberto

    2011-01-01

    Purpose: DNA lesions produced by boron neutron capture therapy (BNCT) and those produced by gamma radiation in a colon carcinoma cell line were analyzed. We have also derived the relative biologic effectiveness factor (RBE) of the neutron beam of the RA-3- Argentine nuclear reactor, and the compound biologic effectiveness (CBE) values for p-boronophenylalanine ({sup 10}BPA) and for 2,4-bis ({alpha},{beta}-dihydroxyethyl)-deutero-porphyrin IX ({sup 10}BOPP). Methods and Materials: Exponentially growing human colon carcinoma cells (ARO81-1) were distributed into the following groups: (1) BPA (10 ppm {sup 10}B) + neutrons, (2) BOPP (10 ppm {sup 10}B) + neutrons, (3) neutrons alone, and (4) gamma rays ({sup 60}Co source at 1 Gy/min dose-rate). Different irradiation times were used to obtain total absorbed doses between 0.3 and 5 Gy ({+-}10%) (thermal neutrons flux = 7.5 10{sup 9} n/cm{sup 2} sec). Results: The frequency of micronucleated binucleated cells and the number of micronuclei per micronucleated binucleated cells showed a dose-dependent increase until approximately 2 Gy. The response to gamma rays was significantly lower than the response to the other treatments (p < 0.05). The irradiations with neutrons alone and neutrons + BOPP showed curves that did not differ significantly from, and showed less DNA damage than, irradiation with neutrons + BPA. A decrease in the surviving fraction measured by 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromide (MTT) assay as a function of the absorbed dose was observed for all the treatments. The RBE and CBE factors calculated from cytokinesis block micronucleus (CBMN) and MTT assays were, respectively, the following: beam RBE: 4.4 {+-} 1.1 and 2.4 {+-} 0.6; CBE for BOPP: 8.0 {+-} 2.2 and 2.0 {+-} 1; CBE for BPA: 19.6 {+-} 3.7 and 3.5 {+-} 1.3. Conclusions: BNCT and gamma irradiations showed different genotoxic patterns. To our knowledge, these values represent the first experimental ones obtained for the RA-3 in a

  4. Extreme Transients in the High Energy Universe

    NASA Technical Reports Server (NTRS)

    Kouveliotou, Chryssa

    2013-01-01

    The High Energy Universe is rich in diverse populations of objects spanning the entire cosmological (time)scale, from our own present-day Milky Way to the re-ionization epoch. Several of these are associated with extreme conditions irreproducible in laboratories on Earth. Their study thus sheds light on the behavior of matter under extreme conditions, such as super-strong magnetic fields (in excess of 10^14 G), high gravitational potentials (e.g., Super Massive Black Holes), very energetic collimated explosions resulting in relativistic jet flows (e.g., Gamma Ray Bursts, exceeding 10^53 ergs). In the last thirty years, my work has been mostly focused on two apparently different but potentially linked populations of such transients: magnetars (highly magnetized neutron stars) and Gamma Ray Bursts (strongly beamed emission from relativistic jets), two populations that constitute unique astrophysical laboratories, while also giving us the tools to probe matter conditions in the Universe to redshifts beyond z=10, when the first stars and galaxies were assembled. I did not make this journey alone I have either led or participated in several international collaborations studying these phenomena in multi-wavelength observations; solitary perfection is not sufficient anymore in the world of High Energy Astrophysics. I will describe this journey, present crucial observational breakthroughs, discuss key results and muse on the future of this field.

  5. Nucleon structure and the high energy interactions

    NASA Astrophysics Data System (ADS)

    Selyugin, O. V.

    2015-06-01

    On the basis of the representation of the generalized structure of nucleons a new model of the hadron interaction at high energies is presented. A new t dependence of the generalized parton distributions is obtained from the comparative analysis of different sets of the parton distribution functions, based on the description of the entire set of experimental data for the electromagnetic form factors of the proton and neutron. Taking into account the different moments of the generalized parton distributions of the hadron, quantitative descriptions of all existing experimental data of the proton-proton and proton-antiproton elastic scatterings from √{s }=9.8 GeV to 8 TeV, including the Coulomb range and large momentum transfers up to -t =15 GeV2 , are obtained with a few free high-energy fitting parameters. The real part of the hadronic elastic scattering amplitude is determined only through the complex s that satisfies the dispersion relations. The negligible contributions of the hard Pomeron and the presence of the non-small contributions of the maximal Odderon are obtained. The non-dying form of the spin-flip amplitude is examined as well. The structures of the Born term and unitarized scattering amplitude are analyzed. It is shown that the black disk limit for the elastic scattering amplitude is not reached at LHC energies. Predictions for LHC energies are made.

  6. High energy cosmic ray composition

    NASA Astrophysics Data System (ADS)

    Seo, E. S.

    Cosmic rays are understood to result from energetic processes in the galaxy, probably from supernova explosions. However, cosmic ray energies extend several orders of magnitude beyond the limit thought possible for supernova blast waves. Over the past decade several ground-based and space-based investigations were initiated to look for evidence of a limit to supernova acceleration in the cosmic-ray chemical composition at high energies. These high-energy measurements are difficult because of the very low particle fluxes in the most interesting regions. The space-based detectors must be large enough to collect adequate statistics, yet stay within the weight limit for space flight. Innovative approaches now promise high quality measurements over an energy range that was not previously possible. The current status of high energy cosmic-ray composition measurements and planned future missions are discussed in this paper.

  7. Future of high energy physics

    SciTech Connect

    Panofsky, W.K.H.

    1984-06-01

    A rough overview is given of the expectations for the extension of high energy colliders and accelerators into the xtremely high energy range. It appears likely that the SSC or something like it will be the last gasp of the conventional method of producing high energy proton-proton collisions using synchrotron rings with superconducting magnets. It is likely that LEP will be the highest energy e+e/sup -/ colliding beam storage ring built. The future beyond that depends on the successful demonstrations of new technologies. The linear collider offers hope in this respect for some extension in energy for electrons, and maybe even for protons, but is too early to judge whether, by how much, or when such an extension will indeed take place.

  8. Treatment of isografted 9L rat brain tumors with beta-5-o-carboranyl-2'-deoxyuridine neutron capture therapy.

    PubMed

    Schinazi, R F; Hurwitz, S J; Liberman, I; Juodawlkis, A S; Tharnish, P; Shi, J; Liotta, D C; Coderre, J A; Olson, J

    2000-02-01

    beta-5-o-Carboranyl-2'-deoxyuridine (D-CDU) is a nontoxic pyrimidine nucleoside analogue designed for boron neutron capture therapy of brain tumors. In vitro studies indicated that D-CDU accumulates to levels 92- and 117-fold higher than the extracellular concentration in rat 9L and human U-251 glioma cells, respectively, and persists for several hours at levels 5-fold higher than the extracellular concentration. Furthermore, D-CDU was not toxic to rats injected i.p. with up to 150 mg/kg. On the basis of these studies, D-CDU was evaluated as a neutron capture therapy agent using rats bearing stereotactically implanted intracranial 9L tumors at single i.p. doses of 30 mg/kg and 150 mg/kg of D-CDU (20% 10B enriched), given 2 h before irradiation with thermal neutrons. Boron concentrations in tumors 2 h after dosing were 2.3 +/- 1.6 and 7.4 +/- 1.3 micrograms boron/g tissue (mean +/- SD), corresponding to tumor/brain ratios of 11.5 +/- 3.6 and 6.8 +/- 2.0 micrograms boron/g tissue for the low and high doses, respectively. All untreated animals died within 28 days, whereas half survived at days 32, 55, and 38 for groups receiving neutrons only, 30 mg/kg D-CDU, and 150 mg/kg D-CDU, respectively. Odds ratios of all treatment groups differed significantly from the untreated group (P < 0.002; logrank test). The median survival time for the 30 mg/kg-treated group but not for the 150 mg/kg-treated group was significantly longer than for rats treated with neutrons only (P = 0.036), which may correlate with the decreased tumor selectivity for D-CDU observed at the higher dose. Additional pharmacodynamic studies are warranted to determine optimal dosing strategies for D-CDU.

  9. Layered semiconductor neutron detectors

    DOEpatents

    Mao, Samuel S; Perry, Dale L

    2013-12-10

    Room temperature operating solid state hand held neutron detectors integrate one or more relatively thin layers of a high neutron interaction cross-section element or materials with semiconductor detectors. The high neutron interaction cross-section element (e.g., Gd, B or Li) or materials comprising at least one high neutron interaction cross-section element can be in the form of unstructured layers or micro- or nano-structured arrays. Such architecture provides high efficiency neutron detector devices by capturing substantially more carriers produced from high energy .alpha.-particles or .gamma.-photons generated by neutron interaction.

  10. High Energy Astrophysics Program (HEAP)

    NASA Technical Reports Server (NTRS)

    Angelini, Lorella; Corcoran, Michael; Drake, Stephen; McGlynn, Thomas A.; Snowden, Stephen; Mukai, Koji; Cannizzo, John; Lochner, James; Rots, Arnold; Christian, Eric; Barthelmy, Scott; Palmer, David; Mitchell, John; Esposito, Joseph; Sreekumar, P.; Hua, Xin-Min; Mandzhavidze, Natalie; Chan, Kai-Wing; Soong, Yang; Barrett, Paul

    1998-01-01

    This report reviews activities performed by the members of the USRA contract team during the 6 months of the reporting period and projected activities during the coming 6 months. Activities take place at the Goddard Space Flight Center, within the Laboratory for High Energy Astrophysics. Developments concern instrumentation, observation, data analysis, and theoretical work in astrophysics. Supported missions include advanced Satellite for Cosmology and Astrophysics (ASCA), X-Ray Timing Experiment (XTE), X-Ray Spectrometer (XRS), Astro-E, High Energy Astrophysics Science Archive Research Center (HEASARC) and others.

  11. High Energy Astrophysics Program (HEAP)

    NASA Technical Reports Server (NTRS)

    Angelini, L.

    1998-01-01

    This report reviews activities performed by members of the USRA contract team during the six months of the reporting period and projected activities during the coming six months. Activities take place at the Goddard Space Flight Center, within the Laboratory for High Energy Astrophysics. Developments concern instrumentation, observation, data analysis, and theoretical work in Astrophysics Missions supported include: Advanced Satellite for Cosmology and Astrophysics (ASCA), X-ray Timing Experiment (XTE), X-ray Spectrometer (XRS), Astro-E, High Energy Astrophysics Science Archive Research Center (HEASARC), and others.

  12. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide.

    PubMed

    Michiue, Hiroyuki; Sakurai, Yoshinori; Kondo, Natsuko; Kitamatsu, Mizuki; Bin, Feng; Nakajima, Kiichiro; Hirota, Yuki; Kawabata, Shinji; Nishiki, Tei-ichi; Ohmori, Iori; Tomizawa, Kazuhito; Miyatake, Shin-ichi; Ono, Koji; Matsui, Hideki

    2014-03-01

    New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear reaction of boron-10 with neutron irradiation. The median survival of BNCT patients with glioblastoma was almost twice as long as those receiving standard therapy in a Japanese BNCT clinical trial. In this clinical trial, two boron compounds, BPA (boronophenylalanine) and BSH (sodium borocaptate), were used for BNCT. BPA is taken up into cells through amino acid transporters that are expressed highly in almost all malignant cells, but BSH cannot pass through the cell membrane and remains outside the cell. We simulated the energy transfer against the nucleus at different locations of boron from outside the cell to the nuclear region with neutron irradiation and concluded that there was a marked difference between inside and outside the cell in boron localization. To overcome this disadvantage of BSH in BNCT, we used a cell-penetrating peptide system for transduction of BSH. CPP (cell-membrane penetrating peptide) is very common peptide domains that transduce many physiologically active substances into cells in vitro and in vivo. BSH-fused CPPs can penetrate the cell membrane and localize inside a cell. To increase the boron ratio in one BSH-peptide molecule, 8BSH fused to 11R with a dendritic lysine structure was synthesized and administrated to malignant glioma cells and a brain tumor mouse model. 8BSH-11R localized at the cell nucleus and showed a very high boron value in ICP results. With neutron irradiation, the 8BSH-11R administrated group showed a significant cancer killing effect compared to the 100 times higher concentration of BSH-administrated group. We concluded that BSH-fused CPPs were one of the most improved and potential boron compounds in the next-stage BNCT trial and 8BSH-11R may be applied in the clinical setting.

  13. Paving the Road for Modern Particle Therapy – What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?

    PubMed Central

    Specht, Hanno M.; Neff, Teresa; Reuschel, Waltraud; Wagner, Franz M.; Kampfer, Severin; Wilkens, Jan J.; Petry, Winfried; Combs, Stephanie E.

    2015-01-01

    While neutron therapy was a highly topical subject in the 70s and 80s, today there are only a few remaining facilities offering fast neutron therapy (FNT). Nevertheless, up to today more than 30,000 patients were treated with neutron therapy. For some indications like salivary gland tumors and malignant melanoma, there is clinical evidence that the addition of FNT leads to superior local control compared to photon treatment alone. FNT was available in Munich from 1985 until 2000 at the Reactor Neutron Therapy (RENT) facility. Patient treatment continued at the new research reactor FRM II in 2007 under improved treatment conditions, and today it can still be offered to selected patients as an individual treatment option. As there is a growing interest in high-linear energy transfer (LET) therapy with new hadron therapy centers emerging around the globe, the clinical data generated by neutron therapy might help to develop biologically driven treatment planning algorithms. Also FNT might experience its resurgence as a combinational partner of modern immunotherapies. PMID:26640777

  14. Extraterrestrial high energy neutrino fluxes

    NASA Technical Reports Server (NTRS)

    Stecker, F. W.

    1979-01-01

    Using the most recent cosmic ray spectra up to 2x10 to the 20th power eV, production spectra of high energy neutrinos from cosmic ray interactions with interstellar gas and extragalactic interactions of ultrahigh energy cosmic rays with 3K universal background photons are presented and discussed. Estimates of the fluxes from cosmic diffuse sources and the nearby quasar 3C273 are made using the generic relationship between secondary neutrinos and gammas and using recent gamma ray satellite data. These gamma ray data provide important upper limits on cosmological neutrinos. Quantitative estimates of the observability of high energy neutrinos from the inner galaxy and 3C273 above atmospheric background for a DUMAND type detector are discussed in the context of the Weinberg-Salam model with sq sin theta omega = 0.2 and including the atmospheric background from the decay of charmed mesons. Constraints on cosmological high energy neutrino production models are also discussed. It appears that important high energy neutrino astronomy may be possible with DUMAND, but very long observing times are required.

  15. Mexican High Energy Physics Network

    NASA Astrophysics Data System (ADS)

    D'Olivo, J. C.; Napsuciale, M.; Pérez-Angón, M. A.

    2016-10-01

    The Mexican High Energy Physics Network is one of CONACYT's thematic research networks, created with the aim of increasing the communication and cooperation of the scientific and technology communities of Mexico in strategic areas. In this report we review the evolution, challenges, achievements and opportunities faced by the network.

  16. Boron neutron capture therapy of glioblastoma multiforme using the p- boronophenylalanine-fructose complex and epithermal neutrons

    SciTech Connect

    Coderre, J.A.; Chanana, A.D.; Joel, D.D.; Liu, H.B.; Slatkin, D.N.; Wielopolski, L.; Bergland, R.; Elowitz, E.; Chadha, M.

    1994-12-31

    The amino acid analogue p-boronophenylalanine (BPA) is under investigation as a neutron capture agent for BNCT of glioblastoma multiforme. A series of patients undergoing surgical removal of tumor received BPA orally as the free amino acid. Favorable tumor/blood boron concentration ratios were obtained but the absolute amount of boron in the tumor would have been insufficient for BNCT. BPA can be solubilized at neutral pH by complexation with fructose (BPA-F). Studies with rats suggest that intraperitoneal injection of BPA-F complex produces a much higher tumor boron concentration to rat intracerebral 9L gliosarcoma that were possible with oral BPA. Higher boron concentrations have allowed higher tumor radiation doses to be delivered while maintaining the dose to the normal brain vascular endothelium below the threshold of tolerance. The experience to date of the administration of BPA-F to one patient is provided in this report.

  17. The Perspectives of the Boron Neutron Capture Therapy-Clinical Applications Research and Development in Saudi Arabia

    NASA Astrophysics Data System (ADS)

    Badhrees, I.; Alrumayan, F.; Mahube, F.

    Boron Neutron Capture Therapy (BNCT) is a binary form of experimental radiotherapy which is based on t